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This thesis is concerned with the epidemiology of vaccine preventable diseases, 
quantifying their burden, and estimating the cost-effectiveness of alternative 
strategies to control them. This subject brings together three fields of research: 
health economics, vaccinology, and infectious disease epidemiology. Health 
economics is a branch of economics which focusses on the scarcity in the allocation 
of health and health care [1]. Within the field of health economics the framework 
of cost-effectiveness analysis was developed. The cost-effectiveness framework is 
focussed on analysing the costs of a new drug or health care intervention related to 
the (projected) health improvement. The outcome of the cost-effectiveness analysis 
enables a direct comparison between mutually exclusive products or interventions. 
Other research in the field of health economics is focussed on the development of 
tools to measure health states or quality of life, investigates methodological issues 
as time preferences and the application of sensitivity analysis [1]. The second field 
of research is the field of vaccinology, this is a science focussed on the development 
and application of vaccines [2]. The field is linked to other areas as immunology and 
bio-chemistry and has as goal to develop sustained immunity against pathogens 
by priming the immune system with a compound. Questions in vaccinology are for 
example the use of adjuvants, conjugation of antigens and optimisation of the prime-
boosting schedule. The third field of research is infectious disease epidemiology. 
Infectious disease epidemiology tries to understand disease transmission and 
transmission control. In this thesis infectious disease epidemiology is applied by 
the use of infectious disease transmission models, risk factor analysis and the 
understanding of transmission patterns. 
In this thesis there is a focus on three different pathogens; varicella zoster, 
influenza A/H1N1 2009 and Streptococcus pneumoniae, and for clarity the thesis is 
structured by these pathogens. 
The main aim of the research described in this thesis was to support sound 
decision making in the application of vaccines. The research in this thesis did/
will support five decisions in the use of vaccines in England and Wales and the 
Netherlands: introduction of Herpes Zoster vaccination among elderly (70+; 
England and Wales) [3], withholding of an introduction of childhood Varicella 
vaccination (England and Wales) [4], to focus the introduction of the pandemic 
H1N1/09 influenza vaccine on risk groups (England and Wales) [5] the introduction 
of a successor of the 7-valent pneumococcal conjugate vaccine (the Netherlands) 
and the decision whether or not to vaccinate pneumococcal risk groups with a 
pneumococcal conjugate vaccine (England and Wales). 
In this general introduction the three pathogens and the individual chapters 
are introduced, and for each chapter the main aim and major issues or discussion 






Varicella Zoster virus (VZV), is a DNA virus from the Herpes family [6,7]. Members 
of this family are able to integrate their viral DNA into the nuclei of host cells, and 
in doing so the virus remains dormant within the human body. The first exposure 
to VZV causes varicella (chickenpox), a disease which in temperate climates mostly 
occurs in childhood [6,7]. After initial infection the virus remains dormant in the 
dorsal root ganglia [8]. Later in life the virus can reactivate, most likely due to a 
waning of cell mediated immunity, and causes Herpes Zoster (HZ; shingles). HZ 
can cause post herpetic neuralgia (PHN), a painful and long lasting complication 
[7]. Cell mediated specific immunity can be boosted by exogenous exposure to VZV 
[9]. Due to this relation of exposure and the activity of the cell mediated specific 
immunity there is a link between getting exposed to VZV via a varicella and/or HZ 
patients, and a reduced risk of reactivation of the dormant virus and subsequently 
HZ disease [10,11]. In this section of the thesis the impact of the introduction of a 
live attenuated VZV vaccine is investigated. There are two versions of the vaccine; 
a high concentrated version aimed at older adults, to boost immunity and prevent 
reactivation of the virus causing HZ, and a version to be used as a childhood vaccine 
against the initial infection. In this part of the thesis we investigate the impact of 
an introduction of HZ vaccination (chapter 2 and 3) and a combined use of the 
childhood and adult vaccine (chapter 4 and 5).
chapTer 2
Aim
Describe the cost effectiveness of Herpes Zoster vaccination for the 60 plus in 
England and Wales.
In 2005 the results of a large randomized, double-blind, placebo controlled clinical 
trial was published. The trial was performed in a cohort of 38,546 individuals aged 
60 years and over and assessed the efficacy of a HZ vaccine at reducing the burden 
of HZ associated disease. The results showed that HZ vaccination reduced the 
incidence by 51.3% [12] in vaccinees compared to the placebo recipients. Following 
these results the vaccine was licensed by the Food and Drug Authority (FDA) in the 
US [13] and the European Medicines Agency (EMA) in the European Union [14]. The 
licensure of an effective vaccine against HZ necessitates a decision whether or not 
to introduce this vaccine in England and Wales. 
To support this decision we investigated the cost-effectiveness of introducing 
HZ vaccination in older adults. The proposed schedule by the manufacturer was one 
dose at the age of 60, but also other ages of introduction were investigated. The 




an increasing incidence of disease by age as well as an increasing severity, and the 
results of the clinical trial suggest that the vaccine is less efficacious among older 
recipients. Within the cost-effectiveness analysis the disease burden needs to be 
expressed in quality adjusted life years (QALYs) lost. QALYs combine the severity of 
disease with the duration of symptoms. The severity of disease is expressed as a 
QALY weight, a measure between 0 and 1. Unfortunately not many data was available 
measuring the QALY weight of HZ at different ages and at different intervals after 
disease onset, however what was available was the measurement of pain levels. 
Therefore we modelled pain levels by age and time after onset and subsequently 
translated those estimated pain levels and duration into QALY losses. 
To use a realistic vaccine efficacy within the model we estimated the waning 
of immunity by comparing the incidence of disease in both arms (i.e. vaccine vs 
placebo) over the duration of the follow-up.
chapTer 3
Aim
Describe the cost effectiveness of Herpes Zoster vaccination for the 60 plus in the 
Netherlands.
The question of whether to introduce the vaccine was also raised in the Netherlands. 
In this chapter we describe the disease burden and implications of Herpes Zoster 
vaccination in the Netherlands using the checklist developed by the Dutch 
institute of Public Health and the Environment (RIVM) [15]. Doing so required re-
parameterisation of the model developed in chapter 2 to the epidemiological setting 
of the Netherlands, as well as an adaptation of the cost-effectiveness model. The 
latter because there are different rules to perform cost-effectiveness modelling 
in the Netherlands compared to England. Firstly in the Netherlands a different 
perspective is applied, a societal perspective instead of a health care payer’s 
perspective [16]. This means that in Netherlands interventions are evaluated 
based on a wider impact for society, including indirect costs such as work loss 
due to disease. In England only the direct effects on health outcomes and health 
care utilization are included in the base case [17]. Secondly in the Netherlands 
differential discounting is in place, this means that costs and health effects are 
discounted separately with each a different discount rate [16], this is different 
from England and Wales where the same discount rate is used for both costs and 
outcomes [17]. Thirdly there is a different threshold for which an intervention is 
considered to be cost effective. In England and Wales this threshold is between 
£20,000 and £30,000 in the Netherlands this was lower with €20,000 (£20,000 
pounds was ~ €25,000 euro on 16 June 2012).
Given the differences in the applied criteria in the cost-effectiveness analyses 






Describe the epidemiological effects of an introduction of a universal childhood 
vaccine against VZV.
After the focus on HZ and HZ vaccination in chapter 2 and 3 the next two chapters 
describe the impact of childhood vaccination against VZV on varicella and HZ.
It took around 200 years between the first description of varicella by William 
Heberden in 1767 to the isolation of the virus by Weller and Stoddard in 1952 [18].
Immediately after the isolation of the virus, researchers started to develop a 
vaccine. The vaccination was introduced in Japan (1987) and South Korea (1988) 
and in the United States in 1995 [19,20]. However until today this vaccine has not 
been introduced in England and Wales or the Netherlands, and most other countries. 
This is because of two reasons. The first is a possible increase in the average age of 
infection in case of a poor uptake of the vaccine. An indirect impact of vaccinating 
children is a reduced transmission of the virus, due to this reduced transmission it 
takes longer to infect a susceptible person. In practice this means that the patient, 
who was born susceptible, will be older when experiencing disease, compared to 
a situation without vaccination. In the case of VZV this possible increase in the 
average age of infection is important because varicella is more likely to be severe 
if acquired later in life, especially during pregnancy. Varicella during pregnancy can 
cause pneumonia and encephalitis in the mother, leading to severe complications, 
and foetal varicella syndrome in the unborn infant [6]. Due to these severe outcomes 
pregnant woman who are exposed to VZV are currently passively immunised with 
VZV-immunoglobulin; a costly intervention to prevent disease. 
The second reason not to introduce the vaccine is because of the relation 
between waning cell mediated specific immunity against VZV and the reactivation 
of the virus as HZ. In normal life the reactivation of VZV is actively suppressed by the 
immune system, which is boosted on re-exposure to the wild type virus. Therefore 
when the transmission of wild virus declines due to vaccination there will be a decline 
in boosting events, and hence an increase of reactivation and HZ cases [10,11]. 
However, HZ vaccine might be able to mimic the re-exposures, possibly counter- 
balancing the decline of natural boosting. 
In this chapter we build on the work of Marc Brisson, who previously developed a 
varicella transmission model [21,22]. Firstly we expand this model by incorporating 
vaccination against HZ. Secondly, since the contact between children and adults 
(driving the boosting) was based on assumptions we replaced those assumptions by 
real data. This contact data was collected as part of the European project Polymod, 
which documented epidemiologically relevant social contact patterns in 8 different 




methodological issues such as how to incorporate uncertainty, the transmission 
probability per contact and how to utilize information of the most likely contact 
structure given the disease pattern by age. 
The final results of this chapter shows the incidence of varicella zoster and 
Herpes Zoster in England and Wales and the projected impact of several vaccination 
schedules (i.e. both with childhood and adult vaccination) on the disease incidence.
chapTer 5
Aim
Describe the cost-effectiveness of a varicella vaccination programme that includes 
both childhood vaccination against varicella and the vaccination of the elderly 
against HZ.
In this chapter we translated the epidemiological predictions from Chapter 4 into 
costs and QALY loss over time and undertake an economic analysis of the alternative 
policy options.
In the context of varicella zoster vaccination the time preference of the decision 
maker is very important. As explored in the previous chapter, exposure to VZV 
appears to act as a booster against HZ, therefore, when this booster falls away 
there is an estimated increase of HZ in the short and medium-term (up to 30-40 
years) following introduction of the vaccine. This increase is reduced when the 
elderly receive HZ vaccine but it will not be prevented. However in the long run (80 
years and over) there is a predicted decline in HZ. This decline is due to the fact that 
varicella vaccinated children are assumed to have a lower probability of developing 
HZ. So there is a negative effect in the medium-term and a positive effect in the long 
term, therefore time preferences of time become important in the interpretation of 
the results in the context of decisions making. 
In cost-effectiveness modelling there are two ways to handle time preferences, 
this is by discounting and the time horizon. Discounting is to give less weight to 
cost and benefits in the future and the time horizon is the numbers of future years 
included in the analysis. In this chapter we extensively explore the effect of different 
assumptions regarding those two parameters, exploring different discount rates in 
combination with different time horizons, including an infinite one. 
The overall conclusion regarding the cost-effectiveness of a combined 
vaccination schedule depends on the time preferences of the decision maker.
parT ii 
vaccination against pandemic influenza a/h1n1 2009 influenza 
In April 2009 a new strain of the influenza virus was recognised in Mexico and 




Organisation declared a pandemic on the 11th June 2009 [25]. Influenza is a 
respiratory RNA virus which is transmitted among birds and mammals such as 
humans, swines and horses. The 2009 influenza strain was a A/H1N1 strain that 
circulated among swines but which adapted to human-to-human transmission 
[26]. This part of the thesis is about the severity of disease caused by pandemic 
influenza A/H1N1 and the cost-effectiveness of the use of pandemic A/H1N1 
influenza vaccine. That is we attempted to measure the health “costs” of this novel 
strain of influenza in comparable units, and estimate the cost-effectiveness of 
vaccination in the same way that other vaccines are routinely evaluated in the UK. 
The decision to purchase a vaccine was made quickly after the emergence of 
the new virus. The production of the vaccine is however a time consuming process 
which took around 5 to 6 months (the virus has to be identified, a vaccine strain has 
to be prepared, the vaccine strain has to be verified, reagents to test the vaccine 
has to be prepared, the growth conditions of the virus has to be optimized, the 
vaccine has to be manufactured in bulk, the quality of the produced vaccine has to 
be controlled, vaccine has to be filled in syringes and the vaccine has to be tested in 
clinical trials [27]). The vaccine became available in the UK on the 21st of October 
2009 [28], and our analysis was performed therefore to inform decisions on vaccine 
implementation at around that date. 
chapTer 6
Aim
Obtain the disease burden of pandemic influenza A/H1N1 2009 by estimating the 
loss of quality of life.
One of the key questions raised when a new disease emerges concerns that of the 
clinical severity of the disease caused by the new pathogen. Indicators of severity 
are hospitalisation and case fatality rates. Apart from these indicators in cost-
effectiveness analysis the impact on the quality of life is considered, expressed as 
the QALYs lost. To calculate this it is necessary to estimate the QALY weight, this is 
the quality of life given the health status, and the duration of that health status. 
When you know both the total amount of QALY can be calculated by multiplying the 
QALY weight by the duration. Subsequently the QALY loss is the difference between 
the QALY in perfect health and the QALY given the disease health status. 
To measure the QALY weight several methods have been developed within the 
discipline of health economics. These methods describe the quality of life with a 
value between 1 and 0, where 1 is perfect health and 0 death. The methods are 
the visual-analogue scale (VAS), the time trade-off (TTO) and the standard gamble 
(SG) [1]. In the visual-analogue scale the patient is asked to value their current 
health state between 0 and 100 (0 being the worst imaginable health state). In 




would be willing to trade off to remove themselves from a certain health stage. In 
the standard-gamble method individuals are provided with a gamble that would 
either return them to full health (or some other state) or result in immediate death. 
They are then asked what the maximum probability of death they would accept. 
The VAS is comparatively easy to administer, but has been criticised on empirical 
and theoretical grounds. The TTO and SG are very difficult to implement in practice. 
Hence, other methods have been developed that are comparatively easy to apply 
and yet have the ability to provide a preference-based measure of health related 
quality of life, that has the correct properties. One such method is EuroQoL (EQ-5D). 
The EQ-5D method assesses health related quality of life in 5 dimensions (mobility, 
self-care, usual activities, pain/discomfort, anxiety/depression). Each of those 
dimensions can be: not affected, a little affected or a lot affected, resulting in 125 
possible combinations (5^3). From a large number of these combinations a QALY 
weight was obtained based on the time-trade off method by asking the general 
public. This makes it possible to calculate QALY losses for patients if you know their 
score for those 5 dimensions. In this chapter we describe a survey among laboratory 
confirmed cases of H1N1 and H1N1 negative controls and estimate the impact on 
the quality of life by the use of the EQ-5D. 
Issues related to the measurement of the quality of life, such as the problems in 
estimating the duration of disease are discussed. The outcomes are compared to 
previous estimates of the impact on the quality of life for influenza.
chapTer 7
Aim
Estimation of the cost-effectiveness of the A/H1N1 2009 pandemic influenza 
vaccine for different target groups taking into account the availability of the vaccine 
in respect to the on-going pandemic.
This chapter describes the analysis we performed to investigate the best use of the 
A/H1N1 2009 pandemic vaccine at the time of availability in October 2009. In this 
analysis we take into account the disease transmission, the disease outcome and 
the availability of vaccine over time. 
During a pandemic it is difficult to make evidence based decisions, as there is 
not much time, and the numbers of options are limited as there are constraints 
on vaccine supply or lack of time to mount large programmes. There are broadly 
two vaccination options: to protect a certain group in the population or to control 
the spread of the disease in the whole population. For influenza this question can 
be very important. The main transmission of influenza is among children; however 
the main burden of disease tends to fall on the elderly. Therefore you can protect 
the elderly by vaccinating them directly, or you can try to control the spread by 




To be able to inform policy making on time we used a real-time modelling approach. 
A real time model is a contemporary exploration of the pandemic, making use of data 
which is collected while the pandemic is on-going. The model estimates are improved 
when there is more data available. There are numerous problems which had to be 
overcome to make a valid assessment of the situation and which are addressed in this 
chapter. The first problem is the estimation of the proportion of the population which is 
immune to the new disease; the base line immunity. The base line immunity is important 
because the total size of the pandemic is directly related to the total number of available 
susceptibles. An estimation of the people who are immune is therefore key. We used 
seroprevelance data as collected from residual laboratory samples to parameterize this 
variable. The second problem is the estimation of the cumulative number of infections; 
the total number of those susceptibles who have become immune. The estimation of 
this number based on health care consultations is problematic due to potential changes 
in health care seeking behaviour. The third problem is the change in contact patterns 
during the pandemic. Changes in the contact patterns can hugely affect the speed of 
the epidemic. These behavioural changes can be for example due to different time in 
the calendar such as holidays [29]. Using the original data from the Polymod study [23] 
it was possible to generate contact matrices for the holiday and non-holiday period. 
The fourth problem was the estimation of the relative risk of clinical disease and the 
hospitalisation and case fatality rate by age and risk group. Important parameters in the 
evaluation of a targeted vaccination approach. 
In this chapter the fitting procedure is described, bringing together the 
information on the base line immunity, the epidemic curve (based on the estimated 
number of influenza cases in the health care system) and the observed growth rate 
after the school holidays. The fitted model allowed for an estimation of the timing 
of the peak and the expected number of remaining infections. Combining the model 
results with the disease outcomes (by risk group) and the estimation of the QALY 
loss (chapter 6) allowed for the estimation of the cost-effectiveness of a targeted 
vaccination approach compared to strategies aimed at controlling the transmission. 
The study is the first, and only, real-time transmission and cost-effectiveness 
analysis evaluating different vaccination strategies during an on-going pandemic.
parT iii
streptococcus pneumoniae
The third part of the thesis is focussed on Streptococcus pneumoniae and the 
epidemiology and cost-effectiveness of a 7-valent conjugated vaccine (PCV-7). This 
vaccine which was introduced in April 2006 in the Netherlands [30] and September 
2006 in England and Wales [31].
S. pneumoniae is a capsulated gram-positive bacteria which colonizes 




commensal bacteria, where carriage is not accompanied by symptoms or disease. 
However occasionally the bacteria does cause disease. Pneumoccocal disease can 
be non-invasive, with outcomes including pneumonia and otitis media or invasive 
with the most severe outcomes including death, meningitis and empyema. The 
incidence by age is U shaped, with a high incidence among children and elderly. 
There are over 90 known serotypes of the bacterium, where each type differs based 
on the expressed polysaccharide in the capsule. These polysaccharides form the bases 
of the conjugated vaccine, for PCV-7 the polysaccharides expressed are of serotypes 
4, 6B, 9V, 14, 18C, 19F and 23F. The conjugate pneumococcal vaccine is a conjugated 
vaccine, the first developed conjugated vaccine was a vaccine against Hemophilus 
influenzae type b. The conjugated vaccines are a great achievement in vaccinology as 
they are the first example of rational vaccine design based on a deep understanding 
of immunology [32]. The rationale is as follows; one of the characteristics of 
polysaccharides is that they are poorly presented on the major histocompability 
complex (MHC), a molecule on antigen presenting cells which activate T-cells, a 
major component of the adaptive immune system. Conjugation of the polysaccharide 
with a highly immunogenic protein, such as the tetanus toxoid or CRM-157, enables 
presentation on the MHC and therefore a T-cell dependent response, leading to relatively 
long-lasting immunity [33,34], a marked improvement on the plain polysaccharide 
vaccine. The generated immune response does not only protect against disease but 
also against carriage of the bacteria [35]. Due to the prevention of carriage the chain of 
transmission is interrupted leading to herd protection, which is the protection of those 
who are not vaccinated. The ability to protect the unvaccinated population by only 
vaccinating children has been an enormous driver in the introduction of the vaccine. A 
cost-effectiveness analysis suggested that if this additional protection occurred, and 
was not cancelled by serotype replacement then vaccine introduction would likely be 
cost-effective, despite the high price of the vaccine [36]. 
This part of the thesis focuses on the post-introduction evaluation, both in terms 
of epidemiology and cost-effectiveness. The effect of vaccinating different target 
groups is evaluated, as are alternative vaccination schedules and the expansion of 
the vaccine coverage from 7 serotypes to a 10 valent vaccine (PCV-10, including 
also serotype 1, 5 and 7F) or a 13 valent vaccine (PCV-13; including PCV-10 + the 
serotypes 3, 6A and 19A).
chapTer 8
Aim
Establish the cost-effectiveness of a programme with more replacement than expected.
The cost-effectiveness of a vaccination programmes is dependent on its ability 
to reduce overall disease burden. There are several factors which can lead to a 




people who you vaccinate do not reflect the people in the clinical trial. For example 
when only healthy elderly are included and the vaccinated cohort consists for 40% 
of immune-compromised people, in such circumstances there might be a lower 
reduction in overall disease burden. A second example is a situation where you 
base the vaccine efficacy on a correlate of protection, an indirect measure of the 
effectiveness, which does not hold in real life. For example the vaccine efficacy has 
been shown to increase the level of antibodies against a certain antigen above a 
certain threshold, however in real life this antigen is poorly presented or the antibody 
response, although reaching a certain threshold, is not strong enough to induce 
protection. A third example might be a situation in which there is an unpredicted 
lower uptake of the vaccine leading to less herd protection, on its turn leading to a 
lower reduction in the overall disease burden. 
A fourth example, and the example focussed on in this chapter, is replacement 
disease. Due to the reduction of vaccine related disease it is possible to get an 
increase in non-vaccine related disease. Bacteria grow in ecological niches where 
they compete among each other for nutrients and space, or indirectly via the 
host immune response. Prevention of the growth of one type might lead to others 
occupying the vacated niche. If the replacing types are disease-causing, then the 
overall reduction in incidence will be reduced by non-vaccine related pathogens. 
In the case of Strep. pneumomiae there are 90 known serotypes, and only 7 
of them are included in the original conjugate vaccine, the rest of the serotypes 
can therefore be considered non-vaccine related. Given that a great number of 
serotypes are found in carriage it is likely that there is competition between the 
serotypes, possibly leading to replacement in the case of vaccination. Initially this 
replacement effect was thought to be minor, because in the United States, where 
PCV-7 was introduced first, low levels of replacement were observed. However the 
post-vaccination experience in England and The Netherlands was different, with 
much higher level of replacement. In this chapter we investigate the impact of the 
greater than anticipated replacement effect on the cost-effectiveness of PCV7 in 
the Netherlands. The analyses also focus on the impact of herd protection, reducing 
the number of doses, and introduction of PCV-10 or PCV-13.
chapTer 9
Aim
Describe the post-vaccination carriage of Strep. pneumoniae after introduction of 
PCV-7 in England and Wales.
To understand the observed replacement trends in IPD we conducted a carriage 
study in two regions in England (Hertfordshire and Gloucestershire). In a carriage 
study samples are taken from the mucosal flora in the nasopharynx, the normal 




material on the swab is transferred into a medium, which is cultured on a plate to 
investigate the existence of strep. pneumoniae. The positive samples are serotyped. 
In our study we included children and adults and the samples were taken in 2009, 
3 years after the introduction of the vaccine. Results were compared to the pre-
vaccination carriage prevalence in 2001-2002 [37,38], when a longitudinal carriage 
study was conducted in the same regions. 
As the conjugated vaccine is effective against carriage there is an expected 
decline in the prevalence of vaccine related serotypes. Some interesting questions 
in this study are: firstly, the overall reduction in carriage, as this will highlight if there 
is a (vaccine induced) reduction in the transmission of streptococcus pneumoniae. 
Secondly, the increase in carriage of serotypes not included in the vaccine, which 
will show the level of serotype replacement and thirdly, the carriage prevalence in 
relation to the observed serotypes in hospitalised disease. This latter will learn us 
if the replacing serotypes are more likely to cause disease given a carriage episode 
(more invasive) compared to the disappearing vaccine serotypes. The invasiveness 
of serotypes will determine the overall reduction of disease in case the overall 
carriage of strep. pneumoniae is not altered due to the introduction of the vaccine. 
When the replacing serotypes are less invasive you will observe a decrease in 
disease, even when the transmission is not reduced. 
In this chapter the outcomes of the carriage study are presented and are placed in 
the context of the ranked prevalence distribution before and after introduction of PCV-7. 
chapTer 10
Aim
Obtain the relative risk of developing pneumococcal disease among different risk 
groups in England.
Similar to the VZV vaccine (chapter 2 to 4) PCV can be used among older age or 
risk groups. Since 1992 clinical risk groups have been recommended to get the 
23-valent pneumococcal polysaccharide (PPV-23) vaccine [39], and since 2003 this 
recommendation has been extended to all people aged 65 and over [39]. The current 
identified clinical risk groups are: asplenics, those with chronic respiratory disease, 
chronic heart disease, chronic kidney disease, chronic liver disease, diabetes, 
the immunosuppressed, individuals with cochlear implants and individuals with 
cerebrospinal fluid leaks [40]. PPV-23 is a non-conjugated vaccine and is therefore 
less effective in inducing lasting immunity in children. As the overall efficacy of the 
PPV-23 vaccine is questionable in risk groups [41], the question can be raised if it 
is better to inoculate these with the conjugated vaccine, given the observed high 
efficacy against vaccine-types among children [31]. However the benefits of a 
possible higher vaccine efficacy are possibly offset by the lower serotype coverage 




this decision our aim was to estimate the extent to which the various clinical risk 
groups had a higher disease incidence compared to the non-risk population. This 
necessitated knowledge of the size of the risk groups in the general population and 
the proportion of IPD in the various risk-groups. To obtain the risk group status of 
the IPD patients we linked laboratory test results (including serotype information) 
to hospital diagnostic data. This linkage allowed us to explore the diagnostic codes 
for each admission, and assign the patient to a risk group if risk group specific 
codes were present. The absolute size of the different clinical risk-groups in the 
population was obtained from a large dataset extract from GP databases, including 
60% of the English population. Patients were assigned to a risk group on the bases 
of their health care seeking behaviour in the year the data was extracted. 
Quantification of the increased risk of IPD for people in risk groups will inform 
decision making, and the absolute estimates of the odds will enable us to obtain the 
cost-effectiveness ratio of a targeted vaccination approach. 
This chapter is an example of performing epidemiological analyses using data 
linkage methods utilizing large electronic databases of routinely collected data, an 
asset which has become available over the last decade or so.
chapTer 11
Aim 
Describe the cost-effectiveness of the vaccination of people in risk groups
In chapter 10 the absolute risk of developing disease in clinical risk-groups was 
estimated, in this chapter we translate this disease risk into disease incidences and 
predict the cost-effectiveness of a targeted vaccination policy with the 13-valent 
conjugated vaccine. PCV-13 had replaced PCV-7 in the childhood vaccination 
programme in England since April 2010. One of the main reasons to introduce 
the conjugated vaccine among children was its ability to reduce transmission of 
vaccine types, creating a reduction of disease even in those who are not vaccinated 
themselves. In this chapter we investigate the impact of this reduction of vaccine-
type related disease in (non-vaccinated) clinical-risk groups and the subsequent 
reduction of the cost-effectiveness of a targeted vaccination policy. 
The vaccine efficacy of PCV-13 in clinical risk groups is not known; therefore 
a part of the study was a formal consultation of an expert panel. Another issue 
which had to be resolved to obtain sound estimates of the cost-effectiveness was 
an evidence based estimation of the reduced life expectancy among patient in 
clinical-risk groups. To do so data from the Royal College of General Practitioners 
(RCGP) was investigated, obtaining a mortality rate by age for different risk-group 
and subsequent the shorter life expectancy. 
Apart from the above, also an extensive sensitivity analysis on the possible 




the cost-effectiveness is very dependent on the projected impact on non-invasive 
disease the reduced transmission of vaccine-types will also apply. Therefore the 
overall conclusion of a reduced cost-effectiveness due to herd protection will hold 
regardless of the level of impact against non-invasive disease endpoints.
chapTer 12
Aim 
To investigate serotype-specific differences in the clinical presentation and quality 
of life of IPD in the context of the newly available PCV vaccines (PCV-10 & PCV-13).
Introduction of serotype specific vaccines necessitates serotype specific 
surveillance and knowledge. To increase the knowledge of disease presentation for 
the different serotypes we expanded the analysis described of the linked dataset of 
hospital admission data and laboratory data described in chapter 10. In this chapter 
we utilize this dataset to document the serotype specific disease presentation, 
case fatality ratio and subsequently the serotype specific QALY loss. The quality of 
life combines disease severity and mortality, including the (population based) life 
expectancy at the moment of death, in one composite number and should therefore 
document the total health impact of the individual serotypes more accurately. 
Knowledge of serotype specific disease outcomes is essential to predict or 
understand the post-vaccination disease burden. This is because replacing serotypes 
can result in less (or more) severe disease outcomes, changing the overall impact 
of the vaccine; for example even with a similar number of hospital admissions the 
number of death can decline due to a lower case fatality in the replacing serotypes. 
In the presented work the different disease outcomes of the various serotypes 
was put into context of the observed serotype distribution in England in the period 
July 2009- June 2010 to show the different predicted impact of PCV-10 and PCV-13 
on the burden of meningitis, the mortality and the QALY loss. This chapter is one of 
the most extensive and detailed descriptions of clinical outcomes differentiated by 
individual serotypes available in the literature.
chapTer 13
Aim
To obtain the cost-effectiveness of the introduction of PCV-13 in April 2010, 4 years 
after the introduction of PCV-7.
There are three parameters driving the overall disease burden caused by the 
individual serotypes of Strep. pneumoniae, this is; the transmission/fitness of the 
serotype (studied in chapter 9), the invasiveness (studied in chapter 9), and the 
disease severity and associated mortality rates (studied in chapter 12), where 




transmission & high invasiveness potential will cause most disease, types with a 
high transmission & low invasive potential or types with a low transmission & high 
invasive potential will cause a significant disease burden but less so than the first 
group, serotypes with a low transmission & low invasiveness will be rare in IPD. 
Depending on the clinical presentation and case fatality rate invading serotypes can 
become important in the overall QALY loss.
These three serotype specific parameters came together in the estimation of the 
cost-effectiveness of the introduction of PCV-13 four years after the introduction 
of PCV-7. The analysis consisted of a dynamic transmission model (developed and 
published by Y. Choi and S. Flasche at the Health Protection Agency [42]) which 
was fitted to the pre-PCV7 carriage data and the pre-and post-PCV7 IPD data, 
differentiated by PCV-7 type disease, PCV-13 type disease and non-vaccine type 
disease. Based on the predicted number of IPD cases by the transmission model, 
the number of vaccine doses and the vaccine type specific disease presentations 
(by age) the cost-effectiveness was estimated. 
The dynamic transmission model focussed only on disease trends in invasive 
disease (pneumonia/bacteraemia/meningitis) and did not investigate the 
disease trends in non-invasive disease (otitis media/pneumonia). The burden of 
non-invasive disease caused by Strep. pneumoniae is hard to estimate, as it is 
unknown which proportion of the recorded disease is caused by the bacteria and 
subsequently what the contribution was of vaccine types. In this chapter we explore 
the impact of PCV-7 on non-invasive disease endpoints based on a regression using 
the post-PCV7 IPD disease trends for vaccine types and non-vaccine types. The 
inclusion of these non-invasive endpoint in the cost-effectiveness analysis does 
affect the overall conclusion however the problems with quantifying this possible 
impact merits caution in the interpretation of the results. 
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A live-attenuated vaccine against herpes zoster (HZ) has been approved for use, 
on the basis of a large-scale clinical trial that suggests that the vaccine is safe and 
efficacious. This study uses a Markov cohort model to estimate whether routine 
vaccination of the elderly (60+) would be cost-effective, when compared with other 
uses of health care resources. Vaccine efficacy parameters are estimated by fitting 
a model to clinical trial data. Estimates of QALY losses due to acute HZ and post-
herpetic neuralgia were derived by fitting models to data on the duration of pain 
by severity and the QoL detriment associated with different severity categories, 
as reported in a number of different studies. Other parameters (such as cost and 
incidence estimates) were based on the literature, or UK data sources. The results 
suggest that vaccination of 65 year olds is likely to be cost-effective (base-case 
ICER = £20,400 per QALY gained). If the vaccine does offer additional protection 
against either the severity of disease or the likelihood of developing PHN (as 
suggested by the clinical trial), then vaccination of all elderly age groups is highly 
likely to be deemed cost-effective. Vaccination at either 65 or 70 years (depending 
on assumptions of the vaccine action) is most cost-effective. Including a booster 
dose at a later age is unlikely to be cost-effective. 
inTroducTion
Herpes Zoster (shingles, HZ) is a disease with high incidence among the elderly, 
causing pain and reduced quality of life. Herpes Zoster is a reactivation of the 
varicella zoster virus (VZV) which causes chickenpox usually during childhood. HZ 
occurs in all age groups but the highest incidence is in the elderly. The life time 
risk of HZ is around 25-35 percent [1, 2]. Immunosuppression increases the risk of 
zoster however the majority of the cases occur in the immunocompetent population. 
Herpes Zoster usually starts with local prodomal pain, which lasts for 2-3 days 
before rash onset. The rash is typically localised and lasts for 3-4 weeks. The most 
common complication of HZ is post-herpetic neuralgia (PHN), which is persistent 
pain following acute zoster. Various definitions of PHN occur in the literature, though 
the most common is pain independent of the rash that persists for 3 months or 
more after onset [3-8], but 1 month [9], 4 months [10] and 6 months definitions 
[11, 12] have also been used. The severity of disease varies among patients but 
HZ and PHN can have a substantial impact on daily living [13-15] due to poorer 
physical functioning and increased emotional distress. Other complications that 
can occur as a consequence of HZ are encephalitis, zoster opthalmicus and retinitis. 
Complications are more common in immunocompromised patients [16].
In 2006 marketing approval was given to Zostavax (Merck&Co in the USA, Sanofi 
Pasteur MSD in Europe) by the European Medicines Agency (EMEA 2006). Zostavax 
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is a vaccine consisting of a live attenuated (OKA strain) varicella zoster virus (VZV). 
The vaccine is a higher dosage of Varivax, the vaccine used to prevent chickenpox 
in children. Vaccination is thought to boost the immune system by increasing VZV 
specific T-cells [17, 18]. A large-scale double-blind placebo controlled clinical trial 
suggested that the vaccine prevents 51% of cases in people aged over 60 years and 
reduces the severity of disease in those that are affected [5, 19]. However vaccine 
efficacy appears to decline with age: from an overall efficacy against HZ of 64% 
when vaccinating at 60-69 years to 38% among those over 70 years of age [5, 19].
Although the clinical trial suggests that the vaccine is safe and effective, it is not 
clear what the long-term impact of vaccination in the general population will be. 
Furthermore, vaccination against HZ needs to be compared with other possible uses 
of health care resources. This paper uses a decision analytical model to assess the 
effectiveness and cost-effectiveness of routine vaccination of the elderly against 




Age-specific incidence rates were taken from a number of different GP-based 
sources: the Royal College of General Practitioners (RCGP) Weekly Returns Service 
[20], the fourth Morbidity Survey in General Practice (MSGP-4) [21], which included 
many of the same practices as in the RCGP database, and the General Practice 
Research Database [22]. See appendix 1 for a more in-depth description. Rates 
were adjusted for misdiagnoses, which is in the range of 5-13% [6, 7, 23-26]. In the 
base case the amount of false positive is set at 10% (7.9% - 12.4%, appendix 1).
As the vaccine was licensed for an immuno competent population, the 
proportion of immuno competent HZ patients was obtained from the MSGP-4, 
a survey conducted in 1991-1992 and covering a 1% sample of England and 
Wales [27]. Patients reporting any of the following conditions were considered 
immunocompromised and thus not eligible for vaccination: cancer (ICD9: 1400-
2399), human immunodeficiency virus (HIV) (ICD9: 0420-0449), tuberculosis (ICD9: 
011-018) and transplantations (ICD9: 9960-9968) (Merck 2006). 
Hospitalisations
Hospitalisation data for England were extracted from the Hospital Episode Statistics 
(HES) database for the years 2002-2005. For each hospital admission the age, date 
of admission, date of discharge and the diagnosis at discharge were extracted. 
Although fourteen diagnostic fields are available in the database, hospitalisations 
were considered zoster related only if a clinical registration code for HZ and/or 
PHN (ICD-10: B02 and G053) was present in any of the first three diagnostic fields. 
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In line with the selection made on GP consultations, patients with an underlying 
immunosuppressive condition were excluded from the analysis; cancer (ICD10: 
C0-C9 and D0-D4), human immunodeficiency virus (HIV) (ICD10: B20-B24), 
tuberculosis (ICD10: A15-A19) and transplantations (ICD10:Y83) [28].
Average annual age-specific hospitalisation rates were derived dividing the 
number of hospitalisations by the average population for England for the same years. 
As hospitalisation rates have to represent those cases that are preventable with the 
vaccine, only admissions that reported HZ as the first diagnosis were considered in 
the base case. Of these 25.5% reported PHN as a co-diagnosis (HES year 2004-5) 
and 18.5% had ophthalmic complications (ICD10: H0–H5, HES year 2004-5). In 
the sensitivity analysis hospitalisation rates were calculated using admissions 
that reported HZ in any of the first three diagnostic fields. Patients with HZ as the 
second or third diagnosis report pneumonia and urinary tract infection as the most 
common main diagnoses. Those conditions are associated with a compromised 
immune system which may justify the focus on the first diagnostic field.
Deaths
Mortality data were extracted from the Office of National Statistics (2001-2005) 
database (ONS 2005). Mortality due to herpes zoster is low until the age of 85 (0-0.5 
deaths per 100,000 per years), and then it increases to 4.3 per 100,000 per year 
(average 2001-2005) (Table 1). This corresponds to a case fatality rate of 0.36% in 
the oldest age group. However due to the pathology of HZ it is probable that many 
of these deaths are not caused directly by HZ, and they may not be preventable by 
vaccination. Therefore a scenario without mortality was also considered. 
Pain, incidence of PHN and quality-adjusted life-year (QALY) loss
Pain is the most important outcome of HZ, and there is believed to be a direct 
relation between QALY loss and severity of pain [29]. Severity is often categorised 
into, no pain, and mild, moderate and severe pain. The last two groups are often 
Table 1. Estimated annual age-specific incidence, hospitalisation rate, length of inpatient 






first diagnosis (first 
three diagnoses)
mean number of 





60-64 706 0.8% (1.3%) 9 (4) 9% 0.00%
65-69 791 1.0% (1.7%) 8 (5) 11% 0.00%
70-74 876 1.5% (2.4% 11 (5) 15% 0.01%
75-79 961 2.2% (3.8%) 14 (7) 20% 0.02%
80-84 1046 3.0% (5.2%) 17 (9) 27% 0.06%
85+ 1216 4.4% (8.1%) 22 (13) 52% 0.36%
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considered clinically relevant pain (CRP) [5, 7, 8, 29-31]. In keeping with the clinical 
trial [5] CRP is defined here as a pain score of 3 or more on an 11 point pain scale, 
from 0 = no pain, to 10 = worst pain imaginable. The duration of pain is related to 
the severity and age of the patient [6]. To estimate the duration of pain by severity 
and age, and subsequently the QALY loss, a model was fitted to the proportion of 
patients in any pain or CRP after 90 days of onset. Details of this model are given in 
appendix 2. The model provides an estimate of the overall QALY loss associated with 
zoster (by age) when combined with data on the health-related quality of life (QoL) 
weights associated with mild, moderate and severe pain. The QoL weights used in 
the analysis are based on studies that report EQ-5D values as recommended by 
the National Institute for Clinical Excellence (NICE); see appendix 3 for details. It is 
possible that the QoL detriment associated with a particular pain severity improves 
over time, as individuals cope with their disease. Alternatively, they may become 
increasingly affected by it (perhaps becoming more depressed or anxious). To allow 
for these possibilities, in the sensitivity analysis we assumed that the QoL detriment 
changes by ± 10 or 20% per year for patients in long-term pain. 
Ophthalmic zoster
In 10-20% [1, 4] of cases there is an ophthalmic localisation of the zoster rash. 
A proportion (~4% of total [32]) of these cases result in long term sequelae. The 
ophthalmic localisation also leads to an increased chance of long term pain [4]. The 
additional costs of ophthalmic zoster are incorporated in the GP and hospitalisation 
costs as found in the GPRD and HES databases. The increased pain is already covered 
in our pain model, as a proportion of the patients in the original studies would have 
had ophthalmic zoster (only in [8] were they excluded). Hence, costs and QALYs lost 
from ophthalmic zoster are included in this analysis, but not identified separately. 
Vaccine parameters
The proportion of vaccinees who respond (vaccine take) and the decline in vaccine 
efficacy with time since vaccination (waning) was estimated by fitting a model to 
the clinical trial data. The estimated take and waning rates are positively correlated 
with each other (the higher the take the higher the estimated waning rate), and 
it is difficult to identify these parameters independently. Hence, in the sensitivity 
analysis 15 different take and waning scenarios were assumed for each age group 
(60-64, 65-69, 70-74, 75+). Waning rates were obtained from overall incidence in 
the first four years after vaccination. Vaccine take was estimated from age-specific 
data. See appendix 4 for more details. Vaccine coverage was assumed to be 73.5%, 
based on the average influenza vaccine coverage in 2007/2008 [33].
 The results of the clinical trial suggested that the efficacy against the burden 
of illness (BOI) (defined as the area under a curve of the pain severity (worst pain in 
last 24 hours marked on an 11-point scale) through time over 182 days after rash 
onset) and PHN was greater than the efficacy against episodes of herpes zoster, 
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suggesting that the vaccine reduced the morbidity associated with herpes zoster 
episodes in vaccinees [19]. This could have been due to a reduction in the pain 
severity, or the duration of pain, or a combination of both. In addition, it is not clear 
whether the reduction in BOI was due to a reduction in PHN, and the estimate of 
vaccine efficacy against BOI may be inflated due to the counting procedure [34]. 
Further analysis of the data on PHN [35], suggest that there were more cases of 
PHN in the placebo group in the first year of the trial than in the subsequent years, 
and that this may have biased the efficacy results for PHN (and therefore also, 
perhaps BOI). Adjusting for this excess of PHN cases in the first year, then additional 
efficacy against PHN only reached statistical significance in the 70+ age group [36]. 
To capture the overall effect of burden of illness (including the effect on reduced 
incidence of zoster), the QALY loss in the first six months of the modelled vaccinated 
cohort was adjusted (downwards) to give the overall age-specific efficacy against 
BOI reported in the clinical trial (see appendix 4). This required adjusting the QALY 
loss to a greater extent in the older age groups, as the reported efficacy against HZ 
declined with age, but the reported efficacy against BOI remained relatively high. 
We also applied a scenario without any additional efficacy (i.e. vaccine only protects 
against developing in a proportion of vaccinees, but does not reduce the severity 
of HZ or the likelihood of developing PHN if HZ occurs). Finally, we also modelled 
a scenario in which there was an additional efficacy against PHN of approximately 
40%, as estimated by Brisson and colleagues [36], after adjusting for possible 
“excess” cases in the placebo group in the first year. These additional effects 
were only applied in the 70+ age group in our scenario analysis, as they were not 
significant in other age groups [36]. 
The clinical trial showed an injection site reaction in ~30% of the cases [28], which 
was significantly higher than in the placebo group. Because of the short nature of 
those complaints and the unknown QALY loss that might be related to this side effect, 
this reaction is neglected in the base case scenario. Its impact is however explored in 
the sensitivity analysis, where we assumed adverse reactions occur in 30% of cases 
lasting for two days with a reduction in health-related quality of life of 0.05.
cost data
Following UK guidance [37] the cost-effectiveness analysis was performed from 
the health care provider perspective, and thus costs to the patient and wider society 
were not considered. The exclusion of productivity costs (as recommended by NICE) 
would not, however, be expected to have a major impact on the cost-effectiveness 
due to the low participation in the active workforce in the target group. All cost are 
presented in £2006. Unit costs from previous years were inflated using the Hospital 
and Community Health Services Pay and Prices Index [38].
The average costs of HZ cases in primary care was based on a study conducted 
among 25,000 enlisted patients with HZ [22] in the GPRD database. This study 
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estimated the cost of HZ to be £75.63 (74.68-76.58) per episode. More than 50% of 
the costs originated from prescribed medications. The average total cost of a PHN case, 
based on a three month definition, was estimated to be £340.04 (319.23-360,85), 
which included GP and outpatient visits as well as prescribed medications. Note that 
this study used data up to March 2006. Recently two further medications have become 
widely available (lidocaine patch and pregabalin). As these treatments are relatively 
expensive, we may have underestimated the cost of HZ here. Although an episode of 
HZ may be a trigger for admission into care homes in elderly and frail patients it is not 
possible to say in what proportion of patients this may occur, or how long they would 
have been able to continue with their previous arrangements if the episode did not 
occur. Hence, we have not attempted to estimate these potential costs. 
To estimate the cost of hospitalised cases, daily inpatient costs for minor skin 
infections (Reference costs 2006; HRG J42 and HRG J41) were used and multiplied 
by the average age-specific number of days spent in hospital (Table 1). Infection 
control measures such as isolation, staff exclusion and administration of Varicella 
Zoster Immuno globulin may be necessary to prevent infection of vulnerable patients 
in the hospital setting. Wreghitt and colleagues [39] has estimated these costs at 
£1010 cost per hospitalisation. However, much of these costs are associated with 
staff exclusion, and since their study was performed routine vaccination of health 
care workers against varicella has been recommended. Hence, in the base-case we 
ignore these costs, but include them in the scenario analysis. 
Although the private sector price of the vaccine is $162 (£82; single dose) the 
CDC price is $108 (£55; 10-pack). A price per dose of £55 was therefore used in the 
base case analysis, as this is likely to reflect the price for bulk purchase by a publicly 
funded programme. Administration costs were set to £10 based on the cost of a GP 
nurse consultation [38]. 
cost-effectiveness model
Quality adjusted life years gained were the primary outcome of interest and were 
compared to net costs in the form of incremental cost-effectiveness ratios (ICER). 
The comparator programme in each case was the no-vaccination option. A scenario 
with a booster dose was also of interest, the two dose schedule was compared with 
a one dose strategy. Future costs and health effects were discounted at 3.5% per 
annum as recommended by NICE [37]. 
A Markov-cohort-model was set up in Excel (Microsoft, USA). In case of Herpes 
Zoster a cohort model is sufficient because the indirect effect of vaccination on 
the force of infection of varicella and cases of zoster is very small. 0Multivariate 
(probabilistic) sensitivity analyses were performed using @Risk (Palisade, USA), 
in which parameter sets were randomly drawn from input parameter distributions, 
assuming that all parameters are independent. As the vaccine efficacy parameters 
are not independent 15 scenarios (combinations of take and waning) were 
COST-EFFECTIVENESS OF VACCINATION AGAINST HERPES ZOSTER IN ENGLAND AND WALES
TWO
36
simulated for each age group (Table 2). Univariate sensitivity analysis was also 
performed in which individual parameters were varied across the range or 95% CI 
of their distribution, while all other parameters were held at their base-case level. 
Background mortality rates for the general population were used. However, to 
take account of increasing life expectancy, a projected mortality schedule for 2028 
was used in the sensitivity analysis. When assuming a zoster-related mortality, 
age-specific background quality of life weights, as derived by Kind and colleagues 
[40], were used to weight the life-years lost.
Table 2. Vaccine parameters. Estimated vaccine take (%) by age group, for different average 
durations of vaccine induced immunity (average duration = 1/waning rate).
age 
group
scenarios based on the duration of protection
3.6 4.1 4.5 4.8 5.2 5.5 6.1 7.5 9.5 11.4 13.5 16.1 20.7 32.7 100.0
60-64 95% 91% 88% 87% 85% 84% 82% 78% 75% 73% 72% 71% 70% 68% 66%
65-69 92% 87% 85% 83% 82% 81% 79% 75% 73% 71% 69% 68% 67% 65% 63%
70-74 64% 61% 59% 58% 57% 56% 55% 53% 51% 49% 48% 48% 47% 45% 44%
75+ 45% 43% 42% 41% 40% 40% 39% 37% 36% 35% 34% 34% 33% 32% 31%
60-69 93% 89% 87% 85% 83% 82% 80% 77% 74% 72% 71% 69% 68% 66% 64%
70+ 55% 52% 51% 50% 49% 48% 47% 45% 43% 42% 41% 41% 40% 39% 38%
Table 3. Unit costs of care and treatment parameters.
description costs source
gp visit, secondary care and prescribed medication
HZ case £75.63 Gauthier et.al. 2008
PHN case £340.04 Gauthier et.al. 2008
hospitalisation
Hospitalisation day, <70 yrs  
(Minor skin infections <70 – HRG J42)
£187 Reference costs 
Hospitalisation day, >69 yrs  
(Minor skin infections >69 – HRG J41)
£215 Reference costs 
cost per vaccine dose
Vaccine cost (per dose) £55 See text 
Administration costs £10 Curtis & Netten 2006
Number of doses 1




current burden of disease
The estimated annual number of HZ cases in England and Wales in the 
immunocompetent population of 60 years and older is 88,650 (95% Credibility 
Intervals 65,000-113,000), of which 18,200 (13,500-23,300) are estimated 
to remain in pain after 3 months. There are an estimated 1,750 (1,300-2,200) 
hospitalisations in the 60+ age group every year, and 55 (54-56) persons are 
estimated to die, with zoster being recorded as a cause of death (Table 4). The 
overall cost to the health care system generated by these cases is estimated at 
£17.3m (£12.9m-£21.8m) annually of which £11.5m (£8.5m-£14.6m) will be 
GP-related costs and the remaining costs fall on secondary care. Almost 50% of 
the total costs originate from disease occurring in the very elderly (80+ years), due 
to the higher incidence and complication rates in these ages.
Table 4. Burden of disease in the immunocompetent population England & Wales (population 
2007)
age group hz cases phn cases hz deaths cases hospital Total costs
60-64 18765 1696 1 149 £2,126,063
65-69 16189 1858 1 161 £1,963,856
70-74 15720 2355 1 242 £2,373,168
75-79 14376 2874 3 321 £2,807,137
80-84 11614 3157 7 352 £3,005,354
85+ 11987 6270 43 522 £5,066,370
Total 88,652 18,210 55 1,746 £17,341,948
effectiveness of vaccination
Vaccination of 65 year olds at 73.5% coverage is estimated to reduce the life-time 
risk of herpes zoster from 15% to 12% (a reduction of 20%, nearly 11,200 cases). 
This is estimated to reduce the incidence of PHN by about 1,500 cases in the cohort, 
and reduce the number of hospitalisations by nearly 150. Overall 1000 QALYs are 
estimated to be gained through vaccination, using the base-case assumptions. 
Vaccination of 65 year olds is estimated to cost about £23.7m, but result in savings 
to the health service of around £1.3m over the life-span of the cohort, most of 
which would occur in primary care. The (discounted) costs saved are only 6% of the 
vaccine cost. The introduction of the vaccine, would result in a significant increase 
in the overall proportion of the health budget spent on herpes zoster.




The estimated impact of the vaccine on the burden of disease, use of the health 
care system and mortality is age dependent, and thus the ICER is sensitive to the 
age at vaccination, particularly if vaccination offers additional protection against 
PHN in the 70+ year olds (Figure 1). The base-case model with vaccination at 65 
years of age results in an ICER of around £20,400, with wide credibility intervals 
(Figure 1). 
The sensitivity of the ICER for the base-case model to changes in the vaccine 
price is shown in Figure 2. The threshold price for the vaccine is around £80-90 
including the additional effect of the vaccine against the burden of disease (at a 
threshold value per QALY gained of £30,000) excluding this additional effect lowers 
the price. 
The effect of varying other assumptions on the ICER is investigated in Table 6. 
Here, one parameter at a time is varied keeping all the other ones at their base case 
values (base-case model is assumed). The results are sensitive to the estimated 
Table 5. Estimated burden of disease in a cohort of vaccinated (at 73.5% coverage) and 
unvaccinated 65 year olds over their life-time. Cases and hospitalisations are shown 
undiscounted, and QALYs and costs are shown discounted (at 3.5% per annum) and 
undiscounted.
no vaccination vaccination difference
Cases HZ 56389 45189 11200
Cases PHN 12856 11351 1514
Hospitalisations 1595 1457 174
QALY lost 6206 5106 1099
QALY lost undiscounted 10128 8785 1343
Vaccine costs (incl. administration costs) 0 £23,763,500 £23,763,500
GP costs £4,978,000 £3,912,500 -£1,065,000
GP costs (undiscounted) £7,666,000 £6,418,000 -£1,247,500
Hospitalisation costs £2,625,000 £2,368,500 -£258,000
Hospitalisation costs (undiscounted) £476,500 £4,401,500 -£325,000
Overall costs £7,603,000 £30,044,500 £22,441,500
Overall costs (undiscounted) £12,392,500 £34,583,500 £22,191,000
Cost per case prevented £2,004
Cost per QALY gained £20,412
Cost per QALY gained (undiscounted) £15,455
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60 65 70 75 
Base case £26,705  £20,412  £15,146  £18,546  
No additional efficacy £28,660  £21,428  £22,406  £24,129  












Age at vaccination 
figure 1. Base-case incremental cost-effectiveness ratio (ICER) of vaccination at different 
ages compared with no vaccination. The 95% credibility interval of ICERs from the multivariate 
sensitivity analysis is shown. The base-case model (green bars) assumes additional decline in the 
burden of illness. The second bar shows the ICER when no additional decline in the morbidity or 
protection against PHN is assumed. The last scenario assumes additional protection in the 70+ 
age group against PHN (see appendix for details of assumptions). The relevant base-case ICERs 
are reported under the graph.
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Price per dose 
Base case  60  Base case  65  
Base case  70  Base case  75  
No additional vaccine efficacy  60  No additional vaccine efficacy  65  
No additional vaccine efficacy  70  No additional vaccine efficacy  75  
Additional vaccine efficacy PHN  70  Additional vaccine efficacy PHN  75  
figure 2. Sensitivity of the ICER to vaccine price under base-case assumptions.
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Table 6. Univariate sensitivity analysis. Incremental cost-effectiveness ratio of vaccination 
at different ages, compared with no vaccination. 
scenario
age at vaccination (yrs)
60 65 70 75









£ 20,145 £ 15,695 £ 11,949 £ 14,822
Incidence – slope; 
lower 95% CI
£ 27,538 £ 21,499 £ 16,326 £ 20,213
Incidence – slope; 
upper 95% CI
£ 25,870 £ 19,353 £ 14,036 £ 16,985
False positive 7.9% £ 26,034 £ 19,875 £ 14,730 £ 18,017
False postive 
12.4%
£ 27,428 £ 20,950 £ 15,525 £ 18,985
vaccine efficacy assumptions
Only an effect 
against HZ 
incidence
£ 28,660 £ 21,428 £ 22,406 £ 24,129
100 year 
protection
£ 6,148 £ 5,660 £ 6,988 £ 9,891
21 year protection £ 12,185 £ 10,232 £ 10,508 £ 14,473
3.6 years 
protection




NA NA £ 6,598 £ 6,576
Qaly assumptions
QALY loss side 
effect vaccination
£ 29,764 £ 22,017 £ 6,636 £ 6,605
10% increase of 
QALY loss over time
£ 22,824 £ 17,198 £ 13,239 £ 15,973
20% increase of 
QALY loss over time
£ 21,286 £ 15,955 £ 12,471 £ 14,963
10% decrease of 
QALY loss over time
£ 32,011 £ 24,925 £ 17,549 £ 21,876
20% decrease of 
QALY loss over time
£ 35,001 £ 27,591 £ 18,921 £ 23,933
Severity CRP; lower 
95% CI
£ 27,436 £ 20,956 £ 15,538 £ 19,005





age at vaccination (yrs)
60 65 70 75
Duration long term 
CRP; upper 95% CI
£ 21,588 £ 16,233 £ 12,700 £ 15,327
Duration long term 
CRP ; lower 95% CI
£ 31,335 £ 24,346 £ 17,286 £ 21,537
QALY loss; lower 
95% CI
£ 32,694 £ 24,841 £ 18,165 £ 22,199
QALY loss; upper 
95% CI
£ 22,613 £ 17,323 £ 12,952 £ 15,848
b of alfa(i); lower 
95% CI
£ 29,176 £ 22,611 £ 16,861 £ 20,925
b alfa(i); upper 
95% CI
£ 24,385 £ 18,356 £ 13,523 £ 16,313
w(i); lower 95% CI £ 26,327 £ 20,143 £ 14,996 £ 18,350
w(i)’ upper 95% CI £ 26,936 £ 20,539 £ 15,172 £ 18,548
hospitalisation
First 3 diagnoses 
hospitalisation




£ 26,558 £ 20,240 £ 14,991 £ 18,333
mortality scenarios
Mortality due to HZ £ 26,505 £ 20,293 £ 15,029 £ 18,311
Background 
Mortality 2028




£ 22,365 £ 17,046 £ 12,641 £ 15,470
price per dose £50 £ 24,522 £ 18,709 £ 13,869 £ 16,967




£ 19,732 £ 15,414 £ 11,039 £ 14,311
Discounting; cost 
6% - effects 1.5%
£ 22,864 £ 17,693 £ 12,858 £ 16,195
Discounting; costs 
5% - effects 5%
£ 29,852 £ 22,653 £ 16,993 £ 20,377
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incidence of HZ, the QALYs lost due to HZ, the waning rate of vaccine protection, and 
whether the vaccine also reduces the severity of disease (in the 70+ years). The model 
is not sensitive to different assumptions about mortality or hospitalisation rates. 
Adopting a differential discount rate of 6% for costs and 1.5% for health benefits (as 
recommended by the UK Treasury), improves the cost-effectiveness of vaccination.
The model is sensitive to whether the QoL detriment associated with pain states 
changes with time (either worsens, or improves). 
Booster doses are less cost effective than the first dose, see table 7. The most 
cost-effective strategy for a two dose schedule is vaccination at 60 and 70, though 
even this strategy results in ICERs over £40,000 per QALY gained, and are therefore 
unlikely to be deemed cost-effective.
Table 7. Incremental cost-effectiveness ratio of a booster dose at different ages, compared 
to one dose. Vertical age at first dose, horizontal age at the second dose.









e 60 £48,381 £42,706 £45,393
65 NA £70,293 £50,545
70 NA NA £83,986
The average QALY loss from acute zoster and, more importantly, PHN is a key 
variable, which is difficult to estimate accurately. Figure 3a shows the estimated 
cost-effectiveness of the model (vaccination at 65 years, no additional efficacy 
against burden of disease), using QALY loss parameters used in previous cost-
effectiveness studies. The average QALY loss per case was estimated to be lower in 
Pellissier et al., which results in higher ICERs, whereas Edmunds et al. estimated the 
QALY loss per case to be higher than is estimated here (Figure 3b). 
Figure 4 shows the results of the multivariate sensitivity analysis. The figure 
shows the change in the ICER for the 65 year old programme given 1 standard-
deviation increase in each of the parameters (vaccine efficacy is a combination 
of two parameters, take and waning and done by scenario, therefore a one SD 
increase from the base-case (Scenario 8) is Scenario 11). The results show that the 
model results are most sensitive to the vaccine efficacy parameters, as well as the 
estimated incidence of zoster and parameters that describe the QALY loss from HZ. 
The proportion of simulations that would be deemed cost-effective at different 
threshold values of a QALY gained (cost-effectiveness acceptability curves) is shown 
in Figure 5. The model suggests that at a maximum willingness to pay for a QALY 
gained of £30,000 then the probability that vaccination at 65years would be cost-
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figure 3. a) Sensitivity of the model to alternative estimates of the average QALY loss per HZ 
episode (including PHN), and b) a comparison of the estimated QALY loss by age group used in 
this, and previous cost-effectiveness analyses.
effective is 87%, whereas vaccination at 70 years has a 98% chance of being cost-
effective, using our base-case assumptions about vaccine efficacy. If, however, the 
vaccine does not provide additional protection against PHN, then vaccination of the 
70+ age groups is less likely to be cost effective (around 80% of simulations would 
be deemed cost-effective). 
discussion
In this work a cohort model has been used to assess the cost-effectiveness of zoster 
vaccination in the elderly. Results from this analysis suggest that the program is 





















Cost effectiveness threshold 
Base Case 60 yrs 
Base Case 65 yrs 
Base Case 70 yrs 
Base Case 75 yrs 
No additional efficacy 65 yrs 
No additional efficacy 70 yrs 
Additional efficacy against PHN 70 yrs 
figure 5. Cost-effectiveness acceptability curves for vaccination at different ages, using the 
base-case model, a model that assumes that there is an additional effect of vaccination on PHN 
in the 70+ year age group.
figure 4. Results of a regression analysis on the multivariate sensitivity analysis. The outcome 
variable is the ICER for vaccination of 65 year olds, and the input variables the parameter values. 
The figure shows the predicted (from the regression analysis) change in the ICER following a 
one standard deviation increase in parameter values from their mean. Only the most influential 
parameters are shown (more than 1% change). 
*vaccine efficacy is based on fifteen scenarios; the presented change is based on scenario 11.
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likely to represent a cost-effective intervention for England and Wales, although 
there is a lot of uncertainty around the duration and range of vaccine induced 
protection and the QALY loss due to long term pain. The most cost-effective age to 
vaccinate is 70 years, or 65 years if the vaccine does not offer additional protection 
against the severity of disease. The ICER does not increase steeply with age, which 
makes a catch-up campaign possible, although more data is needed on vaccine 
efficacy in the extreme elderly to make a decision on the maximum age in case 
of such campaign. Applying a two dose schedule is not likely to be cost-effective. 
The introduction of the vaccine would, however, not be cost saving, as the savings 
derived are low in comparison to the vaccine price. Indeed, vaccination would be 
expected to approximately triple health-care expenditure on HZ. Therefore the 
major gain of the vaccine is the reduction of the burden of illness. 
The conclusions of this study are comparable to previous cost effectiveness 
studies in the UK, suggesting that vaccination may be cost-effective in a number 
of scenarios [41, 42]. These previous cost-effectiveness studies were published 
before the clinical trial, and therefore used speculative vaccine efficacy parameters. 
Since then the clinical trial has become available as well as more data on the quality 
of life impact of HZ. Three further cost-effectiveness studies have been published, 
all of them for the US. Hornberger & Robertus (2006) suggested that it was more 
cost-effective to vaccinate at younger age, because the higher incidence was offset 
by lower vaccine efficacy as age increased. They also showed the sensitivity of 
results to the duration of vaccine efficacy (waning) and concluded that there is 
too little information about the effect of HZ and PHN on quality of life to be able 
to accurately assess the cost-effectiveness of vaccination. Moreover the authors 
point out that the difficulties relate not only to the lack of data but also on the 
lack of generally accepted definitions. Rothberg and colleagues (2007) compared 
vaccination of different genders and ages and found that vaccination was less likely 
to be cost-effective in men (due to a higher incidence in women) and unlikely to be 
cost-effective in the younger and oldest age groups. Only at 70 years of age (the 
most cost-effective age group to vaccinate in their model) did base-case cost-
effectiveness ratios approach $50,000 per QALY gained. Rothberg et al. did not 
assume additional protection against PHN, though they did assume that the vaccine 
reduced the burden of illness in their base-case model. Pellisier and colleagues 
(2007), estimated that vaccination would be cost-effective under a wide range of 
scenarios (base-case ICER $28,000 ≈ £14,000 per QALY gained), although they did 
assume an additional effect against PHN. 
Extensive univariate and multivariate sensitivity analyses have been performed 
to identify key parameters and assumptions and to assess the robustness of the 
results to variation in these. Two key areas of uncertainty are the burden of disease 
associated with PHN, and whether the vaccine offers additional protection over and 
above the protection resulting from a reduced incidence of herpes zoster. 
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To estimate the burden of disease associated with HZ we fitted a model of pain 
severity over time (stratified by age) to data from a large number of studies. This 
provided an estimate of the duration of pain, by severity and age. However, there are 
few data on long-term pain (few studies were carried our over a long-enough time 
period and the numbers of patients remaining in those studies is small). The average 
duration of long term pain used of 2.8 years (95% CI: 1.9-4.3 years) is comparable 
with the average duration (2.3 years) that was found in a retrospective study in the 
UK [1]. However a recent study of the GPRD database suggested that the average 
duration of PHN is much shorter, at 10 months [22], this is however based on care 
seeking behaviour and not on actual pain levels. Thus the estimate of the mean 
duration of PHN is very uncertain, and the value adopted for this parameter accounts 
for much of the difference in average QALY loss per case derived in different studies 
in the cost-effectiveness literature. Further research in this area would be valuable 
to help improve decisions regarding the cost-effectiveness of vaccination as well as 
treatment options for PHN patients.
Vaccine efficacy was estimated from the clinical trial data [5]. However, a number 
of limitations regarding our parameter estimates should be borne in mind. First 
there were many exclusion criteria for enrolment into the clinical trial, and the death 
rate was somewhat lower in trial participants than the average by age (suggesting 
that participants may have been somewhat healthier than average). Second, the 
characteristics of the vaccine (i.e. take and waning rates) were estimated by fitting 
a model to the published clinical trial data. Although it was possible to identify best-
fitting parameter estimates, there were many combinations of take and waning 
that gave a reasonable fit to the data. In particular the 95% confidence interval on 
the duration of immunity is from 3.6 to life-long immunity. Our best-fitting efficacy 
parameters were lower than those used in other studies. The only previous study 
to estimate the waning rate was published by Pellissier and colleagues [43] using 
data not available in the public domain. Their base-case estimate was life long 
protection, with a take of 69.8% and a lower bound of the confidence interval of 12 
years. Our base-case take was 75% (in 65 year age group) with an average period 
of protection of 7.6 years (95% CI 3.6 to infinity). One reason for the difference 
is the apparent use of a lower zoster incidence in the vaccine group in year five 
compared with the data submitted to FDA (comparing Figure 5 with Table 9-7). An 
alternative explanation may be the use of a function describing waning by age. Both 
of these may reduce the apparent effect of waning through time (extending vaccine 
efficacy). We covered a range of durations from 3.6 years to lifelong immunity in 
our scenario and sensitivity analysis. The relatively low duration of protection used 
in the base-case model accounts for the low proportion of zoster cases estimated 
to be prevented by vaccination of 65 year olds - their life-time risk of zoster is only 
decreased by about 20% (at 73.5% coverage), because protection will have waned 
in many individuals before the age of peak incidence. Post-vaccination surveillance 
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data from countries that have introduced the vaccine would be important to improve 
our estimates of the duration of protection.
The results of the clinical trial suggest that the vaccine offers greater protection 
against PHN than it does against herpes zoster, suggesting that those vaccinees 
that do get zoster are less likely to go on to develop its most serious complication. 
However, there is debate in the literature about the validity of this finding. Rothberg 
et al. suggested that much of this effect could be explained by an unusually high 
number of PHN events in the placebo group in the first year of the trial [35]. Brisson 
and colleagues [36], performed a similar re-analysis of the trial data, but separated 
their results by age group. They found that there was a statistically significant 
additional effect of vaccine against PHN in the 70+ age group, even after adjusting 
for the “excess” cases in the placebo group in the first year of the trial. 
The clinical trial also reported that the “burden of illness” (a measure of the 
overall number of days spent in pain weighted by their severity) was also significantly 
reduced in the vaccine group compared to placebo recipients. Some of this 
difference might be accounted for by the additional protection against PHN, though 
it seems unlikely that all of this would be, as the estimated efficacy against BOI was 
significant in all ages. We modelled this by assuming that the QALY loss in vaccinees 
that did develop zoster, was reduced in the first six months. By changing how much 
the QALY loss was reduced we could match the efficacy against BOI reported in 
the clinical trial. Note however, that our estimate of efficacy is not identical to 
that used in the trial, as we used QALY loss, and the trial pain. Furthermore the 
measure of BOI has been criticised, as it would tend to overestimate the efficacy 
[34]. Nevertheless, as efficacy against BOI was one of the primary endpoints in the 
clinical trial (efficacy against HZ incidence was a secondary endpoint), we included 
the apparent additional efficacy against severity of illness in “breakthrough” zoster 
in our base-case.
The introduction of childhood varicella vaccination could increase the incidence 
of herpes zoster due to a decline in natural boosting [44-46]. As a consequence, 
HZ vaccination would become more cost-effective. However, the introduction of 
a HZ vaccination could have an effect on the evaluation of the varicella program. 
Combined varicella and zoster vaccination programmes should be evaluated using 
a comprehensive cost effectiveness model.
Vaccination of the elderly against herpes zoster is likely to be cost-effective. 
Although there is considerable uncertainty in many of the parameters, this finding 
appears to be reasonably robust. The most cost-effective age to vaccinate appears 
to be 70 years of age, unless duration of protection exceeds 20 years or the 
protection is only against HZ incidence. If shingles vaccination is introduced then 
good quality surveillance data should be collected to evaluate duration of protection 
whether further changes to the programme may be necessary in the future. 
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Herpes zoster (HZ) is a painful disease affecting a considerable part of the elderly. 
Programmatic HZ vaccination of elderly people may considerably reduce HZ 
morbidity and its related costs, but the extent of these effects is unknown. In this 
article, the potential effects and cost-effectiveness of programmatic HZ vaccination 
of elderly in the Netherlands have been assessed according to a framework that was 
developed to support evidence based decision making regarding inclusion of new 
vaccines in the Dutch National Immunization Program.
methods
An analytical framework was used combining a checklist, which structured relevant 
data on the vaccine, pathogen and disease, and a cost-effectiveness analysis. The 
cost-effectiveness analysis was performed from a societal perspective, using a 
Markov-cohort-model. Simultaneous vaccination with influenza was assumed.
results
Due to the combination of waning immunity after vaccination and a reduced efficacy of 
vaccination at high ages, the most optimal cost-effectiveness ratio (€21,716 per QALY) 
for HZ vaccination in the Netherlands was found for 70-year olds. This estimated ratio 
is just above the socially accepted threshold in the Netherlands of €20,000 per QALY. If 
additional reduction of postherpetic neuralgia was included, the cost-effectiveness ratio 
improved (~€10,000 per QALY) but uncertainty for this scenario is high.
conclusions
Vaccination against HZ at the age of 70 years seems marginally cost-effective in the 
Netherlands. Due to limited vaccine efficacy a considerable part of the disease burden 
caused by HZ will remain, even with optimal acceptance of programmatic vaccination.
background
The varicella-zoster virus (VZV) causes varicella (chicken pox) as well as herpes 
zoster (HZ, shingles).
Varicella is the primary infection, whereas HZ is caused by reactivation of latent 
VZV in sensory nerve ganglia. HZ is characterized by a painful localized vesicular 
rash. The most common complication of HZ is postherpetic neuralgia (PHN), 
a chronic pain condition that can last for months or even years. In contrast to 
varicella, which is mainly a childhood disease, HZ predominantly affects older adults 
[1]. Presently, a vaccine to prevent HZ is available [2]. In this article, we present 
an assessment of the potential effects of programmatic HZ vaccination of elderly 
in the Netherlands. Fur this purpose we used a framework that was developed to 
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support evidence based decision making regarding inclusion of new vaccines in the 
Dutch National Immunization Program (NIP). This framework consists of a checklist 
that structures all relevant data on vaccine, pathogen and disease [3]. These data, 
presented in the Background section, are input to a cost-effectiveness analysis 
that is presented in the Methods and Results section.
vaccine
Available vaccines and indications 
Only one vaccine (ZOSTAVAX®; SP-MSD) has been registered for the prevention 
of HZ. This live attenuated vaccine is manufactured by the same process as the 
chicken pox vaccine VARIVAX® but has a higher viral load per dose [2]. The vaccine 
has been registered in the EU as a single dose vaccine for the prevention of HZ and 
PHN among people aged 50 years or older. 
Vaccine efficacy
Natural protection against HZ may occur by exogenous boosting (due to circulating VZV 
in the population) or endogenous boosting (through subclinical reactivation of latent 
VZV). Although the mechanism of latency is not fully understood, there is strong evidence 
that the risk of developing HZ is linked to a decline in VZV-specific cellmediated immunity 
(CMI) [1,4]. The functional mechanism of the vaccine is to boost this specific CMI [2]. 
The efficacy of the vaccine was assessed in a large randomized placebo-controlled 
trial. There was a reduction of 51.3% in the incidence of HZ, 61.1% in the burden 
of illness (BOI) and 66.5% in the incidence of PHN [5]. The vaccine appeared less 
effective in the older age group (70+ years) compared to the younger age group 
(60-69 years) (Figure 1), indicating that the effect of vaccination is age dependent 
[5]. The long term efficacy of the vaccine is unknown (mean follow-up duration so far 
was three years), but the immunity seems to decrease over time after vaccination [2]. 
Contra-indications and adverse events following vaccination
Since the vaccine consists of live-attenuated virus, it should not be used in 
immunocompromised people, people with active untreated tuberculosis or in 
pregnant women [2]. 
Adverse events at the injection site occurred more frequently in the vaccine 
group (48.3%) compared to the placebo group (16.6%), but most of them were mild. 
Furthermore, vaccine-related systemic adverse events occurred more frequently in 
the vaccine group than in the placebo group (6.3% vs 4.9%) [5]. 
Factors affecting successful implementation
So far, influenza vaccination is the only generally advised vaccination for elderly 
in the Netherlands. The general practitioner (GP) invites all people aged 60 years 
or older annually for this vaccination, which has a high coverage (in 2008/2009 
76.9%) [6]. HZ and influenza vaccine given concomitantly are well tolerated [7]. 
Furthermore, antibody responses were similar compared to sequential vaccination. 
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A recent study, however, showed that among community-dwelling elderly to 
whom both influenza and HZ vaccination were offered within an existing influenza 
vaccination program, only 39% accepted HZ vaccination, whereas 76% accepted 
influenza vaccination [8]. Determinants of non-compliance with additional HZ 
vaccination were: perceived lack of recommendation by the GP, unwillingness to 
comply with the doctor’s advice, perception of low risk of contracting HZ, perception 
of short pain duration of HZ and the opinion that vaccinations weaken one’s 
natural defenses [8]. Other studies also found that a recommendation by the GP 
is a major determining factor of accepting vaccination in this age group [9,10]. An 
international survey pointed out that the understanding of the risk of developing 
HZ, its symptoms, complications and treatment among adults ≥55 years of age is 
very limited [11]. Moreover, in the United States the lack of patient awareness and 
physician recommendation were pointed to be barriers to HZ vaccine uptake [10]. 
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figure 1. Overview of the vaccine efficacy with respect to the incidence of herpes zoster (HZ), 
burden of illness (BOI) and incidence of postherpetic neuralgia (PHN) by age-group. (source: 
Oxman MN, Levin MJ, Johnson GR et al. A vaccine to prevent herpes zoster and postherpetic 
neuralgia in older adults. N Engl J Med 2005; 352(22):2271-84).
herd immunity
The transmission of VZV resulting from patients with HZ is very low in comparison to 
varicella [1]: therefore no herd immunity effects are to be expected. Reaching a high 
vaccination coverage is therefore not important, unlike for most other vaccinations. 
HZ vaccination will only give benefit on individual level. 





VZV-seroprevalence in the Netherlands approaches 100% from seven years onwards 
[12]. In HIV-infected persons the risk of HZ and its recurrence is increased (12-17 
fold) [1]. Intercurrent infection with viruses that can alter CMI responses (such as 
Epstein-Barr virus and cytomegalovirus) also influences the risk of developing HZ [4]. 
Infectiveness and transmissibility
HZ is not transmitted directly; it is a reactivation of VZV that remains latent in sensory 
nerve ganglia after primary VZV-infection. The herpes lesions are contagious for non-
immune persons (until the lesions have crusted) and can lead to varicella [1]. Subclinical 
reactivation of the VZV virus is possible but the frequency of occurrence is unknown [4]. 
In immunocompetent individuals, the frequency of recurrent HZ is low (1.7-5.2%) [13]. 
Antigenic variation
The VZV genome is extremely stable. So far, seven distinct genotypes of the wild-type 
VZV have been distinguished with a different geographic distribution, but all belong to 
the same serotype. No evidence for recombination among wild-type VZV-strains has yet 
been found [14]. Although recombination events could theoretically alter the virulence 
of circulating VZV strains [15], the impact of such events would probably be very small. 
Ecological consequences after implementation of vaccination are not expected. VZV is 
an exclusively human pathogen. Both the vaccine strain and the wild-type VZV establish 
a latent infection. Furthermore, interaction or competition with other alpha-herpes 
viruses like HSV-1 and HSV-2 has not been described for VZV [16]. 
burden of disease
Risk factors for herpes zoster
It is estimated that 23-30% of the population in Europe will develop HZ during their 
lifetime; approximately 50% of all people reaching the age of 85 years will have 
experienced HZ [13]. Prior infection with VZV, either with wild-type or vaccine virus, is a 
prerequisite for developing HZ. The vaccine virus may have less opportunity to reactivate 
than does wild-type VZV [4]. The vaccine virus usually does not cause viremia or skin 
infection, factors that are both likely to enhance the development of HZ [17]. 
The incidence of HZ increases with age, which is attributed to the natural 
process of age-related immunosenescence. Furthermore, the incidence is higher 
among people with immunity attenuating diseases or medication [1,4,18]. Other 
possible risk factors that have been suggested are physical trauma at the involved 
dermatome, psychological stress, changes in mental health, depression, white race 
and intercurrent infection with viruses that can alter CMI responses [1,4,18]. Some 
studies show also higher incidence rates in women, even after correction for higher 
average age and health care seeking behavior [18,19]. VZV-infection in utero or 
shortly after birth has been found to be a risk factor for (childhood) HZ [1,4,18]. 
COST-EFFECTIVENESS OF HERPES ZOSTER VACCINATION OF ELDERLY IN THE NETHERLANDS
THREE
57
PHN is more likely to occur in older HZ patients and in HZ patients with severe pain 
or rash during the acute phase [4,18,20].
Consequences of herpes zoster
HZ begins with a prodrome, during which abnormal skin sensations and pain of 
varying severity are the most common symptoms, followed by a vesicular rash. 
This rash is typically unilateral, does not cross the mid-line, normally involves a 
single dermatome, is usually accompanied by acute pain and lasts for 7-10 days 
or longer. PHN, a persistent pain after resolution of the rash, is the most important 
complication of HZ and can last for several years [1,4]. Therapeutical options for HZ 
and PHN are scarce. About half of the patients with PHN will benefit from therapy 
with only partial relief [4]. The quality of life during HZ is influenced by the severity 
and duration of the acute and chronic pain that can affect physical, psychological, 
social and functional domains [1,4].
Alternative preventive measures
There are no direct alternatives to prevent HZ. Childhood vaccination against 
varicella might reduce the HZ incidence on the long term, because the vaccine strain 
is less likely to cause HZ than the wild-type. However, reduced VZV transmission due 
to varicella vaccination will diminish exogenous exposure (boosting), which might 
lead to an increase in the incidence of HZ in the mid-term (the first 30-50 years) 
[21]. Studies monitoring the incidence of HZ in the US, where universal vaccination 
against varicella was introduced in 1995, have shown inconsistent findings at this 
point. Two studies did not show an increase in overall incidence [22,23], whereas 
three others demonstrated a rise [24-26]. 
meThods
data sources
GP consultations, hospitalizations and deaths
Most HZ patients will consult their GP as it is a painful condition. Age-specific 
incidence rates for the period 2002-2007 were derived from the Netherlands 
Information Network of General Practice (LINH) [27]. A correction was made for 
false positives (10%; 7.9- 12.4%[28]) and immunocompromised people (5%[28]), 
since both groups will not benefit from vaccination. A linear regression was plotted 
on the HZ incidence of the separate years 2002-2007. 
Hospitalization data (ICD-9 code 053) were taken from the National Medical 
Register (LMR) for the period 2000-2007. Only admissions with HZ as main diagnosis 
were included because these admissions represent cases that are preventable by 
vaccination. The incidence of clinical admissions was rather stable in the period 
2000-2007. However, the incidence of admissions for one day decreased from 7.5 
per 100,000 in 2002 to 4.0 per 100,000 in 2007 [29]. Therefore, an alternative 
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scenario was included in which the daytime hospital visits were excluded. The 
distribution used in the probabilistic sensitivity analysis is listed in Additional file 1. 
Mortality data (ICD-10 code B02 and G530) for the period 2000-2007 were derived 
from Statistics Netherlands (CBS). Only deaths with HZ as primary cause of death 
were included in the base case scenario. An alternative scenario without prevention 
of death was also included since it is likely that death is not caused directly by HZ. 
Pain, incidence of PHN and quality-adjusted life-year (QALY) loss
The duration of pain by severity and age, and subsequently the QALY loss due to 
HZ, was estimated by Van Hoek et al [28] and applied to the Dutch situation. For 
clarity, this does include PHN which was defined as the presence of clinical relevant 
pain after three months. In the model QALY loss after onset was modeled based 
on the duration spent in clinical relevant or mild pain [28] instead of using a fixed 
percentage developing PHN. 
vaccine parameters
We used the vaccine efficacy as estimated by Van Hoek et al [28]. The vaccine 
efficacy was split into two parameters, a take (initial vaccine efficacy) and waning 
(reduction of protection over time) and those two parameters were estimated on 
the data from the initial clinical trial. The base case waning was only 7.5 years and 
was estimated to be between 3.6 to 100 years, with an age dependent take. In the 
sensitivity analyses the effects of a longer and shorter duration of protection were 
calculated. Based on the coverage for influenza vaccination in the Netherlands, we 
assumed a vaccine coverage of 75%. 
The different protection of the vaccine against the three endpoints (Figure 1) 
as measured in the clinical trial was simulated by three different scenarios. In the 
scenario based on the reduction of HZ only, the reduction of HZ and subsequent QALY 
loss was included. In the scenario describing the reduction of BOI, a reduction of QALY 
loss for the first 6 months in people with disease was included above the reduction 
in HZ cases (this is because the vaccine reduces disease severity in cases where HZ 
occurs in spite of vaccination). For the reduction of PHN (only applicable above the 
age of 70 years) the number of people in clinically relevant pain was decreased by the 
specific vaccine efficacy [28,30]. If not mentioned otherwise, presented numbers are 
based on the protection against BOI (base case), the main endpoint in the clinical trial. 
cost data
All costs are presented in 2008 Euros: costs in previous years were deflated with 
the consumer price index according to CBS. To assess the costs of an average HZ 
or PHN case, the in depth patient data as collected within the PINE study was used 
[31]. Patients were considered to suffer from PHN if they had a pain level of at least 
25 (on a scale of 0-100) at three months after onset. The cost assumptions that 
were used in this assessment are described in Additional file 2. 
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Direct costs of disease
The major costs involved in HZ are the prescription of antivirals and repetitive GP 
visits for PHN patients. In the PINE study, detailed information on GP consultations, 
medication and additional use of health services due to HZ was available for the first 
6 months of the study (Additional file 2). Based on those findings the average total 
costs per patient of GP consultations and drug use is €72.05 (€66.90 - €77.20) in 
case of HZ and €101.10 (€81.72 - €120.70) for PHN based on the first 6 months 
of the study. Because the duration of PHN can be longer, these costs were doubled: 
€201.91 (€163.30 - €241.15). Confidence intervals of the mean price (95%) were 
acquired by bootstrapping. 
Indirect costs of disease
Indirect costs were considered for estimated work loss till the age of 65. Data on 
work loss due to HZ is scarce and the participation in the workforce is not high in 
the age group 60+. A questionnaire among 65 HZ patients in the UK [32] showed 
that 29 patients were employed, with an average working loss of 10.1 days (SD of 
mean 1.82). According to CBS, participation in the work force (in 2006) was only 
20.8% in the age group 60-65. The number of hours of labour per week is 32 or 6.4 
per day with a payment of €24.10 per hour. With a correction for participation in the 
workforce this is an average of €32.04 lost per day or €324 for the total work loss 
for someone in the age group 60-65. 
Cost of the vaccine and the vaccination program
Because the HZ vaccine is not yet available in the Netherlands, the Dutch price is 
unknown. The official retail price of the HZ vaccine in the US is $153.93 or €110 
(Pack 10-Vial; January 2009). However, in case of introduction in the NIP, the CDC 
price of $107.67 or approximately €77 (January 2009) seems more applicable. In 
the sensitivity analyses the effect of lower vaccine prices was calculated. 
Based on experience with the introduction of the pneumococcal vaccine in the 
Netherlands in 2006, the once-only costs (not included in the cost-effectiveness 
model) are estimated to be €0.3 million and include costs for education of GPs, 
developing information material (invitation letter, flyer, publicity campaign, website), 
adjustment of software for registration and monitoring, and administration. In case 
of implementing HZ vaccination within the current influenza vaccination program and 
assuming a vaccination coverage of 75%, the estimated yearly administration costs 
range from ~ €14.7 million for vaccinating people at the age of 60 to ~€4.9 million 
for vaccination at the age of 80. This includes compensating vaccination personnel 
(€4.80 per application, this is half the influenza tariff) and coordination costs (€1.65 
per application). In the sensitivity analyses the effect of higher applications costs 
(€9.60 instead of €4.80 per vaccination) was calculated. Monitoring of adverse 
events can be included in the already existing passive surveillance system, for which 
the total costs are estimated to be €0.4 million per year. Vaccine effectiveness, 
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reflected by the reduction of the incidence of HZ, PHN and related hospitalizations, 
could be monitored using GP and hospitalization statistics. 
cost-effectiveness model
The cost-effectiveness analysis was performed from a societal perspective. The 
incremental cost-effectiveness ratio (ICER) was used to compare the quality of adjusted 
life years gained with the net costs of programmatic HZ vaccination (compared to no-
vaccination). The prevented number of cases, costs, QALYs and the Incremental cost-
effectiveness ratio (ICER) were calculated at different ages: 60, 65, 70, 75 and 80 years. 
According to the Dutch guidelines for health technology assessment, future costs and 
effects of vaccination were discounted with 4% and 1.5%, respectively. 
A Markov-cohort-model was set up in Excel (Microsoft, USA) and univariate 
and probabilistic sensitivity analysis were performed with @Risk (Palisade, USA).
The same model was used in a cost-effectiveness model for HZ vaccination in 
England and Wales [28]. The effect of different assumptions regarding the duration 
of protection of the vaccine, discount ratio, prevention of death, vaccine price, 
application costs and hospital day care were investigated in the sensitivity analyses. 
figure 2. Age-specific average annual incidence of GP-consultations due to herpes zoster per 
100000 by sex 2002-2007. (source: Verheij RA, van Dijk CE, Abrahamse H et al. Netherlands 
Information Network of General Practice (LINH): Facts and figures on GP care in the Netherlands.
Utrecht/Nijmegen: NIVEL/WOK, 2008).
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current burden of disease
For the Netherlands, the average annual incidence of HZ based on GP consultations 
was 332 (range 310-370) per 100000 in the period 2002-2007. The incidence 
increases with age (Figure 2) [27]. The linear regression that was plotted on the 
HZ incidence of the separate years 2002-2007 predicted an incidence of 509 
(394 - 626) per 100000 at the age of 60 and going up with 22 (17.1 - 27.0) per year. 
The average annual incidence of clinical hospital admissions due to main 
diagnosis HZ in the period 2000-2007 was 2.3 (range 2.0-2.7) per 100000 (when 
including side diagnosis HZ too, the total incidence was 4.7 (range 4.0-5.1) per 
100000). In the same period, another 6.3 (range 4.0-7.5) hospital admissions for 
one day due to main diagnosis HZ were registered per 100000. The incidence of 
hospital admissions also increases with age (Figure 3). In the period 2000-2007 on 
average 18 deaths (range 13-26) with HZ as primary cause of death were registered 
annually. Most deaths occurred among people aged 75 years and older (92%). 
The burden of disease in the Netherlands is estimated to be at highest in a 
cohort of 60 year olds (a loss of 3024 QALYs, discounted) and at lowest in a cohort 
of 80 year olds (a loss of 1060 QALYs, discounted) (Table 1). The ratio of QALY loss 
per HZ case (discounted), however, increases by age towards a maximum at the 
age of 80. Therefore the relative burden of disease is the highest at the age of 80. 
The estimated total costs for HZ for the group 60 year olds are almost €3.5 million 
per year; this is including an estimated €1.2 million of indirect costs. Although the 
estimated total costs for the group 80 year olds are lower (€0.8 million per year), 
the cost per HZ case in this age-group is higher than for 60 year olds (€177.79 
versus €128.86) (Table 1).
effect of vaccination on cases and costs
Most cases (~4300) are prevented by vaccination at the age of 60. This number 
decreases to ~470 at the age of 80. The prevented number of deaths, however, increases 
by age at vaccination. From 0.2 prevented deaths by vaccination at 60 towards the 
maximum of 1.2 prevented deaths at the age of vaccination at 75 (Table 1). 
By vaccinating people, costs regarding GP visits, prescription of antivirals and 
painkillers are prevented as well as hospitalization costs and costs due to work 
loss. For HZ vaccination the prevented costs are distributed equally between 
hospital costs and prevented cost generated in the GP practice. Prevented costs 
will reach a maximum of about €1085146 (or €384658 excluding indirect costs) 
for vaccinating people at the age of 60. The saved discounted costs, however, are 
low for each vaccinated person. Per vaccinee between €1.49 and €2.65 (or €6.17 
including indirect costs) will be saved. Subsequently a vaccine price higher than this 
will have to be justified by preventing QALYs. 
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Figure 3 Age-specific average annual incidence of hospital admissions due to main diagnosis 
 herpes zoster per 100000 2000-2007  





























clinical admission admission for one day
figure 3. Age-specific average annual incidence of hospital admissions due to main diagnosis 
herpes zoster per 100000 2000-2007.(source: Prismant. National Medical Registration. Utrecht: 
Prismant, 2000-2007).
The absolute number of gained QALYs is the highest by vaccination at the age of 
60 years with ~353, and the lowest by vaccination at the age of 80 years with a total 
gained of ~140. However this absolute number must be seen in the context of the 
number of people who have to be vaccinated to gain those QALYs. The number of 
people needed to be vaccinated to gain one QALY is a good proxy: the lowest number 
is 268 at the age of 70 years, the highest 498 at the age of 60 years.
cost-effectiveness of vaccination
The information on the number of doses, vaccine efficacy, prevented costs and 
QALYs gained together is expressed in the cost-effectiveness ratio (Figure 4). Using 
the reduction of BOI as an endpoint the most optimal cost-effectiveness ratio is 
€21,716 (95% CI: €11,569 - €31,870) for vaccination at the age of 70. The worst 
ratio is €38,519 (95% CI: €12,176 - €67,158) for vaccination at the age of 60 under 
the same perspective (indirect costs included) or €40,503 under the healthcare 
payer perspective (indirect costs excluded). This implies that vaccinating at the age 
of 70 results in the best value for money. 
In the scenario with reduction of HZ cases only the cost-effectiveness ratio 
increases towards ~€33,500 at the age of 70; using the scenario with reduction of 
PHN improves the cost-effectiveness to a ratio of ~€10,000. Although the clinical trial 
showed a higher impact of vaccination on the BOI compared to the incidence of HZ, we 
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Table 1. Absolute outcome and prevented cases for different ages at vaccination in the base 
case scenario
60 years 65 years 70 years 75 years 80 years
before vaccination:
Cases HZ 26845 15513 11093 7630 4769
Cases PHN 4639 2936 2351 1857 1370
Hospitalisation 320 205 163 128 89
1 day visit hospital 1102 683 515 363 210
Deaths 30.7 20.9 18.6 17.6 16.5
Direct costs* €2217577 €1527388 €1306022 €1100313 €847884
Indirect costs* €1241555 €0 €0 €0 €0
QALYs lost* 3024 2024 1703 1402 1060
after vaccination: (75% coverage)
Nr. of vaccinees 175925 115943 94354 80712 58724
Vaccination costs** €14680941 €9675443 €7873841 €6735416 €4900518
Cases HZ 22512 12496 9201 6277 4299
Cases PHN 4222 2581 2071 1603 1257
Hospitalisation 292 178 141 107 81
1 day visit hospital 966 563 426 294 188
Deaths 30.5 20.6 18.1 16.4 15.4
Direct costs* €1832919 €1219724 €1082777 €902727 €760458
Indirect costs* €541068 €0 €0 €0 €0
QALYs lost* 2671 1724 1350 1133 921
prevented:
Cases HZ 4334 3017 1892 1352 471
Cases PHN 417 355 280 254 113
Hospitalisation 28 27 21 20 9
1 day visit hospital 136 120 89 70 22
Deaths 0.2 0.3 0.5 1.2 1.1
Direct costs* €384658 €307664 €223245 €197586 €87427
Indirect costs* €700487 €0 €0 €0 €0
QALYs lost* 353 300 352 269 140
* Costs are discounted with 4% and QALYs with 1.5%
** Vaccination costs are based on a vaccine price of €77, application costs of €4.80 per vaccination 
and coordination costs of €1.65 per vaccination
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want to mention that using BOI or PHN endpoints will be more sensitive towards the 
decisions made in the way the QALY loss due to HZ is currently modeled/estimated. 
According to the sensitivity analyses (Table 2), changing assumptions regarding 
the discounting rate, vaccine price and duration of protection of the vaccine have 
the greatest impact on the ratio, especially with a longer duration of protection or a 
lower vaccine price the costeffectiveness profile improves. 
If a diagnostic test to determine immunity against VZV would become available 
in the future, a more targeted vaccination strategy could be implemented. 
Furthermore, people with a history of HZ could be excluded to save costs, as HZ 
does not frequently reoccur.
discussion
In view of the scarce therapeutic options for HZ and its sequelae the reduction of the risk 
of this disease by vaccination is an important development. Moreover, the HZ vaccine 
could be relevant because of the predicted temporary increase in the incidence of HZ 
after introducing childhood varicella vaccination [21]. HZ vaccination could prevent 
part of the disease burden of this often painful disease among elderly. However, the 
number of prevented GP-consultations, hospitalizations and deaths is relatively limited 
compared to other vaccine preventable diseases. In the decision process it is important 
to consider that the health gain that could be realized by HZ vaccination is in particular 
related to the reduction of (long term) pain; the number of life years gained is rather 
small. Furthermore, a considerable part of the disease burden caused by HZ will still 
remain despite programmatic vaccination since the vaccine efficacy is suboptimal. The 
indirect disease burden estimations might increase in future, if the recently reported 
increased risk of stroke after HZ is being confirmed in future research [33]. The relative 
low efficacy and the lack of knowledge on protection of the vaccine on the long term 
might be a problem for general acceptation of vaccination against HZ. 
Offering HZ vaccination in combination with influenza could be a promising 
option. However, a previous Dutch study showed that the acceptance of HZ 
vaccination given simultaneously with influenza vaccination was only 39%, i.e. 
considerably lower compared to the vaccination coverage for influenza (76%) [8]. 
Insight into the degree of acceptance by the public is important, especially in the 
light of the recent experiences in the Netherlands with objection to introduction of 
the vaccine against human papillomavirus (HPV).
It will be difficult to make a decision on the target group for HZ vaccination: the 
HZ incidence increases whereas the vaccine efficacy decreases with age. Based on 
the cost-effectiveness analysis (base case scenario), vaccinating at the age of 70 
years would be the best option. However, the value of €21,716 lies just above the 
socially accepted threshold in the Netherlands of €20,000 per QALY. This implies that 
the cost-effectiveness profile is marginal, although this is not the first evaluation 
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criterion for introduction of a new vaccine [34]. The scenario with additional reduction 
of PHN improves the cost-effectiveness to a ratio of ~€10.000. However, this scenario 
has some major limitations. First, the definition of PHN as used in the clinical trial 
does not necessarily concern pain on the long term. Second, the effectiveness of the 
vaccine against PHN is not straightforward (extra effectiveness only above the age 
of 70 years) and has a high uncertainty. If the duration of protection turns out to 
be longer, the vaccination could be given at an earlier age which might improve the 
cost-effectiveness of the vaccine. Research on new vaccines with a higher vaccine 
efficacy, in particular at older age, is recommended. 
There are several other estimations of the costeffectiveness of HZ vaccination 
[28,35-39]. Most of those cost-effectiveness studies apply for the USA [35-37] and 
Canada [38,39] and one for the UK [28]. Because of differences between countries 
in health care costs and health care seeking behavior, direct comparisons are hard 
to make. Also, the assumptions regarding the vaccine price were different: $150 
(€107) instead of the €77 assumed in this analysis (which is based on the lower 
price CDC pays for its vaccine). Nevertheless the majority of studies conclude that 
vaccination against HZ is costeffective in their health care system, in contradiction 
with this study where it is marginally cost-effective. This difference can be 
figure 4. Incremental cost-effectiveness ratio (ICER) for different scenarios and ages; indirect 
costs are included (loss of working hours,only relevant for vaccination at 60 years of age). The 
base case (dark grey) is including a lower QALY loss in the first 6 months of HZ among vaccinees, in 
the ‘without additional effect’ (light grey) this is not included. Error bars represent 95% confidence 
intervals and under the bars the relevant cost-effectiveness ratios are shown.
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mainly attributed to the differences in the threshold value used by the countries. 
Internationally the threshold of €20,000 per QALY as used in the Netherlands is the 
lowest among the countries where a costeffectiveness study was done. Moreover, 
the incidence among the elderly seems to be slightly lower in the Netherlands. 
Whether this is due to a slightly lower reportage in the Dutch general practice, due 
to uptake of patients in nursing homes (that are not included in the Dutch reporting 
system) or due to other factors is unknown.
Table 2. Cost-effectiveness ratio under different circumstances and at different ages of 
vaccination
60 years* 65 years 70 year 75 years 80 years
Base case €38519 €31228 €21716 €24336 €34449
No prevention of death €38901 €31489 €21910 €25020 €35930
No daytime visits hospital €38540 €31251 €21731 €24351 €34458
No discounting €33305 €27482 €18827 €21688 €31285
Discounting 3.5%/3.5% €45313 €36210 €25647 €27874 €38725
Vaccine price €60 per dose €30045 €24658 €17163 €19228 €27304
Vaccine price €50 per dose €25061 €20793 €14485 €16224 €23100
Application costs €9.60** €40911 €33083 €23002 €25778 €36466
Duration protection 4.8 years*** €61247 €48828 €27817 €32449 €42428
Duration protection 16.1 years*** €16954 €15031 €14030 €16013 €25953
* indirect costs included (loss of working hours, only relevant for vaccination at 60 years of age)
** full influenza tariff (instead of half the influenza tariff €4.80, that was used in the base case)
*** based on van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ. Estimating the cost 
effectiveness of vaccination against herpes zoster in England and Wales. Vaccine 2009; 27(9):1454-67.
conclusion
In conclusion, programmatic vaccination could reduce the burden of disease due to HZ 
considerably but is estimated to be marginally cost-effective even at the economically 
most attractive option, i.e. vaccination at the age of 70 years simultaneously with 
influenza vaccination. A final judgment on the cost-effectiveness will depend on 
price negotiations with the different parties involved. Even with vaccination at levels 
comparable to influenza vaccination, less than half of the disease burden caused by 
HZ will be prevented by vaccination, due to the relative low efficacy of the vaccine. It 
would be a challenge to reach high acceptance of vaccination despite the occurrence 
of HZ among vaccinees; involvement of the GP is essential. 
While for many childhood vaccinations in addition to individual protection, 
indirect protection by herd immunity is offered, this does not hold for HZ. Making 
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the public aware of the existence of a HZ vaccine (with its current limitations) that 
could be obtained individually is necessary, irrespective of the decision whether or 
not to implement programmatic vaccination. 
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chapter four
summary
This study updates previous work on modeling the incidence of varicella and Herpes 
Zoster (HZ) following the introduction of childhood vaccination. The updated model 
includes new data on age-specific contact patterns, as well as data on the efficacy 
of zoster vaccination in the elderly and allows for HZ among vaccinees. The current 
study also looks at two-dose varicella childhood programmes, and assesses the 
combined impact of varicella vaccination in childhood and zoster vaccination of 
the elderly. The results suggest that a two-dose schedule is likely to reduce the 
incidence of varicella to very low levels, provided first dose coverage is around 90% 
and second dose coverage is in excess of 70%. Single dose varicella vaccination 
programmes are expected to result in large numbers of breakthrough cases. 
Childhood vaccination is expected to increase the incidence of zoster for more than 
40 years after introduction of the programme, the magnitude of this increase being 
influenced primarily by the duration of boosting following exposure to the varicella 
zoster virus. Though this increase in zoster incidence can be partly offset by 
vaccination of the elderly, the effectiveness of this combined strategy is limited, as 
much of the increase occurs in those adults too young to be vaccinated. Childhood 
vaccination at intermediate levels of coverage (70% and 60% for first and second 
dose coverage respectively) is expected to lead to an increase in adult varicella. 
At high coverage (90% and 80% coverage) this is unlikely to be the case. These 
results will be used to inform a cost-effectiveness analysis of combined varicella 
and zoster vaccination programmes.
background
In 1995 childhood vaccination against varicella (chickenpox) was introduced in the 
US [1-3]. However there is an ongoing debate about the potential negative effect of 
childhood varicella vaccination on the incidence of Herpes Zoster (HZ) and varicella in 
adults [4-7]. Herpes Zoster is a reactivation of the same virus (Varicella Zoster Virus, 
VZV) that causes varicella on initial infection [8]. Following primary infection the virus 
remains latent in the dorsal root ganglia. Reactivation of the virus is suppressed 
by cell-mediated immunity, which can be boosted by exposure to a varicella case 
[9,10]. With the introduction of childhood vaccination this exogenous boosting 
would be expected to decrease due to the reduction of varicella incidence, which 
may lead to an increase of HZ [9,11,12]. With the licensure of a vaccine to prevent 
HZ [13,14] , any increase in HZ following childhood vaccination could be offset (at 
least in part) by vaccination of the elderly (60+ years) against Herpes Zoster. There 
are other concerns with varicella vaccination, which include the potential increase in 
adult varicella (which tends to be more serious than childhood infection) that may 
occur following mass childhood vaccination [11,15,16], and concerns regarding the 
efficacy of a single dose of the vaccine at preventing varicella [17-19]. This latter 
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concern has lead to recommendations for two-dose policies in childhood [3,20], 
which has an obvious impact on the economic attractiveness of the programme. 
Several studies have explored the effectiveness and cost-effectiveness of 
different varicella vaccination programmes in the UK and around the world [4,21-24]. 
However, to our knowledge no previous models have looked at a combined strategy 
of vaccination in childhood and of the elderly. Furthermore, previous modeling work 
has concentrated on single-dose varicella vaccination programmes [11,12,15,16]. 
Many of the indirect effects (such as an increase of adult varicella or HZ) depend on 
estimates of the rate of transmission across age groups. Previous analyses had to 
assume the relevant contact rates, as little relevant quantitative information was 
available at the time. However we update previous models [9,11,25] by using UK 
contact patterns collected as part of a European project (POLYMOD) [26]). In this 
paper we describe the estimated impact of one and two-dose varicella vaccination 
strategies, either alone or in combination with vaccination of the elderly against 
Herpes Zoster. The described epidemiological impact will constitute the basis for an 
economic evaluation of these strategies 
meThods
model structure 
To assess the impact of combined varicella and zoster vaccination programmes, 
a transmission dynamic model based on that of Brisson and colleagues [11] was 
adapted. The model consists on a set of ordinary differential equations and incorporates 
realistic age-structure (RAS) and age-specific mortality rates for England and Wales 
(Office for National Statistics). A stable population of 48 million people is considered, 
with 621,300 individuals born (=number of live births in E&W in 2003) every year on 
the 31st of December. The mortality of individuals in the oldest age group (95+ year 
old) is calculated separately so that the age distribution remains constant over time. 
Both varicella and zoster vaccination programmes are incorporated in the model as 
discrete events at the end of each year, when individuals age.
The model structure is illustrated in the flow diagram in Figure 1, which describes 
the natural history of VZV with and without varicella and/or zoster vaccination. 
People are initially protected by maternal antibodies, become susceptible to 
varicella, can be infected with varicella, develop disease and become immune to 
varicella. After a certain time (average period of natural protection = 1/δ) people 
become susceptible to zoster. In this state, they can either progress to zoster, or 
they can be boosted by an infectious case, rendering them (temporarily) protected 
against developing zoster. Therefore within the model infectious people can do 
two things – infect susceptible people or boost zoster susceptible persons. In 
case of vaccination against zoster, individuals pass into the vaccine protected 
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compartment. These people become zoster-susceptible again over time (average 
period of vaccine protection = 1/δv). When natural protection is assumed to be 
longer than vaccine-induced protection, vaccinated individuals are not moved from 
the immune compartment into the vaccination compartment because in that case 
vaccination will reduce their time protected.
Vaccinated individuals are tracked separately because of the difference of 
infectiousness and severity of breakthrough cases. In the model described by 
Brisson et.al. [11] individuals who had been immunised against varicella were 
not able to develop zoster. In the current model this possibility is allowed for, as 
studies suggest that vaccinees can, in fact, develop HZ, though it appears that they 
may do so at a somewhat lower rate [27-29]. In the new structure it is possible to 
distinguish between HZ among vaccinees after breakthrough or after vaccination 
only, because in the latter zoster will be caused by vaccine virus instead of wild type. 
varicella vaccination
Vaccination with varicella vaccine is assumed to result in three different outcomes. First, 
a proportion of individuals (p) suffer an initial vaccine failure and remain susceptible. 
Second, a proportion of individuals who respond initially (1-p) are protected from 
varicella infection ((1-p)*T; in which T is the proportion of vaccine responders who are 
protected). Third, a proportion of individuals respond, but they are liable to be infected 
(i.e. become a breakthrough case) if they are exposed. This proportion is therefore ((1-p)
(1-T)). Those in the vaccine immune class (V Immune) can lose protection over time and 
pass into the vaccinated susceptible class (V Susceptible) at a rate (w). If individuals 
receive a second dose of varicella vaccine, the responders (TVii) move on to a vaccine 
protected class (VP 2nd dose) and when they lose protection pass into the vaccinated 
susceptible class (V Susceptible) at a rate (wii). Those who do not respond to the second 
dose remain in whatever compartment they were already in. 
zoster vaccination
Zoster vaccination is given irrespective of a history of varicella. Those who are still 
susceptible for varicella are handled as if they are vaccinated against varicella and 
moved to the varicella vaccinated arm of the model, this because the Zoster vaccine 
is a high dose version of the Varicella vaccine. Within the model it is assumed 
that individuals can experience only one episode of zoster throughout their life, 
vaccination was thus not effective among individuals in the zoster infected or 
immune compartments (ZI and ZR) because that will mean they become susceptible 
to zoster again. 
mixing patterns
Data on the contact patterns among individuals of different ages were collected as 
part of the POLYMOD project [25] and were used to parameterize the mixing patterns 
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assumed in the model. A general base-case Who-Acquired-Infection-from-Whom 
(WAIFW) matrix (β-matrix) was derived from a contact matrix based on the UK study 
population (all contacts) combined with an age-specific transmission parameter 
(q) following the methodology originally developed by Wallinga and colleagues [30]. 
The β-matrix influences the steady state disease incidence, which is assumed 
to reflect the cumulative proportion of individuals with serological evidence of 
infection by age. Therefore information about contacts is combined with information 
about the disease incidence to find a best-fitting value of q. In this case the q is 
fitted in such way that the resulting age-specific force of infection based on the 
resulting β-matrix fits observed seroprevalence (<20years of age) [31] and varicella 
incidence (20> years of age) [32]. To fit the data three different values for q where 
estimated, for the age 0-3, 4-21 and 22+, under the assumption of differential 
susceptibility to infection by age-group. Fifty thousand different contact matrices 
were obtained by bootstrapping the individual contact data. For each of the matrices 
the transmission parameters were fitted, and the best fitting matrix was used as the 
base case scenario. In the sensitivity analyses a set of 1000 different β-matrices 
were obtained by rejection sampling. For each contact matrix 750 different sets of 
q where sampled, by varying q as a percentage of the most optimal q for that given 
matrix. In the rejection sampling process only contact matrices were used with at 
least 1% probability based on their most optimal transmission parameter, this to 
improve the speed of the process. Of the obtained possible matrices a subset of 
1000 matrices where randomly selected to use in the sensitivity analyses. 
reactivation rate
In the model the β-matrix influences the steady state varicella incidence, and the 
incidence of herpes zoster is determined by the reactivation rate. This reactivation 
rate is fitted to the zoster incidence data given the β-matrix and the assumption 
about the duration of protection acquired by boosting. In the sensitivity analyses 
for each of the 1000 iterations the reactivation rate was refitted based on the 
different β-matrix and assumption about the duration of protection. Age-specific 
zoster reactivation rates ρ(a) (see Brisson et.al. [9] for formula used) were fitted 
by maximum likelihood to the age specific zoster incidence as found in the 4th 
Morbidity Survey in the General Practice [31]. 
biological parameters
For varicella the duration of the infectious period was assumed to be 7 days after a latent 
period of 14 days [11]. The infectious period for Zoster is also assumed to be 7 days. 
efficacy of varicella vaccine
In this paper we reviewed the two dose schedule of vaccine Varivax (Merck/SPMSD). 
Unfortunately only one trial is available investigating the efficacy of a two dose 
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schedule [33], this trial has several short-comings. Firstly the number of plaque 
forming units of the vaccine used in the trial was higher than the licensed version; 
1350 plaque forming units in the licensed vaccine compared to a minimum of 2900 
in the trial. Secondly the age distribution was wide (4-12 years), and each age group 
face a different force of infection making it hard to extrapolate to the effectiveness 
of vaccination at 1 year old. Thirdly the presented results include the years 1996 
and onwards, in those years widespread vaccination was in place in the US. Due to 
the dramatic change in force of infection caused by the vaccination program those 
years should be dropped from the analysis. However because no other trial data was 
available we have used this data.
Values for take (T) and waning (W) were fitted with a simple model by maximum 
likelihood (Figure A1-1), assuming that the force of infection (λ) = 0.2 per year, and 
the rate of flow to zoster susceptible (π) = 1/20 per year. To reduce the number 
of parameters describing vaccine efficacy we assumed that the susceptibility of 
vaccinated individuals to become infected (parameter b, Figure 1) is the same as 
non-vaccinated people (hence takes a value of 100%). Vaccinated people are as likely 
as non-vaccinated people to become boosted when they come into contact with a 
varicella case (described by parameter k – assumed value of 100%). For the sensitivity 
analysis 1000 sets of take (T) and waning (W) were obtained by rejection sampling.
zoster vaccine efficacy
Parameters describing vaccine take and waning associated with HZ vaccine were 
estimated by fitting a model (figure A1-2) to the zoster vaccine trial [14]. The 
vaccine efficacy is age dependent but the available data is not detailed enough 
to estimate age specific take and waning rates. Therefore a previously estimated 
duration of protection was assumed and subsequently the take was fitted [34] 
(Appendix 1). The base-line proportion of people who are immune and protected 
was based on the placebo group in the clinical trial. For the sensitivity analyses 
1000 sets of take and waning combinations were obtained. 
The probability of developing zoster after vaccination was set so that the 
incidence will be lower in vaccinated people. Two parameters describe this process 
π and χ (Figure 1). π describes the rate at which individuals in the vaccine protected 
class become susceptible to boosting (or development of zoster), and χ describes 
the reduction in the probability of developing zoster by age given that an individual 
is susceptible to boosting, but has been vaccinated with varicella vaccine. As the 
data are simply reports of the reduction in zoster incidence in vaccinees compared 
to non-vaccinees, it is not possible to identify these two parameters independently. 
Thus π was set to be equal to 0.05 (based on Brisson’s base-case estimates for the 
duration of a boost from a wild-type infection [11]), and χ was estimated to give 
the required long-term reduction in the incidence of zoster. Furthermore as these 
studies generally do not distinguish whether zoster cases in vaccinees are caused by 
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the vaccine strain or wild-type infection the rate of development of zoster in these 
two groups was set to be equal. In the base case scenario χ was set in such way 
that among the vaccinees the zoster incidence will be 10% of that of zoster before 
vaccination, assuming no background boosting (Appendix 2). This percentage is 
varied between 0 and 100% in the sensitivity analysis (with such distribution that 
50% is below 10% and 50% above the 10%). 
VZV was assumed to be at endemic equilibrium prior to vaccine introduction, 
and the model was run for 100 years after the start of the vaccine programme. The 












































figure 1. Flow diagram of the model structure.(bold lines are vaccination flows), WT= wild 
type virus, VT = Vaccine type, MA = Maternal antibody, V = vaccinated, P =initial vaccine 
failure, Tv =Take first vaccine dose varicella, TvII =Take second vaccine dose varicella, σ =Duration 
infectious period, α =Duration of infectious period ρ(a) =Reactivation rate, π=Progression rate 
from vaccine protected to zoster susceptible, λ =force of infection, K=probability to be boosted 
after contact when you are vaccine protected, χ=Change in zoster reactivation rate in varicella 
vaccines, Z=probability to be boosted after contact when you are zoster susceptible, s=Duration 
of latency (rate to become infectious), W =Waning rate first dose, WII=Waning second dose, b 
=susceptibility of vaccinated individuals. (1) In case of δ > δ v, people will remain in the immune 
compartment although they are vaccinated against HZ. (2) In case of π> δ v people will remain in 
the immune compartment although they are vaccinated against HZ




The following vaccination strategies were considered in the model simulations:
 – single dose childhood programme (1 year of age)
 – two-dose childhood programme (1 and 3 years of age) 
 – single dose adult vaccination programme against HZ (70 years of age [35]) 
 –  combined programme of two varicella doses in childhood and 1 dose adult 
vaccination against HZ. 
The base-case coverage was assumed to be 90% for the first varicella dose, 
and 80% for the second varicella dose. Only those who receive the first dose, get a 
second dose (that is there is assumed to be no catch-up of unvaccinated individuals 
at 3 years of age). The base-case age at which HZ vaccine is given (70 years) was 
based partly on the results of an economic analysis [34], and partly on the basis 
of guidance from the JCVI subcommittee [35]. The base-case coverage for the 
elderly vaccination is assumed to be 70%. In the sensitivity analysis the impact 
of vaccination coverage was investigated using lower coverage rates. The duration 
of protection due to contact with wild type virus or zoster vaccine was elucidated 
looking to the extreme scenarios as possible in the parameterization.
resulTs
comparison to epidemiological data, and estimation of force of 
infection
Figure 2 compares the best-fitting model fits with the age-specific seroprevalence 
data [31], age specific incidence of varicella GP consultations [32] and the age 
specific incidence of herpes zoster [32]. Although the model describes infection 
and not GP visits 100% reporting was assumed for varicella above the age of 20 
years and for Herpes Zoster in all age groups. The estimated force of infection with 
associated 95% credibility intervals is shown in Figure 2d. As the figures show, a 
good fit was obtained.
dynamics of varicella and zoster post vaccination
Figure 3 shows predicted impact of alternative vaccination programmes on the 
incidence of varicella (a) and Herpes Zoster (b) over time. The model predicts 
that a single dose of varicella vaccine is likely to result in substantial numbers 
of breakthrough varicella cases in the long-run with an incidence around 330 
(190-447) per 100,000 per year. On the other hand, vaccinating infants at such high 
levels of coverage with a two dose schedule is expected to result in a large reduction 
of varicella in both the short and long-term. However, there is predicted to be an 
increase in Herpes Zoster incidence for about 40-60 years after varicella vaccination. 
The incidence of zoster is expected to increase by up to , 20% (12-36%) to almost 

















































figure 2. Best-fit model (line) compared to data (points): a) is the fit to seroprevalence data; 
b) is the fit to the varicella GP consultations and c) is the fit to the zoster incidence (both of the 
latter are from MSGP4). The resulting best-fitting force of infection estimates and associated 95% 
































Vaccination only children, 2 doses
Vaccination children (2 doses) and elderly
figure 3. Model results on the incidence of varicella (a) and Herpes Zoster (b). The boxes show 
the inter-quartile range the whiskers 10-90% of the range of results generated by the model. 
The different shading represent different programmes: black boxes elderly vaccination only (70% 
coverage); white 1 dose infant varicella (90% coverage); dark grey two-dose infant vaccination (90% 
first dose, and 80% second dose coverage); and light grey combined infant and elderly programme. 
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Table 1. Model parameters
model parameTers mean value (ci) source
biological parameters
Duration of maternal protection (months) (12/ε 6 Assumed
Duration of latent period (days) (365/σ) 14 [11]
Duration of infectious period (days) (365/α) 7 [11]
Duration of immunity to zoster after varicella 
infection (years) (1/δ)
20 [11]
Proportion of effective varicella contacts that 
boosts against zoster (z)
100% [11]
varicella vaccine efficacy parameters
Rate of varicella acquisition of vaccines 
compared to non vaccines (b)
100% Assumed
Proportion of temporarily protected individuals who 
become immune due to contact with varicella (k)
100% Assumed
Rate at which temporarily protected individuals 
become susceptible to Herpes Zoster (1/year) (π)
0.05 Duration of protection 
of natural boosting.
Rate of varicella infectiousness of vaccines 
compared to non-vaccinees (m)
50%
Coverage varicella: first dose 90%
80%Coverage varicella: second dose
Change in the reactivation rate χ 0.052 (0.021 – 0.793) See Appendix 2
zoster vaccine efficacy parameters
Percent of individuals who become temporarily 












first dose second dose
Percent of individuals for which vaccine fails 
completely (P)
4%
Percent of individuals who become temporarily 
protected after vaccination (T)
100% (93%-100%) 100% (97%-100%)
Rate at which temporarily protected individuals 
become susceptible to varicella (1/year) (W)
0.04 (0.067-0.015) 0.013(0.026-0.005)
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620 per 100,000 per year. With only vaccination against Herpes Zoster there is no 
reduction in the incidence of Varicella and a modest reduction in the incidence of 
Herpes Zoster. In case of a combined programme there is estimated to be a large 
reduction of varicella but still an increase of Herpes Zoster, although to a lesser 
extent than only childhood vaccination, a median increase of 10% (5.6%-25%). 
This is because a large increase in zoster incidence occurs in middle-aged adults, 
i.e. adults who are too young to be vaccinated by a programme targeted at the 
elderly (70 years) (see Figure 2c). There is considerable uncertainty with regards 
estimates of the impact of varicella vaccination on the incidence of HZ, in both the 
medium and long-term.
Figure 4 shows the sensitivity of these results to vaccine coverage, using the 
base case strategy and base-case model parameters. As expected, the incidence of 
varicella is more sensitive to first-dose coverage than second dose coverage. The 
short-and medium term incidence of zoster is not sensitive to variation in infant 
coverage levels (only with very low coverage is there a difference, not shown), as 
breakthrough infections are assumed to be less infectious than natural cases. 
The long-run incidence of zoster is affected by varicella first dose coverage, as 
vaccinees are assumed to be less likely to subsequently develop zoster than those 
who are infected by the wild virus.
The sensitivity of the model results towards duration of protection after a 
contact with a varicella case or zoster vaccination is presented in figure 5 assuming 
a two dose varicella vaccination programme is combined with vaccination of the 
elderly against HZ. Only the base case and the two extreme combinations of the 
possibilities are presented. As expected assumptions regarding the duration of 
boosting from natural infection or vaccination of the elderly have little impact on 
varicella incidence. However, they do influence the expected change in the incidence 
of zoster post varicella vaccination. When there is a short natural protection and an 
extremely long protection from the zoster vaccine there is expected to be almost 
no increase in HZ. In the case of very long protection due to a natural boosting and 
very short protection from vaccination of the elderly, there will be a more dramatic 
increase in the zoster incidence. 
Changes in the long-run incidence of adult varicella (among those aged 15 and 
over) are shown in Figure 6, for a two-dose vaccination strategy aimed at children. 
Coverage was lowered from 90% first dose and 80% second dose to 50% and 40% 
coverage for the first and second dose respectively. It can be seen that at high levels 
of two-dose coverage the model predicts that a decrease in adult cases is likely, 
whereas at the lower level of coverage, especially below 70% an increase in adult 
disease, with an increasing contribution of natural varicella in the overall varicella 
burden after vaccination.
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figure 4. Sensitivity of base-case model results to different levels of first and second dose 




We present an updated analysis of the possible impact of varicella and/or zoster 
vaccination on the incidence of varicella and zoster. A number of changes have been 
incorporated into this model compared to previous work [11]. The most important 
of which is the use of data on observed age-specific contact patterns from a 
population-based survey [26] and subsequent uncertainty in the contact rates. The 
incorporation of these data, necessitates the re-estimation of zoster reactivation 




























figure 6. The post-vaccination equilibrium (at 100 years) annual incidence of varicella in adults 
age 15 and above by levels of coverage (2 dose combined policy). The height of the bar is the 























Years after start of the program
Natural boosting 20 yrs - Zoster vaccine boosting 7.5 yrs
Natural boosting 42 yrs - Zoster vaccine boosting 3.6 yrs
Natural boosting 7.5 yrs - Zoster vaccine boosting 100 yrs
figure 5. Incidence of zoster for different durations of natural boosting and vaccine protection. From 
the different combinations of the two durations only the base case and the two extremes are shown.
rates, with updated information on the force of infection in adults due to contact 
with children. Importantly, the model now also includes a two-dose schedule 
and vaccination of the elderly to reduce the incidence of zoster (the parameters 
describing this being based on analyses of a double-blind placebo controlled trial of 
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the zoster vaccine). The updated model also allows for vaccinees to develop zoster, 
though at a reduced rate compared to those experiencing natural protection. 
The average duration of boosting against zoster (exogenous boosting) following 
exposure to VZV remains an uncertain and influential parameter. As can been seen 
in figure 3 the joint uncertainty in the contact rates, duration of natural protection 
and other epidemiological parameters lead to wide confidence intervals, meaning 
that the presented outcomes are more disease trends, since individual outcomes 
are dependent on a spectrum of parameter values.
The results of the model with regards a one-dose policy are similar to those 
published by Brisson et al. [11,16] That is, vaccination of infants at achievable levels 
of coverage in the UK (around 90%) is likely to result in a rapid decline in incidence 
of varicella, followed by a period of low incidence (for perhaps a decade), which may 
be followed by a series of epidemics, before the system finally settles around a new 
level of incidence which is considerably lower (i.e. reduced by about 75%) than in 
the pre-vaccine era. Breakthrough varicella makes up a substantive portion of these 
cases. No increase in adult varicella is expected with our base-case parameters. 
However, if lower coverage is achieved (<70%) than an increase in varicella among 
adults is expected in the long run. Our results for the varicella only schedules are 
comparable with the recent publications by Karhunen et.al. [23] and Gao et.al. [24], 
and Brisson et.al. [4]. None of these publications incorporate zoster vaccination on 
top of varicella vaccination in a combined schedule.
Two-dose routine vaccination at the coverage levels that may be achievable in 
the UK (90% and 80% for the first and second dose respectively), is expected to 
result in very low incidences of varicella among all age groups in the long-run and 
may even lead to elimination of the virus. However, the magnitude of this reduction 
is dependent on our assumptions on the efficacy of the second dose of vaccine, 
for which there is little good data. As with the one-dose strategy, vaccination of 
young children is expected to result in an increase in zoster in the medium term. 
This increase in incidence can be partly attenuated by routine vaccination of the 
elderly. The long-run incidence of HZ following vaccination of children is highly 
uncertain, as this depends on the likelihood of vaccinees developing zoster, either 
via the vaccine strain, or from wild-type breakthrough infection. The data on this 
are scarce, and no consistent pattern has emerged. Most, but not all, studies have 
suggested that the incidence of zoster in vaccinees is likely to be reduced [25,28], 
but exact quantification of this risk is difficult [28, 29]. 
As with all models the findings are reliant on the reasonableness of the 
assumptions made and the values of the parameters. We estimated the force 
of infection of varicella for people above the age of 20 based on the incidence 
of GP notifications. This is not ideal because there is a possibility varicella was 
misdiagnosed as Herpes Zoster or vice versa. More data on the actual force of 
infection in adults would be welcome since the changes in Zoster and adult varicella 
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incidence after vaccination depends on this. A key assumption with regards zoster 
epidemiology is the degree and duration of boosting that results from exposure 
to the virus. We used Brisson et al.’s best fitting estimates in our base-case 
model (an average duration of boost of 20 years). In this estimation the duration 
of boosting was identical for all ages. Brisson et.al. [4] have shown that an age 
dependent duration of boosting can decrease the relation between varicella and 
zoster, leading to a smaller increase of zoster after vaccination. By fitting models 
to the data from the large-scale clinical trial of the zoster vaccine [14], van Hoek et 
al. [34] estimated that the average duration of vaccine-induced protection may be 
significantly shorter than Brisson et al.’s estimates (best fitting estimates are in the 
range of 3.6-100 years). The shorter the duration of boost, the smaller the increase 
in zoster following childhood varicella vaccination (Figure 5). It is therefore possible 
that the base-case results overestimate the post-vaccination increase in zoster. 
Even using Brisson et al.’s estimates of the duration of boost, our estimates of the 
increase of zoster following varicella vaccination are lower than those of Brisson et 
al. [11, 16]. This is because we re-estimated the force of infection in adults using 
the POLYMOD contact survey, which resulted in a revision of our estimates of the risk 
of reactivation. Although the data on the incidence of HZ in the US are limited and 
contradictory, the evidence suggests that the incidence is probably increasing (four 
of the five published studies reports an increase in HZ [36-40]), though whether this 
is attributable to varicella vaccination, or some other factors (like increased use of 
corticosteroids) is less clear. Further surveillance data on zoster (accompanied by 
good varicella coverage and incidence data) is clearly needed. 
We used Kuter et al.’s data to re-estimate the vaccine efficacy parameters [33]. 
A number of these, particularly those concerned with breakthrough varicella, are 
uncertain. However, since a two-dose schedule would be expected to reduce the 
number of breakthrough cases to low levels, and it is likely that two-dose schedules 
will be adopted, then this uncertainty does not significantly affect findings. 
This study updates previous work [11,16] on the impact of vaccination on the 
incidence of both varicella and zoster. The results suggest that a single-dose policy 
may result in significant numbers of breakthrough cases, a pattern which has been 
observed in the US [17]. A two-dose schedule is likely to lead to a low incidence 
of varicella, provided coverage is maintained at around 90% for the first dose. 
An increase in zoster incidence is still expected following varicella vaccination in 
childhood, and this increase can only be partly ameliorated by introduction of zoster 
vaccination in the elderly.
appendices
The appendices can be found at: http://www.sciencedirect.com/science/article/pii/
S0264410X11000764
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Despite the existence of varicella vaccine, many developed countries have not 
introduced it into their national schedules, partly because of concerns about whether 
herpes zoster (HZ, shingles) will increase due to a lack of exogenous boosting. The 
magnitude of any increase in zoster that might occur is dependent on rates at which 
adults and children mix - something that has only recently been quantified - and 
could be reduced by simultaneously vaccinating older individuals against shingles. 
This study is the first to assess the cost-effectiveness of combined varicella and 
zoster vaccination options and compare this to alternative programmes. 
methods and findings
The cost-effectiveness of various options for the use of varicella-zoster virus (VZV) 
containing vaccines was explored using a transmission dynamic model. Underlying 
contact rates are estimated from a contemporary survey of social mixing patterns, 
and uncertainty in these derived from bootstrapping the original sample. The model 
was calibrated to UK data on varicella and zoster incidence. Other parameters were 
taken from the literature. UK guidance on perspective and discount rates were 
followed. The results of the incremental cost-effectiveness analysis suggest that a 
combined policy is cost-effective. However, the cost-effectiveness of this policy (and 
indeed the childhood two-dose policy) is influenced by projected benefits that accrue 
many decades (80-100 years or more) after the start of vaccination. If the programme 
is evaluated over shorter time frames, then it would be unlikely to be deemed cost-
effective, and may result in declines in population health, due to a projected rise in the 
incidence of HZ. The findings are also sensitive to a number of parameters that are 
inaccurately quantified, such as the risk of HZ in varicella vaccine responders. 
conclusions
Policy makers should be aware of the potential negative benefits in the first 30-40 
years after introduction of a childhood varicella vaccine. This can only be partly 
mitigated by the introduction of a herpes zoster vaccine. They have to decide how 
they value the potential benefits beyond this time to consider childhood vaccination 
cost effective. 
inTroducTion
Varicella vaccination was introduced into the United States in the mid 1990s 
(1-3). However, other countries have been slower to introduce varicella prevention 
programmes, partly as a result of concerns that infant vaccination may increase 
the occurrence of adult varicella (which tends to be more serious) (4,5), or may 
increase the incidence of herpes zoster (6-9), and partly because data from the 
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clinical trials (10) and subsequent surveillance (3,11,12) suggest that vaccination 
may not provide solid, lasting protection for many vaccinees. Previous modelling 
and economic analyses (e.g. (13)) have addressed some, or all of these concerns 
(see (14) and (15) for reviews), and shown that an increase in herpes zoster (in 
particular) can have a profound effect on the estimated cost-effectiveness of 
infant varicella vaccination (13). Since these studies were published further data 
have become available from the US on the impact of childhood vaccination on 
the incidence of varicella in different age groups (16,17), as well as the incidence 
on zoster (18-21) . Furthermore, data are now available on underlying patterns 
of mixing (22), which should lead to a more accurate estimate of the impact of 
vaccination of one age group on the incidence of infection and disease in other 
age groups. In addition, two-dose strategies are now recommended for varicella 
vaccination to counter the high rates of breakthrough infection (3). Finally, a vaccine 
is now available against herpes zoster (HZ, shingles) (23,24), raising the possibility 
that combined strategies of varicella vaccination of children and zoster vaccination 
of the elderly are possible. The current study updates previous analyses (13), takes 
into account new data, and is the first to evaluate combined strategies, as well as a 
two-dose childhood programme. 
There are three basic uses of these two vaccines:
 – Childhood varicella vaccination alone
 –  Varicella vaccination in children and HZ vaccination of the elderly (the vaccine is 
licensed for use in those aged 60 years and above). 
 – Herpes zoster vaccination of the elderly alone.
In this paper we investigate the incremental cost effectiveness of these different 
strategies, and compare them to no vaccination. Further details of the strategy of 
vaccination of the elderly are given in van Hoek et al. (25). As the Advisory Committee 
on Immunization Practices (ACIP) no longer recommend varicella vaccination be 
given as a single dose (3) we do not consider a single dose varicella schedule here. 
To investigate the cost effectiveness of these programmes a dynamic 
transmission model (26) was set up and combined with a cost effectiveness model. 
Within this combination it was possible to investigate for the first time the joint 
uncertainty in assumptions and parameters regarding the transmission model as 
well as uncertainty in economic parameters. This approach allowed us to include 
uncertainty around the contact patterns, which has not been previously integrated 
fully in economic analyses of vaccination programmes, as it has not been previously 
possible to quantify this uncertainty accurately. 
meThods
The cost-effectiveness of different VZV vaccination programmes were assessed, 
from the perspective of the National Health Service (NHS), as recommended by the 
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National Institute of Health and Clinical Excellence (NICE) (27) in the UK. All costs 
are presented in GB£2007. Unit costs from previous years were inflated to this year 
using the Hospital and Community Services Pay and Prices Index (28).
An age-structured transmission dynamic model of varicella and zoster was 
developed and used in the economic analysis. The model is based on that of Brisson 
and colleagues (5), updated to include two-dose strategies and HZ vaccination. 
It was parameterised via an updated review of the literature, and secondary data 
analyses. The model structure and results are given elsewhere (26). The model uses 
contemporary data on age-related contact patterns (22). Cost-effectiveness was 
assessed by projecting the outcome of vaccination from the dynamic infectious 
disease model on the number of cases of both varicella and HZ and subsequent loss 
of Quality Adjusted Life Years (QALY) associated with these diseases and costs to the 
NHS. To be able to investigate both the uncertainty in the transmission parameters 
and economic parameters the economic parameters were directly integrated into 
the dynamic model. This means that the number of cases were discounted over time 
(after introduction of the vaccine) and multiplied by the cost and QALY loss per case. To 
calculate the cost and QALY loss per case by age group, a decision analytic model was 
set up in Excel that estimated the cost per case by projecting the number of general 
practice (GP) visits, treatment costs and hospitalisations and associated QALY losses. 
Within this model distributions were attached to the different inputs and a set of 1000 
different parameter combination were generated to feed into the transmission model. 
Distributions in Excel were generated with @Risk 5.0 (Palisade, USA). 
Sensitivity analysis was done by running the infectious disease model with 
economic parameters with 1000 different datasets for cost and QALY loss but also 
for disease characteristics as the duration of acquired immunity due to boosting, 
contact patterns and vaccine efficacy. Each simulation resulting in a unique cost 
per QALY gained for that specific run. 
varicella-related parameters
The infectious disease model simulates the number of infectious cases and not GP 
visits or hospitalisations, therefore an adjustment must be made for the probability 
that an infectious person will seek medical care. This was done by comparing the 
incidence of infection by age as generated by the transmission dynamic model 
(which itself is parameterised by comparing to serological data) with the age-
specific incidence of GP attendance. GP visits due to varicella were estimated 
based on the database of the Royal College of General Practitioners Weekly Returns 
Service (29) over the time period 2004-2007. From this database the number of GP 
visits per case was estimated. See table 1 for the outcomes.
Hospitalisation was expressed as admissions per varicella infection and is based 
on the number of varicella cases as found in the Hospital Episode Statistics database 
(HES – 2000-2005, which covers all NHS admissions in England) (ICD-10 code B01 
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in first 3 diagnostic fields), divided by the modelled incidence of varicella, see table 1. 
Information about the average duration of hospitalisation by age was obtained from 
the same source. The cost of hospitalisation was estimated by multiplying the 
number of days in the hospital with the average cost of an inpatient day. For children 
under the age of 15 years a cost of £475 (code PA18 reference costs, www.ic.nhs.uk) 
per day was used, for children and adults of 15 years and above a daily cost of £340 
(code WA06Y reference costs) was assumed, as shown in table 2. Additional costs 
may be associated with infection control measures. These have been estimated to 
be £865.1 per case (30), and were added to each inpatient episode.
To protect risk groups such as immunocompromised patients, pregnant women 
and neonates varicella zoster immune globulin (VZIG) is provided. Treatment with 
VZIG costs £280. In 2007 6813 vials were distributed within the UK of which 5514 
were for pregnant women and neonates and 1299 for other risk groups. The vials for 
pregnant women were distributed according to data of the Office of National Statistics 
(ONS) about the mothers’ age in case of a live birth, the remaining vials (apart from 
neonates) were evenly distributed over all age groups as presented in table 1.
Mortality due to varicella by age was extracted from ONS for 2005. There were 20 
deaths, 16 of which were in adults.
The QALY loss per case of varicella was obtained from Brisson and Edmunds 
(13) and is based on the HUI2 questionnaire that was distributed among parents 
of young children within GP practices. Due to the questionnaire used in the study 
data collection might have been biased towards more severe disease presentation 
(>50 spots), therefore a correction was made based on the observed distribution 
of patients with less than 50 spots and more than 50 spots (31). Patients with less 
than 50 spots were believed to have only 25% (triangular distribution between 5% 
and 50%) of the QALY loss compared to patients with more than 50 spots. See the 
supplementary data online for more information.
Varicella vaccination parameters for the 2 doses were estimated by fitting a 
model to data from a clinical trial as presented by Kuter et al.(32) The values for 
vaccine take and waning are based on a clinical trial with an average of 2900 – 
9000 plaque forming units (pfu’s), which is slightly above those used in the licensed 
varicella vaccines (minimal 1350pfu), see reference (26) for the parameter values 
used. The first dose is assumed to be given at 1 year of age, and the second at 3 
years of age. It is assumed that these would be given as a combined preparation 
with MMR vaccine, and so the administration costs would be negligible. In the 
base-case we assume that the coverage will be 90% for a first dose, and 80% 
for the second dose, and that there is no catch-up of unvaccinated individuals at 
the second opportunity. These coverage levels are optimistic at the moment, as 
coverage has fallen due to concerns over the safety of the MMR vaccine in the UK, 
but as the coverage is assumed to remain constant through time, we are implicitly 
assuming that the MMR coverage (and therefore VZV coverage) will return to levels 
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Natural varicella  < 15 years 0.0027 (13,31) See online supplement
   > 15 years 0.0038 (31,41) See online supplement
Breakthough varicella < 15 years 0.0014 (13,31) See online supplement
   > 15 years 0.0019 (31,41) See online supplement
costs
Cost GP consultation £50 (28)
Treatment costs per GP consultation £ 2.78 (9) 
Cost per inpatient day age < 15 £475 (42) Non elective inpatient day 
2006-2007 Minor infection PA18 
(most used reference cost in children)
         age >15 £340 (42) Non elective inpatient day 
2006-2007 Other viral illness WA06Y 
(most used reference cost in adults 
and elderly)
Average treatment cost hospitalisation £ 865.1 (30)




The QALY loss is age dependent See reference (25)
             For example at age: 20 0.022
   40 0.032
   60 0.067
   80 0.201
costs
Cost GP consultation (incl. treatment) £ 75.63 (33)
Cost treatment postherpetic neuralgia £ 340.04 (33)
Cost Inpatient day age <69 £195.2 (42) Minor skin infections  
<70 – HRG J42)
         age >70 £224.4 (42) Minor skin infections  
>69 – HRG J41)
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seen previously. However, in acknowledgement that this may not be the case, we 
also vary the coverage as part of the sensitivity analysis.
In the base-case, each dose of varicella vaccine is assumed to cost £31, based 
on the price that the Centers for Disease Control and Prevention pay for a publically 
funded VZV vaccination in the US.
zoster-related parameters
Estimates of the age-specific costs and QALY losses associated with HZ in the UK 
are described by van Hoek et al. (25) but are also presented in table 1, 2 and the 
online supplement. The average costs of treating zoster cases (including the costs 
of treating post-herpetic neuralgia (PHN) were taken from a retrospective analysis 
of the UK General Practice Research Database (33). As for varicella the details 
about hospitalisation and associated cost was obtained from the HES database 
(HES 2002-2005, ICD-10 code B02, G053 in the first three diagnostic fields). 
The QALY loss due to HZ was estimated by estimating the severity and duration 
of pain by age with subsequent QALY loss and fully described by van Hoek et al. (25).
Parameters describing vaccine take and waning associated with HZ vaccine 
were estimated by fitting a model to the data from the Shingles Prevention Study 
(24). The published data is not detailed enough to estimate age specific take and 
waning rates. Therefore a duration of protection was assumed and the take was 
then fitted (25). This resulted in a number of parameter sets for take and waning, 
which also varied by age group. For the sensitivity analyses 1000 sets of take and 
waning combinations were used. Note that the clinical trial (24) has as primary 
endpoints, the burden of illness (BOI) associated with zoster (a measure of days 
spent in pain) and the incidence of PHN, and as a secondary endpoint protection 
against an episode of HZ. Analysis of these data suggest that the vaccine may 
have had an additional effect on severity of disease (BOI and PHN), over and above 
the prevention of HZ (that is, some of the cases that occurred, may have had less 
severe disease). However, in this analysis, we have simply assumed that the vaccine 
protects against HZ (and therefore those episodes of PHN associated with this). 
That is, we may have underestimated the (cost-) effectiveness of the HZ vaccination 
programme (see (25) for details). In the base-case we assume a 70% coverage of 
zoster vaccine using a single dose. We determine the optimum age to vaccinate and 
then use that in the remainder of the paper. In the base-case combined programme 
we assume that zoster vaccination is not switched off, though in the sensitivity 
analysis we show a scenario where vaccination of the elderly is terminated when the 
vaccinated cohorts become old enough to receive the zoster vaccine. 
It was assumed that individuals who had responded to the vaccine would be less 
likely to develop zoster than individuals infected by the wild-type virus. This is based 
on a summary of the evidence provided by Gershon et al.(34) and Civen et al. (35). 
Gershon et al. provide a review, of studies in both healthy and immunocompromised 
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children. The findings from the different studies are highly heterogeneous, though 
overall, most studies suggest a lower incidence of zoster in those who were vaccinated 
compared to those who are naturally infected. This is confirmed by Civen et al. (35) who 
estimated that the incidence of zoster was 4 to 12 times lower in vaccinated children. 
It should be noted, however, that in the long term post-vaccination equilibrium 
(almost) everybody is vaccinated with two doses of varicella vaccine, and where there 
is a very low transmission of wild type virus, due to this low disease transmission 
there is almost no exogenous boosting and (all) people only carry the vaccine virus. In 
short; a situation which will be different to any situation currently available to study. 
Given the uncertainties in the literature and the uncertainty with the interpretation 
of this literature we assume here, that in the base-case the incidence of zoster in 
vaccine responders will be 10% of those infected naturally. This percentage is varied 
between 0 and 100% in the sensitivity analysis (using a triangular distribution the 
mass of which is 50% below 10% and 50% above 10%).
The base case cost of the zoster vaccine is assumed to be £55, with an addition 
£10 for administration costs (based on the costs of a nurse consultation) (25).
The parameters used in the cost effectiveness analyses are given in Tables 1-6. 
Further details of the distributions used in the sensitivity analysis are given in the online 
supplement (for varicella related parameters) and in (25) for HZ-related parameters.
sensitivity analysis of uncertain parameters
To assess how influential each uncertain input parameter is on the cost-effectiveness 
of vaccination, parameter specific coefficients of determination (R²) are estimated 
(36). The R² measures how much of the variance in the outcome (incremental 
costs and QALY’s) is explained by a linear relation with that input parameter. For the 
contact matrix (analysed as a group of 100 beta coefficients since it is a 10 by 10 
matrix) a single R² is obtained, as these parameters are interdependent because 
they are estimated using a single model and dataset. For the same reason, a single 
R² is obtained for the 2 parameters describing vaccine efficacy, i.e. take and waning, 
and for parameter delta (δ) and chi (χ). A full description of the parameters used in 
the model can be found in reference (26). Assumptions of linearity and normality 
of residuals for these regression analyses are checked. Analyses were performed in 
SAS 9.1. Analysis is done for the base-case scenario of the combined strategy of 
vaccination of children against varicella and the elderly against zoster.
discounting and time horizons
Future costs and benefits are discounted to account for time preferences and the 
opportunity costs of capital investments. In the base-case discount rates of 3.5% 
per annum are applied to both benefits and costs, as recommended by NICE (27). In 
the case of varicella vaccination there is a possibility that the incidence of HZ will rise 
in the short to medium term, and then decline. As the incidence of HZ may be much 
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lower among vaccinees a large decrease in the HZ incidence might be expected once 
the whole population becomes vaccinated (after about 80 years) (see Figure 1). After 
this period there is estimated to be a low incidence of varicella and zoster. For this 
reason, results are sensitive to the time horizon and discount rates. Previous authors 
have used cut offs of 80 years (13). In this paper as a base-case we use an infinitive 
time horizon, in the following way. At 100 years after vaccination has been introduced, 
when a new steady state has been achieved (Figure 1), the number of cases in that 
year are handled as a perpetuity and discounted to year 0. Because this has strong 
effects on the cost effectiveness of the program over all, cost effectiveness profiles 
are shown after 50, 80 and 99 years after start of the program. In addition, the 
sensitivity of the results to variation in the discount rates is also shown. 
resulTs
impact of the programmes on vzv incidence over time
Figure 1 provides estimates of the impact of the different vaccination programmes 
over time: a two dose infant policy (90% and 80% coverage); a two dose policy with 
vaccination of the elderly (70% coverage); and vaccination of the elderly alone. It 
can be seen that a two-dose strategy, is expected to result in a large reduction 
in incidence of varicella, which is not affected by whether zoster vaccination 
is included as well. A one dose strategy results in far smaller reductions in the 
incidence of varicella in the long run, though many of these cases are expected 
to be breakthrough varicella cases (not shown). Infant vaccination is expected 
to increase the incidence of zoster in the medium term (up to 30-50 years after 
vaccination), and this is only partly offset by vaccination of the elderly, as the 
estimated duration of protection is rather short, and the largest increase in zoster 
incidence is expected to occur in adults too young to be vaccinated. 
vaccination of the elderly against hz
We first investigated what was the optimum age to vaccinate the elderly against HZ. 
Figure 2 shows the results of this analysis. It can be seen that there is little difference 
in the estimated cost-effectiveness of vaccination over the age range 65-75 years. 
However, using our base-case assumptions for vaccine efficacy (that there is no 
additional effect over and above the protection against HZ) then vaccination at 75 
years is marginally more cost-effective than the other ages. Therefore in further 
analyses, vaccination of the elderly is assumed to be given at this age.
impact of different vaccination programmes on vzv-related costs 
and Qalys lost
Table 3 gives the estimated discounted cases, costs and QALYs lost after vaccine 
introduction for each of the programmes. Over an infinite time horizon, and 
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figure 1. The estimated incidence of varicella (a) and herpes zoster (b) over time, following vaccine 
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discounted at 3.5% per annum, then the two-dose programme costs less than 
vaccination of the elderly (at the base-case prices of £62 per varicella course, and 
£65 per zoster course).
The change in the costs and change in QALYs arising from each of the programmes 
when compared with the “no vaccination” alternative are shown in Figure 3. It is 
clear from this figure, that there is large variation in the estimated benefits derived 
from the two-dose programme, with a significant proportion of simulations resulting 
in QALYs lost (points on the left-hand side of the figure). The estimated impact of 
vaccination of the elderly against HZ has much lower variance (the points are more 
clustered in the cost-effectiveness plane). The combined programme is clearly 
much more costly than its two component programmes, and as with the two-dose 
strategy is highly variable in effectiveness. This high variability is mainly due to the 
uncertainty about the probability of developing zoster among the vaccinated, the 
duration of protection from a boosting event, and the contact patterns (table 5). 
cost-effectiveness of the different vaccination programmes
The cost-effectiveness of the different strategies as compared to the no vaccination 
alternative, and an incremental analysis are shown in Table 4 a and b. The model 
suggests that the optimum strategy is the two-dose policy with vaccination of the 
elderly. However, this strategy should, nevertheless be viewed with some caution, 
as some simulations (1%) result in QALYs lost (i.e. losses to the population health), 


























figure 2. The cost-effectiveness of vaccination of the elderly against herpes zoster at different 
ages. The height of the bars is represents for each age group the percentage of 1,000 simulations 
which results in a cost effectiveness ratio below the threshold. Base-case model assumed.































































































































































































































































































































































































































































































































































































































































































































































































































































































































Total QALY's gained Thousands
Only elderly
2 Dose
2 dose + elderly
Threshold £20,000
Threshold £30,000
figure 3. The estimated change in costs (vertical axis) and QALYs (horizontal), of the two-dose 
infant programme (light grey points), one dose elderly vaccination (white points) and the combined 
programme (dark grey). All programmes are compared to the no vaccination alternative. Each 
point represents a model simulation (there are 1000 for each strategy). An infinite time horizon 
is assumed, with 3.5% per annum discount rates for both benefits and costs. Base-case levels of 
coverage are assumed. Vaccination of the elderly is assumed to occur at 75 years, as this is the 
most cost-effective age to vaccinate. For reference the two lines represent a cost per QALY gained 
ratio of £30,000 (heavy line) and £20,000 (light line).
Sensitivity to discount rate and time frame - Table 4 a and b also shows how 
sensitive these findings are to the discount rate. Using a lower rate of discount 
for health gains, results in the childhood programmes appearing more cost-
effective in the long run (virtually all of the simulations resulting in a cost-per QALY 
gained of below £20,000). That is, benefits occurring 60+ years after vaccination 
(when the incidence of both zoster and varicella is very low under the two-dose 
or combined policies) are even more influential on the results. Over shorter time 
frames, adopting a lower discount rate will result in the two-dose or combined 
policies appearing less cost-effective, and the overall QALY loss can be negative 
over shorter time periods (not shown). 
The effect of the time frame of analysis is explored in more detail in Figure 4. It is 
clear from this figure that vaccination would not be deemed cost-effective for many 
years after implementation (even after about 100 years the median is above the 
£20-30,000 per QALY gained). Before this period the combined programme would 



















Total QALYs gained Thousands
Horizon of 30 years
Horizon of 50 years
Horizon of 80 years
Horizon of 100 year
Infinitive time horizon
Median costs/QALY over time
Threshold: £20.000
Threshold: £30.000
figure 4. The estimated change in costs and benefits of the combined vaccination programme 
compared with no vaccination over different time frames of analysis (time since programme 
implantation). A 3.5% discount rate for benefits and costs is used. 
be unlikely to be deemed cost-effective, and for 30-50 years has a high probability 
of being not effective (i.e. many points lie to the left of the vertical axis, implying 
QALY losses). That is, with an infinite time horizon benefits accruing many decades 
(even centuries) into the future are very influential on the overall assessment of the 
cost-effectiveness of varicella (or a combined) programme.
Sensitivity to coverage - The cost effectiveness of the combined programme is not 
very sensitive to coverage, over the range of coverage levels explored (Figure 5). The level 
of vaccine coverage in both the children and elderly is a major driver of the overall costs of 
the programme (vertical shifts in the cloud of points in Figure 5), and affects the benefits 
(horizontal shifts), but does so in roughly equally. Lowering the coverage improves the 
cost effectiveness marginally due to a lower increase in HZ post-vaccination. 
The supplementary information provides a sensitivity analysis on the price per 
dose and changes in the probability of developing zoster in vaccinees. 
discussion
Although there have been a large number of economic analyses of varicella 
vaccination (14,15), only a small number of previous cost-utility analyses has 
taken into account the possible impact of varicella vaccination on the incidence 
of HZ. These updated analyses are more favourable to chickenpox vaccination 
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than previous analyses concluded (13), due to a combination of factors. The most 
important are that the time frame of analysis has been extended and the increase 
in zoster following varicella vaccination is expected to be somewhat less than 
previous modelling work suggested (13). These issues are addressed in turn, below.
The results are very sensitive to the time-frame of analysis. Childhood varicella 
vaccination evaluated over 30 or 50 years post-vaccination are unlikely to be cost-
Table 5. Proportion (R²) of total variance in the incremental costs and incremental QALY’s 
explained by each (group) of the input parameters. Only the (group of) input parameters that 
explain 1% or more of the variance of incremental costs and/or QALY’s are shown. Chi is the 
zoster reactivation rate in varicella vaccinees compared to people who are not vaccinated 
against varicella, delta represents the duration of boosting after exposure. R² of the linear 
model with all input parameters (main effects only) are 0.92 and 0.87 for incremental costs 
and incremental QALY’s respectively, indicating the models approximate well the relationship 
between input parameters and incremental costs and incremental QALY’s. Residuals are 
normally distributed (Shapiro-Wilk normality test, W>0.95). 
parameter (groups) incremental costs incremental Qalys
Chi and delta
Contact patterns



























Total QALYs gained Thousands
Base case
80%/70% children and 60% elderly
70%/60% children and 50% elderly
Threshold: £20.000
Threshold: £30.000
figure 5. The estimated impact of changes in coverage on the cost-effectiveness of the combined 
programme (as in Fig 4 change in costs compared to the no vaccination scenario is shown on the 
vertical axis, and change in QALYs on the horizontal axis). 
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effective. However, programmes evaluated over a longer time frame are increasingly 
likely to be cost-effective. That is, benefits occurring 60 years or more after infant 
vaccination is initiated are very influential on the results (even when discounted). 
This is the period when the incidence of HZ is expected to decline, as the vaccinated 
cohorts pass into the age groups when they are at greatest risk of developing 
zoster. The model assumes that individuals who respond to the varicella vaccine 
are less likely to develop zoster than those naturally infected. The data on this is 
scarce, and as our findings are sensitive to this the results should be viewed with 
considerable caution. That is, the conclusions are influenced by a parameter value 
for which there is very little quantitative support, and depend on very long time-
frames of analyses (time frames over which it is not realistic to conclude that other 
aspects of VZV epidemiology and economics would remain stable).
The increase in zoster that is expected after vaccination is less than was estimated 
by Brisson and colleagues (5,6,9,13). This results from an updated estimation of 
the force of infection in adults (derived from the analysis of contact patterns), 
which then necessitated a re-estimation of the reactivation rate. There remains 
considerable uncertainty regarding these parameters, which influences strongly 
the results. and continued surveillance of HZ in countries that have introduced the 
vaccine should, given time, help to improve our quantitative understanding of these 
processes. Leung et al. have shown that there has been an increase in hospitalisation 
for HZ in the US in the years after vaccination (37). Unfortunately there is no good 
baseline data available, hence it is not possible to attribute this increase with any 
certainty to vaccination practice. In addition there does not seem to be a striking 
difference between states with a low and high vaccine uptake, although the absolute 
difference in vaccination coverage is not presented, and a substantial difference is 
needed before an effect might become apparent (37). On the other hand, Leung 
have also shown that the incidence of zoster in adults living with children is lower 
than in those who do not (as has been shown in the UK(5)), added suggesting that 
exposure to varicella does indeed reduce the risk of zoster. In addition, this gap 
in incidence between those living with/out children has been decreasing (37); as 
would be expected if, as children became vaccinated, the influence of living with 
children (and being boosted) disappears. Overall, although the pattern of increase 
in zoster in the US is consistent with a boosting hypothesis, no definitive proof can 
ever be derived from such associations.
The current study also looked at a two-dose strategy and combined strategies 
of vaccination of children against varicella and the elderly against zoster. The 
results suggested that a combined policy may be cost-effective, though there are 
a number of caveats attached to this statement (see above). Terminating zoster 
vaccination when the cohorts who have had varicella vaccine become old enough to 
receive zoster vaccine is slightly more cost-effective. This is because the varicella 
vaccinated cohorts are assumed to be less likely to develop zoster. If such a combined 
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strategy were to be employed there should be ample opportunity to accurately 
estimate the rate of acquisition of zoster in vaccinees, before considering when (or 
if) HZ vaccination can be terminated.
The Shingles Prevention Study (a large placebo controlled trial of HZ vaccination) 
took as its primary endpoints the burden of illness associated with HZ (a measure of 
days spent in pain weighted by the severity of that pain) and prevention of PHN (24). 
Prevention of HZ was a secondary endpoint. The efficacy against these BOI and PHN 
was higher than that against HZ, suggesting that the vaccine may have an effect over 
and above prevention of shingles. However the burden of illness was measured as a 
reduction in days of pain, which does not have to correspond with a reduction in QALY 
loss. We ignored these potential additional effects in our analyses, and so we may 
have underestimated the benefit of the HZ vaccine. The inclusion of these additional 
effects alters the optimum age at HZ vaccination as the severity of HZ increases with 
age, and the additional effects also appear to be age dependent (see (25) for further 
details). Based on the assumption of an exponential decline our most likely duration 
of protection of HZ vaccination was 7.5 years (3.6 – 100 years) (25) which is shorter 
than previous estimates (38), due to different model assumptions (39). A longer 
duration of protection will lower the optimal age of HZ vaccination. Thus, the optimal 
age of HZ vaccination is not as clear as seems apparent here.
The transmission model assumed a stationary population, with constant 
mortality and birth rates over time. This is, perhaps, an oversimplification, as the 
elderly population, in particular, is expected to increase in size (40). Indeed, the 
over 85s are expected to more than double in size over the next 20 years (from 
1.3 million to 3.3 million). As the risk of zoster increases exponentially with age 
we would expect the crude incidence to increase over time due to population 
aging. Modelling these changes would complicate the interpretation of the zoster 
incidence trends shown here. In addition allowing a variable demographic structure 
would necessitate constant re-evaluation of contact rates, as there would be a 
different number of individuals by age group. Incorporating these changes into the 
model would be a major undertaking, especially for the fitting procedures, and we 
have therefore chosen to ignore them. It should, however, be borne in mind that 
an increase in the incidence of zoster would, other things being equal, render 
vaccination against zoster more cost-effective than is shown here. 
One of the strengths of this paper is in how it has handled uncertainty. To our 
knowledge no previous economic analysis of any vaccination programme has 
incorporated uncertainty in the underlying epidemiology (including contact patterns) 
as well as uncertainty in the economic and health outcome parameters. The existence 
of the contact pattern data allowed us not only to quantify the relevant average 
contact patterns between and within age groups, but also a measure of the statistical 
uncertainty in this. This parameter uncertainty was found to be, given the base-case 
scenario, one of the most influential on the expected impact of the vaccination 
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programs. Hence, quantifying this uncertainty, and propagating it through the 
epidemiological and then economic analysis, is a key methodological advance. 
The fact that the time-frame of analysis and discount rate chosen are so 
influential is very problematic for decision-making. Over the time-frames modelled 
here (including an infinite time frame) huge changes in society are likely to result, 
as are enormous technological changes and changes to the health service. Model 
results are also likely to be inaccurate over such time frames. Decision-makers need 
to be aware of this, and that an infant vaccination programme may not be cost-
effective for many decades following vaccination, when judging whether childhood 
varicella vaccination should be adopted. 
appendices
Appendices are online available at: http://www.sciencedirect.com/science/article/
pii/S0264410X11017932
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While the H1N1v influenza pandemic in 2009 was clinically mild, with a low case-
fatality rate, the overall disease burden measured in quality-adjusted life years (QALY) 
lost has not been estimated. Such a measure would allow comparison with other 
diseases and assessment of the cost-effectiveness of pandemic control measures. 
methods and findings
Cases of H1N1v confirmed by polymerase chain reaction (PCR) and PCR negative 
cases with similar influenza-like illness (ILI controls) in 7 regions of England 
were sent two questionnaires, one within a week of symptom onset and one two 
weeks later, requesting information on duration of illness, work loss and antiviral 
use together with EQ-5D questionnaires. Results were compared with those for 
seasonal influenza from a systematic literature review. A total QALY loss for the 2009 
pandemic in England was calculated based on the estimated total clinical cases and 
reported deaths. A total of 655 questionnaires were sent and 296 (45%) returned. 
Symptoms and average illness duration were similar between confirmed cases 
and ILI controls (8.8 days and 8.7 days respectively). Days off work were greater 
for cases than ILI controls (7.3 and 4.9 days respectively, p=0.003). The quality-
adjusted life days lost was 2.92 for confirmed cases and 2.74 for ILI controls, with a 
reduction in QALY loss after prompt use of antivirals in confirmed cases. The overall 
QALY loss in the pandemic was estimated at 28,126 QALYs (22,267 discounted) 40% 
of which was due to deaths (24% with discounting).
conclusion
Given the global public health significance of influenza, it is remarkable that no 
previous prospective study of the QALY loss of influenza using standardised and 
well validated methods has been performed. Although the QALY loss was minor for 
individual patients, the estimated total burden of influenza over the pandemic was 
substantial when compared to other infectious diseases.
inTroducTion
Influenza severity is usually characterised by the case-fatality rate (CFR). There are 
major problems with this measure as the denominator (the number of cases) is 
difficult to ascertain, resulting in widely varying estimates for the same viral strain 
(1) Using the CFR to characterise severity ignores the burden of disease in the 
vast majority of individuals who have symptomatic influenza (possibly severe) but 
do not die. Many millions of individuals were infected with the pandemic strain of 
influenza A H1N1v in 2009, and it is likely that many more will be infected by related 
strains in the coming years. In order to help evaluate the overall impact of the 2009 
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H1N1v pandemic on the health of populations it is necessary to measure the burden 
associated with non-fatal as well as fatal cases. One simple way to measure the 
impact would be to use a measure that combines morbidity and mortality in a single 
unit. Quality Adjusted Life Years (QALYs) are a commonly used metric that has this 
property. The EQ-5D is a generic preference-based instrument designed to measure 
the health related quality of life (QoL or QALY-weight) of any disease state. Using 
this instrument allows quantification of the severity of H1N1v on a comparable and 
standardised scale. It enables rational decisions to be made about interventions in 
future waves of H1N1v by comparing, for instance, the cost per QALY gained from 
such interventions with nationally accepted norms. In addition, it gives more in 
depth understanding of the impact of influenza on different aspects of well being. 
The health-related quality of life detriment from a population-based sample of 
confirmed H1N1v patients was prospectively measured and compared to controls who 
were investigated because they had influenza like illness (ILI), but were not laboratory 
confirmed as H1N1v. The aims were: 1) to quantify the burden of H1N1v for individual 
patients and investigate factors, such as age and treatment with antivirals, that may 
affect this; 2) compare the severity of the 2009 strain to other infections that cause 
ILI and previous estimates of the severity of influenza from a systematic literature 
review; and 3) to estimate the overall burden attributed to H1N1v in the population. 
The findings can then be used to inform effectiveness and cost-effectiveness analyses 
on policy decisions related to the control of future waves of this (or related) viruses. 
meThods
prospective study of severity of h1n1v
The EQ-5D is a combination of a questionnaire and a valuation technique. The tool 
values health-related quality of life in five dimensions: mobility, self-care, usual 
activities, pain/discomfort and anxiety/depression. For each dimension there are 
three levels: no problems, some problems and severe problems. The overall health 
status is also measured using the visual analogue scale (VAS). The power of the 
EQ-5D is that it makes it possible to convert an outcome for each dimension of 
this scale into a quality of life score. It is recommended by the National Institute for 
Clinical Excellence for use in cost-effectiveness analyses in the UK (2). During the 
early stages of the 2009 pandemic PCR confirmed cases of influenza A H1N1v and 
a control group of PCR negative cases of ILI were identified. The PCR test used was 
validated and has a good specificity and a sensitivity of 95.4% (3). During this time 
(weeks 27/28 2009) the containment phase of the response to the pandemic was 
still in place in England and all cases of influenza were being actively traced and 
centrally registered on a single database (Fluzone), irrespective of risk status, age 
group, complications, etc. Demographic, clinical, and epidemiological information 
was recorded on each case, including name, age, address, date of onset, and 
THE IMPACT OF PANDEMIC INFLUENZA H1N1 ON THE QUALITY OF LIFE
SIX
121
whether the case had been confirmed as H1N1v, tested and confirmed as not being 
H1N1v (discarded), or was awaiting test confirmation. The database was updated 
daily. Cases found to be negative for H1N1v (ILI controls) were not investigated 
further, and so their aetiological causes are unknown. From this database patients 
who had confirmed H1N1v and those who had ILI but had tested negative for H1N1v, 
who had a date of onset within 1 week of the (then) current date were contacted by 
post and asked to take part in the survey. During the period of the study, two regions 
of England (London and the West Midlands) stopped investigating every case. To 
avoid biasing the results of the survey, we excluded cases from these regions.
The Fluzone database was checked daily during the recruitment period (weeks 
27 and 28 2009) for new cases of ILI with recent onset (i.e. onset within 1 week of 
the day on which the database was checked) who were not resident in London or 
West Midlands. These were then contacted and asked to participate. The covering 
letter explained the study and contained instructions for completing the survey. The 
questionnaire asked for age, sex, presence of pre-disposing conditions (diabetes, 
asthma or other chronic respiratory disease, chronic heart, kidney or liver disease, 
long-term neurological disease, or immuno-suppression), attendance at hospital, 
date of onset of symptoms, whether antivirals were being taken, and if so when 
they were first taken, and a checklist documenting their symptoms on the day of 
the survey and on their worst day of illness. In addition, they were asked to fill in 
the two copies of the EQ-5D, one for the worst day of their illness and one for the 
day they filled in the questionnaire. A second questionnaire was sent out two weeks 
after the first, which requested information on the total duration of symptoms, and 
absenteeism from work or school. Respondents were also asked to fill in another 
EQ-5D questionnaire on that day to obtain a base line score for their health-related 
quality of life. In case there was no response from the first mailing a reminder 
was sent out, containing both questionnaires. Non-responders to the second 
questionnaire were not followed up. Patients could fill in the questionnaires by post 
or on-line (they were provided with a secure login to enable this). 
Children (<16 years) were sent a child version of the EQ-5D (4) and questions 
were altered somewhat (e.g. absence from school instead of work). A separate 
question on the work loss of the parents due to disease in the child was added. In 
the covering letter (addressed to the guardian) it was suggested that older children 
fill in the survey themselves (with the assistance of the parent/guardian) and that 
for younger ones the parent/guardian fill out the survey on their behalf. Copies of 
the questionnaires and cover letters are available from the authors on request.
Enquiry to the NHS Research Ethics Committee indicated that ethics approval 
for this study was not required, since collection of QoL information from patients 
is part of the routine surveillance activities of the Health Protection Agency (HPA).
Only individuals with an ILI should have been investigated for H1N1v but to 
be certain, we asked respondents whether they had fever plus at least one other 
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respiratory symptom on their worst day of illness. In the statistical analysis, only 
cases and control participants who recorded that they had symptoms consistent 
with an ILI were included. Differences between the two groups (confirmed cases and 
ILI controls) were tested having corrected for multiple comparisons using the Šidák 
correction (an exact version of the Bonferroni correction). For the QALY analysis we 
only included patients for whom a complete set of data was available to calculate 
the QALY loss; this is an onset and end date, as well as quality of life weights for the 
worst day and the date of onset. The overall QALY loss was estimated to be the area 
denoted by the triangle with vertices being the background quality of life weight 
at onset date, the quality of life weight at the worst day and the time since onset 
of the worst day, and the background quality of life weight at the recovery date. 
Attribution of risk factors to the QALY score was investigated by linear regression. In 
the regression QALY scores were logged to take account of the skew in the original 
data. Statistical analysis was performed with R version 2.11.0.
systematic literature review
To compare our results with previous estimates of the quality of life detriment due 
to influenza we performed a literature review. Pubmed was searched for the terms 
‘influenza’ and ‘quality-adjusted life year’, ‘QALY’, ‘QALD’ or ‘EQ-5D’. The abstracts 
of all identified papers were reviewed, and original articles (not reviews) published 
in English were retained. 
overall disease burden
To estimate the overall disease burden in England for the 2009 H1N1v pandemic, 
we focussed on the number of cases presenting with fever and those who died. The 
estimated number of people presenting with ILI (fever + respiratory symptom) was 
based on the estimated number of infections. To obtain the latter the estimated total 
number of clinical cases (5) in the first and second waves in England was multiplied 
by a factor 10. This factor is based on a comparison of the estimated clinical cases 
and seroprevalence after the first wave in England (6). Although it might be justified 
to use a higher multiplication factor for the second wave based on mortality and other 
surveillance data (5; 7), the same multiplier was used for the whole period and can 
therefore be seen as a conservative approach. To obtain the estimated number of 
infected persons presenting with ILI, the number of infections was multiplied by the 
proportion of infections presenting with fever (27%) as estimated from an intensive 
household follow up during the initial stages of the 2009 pandemic (8). The total 
burden expressed in QALYs was a multiplication of the QALY loss obtained in this study 
by the number of infections presenting with ILI, plus the QALY loss for fatal cases. The 
QALY loss for fatal cases was estimated as the average life-expectancy corrected for 
the expected quality of life in those years (9). This assumes that each recorded death 
was actually caused by H1N1v, that there was no under-reporting of deaths, and that 
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despite most deaths being in risk groups, the average life-expectancy was lost per 
death. The base-line estimate assumed no discounting of future life-expectancy. 
Discounting at 3.5% (2) was also used in the sensitivity analysis. 
resulTs
prospective study of severity of h1n1v
A total of 655 patients met the inclusion criteria and were sent a questionnaire, 
of whom 390 were confirmed cases and 265 were ILI controls. We received 287 
responses, of which 269 reported ILI and were included in the analysis, 186 from 
confirmed cases and 83 from ILI controls. The response rate was significantly higher 
in the confirmed H1N1v group (48% vs 31% p<0.001). This difference was slightly 
larger in children (55% vs 31%).
The demographic composition of the two groups was similar (Table 1). Although 
there was a slightly higher fraction of the control group that was in a risk group (25% 
vs 19%) this was not significant. The hospitalisation rate was 8-9% in both groups. 
This high level of hospitalisation may represent heightened concern at the outset 
of the epidemic. Antiviral use was higher among the confirmed cases (although this 
was not significant after adjusting for multiple comparisons). The proportion of cases 
receiving antivirals within 2 days of onset was similar between the two groups.
Table 1. Background characteristic of patients.
confirmed h1n1v ili 
cases
ili controls  
(non-h1n1v ili cases)
IlI (fever+1 other symptom) 186 (96%) 83 (89%)
Of those with ILI
Adults 115 (62%) 58 (70%)














* not significant when corrected for multiple comparisons
The symptoms recorded by both groups were similar (Table 2). The only significant 
difference was that the confirmed H1N1v cases recorded more occurrences of cough 
(90% vs 64%, p<0.001). The duration of symptoms was not known for everybody 
due to non-respondents to the second questionnaire. Nevertheless, the duration 
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was similar for the two groups (average duration of 8.8 and 8.7 days respectively 
for the confirmed and control group). The duration of time off work was 7.3 days for 
the confirmed cases and 4.9 for the ILI controls: a significant difference using the 
Welch two sided t-test (p=0.003). The worst day of disease appeared shortly after 
onset of the symptoms for both groups, however for the control group the worst day 
was slightly later (median 2 days) after onset than for the confirmed cases (median 
1 day after onset) (Table 2).
Table 2. Symptoms reported by patients.
symptoms
confirmed h1n1v ili 
cases
ili controls  
(non- h1n1v ili cases)
Sore throat 152 (82%) 68 (82%)
Cough 167 (90%) 53 (64%) p>0.001
Headache 160 (86%) 69 (83%)
Tiredness 176 (95%) 77 (93%)
Chills 142 (76%) 49 (59%) p= 0.006*
Loss of appetite 147 (79%) 62 (75%)
Muscle pain 128 (69%) 54 (65%)
Joint pain 99 (53%) 51 (61%)
Nausea 87 (47%) 38 (46%)
Diarrhoea 46 (25%) 28 (34%)
Conjunctivitis 53 (28%) 18 (22%)
Average duration of symptoms (min-max) 8.8 (1 – 28) n=133 8.7 (2-32) n=56
Worst day (median, mean, modus) 1, 1.64 ,day 1 2, 2.18, day 1
time off work information available 82 (44%) 39 (47%)
Average time off work (min-max) 7.3 (1-28) 4.9 (1-21) p = 0.003
* not significant when corrected for multiple comparisons
All five of the dimensions measured in the EQ-5D were affected by ILI, in both 
groups of patients, though usual activities and pain/discomfort were the most 
affected (Table 3). Only about 5% of patients said that they had no problems with pain 
or discomfort on the worst day of illness, and 2% (8%) said they had no problems with 
usual activities on the worst day of their illness in the confirmed (control) groups. 
The overall quality of life weight for the worst day was 0.29 for the confirmed 
cases and 0.34 for the ILI controls (Table 4). After the symptoms had gone the 
quality of life weights were 0.96 and 0.97 respectively. Based on the VAS scale the 
QALY weight was 90 (on scale 0-100) for the background and 30 for the worst day. 
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The comparable values for the ILI controls were similar, 89 and 30 respectively. 
Complete information to calculate an overall QALY loss was only available for 114 of 
the 186 (61%) confirmed cases and 46 (55%) of the 83 control ILI cases. The final 
QALY loss due to the whole period of disease was 0.0075 for the confirmed cases 
and 0.008 for the cases in the control group, i.e. 2.7 and 2.9 Quality Adjusted Life 
Days (QALDs), respectively.
In multivariable linear regression only antiviral use (within 48 hours) was 
associated with the number of QALDs lost, and only in confirmed H1N1v cases 
(p= 0.084). Prompt antiviral use was found to reduce the number of QALDs lost by 
50% (22%-110% CI 95%). No other factor (including age, sex, presence of risk-
factors, whether hospitalised, whether the case was confirmed H1N1v or not) was 
significantly associated with the number of QALDs lost. 
systematic literature review
Sixty-one articles were found, 10 of which were reviews and discarded. A further 
10 studies only estimated life years lost, two papers described different diseases, a 
further two were not published in English, leaving 36 studies mentioning the burden 
of influenza or ILI. However, none of the reviewed papers was specifically dedicated 
to the burden of disease, but gave values for this as part of a cost effectiveness 
study. A number of papers present the same data from the clinical trials of the 
antiviral zanamivir but with different analyses. Overall we were only able to identify 
Table 3. Impact on the 5 dimensions as measured in the EQ5D









Self care 125 (98%) 51 (96%) 1 (1%) 2 (4%) 1 (1%) 0 (0%)
Mobility 122 (96%) 52 (98%) 4 (3%) 1 (2%) 1 (1%) 0 (0%)
Usual activities 115 (90%) 50(94%) 11(9%) 3 (6%) 1 (1%) 0 (0%)
Pain/discomfort 118 (93%) 50(94%) 8 (6%) 3 (6%) 1 (1%) 0 (0%)
Anxiety / Depression 123 (97%) 50(94%) 4 (3%) 3 (6%) 0 (0%) 0 (0%)
Worst day
Self care 83 (46%) 38 (48%) 57 (31%) 28(35%) 41(23%) 13(16%)
Mobility 31(17%) 17 (20%) 72 (39%) 34 (41%) 81 (44%) 32 (39%)
Usual activities 3 (2%) 7 (8%) 53 (29%) 25 (30%) 126 (69%) 51 (61%)
Pain/discomfort 8 (4%) 4 (5%) 111 (60%) 48 (59%) 65 (35%) 30 (37%)
Anxiety / Depression 82 (45%) 30(37%) 57 (31%) 37 (46%) 43 (24%) 14 (17%)
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four original sources of information on the burden of disease due to ILI as measured 
in QALYs, including the trial data as one source, see table 5 for an overview.
The first original source of data is a study by Griffin et.al (10) in which 21 working 
adults were asked to fill an EQ-5D questionnaire within 3 months of onset of ILI, and 
8 GPs were asked to do the same. The study reported relatively low QALY weights 
for ILI with values below zero (corresponding to a state worse than death) being 
recorded. The weights were, however, applied to a very short duration of illness which 
was measured separately on a different group of patients (2.48 days). Hence the 
overall loss was estimated at 2.19 QALDs. The second source of data is the clinical 
trials of zanamivir, reported by O’Brien et al.(11) In the zanamivir trials almost 
640 patients with ILI were asked within 48 hrs of onset of disease to value their 
health on a scale between 0 and 10 every day for 21 days. Since this is not a QALY 
scale, several separate analyses have been performed on the same data to map the 
disease-specific scale onto a QALY scale. In addition, since these data have mostly 
been used in cost-effectiveness studies of the use of antivirals, no figures for overall 
QALY loss due to ILI have been published, only the difference in QALY loss due to 
ILI in patients with and without antivirals (11-14). Only two studies (15; 16) use 
these data to estimate the overall QALY loss: the first uses a separate estimation of 
the background quality of life weight based on population estimates and the second 
a separate estimation of the duration of illness. The final estimates differ by up 
to 6-fold. The QALD lost estimated by Siddiqui et al. (16) is 1.68 for complicated 
influenza and 1.57 for non-complicated, non-influenza ILI whereas the QALD loss 
calculated by Sander et al. (15). is 5.33 for 0-19yrs, 6.35 for 20-64yrs and 10.69 in 
over 65s. A third potential source of QALY loss data is a study in which 15 randomly 
selected working age patients and health care workers (17) were asked to fill in the 
HUI-3 questionnaire based on their recollection of their most recent episode of ILI. 
The results were used to estimate a quality of life weight of 0.25 for an individual with 
ILI. Unfortunately, the duration that someone is in this state was not determined and 
so no QALY loss due to an episode of ILI can be easily calculated from these data. The 
Table 4. Impact of ILI on health related quality of life for confirmed and control patients. 
confirmed h1n1v ili 
cases
ili controls  
(non-h1n1v ili cases)
EQ-5D Background (min-max,median) 0.96 (0.15-1,1) 0.97 (0.5-1,1)
EQ-5D Worst day (min-max,median) 0.29 (-0.073-1,0.24) 0.34 (-0.073-1,0.24)
VAS Background (min-max,median) 90 (20-100,95) 89 (55-100, 90)
VAS Worst day (min-max,median) 30 (0-100,25) 30 (5-80,30)
Overall QALY loss (min-max,median) 0.0075 (0-0.027,0.006) 0.008 (0-0.044,0.006)
Overall QALD loss (min-max,median) 2.74 (0-9.84, 2.18) 2.92 (0-16.2, 2.12)
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fourth source of data is a study by Prosser et al in which parents were asked how 
much time they were willing to trade off their own life to prevent ILI in their children, 
which resulted in a value of 1.825 QALDs lost per ILI case.
Total burden of disease pandemic
Given the estimated QALY loss in this study the overall burden of the 2009 H1N1v 
pandemic in England was around 27,070 QALYs (21,211 discounted). This is because 
almost a 7.8 million people were estimated to be infected with the novel virus over 
the course of the two waves of disease. Of these, around 2.1 million were estimated 
to have experienced fever and there were 337 deaths (5). Mortality accounted for 
41% (25% with discounting) of the QALY loss attributable to H1N1v.
discussion
Given the global public health significance of influenza, it is remarkable how few studies 
have tried to quantify the morbidity and mortality impact in QALYs of this ubiquitous 
disease. In addition, as our systematic review reveals, the studies that have been 
performed often have considerable methodological limitations. For instance, two of 
the studies were small and retrospective (10; 17), two studies collected data from 
proxies (such as GPs) in addition to or instead of patients (10; 18), and the studies 
based on the zanamivir trial did not use standardised instrument and only estimated 
the difference in QALYs lost when on antivirals (11) . Finally, many of the studies did 
not estimate the duration of illness, and no previous study explicitly mentions their 
assumptions about the shape of the QALY loss (e.g. rectangular or triangular). This 
study is the only prospective population-based study of the health-relative quality of 
life impact of confirmed influenza and influenza-like illness that uses a standardised 
and well-validated instrument (the EQ-5D). The study shows that the overall QALY 
loss for confirmed H1N1v and other non-H1N1v influenza-like-illness was similar, at 
around 2.8 QALDs per patient. The study also confirmed that the range of symptoms 
and the severity of illness appeared similar in the two groups of patients, with the 
vast majority of patients reporting some problems with usual activities and pain 
and discomfort when they were ill with influenza or ILI. Only the prompt use of 
antivirals was significantly associated with a reduction in the QALDs lost, and only 
in the confirmed cases. Although deaths from H1N1v were comparatively rare, our 
study suggests that the overall burden of illness was considerable with more than 
28,000 QALYs lost over the two waves of infection in England. This compares with an 
estimated QALY loss per year of 18,000 for chickenpox and shingles combined (19) 
and 97,000 for type 1 diabetes (20). However compared to a high mortality disease 
such as coronary heart disease which has an estimated annual burden of 8.2 million 
QALYs lost (20), it is relatively small.
The main strength of the study was that it was a population-based prospective 
controlled study. The study was carried out during a period when every case seeking 
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health care actively was investigated, with follow-up of all confirmed cases and 
their contacts. Therefore it should be as representative a study as is likely to be 
possible. Indeed, during the period of the study the two regions that were most 
heavily affected at the beginning of the epidemic (London and the West Midlands) 
stopped investigating every possible case, and so we excluded data from these 
regions to prevent bias. Nevertheless the possibility remains that more severe 
cases were more likely to come to the attention of medical authorities. In addition, 
although the overall response rate was good for a postal survey (>40%), there is 
always the possibility that more severely affected patients were more likely to return 
the questionnaire. Most patients probably knew their status (i.e. whether they were 
a confirmed H1N1v case or not), which may have led to the differential response 
between confirmed and other ILI cases. Hence, although every effort was made to 
reduce bias, there remains the possibility that the average loss estimated here is an 
overestimate of the true QALY loss per case.
The total burden of influenza in the population is probably underestimated, 
however, as we do not include the QALY loss from atypical cases i.e. those without 
fever. Only patients with ILI were investigated and their data recorded on the Fluzone 
database. Thus patients with milder symptoms – particularly those lacking fever – 
were not followed up. Carat et al. (20) suggest that about one half of influenza 
patients with respiratory symptoms do not develop fever. These individuals probably 
have a lower QALY loss than febrile cases. Indeed, of the 18 individuals who reported 
not having fever, 7 responded to both questionnaires, with an average loss of 1.2 
QALDs per case. Little weight should be put on these numbers as the study was 
not designed to ascertain the burden of non-febrile acute respiratory illness, and 
the sample is small. However, as there may have been large numbers of patients 
without fever their contribution to the overall burden may have been significant. A 
preliminary literature review for QALY loss for acute respiratory illness revealed no 
papers, and so this remains an area for further study. 
Our findings suggest that prompt use of antivirals reduces the number of QALDs lost. 
There are (to our knowledge) no other data on the effect of antivirals on health related 
quality of life of H1N1v patients. Our findings confirm the results from clinical trials on 
seasonal influenza (11), and are also in accordance with virological data, which seem to 
suggest that antivirals reduce viral load in H1N1v infected patients (21). Other factors, 
such as age, were not significantly associated with severity as measured by QALDs lost, 
which also seemed to confirm the findings of virological studies of H1N1v (21)
This study provides important baseline information on the severity of H1N1v and 
other influenza-like-illnesses that can be used to judge the overall impact of these 
diseases on the health of populations. This will facilitate rational decision-making 
regarding the control of influenza over the coming seasons. 
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chapter seven
absTracT
Decisions on how to mitigate an evolving pandemic are technically challenging. 
We present a real time assessment of the effectiveness and cost-effectiveness 
of alternative influenza A/H1N1v vaccination strategies. A transmission dynamic 
model was fitted to the estimated number of cases in real-time, and used to generate 
plausible autumn scenarios under different vaccination options. The proportion of 
these cases by age and risk group leading to primary care consultations, National 
Pandemic Flu Service consultations, emergency attendances, hospitalisations, 
intensive care and death was then estimated using existing data from the pandemic. 
The real-time model suggests that the epidemic will peak in early November, with 
the peak height being similar in magnitude to the summer wave. Vaccination of the 
high risk groups is estimated to prevent about 45 deaths (80% credibility interval 
26-67), and save around 2,900 QALYs (80% credibility interval 1,600-4,500). Such 
a programme is very likely to be cost-effective if the cost of vaccine purchase 
itself is treated as a sunk cost. Extending vaccination to low-risk individuals is 
expected to result in more modest gains in deaths and QALYs averted. Extending 
vaccination to school-age children would be the most cost-effective extension. 
The early availability of vaccines is crucial in determining the impact of such 
extensions. There have been a considerable number of cases of H1N1v in England, 
and so the benefits of vaccination to mitigate the ongoing autumn wave are limited. 
However, certain groups appear to be at significantly higher risk of complications 
and deaths, and so it appears both effective and cost-effective to vaccinate them. 
The United Kingdom was the first country to have a major epidemic in Europe. In 
countries where the epidemic is not so far advanced vaccination of children may be 
cost-effective. Similar, detailed, real-time modelling and economic studies could 
help to clarify the situation.
inTroducTion
In March 2009, an outbreak of a novel strain of influenza A/H1N1 (hereafter H1N1v) 
linked to swine influenza was detected in Mexico. By 12 June 2009, the infection 
had shown sustained human-to-human transmission across the world, leading the 
World Health Organization to declare an influenza pandemic. The first wave of the 
outbreak of H1N1v in the United Kingdom (UK) appeared to peak around 25 July 
2009, but cases began to increase again in September.
Vaccines specific to pandemic influenza have been successfully developed. The 
UK has a contract with two vaccine manufacturers (GlaxoSmithKline and Baxter) 
to procure H1N1v vaccines. On 7 August 2009, the Joint Committee on Vaccination 
and Immunisation (JCVI) recommended that high-risk individuals be prioritised 
for vaccination[1]. These individuals consist of everyone in the current seasonal 
influenza vaccine clinical at-risk groups (those with chronic respiratory, heart, 
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kidney, liver neurological disease, diabetes, and immunosuppression), excluding 
the low-risk elderly but including pregnant women and household contacts of 
immunocompromised individuals. The vaccination programme was rolled out on 21 
October 2009, with primary care surgeries receiving the vaccine in the following 
week [2]. The UK has ordered sufficient doses to cover the entire population, so 
there is the opportunity to extend these recommendations to lower risk individuals. 
However, the extent of vaccination is restricted by other considerations including 
the timeliness of the arrival of vaccine doses, the cost of distribution and likely 
vaccine uptake among different population groups.
Decisions about extending vaccination to low-risk individuals depend partly on 
the epidemiological impact and cost-effectiveness of such options. Here we describe 
how we fit an epidemic model to the estimated number of cases in real-time to 
predict the impact and cost-effectiveness of a range of vaccination options.
meThods
epidemiological modelling
An age-and risk-group structured deterministic transmission dynamic model 
was used to estimate the impact of vaccination. The model has a modified SEIR 
structure, meaning that it has compartments for individuals who are susceptible to 
being infected by H1N1v (S), latently infected (E), infectious (I), and recovered (R). 
The population is also split into three risk groups – those in a seasonal influenza risk 
group, pregnant women, and those who are not in a risk group, with random mixing 
(within an age group) between the groups. The size of these groups is 8.6 million, 
0.5 million and 42.3 million respectively. Population data were obtained from the 
Office for National Statistics (ONS) estimate from England mid 2008 and estimates 
of the size of each risk group provided by the Department of Health, England (Peter 
Grove, personal communication).
At the onset of the widespread epidemic (1 June) a small fraction of individuals 
in each age class were assumed to be infectious, and the remainder susceptible. 
However, older individuals were assumed to have a lower susceptibility, based on 
results from recent sero-epidemiological analyses [33]. An individual who became 
infected in the model was assumed to have natural immunity to further infections of 
H1N1v throughout the time course of the model (12 months). In addition, a fraction 
of individuals who were vaccinated were assumed to respond and become immune 
to infection and therefore disease, while non-responders remained susceptible to 
infection and disease. Vaccination was assumed to begin in the autumn of 2009 and 
be spread out over a number of weeks. Protection was assumed to occur on average 
2 weeks after vaccination (see Appendix 1 for details). The model population was 
subdivided into seven age groups: under 1 year, 1-4 years, 5-14 years, 15-24 years, 
25-44 years, 45-64 years and over 64 years. 
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In order to estimate plausible epidemiological scenarios for a second wave, 
the model was fitted using maximum likelihood to central estimates from the 
Health Protection Agency (HPA) of the weekly number of H1N1v cases from 1st 
June to 18th October 2009[3]. Key parameters (the initial reproduction number, 
latent and infectious periods) were sampled from uniform distributions which 
were wide enough to encompass the range of values suggested in analyses of the 
initial influenza epidemic[4] (see Appendix 1 for details). Those combinations of 
parameters that gave an acceptable fit to the observed data were retained and used 
to simulate the future incidence of infection and disease with different vaccination 
programmes in place.
The rates at which individuals from different age groups came into contact with 
each other was based on the reported frequency of close contacts by UK respondents 
in the recent POLYMOD study of epidemiologically relevant contact patterns[5]. 
The method of Hens et al.[6] was used to take into account uncertainty in contact 
patterns. Two sets of contact patterns were used: one for term-time and one during 
summer holidays when schools are closed. School holidays were assumed to start 
46 to 52 days after June 1[7]. Each of these model realisations were compared to 
the 20 weeks of data by minimising the Poisson deviance between the number of 
cases each week reported by the HPA, and the model estimate of this. The best-
fitting 1% of the realisations were retained to simulate the effect of vaccination. 
Every vaccination programme evaluated was implemented on each of the retained 
(i.e. best fitting) realisations to generate an estimate of the expected impact of 
vaccination, including epidemiological uncertainty. 
A significant fraction of influenza infections are subclinical, or do not result 
in typical febrile symptoms. Thus, there are likely to have been more influenza 
infections over the summer and early autumn than the estimate of clinical cases 
by the HPA predict, requiring the data to be re-scaled to take account of this. The 
epidemic has grown more slowly in the autumn than occurred in the summer, 
suggesting that a significant fraction of individuals were infected in the early wave. 
By rescaling the estimated cases by different factors and comparing the model 
fits (including the fit to the autumn growth rate) it is possible to estimate by how 
much the weekly number of clinical cases underestimates the number of infections 
(see Appendix 1). A multiplication factor of 10 gives a good overall fit to the data, 
though multipliers of 7.5 and 12.5 were used in the sensitivity analysis. To check 
the validity of the multiplication factor and selected model runs, we compared the 
proportion of children who were infected during the first wave with sero-incidence 
data collected by the HPA [33], using samples taken in September (a sufficient time 
after the first wave to allow for a delay in seroconversion). The clearest signal in the 
sero-incidence data is an increase in the proportion of children under 15 years old 
who were seropositive between baseline and the first wave, and this corresponded 
well with our model predictions (see Appendix 1).
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Figure 1(a, c, d) show the predicted size of the first and second waves, using 
different multiplication factors. In each case, the model predicts that the peak 
height of the autumn wave will be similar in size to the summer wave (though, 
on average, if a high multiplication factor is assumed, then a lower second wave 
results). The epidemic is expected to peak in the first two weeks of November 2009, 
and epidemic activity is expected to cease around January 2010. Figure 1(b) shows 
the results of the model validation exercise. The model was fitted to data on 27 
September, and the resulting model projections (blue shaded area) are compared 
with the HPA’s estimated weekly numbers. The pink shaded area shows a similar 
comparison using data up to 18 October. It can be seen that the model gives accurate 
short-term projections. For instance, using data up to the end of September the 
model accurately predicts the height and timing of the peak, 6 weeks later. The 
uncertainty around the projections is narrowed as more data become available. The 
good description of the subsequent epidemic suggests that the model provides a 
sound basis for projecting forward over the forthcoming weeks. 
economic modelling
Following the guidelines used by the National Institute of Health and Clinical Excellence 
(NICE) [8], the reference case was a cost-utility analysis performed from the perspective 
of the health care provider (the NHS) and lifetime time horizon, with future benefits 
and costs discounted at 3.5% per annum. The burden of disease due to the number of 
infections predicted by the epidemiological model was estimated, and a proportion of 
them assumed to result in clinical symptoms. Each clinical case was associated with 
an age- and risk-group specific risk of a general practitioner (GP) consultation (either 
telephone or clinic), National Pandemic Flu Service (NPFS) consultation (either telephone 
or internet), antiviral delivery, hospitalisation, intensive care and death. Each of these 
health care or clinical endpoints was then associated with a cost to the health service 
and quality of life detriment. The cost-effectiveness of different vaccination options was 
then estimated by calculating a net incremental discounted cost per quality adjusted life 
year (QALY) gained. This incorporated the discounted cost of each option (cost of vaccine 
programme minus treatment costs saved) as well as the number of discounted QALYs 
gained as a result of averting cases of H1N1v.
All costs are expressed in 2008 prices, and were assumed to occur in the current 
financial year, although benefits from deaths averted that occurred in future years were 
discounted at the recommended rate. Unit costs taken from previous years were inflated 
to £2008 using the Hospital and Community Services Pay and Prices Index[9]. 
estimate of health outcomes and health service utilisation
Symptomatic cases
The clinical definition of ILI is a report of fever and at least one other influenza-related 
symptom. A review of volunteer challenge studies found that 37% of individuals infected 
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with influenza A/H1N1 had fever[10], so this was assumed to be the proportion of H1N1v 
cases with symptoms. Thus 37% of infections (on average) are assumed to result in 
clinical cases that may then incur costs, and incur a health (QALY) loss.
Calls to the National Pandemic Flu Service (NPFS)
The NPFS is a telephone and internet service that was launched on 23 July 2009 to allow 
people in England with ILI to obtain antivirals without visiting their GP[11]. The number 
of assigned unique numbers for receipt of antivirals (equivalent to a prescription) by 
age up to 29 September 2009 was multiplied by the age-specific proportion positive, 
using data from 3 August – 26 September. Cases were distributed according to risk 
groups, using the data available from two separate weeks (23-30 July, and 23-29 
September), giving the estimated number of antivirals distributed for H1N1v. Dividing 
this by the model estimate of the number of symptomatic cases gave the proportion 
of cases that received antivirals via NPFS. We attributed antiviral prescriptions to a 
telephone or internet consultation using data from the NPFS. 
GP calls and consultations
FluSurvey (www.flusurvey.org.uk) [12] is an internet-based cohort in which 
participants report the occurrence of respiratory symptoms, as well as contact 
with health service and usage of medication. The number of cases of influenza-like 
illness (ILI) reported in FluSurvey was extracted. A respondent was assumed to have 
ILI if he or she reported a fever and at least one other influenza-related symptom 
(blocked/runny nose, cough, sore throat, headache, muscle/joint pain, chest pain, 
stomach ache, diarrhoea, nausea, chills, weakness or eye irritation). The age and 
risk group dependent ratio of cases reporting calls or office consultations to GPs 
to total cases was calculated. Between 8 May and 18 September there were 1551 
cases recorded in FluSurvey resulting in 476 calls and 145 consultations.
Uncertainty around parameters governing the proportion of cases requiring 
calls to the NPFS, calls to a GP, GP office visits, hospitalisations and intensive care 
treatment was estimated by sampling from binomial distributions representing the 
number of cases among all individuals reporting ILI (for the FluSurvey database) 
or confirmed pandemic influenza (for the Regional Microbiology Network (RMN) 
database). This was multiplied by similar binomial samples representing uncertainty 
in the age and risk group breakdown of cases.
Hospitalisations
The age-specific hospitalisation rate was estimated using information collected 
by the Regional Influenza Centre via the FluZone database during the containment 
phase of the epidemic. Out of the 7,564 people with confirmed swine flu 129 were 
hospitalised. Risk-group specific rates were estimated using the distribution of 
hospitalised cases in a study of laboratory-confirmed pandemic influenza cases 
admitted to hospitals, reported through the Regional Microbiology Network (RMN). 
Data were available for 456 patients of whom 203 were in a risk group. Empirical 
REAL-TIME ECONOMIC EVALUATION OF VACCINATION AGAINST PANDEMIC INFLUENZA A/H1N1V
SEVEN
140
distributions were used for sampling since the long tail made fitting to standard 
parameterised distributions (gamma or lognormal) difficult. Distributions were 
adjusted for age and risk group according to the ratios in the data set. The 
proportions of risk group and non-risk group patients admitted to intensive care, 
paediatric intensive care and intensive treatment units were also recorded. No 
cases were recorded as being admitted to high dependency units.
Deaths
The case fatality ratio was estimated using two methods. Firstly, we used the likely 
number of deaths due to H1N1v in two Southern Hemisphere countries (Australia and 
New Zealand), where the pandemic wave is believed to be largely ended [13]. Data 
from other Southern Hemisphere countries were not used since they were either 
extremely small (French Polynesia, New Caledonia) or were in different income levels 
from the UK as defined by the World Bank. This number was then inflated by the ratio 
of the population size to the size of the UK population, and divided by the total number 
of H1N1v cases predicted by real-time modelling. Secondly, the cumulative number 
of confirmed deaths due to pandemic influenza on 16 September was divided by the 
estimate of the cumulative number of symptomatic pandemic influenza cases on 
16 September[3]. As a form of sensitivity analysis, the ratio was recalculated after 
assuming that deaths occurred several weeks after the case was assumed to have 
occurred, as highlighted in a previous estimate of the case-fatality ratio of H1N1v 
[14]. Four scenarios (instantaneous deaths, one week after case, two weeks after 
case, and three weeks after case) gave very similar case fatality due to the slow rate 
of growth in cumulative cases after mid-August. The mean of the three estimates 
(one each using Australian, New Zealand and UK data) was thus obtained. The overall 
rate was then combined with a risk- and age-group dependent multiplier which was 
calculated using data from 59 of the 66 reported deaths with risk-group information. 
The estimated mortality rate was assumed to have a normally distributed error term, 
with standard error calculated from the three estimates used to estimate the mean. 
Uncertainty around age and risk group information was estimated from sampled 
binomial distributions representing the number of individuals in particular groups 
among the 59 reported deaths with risk group information.
The differential life-expectancy for those in influenza-risk groups was calculated from 
the MSGP4 survey of 500,000 individuals in general practices in England and Wales[15], 
using a previous analysis used to estimate the benefit of pneumococcal vaccination[16]. 
This assumes that those who did not consult over the period of the study (1 year) for 
any of the risk conditions were not in the risk group, and that the relative mortality risk 
has not changed since 1991-2 (even though overall life expectancy has improved). The 
resulting age-group specific relative risk (compared to the general population) was 
multiplied by the current (2008) age-specific risk of death to calculate the age- and 
risk-group specific life-expectancy. Pregnant women were assumed to have the same 
life-expectancy as the low risk group. The age- and risk-group specific discounted 
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life-expectancy was used to estimate the (discounted) life-years lost per case. Life-
expectancy was assumed to be higher for those in the low-risk group.
QALY loss 
To estimate the health related quality of life loss from non-fatal cases of H1N1v, 
we contacted individuals with confirmed H1N1v infection in the first and second 
week of June. These individuals were identified using an electronic reporting 
system of suspected H1N1v cases, which contained information on all detected and 
confirmed, rejected and presumed cases outside London and the West Midlands 
for the first two and a half months of the pandemic (the survey was not conducted 
among individuals from London and the West Midlands)[17]. Only cases that had 
occurred in the previous eight days were sent the questionnaire, to minimise recall 
bias. Confirmed H1N1 cases and controls (investigated for ILI, but found not to have 
H1N1v) were sent a questionnaire about their age, pre-existing risk conditions and 
the symptoms of their recent illness. In addition they were asked to complete the 
EQ-5D questionnaire (a generic health status instrument) [18] for the worst day 
of illness and for the day of receipt of the questionnaire. They were followed up 
two weeks later to obtain base-line data (i.e. their health status after recovery), 
as well as data on the duration of symptoms. Children (11 years or over) received 
a child-friendly version of the questionnaire (using slightly modified language). 
Parents or guardians were asked to fill out the questionnaire on behalf of younger 
children. A total of 647 questionnaires were sent out and 288 (45%) returned. The 
results suggested that the mean QALY loss per episode in children was 0.0074 
(SD = 0.00085) and 0.0082 (SD = 0.00081) in adults. Although the differences 
were not significant we used these differential age-based QALY losses in the later 
analysis. A QALY loss of 0.008 is equivalent to losing 2.9 days of full health. We 
assumed that this QALY loss described cases not requiring hospital treatment. For 
hospitalised cases we assumed a QALY loss 2.17 times greater, based on the ratio 
of QALY loss between hospitalised and uncomplicated influenza cases used in a 
previous economic evaluation of interventions during an influenza pandemic [19].
Costs
Unit costs of a clinic and telephone consultations, hospitalisations, stays on 
intensive care and antivirals were taken from standard or published sources. The 
cost of an NPFS telephone consultation was assumed to be equal to that of an NHS 
Direct consultation [20]. Internet based consultations are assumed to be free (that 
is the sunk costs of setting up the NPFS website are ignored). In the base case, the 
cost of the vaccines is also assumed to be sunk. This is because the vaccines were 
ordered at the start of the pandemic and the cost of the vaccines cannot be readily 
recovered. Delivery costs of £5.25 per dose are assumed [21]. Transport and other 
costs are assumed to be small, and are ignored. The costs of the vaccine are varied 
in the sensitivity analysis. Unit costs and their sources are given in Table 1.




In the base case, a two dose strategy for children under 10 years old and one dose for 
all others was assumed, based on advice by the Joint Committee on Vaccination and 
Immunisation (JCVI)[21]. The efficacy of Pandemrix® (the main H1N1v vaccine used 
in the United Kingdom) against clinical endpoints has yet to be determined, although 
it short-term safety and immunogenicity has been established in clinical trials [23]. 
Seasonal influenza vaccines have been found to have a clinical efficacy of over 
70% [24], and Pandemrix®, whose trials have demonstrated very good serological 
responses in adults, may be expected to have better clinical efficacy due to its novel 
adjuvant. Hence we investigated two scenarios for clinical efficacy in individuals 10 
years and over: a base case scenario with single dose clinical efficacy of 70%, and a 
more optimistic scenario with efficacy of 85%. For children under 10 years old, only 
half the usual adult dose is given, so we assumed 35% efficacy after a first dose and 
70% after a second dose (or 42.5% and 85% for the optimistic scenario). We also 
investigated the possibility that a single half-dose of vaccine in these children would 
provide the same efficacy as in older individuals (70% or 85%). In these scenarios, it 
was assumed that these children would only be given a single vaccine dose. Vaccine 
uptake was assumed to be 70% in risk groups and 40% in other groups. 
The schedule over which doses are expected to be procured puts constraints on the 
vaccination programmes that can be implemented over the autumn. It was assumed 
that high risk groups are vaccinated first (as decided by the JCVI in August[1]), and 
that the first dose of the vaccine is delivered between Oct 26 and Nov 8 [2]. Children 
under 10 years old were assumed to receive the vaccine 3 weeks after the first dose. 
We then explored the possibility of extending vaccination to low risk groups in any 
of four age categories (6 months – 4 year olds, 5-14 year olds, 6 months – 14 year 
olds and 65+ year olds). In the base case, it was assumed that vaccination of low risk 
groups would begin on Nov 16, that it would take two weeks for the first dose to be 
given and that children under 10 years would receive the second dose after 3 weeks. 
We also explored the effect of delays in vaccinating the low risk groups.
Since there are likely to be large operational constraints to vaccinating 
significant numbers of individuals in a very short space of time, we assume that 
these strategies are mutually exclusive: that is, vaccination can be extended to one 
of these low-risk groups. We ignore policies involving vaccination of low-risk adults 
aged 15 – 64 years old, since they would have to wait until the epidemic was largely 
over (see later) before sufficient doses would be available to start vaccinating.
sensitivity analyses
Parametric sensitivity analyses were conducted in order to quantify the impact 
of uncertainty around parameters governing the incidence of different levels of 
severity of illness, costs and quality of life weights. These were sampled across 
the distributions given in Table 1. For each of the 600 accepted realisations from 
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Table 1. List of parameters used in the model as well as distributions representing uncertainty 
around them used in sensitivity analysis.
parameter estimate uncertainty distribution source
vaccation parameters
Days between vaccination 
and vaccine protection
14 Triangular on [7,21] Assumption
incidence and risk estimates
Proportion of infected cases 
with symptoms
0.37 Triangular on [0.25, 0.51] Review of volunteer 
studies[10]
Proportion of ILI cases calling GP FluSurvey [12]
 Low risk 0-14 years 0.35 Bootstrap sample from binomial (np=26, n=74)
 Low risk 15-64 years 0.29 Bootstrap sample from binomial (np=285, n=969)
 Low risk 65+ years 0.28 Bootstrap sample from binomial (np=30, n=107)
 High risk 0-14 years 0.13 Bootstrap sample from binomial (np=2, n=16)
 High risk 15-64 years 0.36 Bootstrap sample from binomial (np=124, n=343)
 High risk 65+ years 0.22 Bootstrap sample from binomial (np=9, n=42)
Proportion of ILI cases visiting GP FluSurvey [12]
 Low risk 0-14 years 0.11 Bootstrap sample from binomial (np=8, n=74)
 Low risk 15-64 years 0.08 Bootstrap sample from binomial (np=74, n=969)
 Low risk 65+ years 0.06 Bootstrap sample from binomial (np=7, n=107)
 High risk 0-14 years 0.12 Bootstrap sample from binomial (np=2, n=16)
 High risk 15-64 years 0.13 Bootstrap sample from binomial (np=45, n=343)
 High risk 65+ years 0.21 Bootstrap sample from binomial (np=9, n=42)
Proportion of ILI cases calling NPFS NPFs[11]
 Low risk 0-14 years 0.12 Data-derived; 95% interval [0.09,0.17]
 Low risk 15-24 years 0.16 Data-derived; 95% interval [0.11,0.22]
 Low risk 25-44 years 0.11 Data-derived; 95% interval [0.08,0.16]
 Low risk 45-64 years 0.07 Data-derived; 95% interval [0.04,0.10]
 Low risk 65+ years 0.02 Data-derived; 95% interval [0.00,0.07]
 High risk 0-14 years 0.26 Data-derived; 95% interval [0.18,0.36]
 High risk 15-24 years 0.09 Data-derived; 95% interval [0.06,0.12]
 High risk 25-44 years 0.07 Data-derived; 95% interval [0.05,0.09]
 High risk 45-64 years 0.11 Data-derived; 95% interval [0.07,0.16]
 High risk 65+ years 0.01 Data-derived; 95% interval [0.00,0.04]
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Proportion of ILI cases calling NPFS NPFS [11]
 <1 years 0.32 Bootstrap sample from binomial (np=682, 
n=2134)
 1-4 years 0.65 Bootstrap sample from binomial (np=13970, 
n=21642)
 5-14 years 0.64 Bootstrap sample from binomial (np=30734, 
n=48116)
 15-24 years 0.53 Bootstrap sample from binomial (np=47620, 
n=89207)
 25-44 years 0.50 Bootstrap sample from binomial (np=72162, 
n=143619)
 45-64 years 0.59 Bootstrap sample from binomial (np=36380, 
n=61344)
 65+ years 0.80 Bootstrap sample from binomial (np=10522, 
n=13088)
Proportion of ILI cases admitted to hospital RMN, FluZone
 Low risk 0-4 years 41.8 per 
1000
Bootstrap sample from binomial (np=64, n=82) × 
binomial (np=21, n=414)
 Low risk 5-14 years 5.6 per 
1000
Bootstrap sample from binomial (np=55, n=91) × 
binomial (np=31, n=3514)
 Low risk 15-64 years 11.5 per 
1000
Bootstrap sample from binomial (np=132, n=260) 
× binomial (np=69, n=3585)
 Low risk 65+ years 24.4 per 
1000
Bootstrap sample from binomial (np=2, n=23) × 
binomial (np=8, n=51)
 High risk 0-4 years 214.4 per 
1000
Bootstrap sample from binomial (np=18, n=82) × 
binomial (np=21, n=414)
 High risk 5-14 years 67.1 per 
1000
Bootstrap sample from binomial (np=36, n=91) × 
binomial (np=31, n=3514)
Proportion of hospitalised cases requiring intensive care 
Low risk 41.4 per 
1000
Bootstrap sample from binomial (np=6, n=145)
High risk 70.0 per 
1000
Bootstrap sample from binomial (np=7, n=100)










parameter estimate uncertainty distribution source
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Proportion of deaths by age and risk group Pandemic 
influenza death 
register
 Low risk 0-14 years 0.039 Bootstrap sample from binomial (np=2, n=51)
 Low risk 15-64 years 0.098 Bootstrap sample from binomial (np=5, n=51)
 Low risk 65+ years 0.020 Bootstrap sample from binomial (np=1, n=51)
 High risk 0-14 years 0.20 Bootstrap sample from binomial (np=10, n=51)
 High risk 15-64 years 0.67 Bootstrap sample from binomial (np=34, n=51)
 High risk 65+ years 0.14 Bootstrap sample from binomial (np=7, n=51)
costs
GP telephone consultation £22 None Costs of Health 
and Social Care [9]
GP clinic consultation £37 Lognormal (normal � 37, 
normal σ 8.4)
NPFS call £17 Harris et al. [20]
Antiviral (oseltamivir) course 
including delivery
£16 British National 
Formulary [32]
Hospital admission £840 Lognormal (normal � 839, 
normal σ 192.1)








Vaccine (per dose) £10 None Assumption
Vaccine delivery costs £5.25 None Department of 
Health [21]
utilities
QALY loss for non-
hospitalised children
0.0074 Normal (� 0.0074, σ 0.00085) EQ-5D study
QALY loss or non-
hospitalised adults
0.0082 Normal (� 0.0082, σ 0.0018) EQ-5D study
QALY loss for hospitalised 
children
0.016 Normal (� 0.016, σ 0.00082) Siddiqui and 
Edmunds [19]
QALY loss for hospitalised 
adults
0.018 Normal (� 0.018, σ 0.0018) Siddiqui and 
Edmunds [19]
Table 1. continued
parameter estimate uncertainty distribution source
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the epidemic model 20 simulations were produced, sampling randomly over 
the parameter space in the economic model, to give a total of 12,000 samples. 
Hence the sensitivity analyses incorporated uncertainty in both epidemiological 
and economic parameters. The number of simulations preformed represented a 
compromise between computational effort and validity of findings. The results of 
the base-case model were checked using a larger sample (120,000 simulations) 
and were found to be very similar to those shown (data available on request).
Regression analysis was used to assess the key drivers of the cost-effectiveness 
results. Variables that were found to be multicollinear with other variables were 
excluded. The influence of each non-multicollinear variable on cost-effectiveness 
was shown as a tornado graph. A net benefit approach was used by assuming 
that the marginal societal willingness to pay for a QALY gained was £20,000. This 
approach was taken to ensure that the error terms were well behaved.
resulTs
Figure 1(e) shows the estimated impact of the different vaccination programmes 
on number of infections during the second wave of the H1N1 epidemic. The impact 
of vaccination is attenuated by the fact that vaccination can only occur late in the 
epidemic. Table 2 shows the estimated number of cases and deaths prevented, 
QALYs gained and treatment costs averted for the different vaccination strategies, 
compared with the no vaccination alternative. Vaccination of the high risk groups 
is estimated to avert about 45 deaths (80% credibility interval 26-67), and save 
2,910 QALYs (80% credibility interval 1,579-4,471). Extending vaccination from 
the risk groups to low-risk individuals is estimated to have a modest impact on 
deaths averted as few deaths occur in the low risk individuals, and vaccination is 
assumed to start later in these groups. The impact on cases is greater, particularly 
if vaccination is extended to low-risk school children.
Figure 2 shows the range of values for the incremental cost-effectiveness ratios 
for the different strategies across all realisations of the model. Each realisation of the 
model is a single set of model parameter values sampled over the entire distribution of 
possible values that they can take. The horizontal lines represent £20,000 and £30,000 
per QALY gained, the thresholds used by the National Institute for Health and Clinical 
Excellence as a guide to determine if a policy is cost-effective[25]. Hence realisations 
below the two thresholds are likely to be deemed cost-effective, realisations above the 
thresholds are unlikely to be deemed cost-effective, and there is less certainty about 
decisions regarding realisations located between both thresholds. 
The largest incremental benefit is obtained by vaccinating risk groups compared to 
not vaccinating anybody. Such a strategy is also very likely to be cost-effective, since 
most model realisations lie below the £20,000 per QALY gained threshold. Extending 
vaccination to low risk groups as well is relatively less costly than vaccinating high risk 
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figure 1. Projections of the number of 
infections over time across the best-fitting 
1% of model realisations, for the different 
multipliers of the central estimates of weekly 
clinical cases (a) 10 times (base case), (c) 
7.5 times and (d) 12.5 times, as well as 
(b) a model validation exercise and (e) the 
average predicted impact of vaccination on 
infections. In Figure (b), projections from the 
30 best-fitting simulations with a multiplier 
of 10 are shown: the light grey shaded area 
gives the range of model projections using 
data up to 27 September (first vertical line), 
the dark grey shaded area gives the range of projections using data up to 18 October (second 
vertical line). The estimated number of infections (rescaled HPA weekly estimates) is shown as 
points joined by a line. Note that data up to 1st November are shown. In Figure (e) the black curve 
shows the course of the epidemic without vaccination, red with vaccination of high risk individuals, 
green with vaccination of risk groups and 0.5 – 4 year olds, while blue shows vaccination of risk 
groups of 5 – 14 year olds.
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groups, partly because uptake among these groups is assumed to be lower. However, 
such strategies also achieve lower incremental benefits, and are less likely to be 
cost-effective. Of the strategies involving extending vaccination beyond high risk 
individuals, extending vaccination to the low-risk adults over 64 years appears least 
likely to be cost-effective. Vaccinating either 0-4 year olds or 5-14 year olds appears 
to be more cost-effective than vaccinating older adults, with vaccinating 5-14 year 
olds having a more attractive cost-effectiveness profile. Choosing to vaccinate all 
children under 15 year old would prevent more cases than vaccinating 5-14 year olds 
only, but would be less cost-effective because many of the 0-4 year olds would be 
protected due to herd immunity as a consequence of vaccinating older children.
Table 3 shows the effect of varying key assumptions in the model around the size of 
the epidemic, effectiveness of vaccination, speed of vaccine roll-out and likely vaccine 
uptake. The proportion of model realisations that are cost-effective are shown for two 
figure 2. Incremental cost-effectiveness ratio of the base case model across different realisations 
of the model, assuming £5.25 administration costs per dose of vaccine. Vaccination high risk 
individuals only is compared to no vaccination, while low risk group vaccination strategies are 
compared to vaccinating risk groups only. Horizontal dotted and straight lines respectively show 
the £20,000 and £30,000 per QALY thresholds used by NICE for decision making. Note the change 
in scale on the right-hand panel.
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Table 2. The estimated number of cases and deaths prevented, QALYs gained and treatment 







& 0-4 year 
olds 
risk groups 
& 5-14 year 
olds 
risk groups 
& 65+ year 
olds 
risk groups 
& 0-14 year 
olds 
risk groups 
& 0-14 & 
65+ year olds 
number of cases prevented 
Mean 452,990 486,532 558,168 458,954 573,355 576,503
Median 422,175 448,900 511,930 427,119 524,127 526,817
10th centile 234,274 243,375 267,800 236,046 272,628 273,636
90th centile 710,252 777,693 908,364 721,682 938,357 944,056
number of deaths prevented  
Mean 45 46 48 45 48 49
Median 43 44 46 43 46 46
10th centile 26 26 27 26 27 27
90th centile 67 68 72 67 73 73
number of hospital admissions prevented 
Mean 10,386 10,808 11,398 10,460 11,604 11,645
Median 9,569 9,927 10,456 9,629 10,631 10,662
10th centile 5,225 5,349 5,565 5,246 5,627 5,640
90th centile 16,547 17,377 18,430 16,688 18,830 18,911
Total Qalys saved 
Mean 2,910 3,065 3,396 2,938 3,466 3,481
Median 2,733 2,855 3,147 2,757 3,202 3,215
10th centile 1,579 1,619 1,732 1,587 1,753 1,757
90th centile 4,471 4,779 5,380 4,526 5,517 5,546
Treatment costs avoided  (£m)
Mean 13.4 14.0 15.1 13.5 15.4 15.5
Median 12.3 12.8 13.8 12.4 14.0 14.1
10th centile 6.7 6.9 7.2 6.7 7.3 7.3
90th centile 21.5 22.7 24.7 21.7 25.2 25.3
†Vaccine efficacy of 70% after 1 dose in ≥10s and 2 doses in <10s, vaccine efficacy of 35% after 1 dose 
in <10s, no vaccine purchase costs (administration cost of £5.25 only), 70% vaccine coverage in high risk 
groups, 40% vaccine coverage in low risk groups and vaccination of low risk groups beginning on Nov 16.
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Table 3. Proportion of model realisations that indicate that either (i) vaccinating risk groups 
or (ii) extending vaccination from risk groups to low risk 5-14 year old children, is likely to be 
cost-effective, when model assumptions are altered.
proportion of model realisations deemed cost-effective
no one → risk groups risk groups → risk groups + 5-14s
Threshold (£ per QALY gained) £20,000 £30,000 £20,000 £30,000
Base case† 93% 98% 20% 37%
Vaccinating low risk groups 
begins on Nov 23 (1 week delay)
93% 99% 7% 16%
Vaccinating low risk groups 
begins on Nov 30 (2 week delay)
93% 99% 2% 6%
Vaccinating low risk groups 
begins on Dec 7 (3 week delay)
93% 99% 0% 2%
Vaccinating low risk groups 
begins on Dec 14 (4 week delay)
93% 98% 0% 0%
50% vaccine coverage in high risk 
groups
81% 94% 31% 48%
20% vaccine coverage in low risk 
groups
93% 98% 5% 15%
Vaccine efficacy of 85% after 1 
dose in ≥10s, 2 doses in <10s
96% 100% 18% 34%
Vaccine efficacy of 70% after 1 
dose in all (no second dose given)
95% 99% 45% 61%
Vaccine efficacy of 85% after 1 
dose in all (no second dose given)
95% 99% 41% 57%
Cost of vaccine £10 per dose + 
£5.25 administration cost
15% 43% 0% 1%
Lower first wave incidence 96% 100% 34% 51%
Higher first wave incidence 91% 98% 19% 35%
strategies. The first is vaccination of high risk groups only compared to no vaccination. 
The table shows that vaccinating high-risk individuals remains almost certain to be 
cost-effective across most changes in assumptions. Only if vaccine cost is not treated 
as a sunk cost is the cost-effectiveness profile of this strategy affected. Even so, with 
an assumed cost per vaccine dose of £10 (seasonal influenza vaccines cost about £6 
per dose), vaccinating risk groups may still be cost-effective at a threshold of £30,000 
per QALYs gained. Since this strategy is almost always cost-effective, we also show the 
cost-effectiveness of extending vaccination to the next most cost-effective group to 
vaccinate. This is always low-risk children from 5 to 14. This strategy is more sensitive 
to model assumptions. In particular, delays in the programme by just a few weeks 
are likely to cause a large part of the benefit of vaccination to be lost, and hence the 
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strategy to be deemed not cost-effective. Extending vaccination from this group to 
children under 5 or adults over 64 is highly unlikely to be cost effective across all the 
scenarios considered (not shown in the table).
Figure 3 is a tornado diagram that shows the most influential parameters driving 
the cost-effectiveness of vaccinating high risk individuals, as well as the effect of 
varying them across their likely range. The most influential parameter is the overall 
size of the epidemic without vaccination (which is a measure of the uncertainty 
within the epidemiological model). Other key parameters for cost-effectiveness are 
the QALY loss per case, hospitalisation rates and costs, and case-fatality ratios.
figure 3. Tornado diagram showing the influence of the most important parameters on the incremental 
cost-effectiveness ratio of vaccinating high-risk groups. Each bar shows the change in the ratio from its 
baseline figure of £19,600 when each variable is varied between its 25% and 75% endpoints.




The model suggests that a significant fraction of individuals were infected in the 
first wave of the epidemic, and that the peak height of the autumn wave is likely 
to be similar to that observed in summer (subsequent data confirmed this model 
prediction, see Appendix 2). As the risk of serious consequences following infection 
is much higher in the risk groups, it appears that vaccinating these groups is likely 
to be effective at reducing deaths and cost-effective, when compared to widely 
used norms. Extending vaccination to low-risk groups is likely to be much less 
effective at reducing deaths and QALYs lost, partly because of the lower risk in these 
individuals, and partly because the programmes must start later in the epidemic, to 
allow for stocks of vaccine to become available. Furthermore, the effect and cost-
effectiveness of such an extension is highly dependent on its timing. 
The main strength of the paper is that the epidemiological model is fitted to 
the data, well describing the particular double-peaked epidemic observed in 
England. This represents a significant advance over previous assessments of 
H1N1v vaccination policy [e.g. 26,27], as the model is specifically fitted to the 
emerging epidemic data in real-time, which should greatly improve the validity of 
the projections and findings. As the model well describes the unfolding epidemic, it 
provides a sound basis for estimating future infections as well as an assessment of 
the uncertainty around these predictions. We have combined this information with 
economic and health outcome data (including a bespoke study of the impact of 
H1N1v on health-related quality of life) to estimate the potential impact and cost-
effectiveness of vaccination options. Importantly, our key finding that vaccination 
of the high risk groups is probably both effective and cost-effective, is robust to 
uncertainty in epidemiological, outcome and economic parameters. 
The model used was relatively simple. The model was a deterministic mass-
action type transmission dynamic model with no spatial structure assumed. The 
model had to be transmission dynamic in nature in order to assess the impact of 
vaccinating the key transmitters (children) and compare this to other strategies 
(such as vaccinating the elderly or risk groups). It was also clearly necessary to 
structure the model by age and risk group. No further stratifications were necessary 
to evaluate the policy options, and it was thus the simplest model that could be 
chosen. Its simplicity enabled the model to be fitted in real-time. Fitting a stochastic, 
individual based model, for instance, would have been far more computational 
demanding, with no additional benefit for policy evaluation. 
The model provides an estimate of the underlying number of individuals infected in 
the population and how this changed over time. By comparing this with the estimated 
case numbers we could derive a multiplication factor (which we estimated to be 10 
times). This is partly because we are comparing estimated infections (some of which 
would be subclinical) with estimated clinical cases. It is possible that this factor could 
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have changed over time. However, in order to estimate changes in this factor, it would 
have been necessary to have data on changing health seeking behaviours and/or 
changes in the sero-incidence over time. These data were not available in sufficiently 
large samples sizes to infer whether this ratio was changing over time. A constant 
ratio also fitted the data very well (figure 1), and was therefore used. 
One weakness is the lack of information on key parameters surrounding 
vaccination. For example, vaccine efficacy data used for licensing were based on 
H5N1 strains instead of H1N1v strains, and only provided immunogenicity rather than 
efficacy endpoints. Clinical trials of actual H1N1v vaccines are underway, but again 
these will only provide immunogenicity endpoints in the short term. Consequently we 
based our assumptions about vaccine efficacy on experience with seasonal influenza 
vaccines. It is quite possible that H1N1v vaccines will have better efficacy than this. 
If this is the case, scenario analyses suggest that vaccinating low-risk children will 
be substantially more cost-effective than our base case indicates. In addition, it is 
possible that the vaccines will have differential impacts against infection and clinical 
disease. In the absence of any data on the action of the vaccine, we have taken the 
simplest assumptions – that it provides complete protection in those that respond. 
There is also considerable uncertainty in the level of vaccine uptake in different age 
and risk groups. We assumed that 70% of the risk groups would accept vaccination, 
on the basis of a targeted vaccination programme being aimed at them early in the 
second wave of the epidemic. There is no experience of vaccinating low-risk groups 
routinely in the UK (except for the low-risk elderly), and recent attitudinal surveys in 
other countries suggest that uptake is likely to be low in these groups[27;28]. It is 
unavoidable that there will be these gaps in our knowledge, since we are evaluating 
new vaccines aimed at a novel infection, and no similar vaccination programme has 
been attempted in the past. In the time since submission of this paper, it seems that 
the coverage in the high risk group has been lower than anticipated here, and it has 
taken longer to vaccinate them. The impact on the incidence of disease will therefore 
be lower than anticipated here (see Appendix 2 for an updated analysis) and the cost-
effectiveness of the high risk strategy will be lower than is presented in the results. 
Lastly, there is uncertainty about the long-term benefit of vaccination. We have 
assumed that benefits of vaccination only last for the duration of pandemic (assumed 
to be from June 1 2009 to May 31 2010). However, it is likely that H1N1v will be one 
of the circulating seasonal strains in 2010 [30], albeit with some antigenic drift, and 
it is possible that the adjuvanted vaccine will provide some degree of protection a 
year or more after vaccination [31]. If this is the case, then the benefit of vaccinating 
even in December 2009 would be greater than our model currently suggests
Vaccinating school children is the most cost-effective option after vaccination 
of high-risk individuals. Such an option is far more cost-effective if the vaccines can 
be made available by mid-November, but by mid-December would have little effect 
and is almost certainly not cost-effective. Such a rapid roll out of sufficient doses 
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of vaccine may be difficult for operational reasons, since such an extension can only 
begin when high risk individuals have been vaccinated. This suggests that vaccine 
uptake in high risk groups needs to be closely monitored. Once this appears to have 
saturated, making any remaining doses available to low risk groups as promptly as 
possible could be beneficial. Such a move would benefit high risk groups as well, 
since they would be indirectly protected through herd immunity.
Decisions on how to control a novel infection in a rapidly evolving situation 
necessarily have to be made on the basis of incomplete information. In particular, 
the long manufacturing lead-time means that decisions about ordering vaccines 
had to be made before detailed information on the severity of this strain were 
available. As information has become available decisions about how to use this 
stockpile can be refined. Mathematical and economic models are well suited to this 
task as they synthesise information from different sources and provide projections 
under different scenarios. The modelling work presented here has highlighted that 
England had a much larger epidemic in the summer than was previously thought, 
and that the second wave will be of a similar size. This means that vaccination of 
children and other low-risk groups during the latter part of the autumn is likely 
to have a modest impact. This is not necessarily the case elsewhere, where the 
epidemic is not so far advanced. Similar, detailed, real-time modelling and economic 
studies could help to clarify the situation in other countries.
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The appendices can be found at: http://www.sciencedirect.com/science/article/pii/
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To update cost effectiveness estimates for the four dose (3+1) schedule of the seven 
valent pneumococcal conjugated vaccine (PCV7) in the Netherlands and to explore 
the impact on cost effectiveness of reduced dose schedules and implementation of 
10 valent and 13 valent pneumococcal vaccines (PCV10 and PCV13).
design 
Economic evaluation comparing PCV7, PCV10, and PCV13 with no vaccination using 




A cohort of 180,000 newborns followed until 5 years of age. 
Main outcome measures
Costs; gains in life years and quality adjusted life years (QALYs); and incremental 
cost effectiveness ratios.
results
Under base case assumptions—that is, assuming a five year protective period of 
the vaccine and no assumed net indirect effects (herd protection minus serotype 
replacement) among children aged over 5 years—vaccination with PVC–7 in a four 
dose (3+1) schedule was estimated to prevent 71 and 5778 cases of invasive and 
non–invasive pneumococcal disease, respectively, in children aged up to 5 years. 
This corresponds with a total net gain of 173 life years or 277 QALYs. The incremental 
cost effectiveness ratio of PCV7 was estimated at €113,891 (£98,300; $145,000) 
per QALY, well over the ratio of €50,000 per QALY required for PCV7 to be regarded 
as potentially cost effective. A three dose (2+1) schedule of PCV7 reduced the 
incremental cost effectiveness ratio to €82,975 per QALY. For various assumptions 
and including 10% of the maximum net indirect effects among individuals aged 5 
years and over, PCV10 and PCV13 had incremental cost effectiveness ratios ranging 
from €31,250 to €52,947 per QALY.
conclusions 
The current Dutch infant vaccination programme of four doses of PCV7 is not cost 
effective because of increases in invasive disease caused by non–vaccine serotypes, 
which reduces the overall direct effects of vaccination and offsets potential positive 
herd protection benefits in unvaccinated individuals. The 10 valent and 13 valent 
pneumococcal vaccines could have better net health benefits than PCV7 through 
COST EFFECTIVENESS OF PNEUMOCOCCAL VACCINATION AMONG DUTCH INFANTS
EIGHT
162
less replacement disease and increased herd protection. Both these effects could 
substantially reduce the incremental cost effectiveness ratio to possibly acceptable 
levels, if total programme costs can be lowered by reduced schedules, reductions 
in vaccine prices, or both.
inTroducTion
Given the multitude of new vaccines available for introduction into national 
immunisation programmes, health economic modelling of various immunisation 
plans is becoming increasingly important in informing decisions on health policy. 
The decision to introduce the seven valent pneumococcal conjugated vaccine 
(PCV7) into the Dutch national immunisation programme for infants, for example, 
has in part been driven by cost effectiveness considerations [1]. The Dutch Health 
Council estimated the incremental cost effectiveness ratio of vaccination with 
PCV7 compared with no vaccination at €70,000 (£60,300; $89,200) and less than 
€20,000 per quality adjusted life year (QALY) in 2001 and 2005, respectively [1]. 
Crucial factors responsible for the change from a potentially unfavourable cost 
effectiveness ratio in 2001, exceeding €50,000 per QALY, to a favourable ratio 
in 2005 were the inclusion of data on observed herd protection effects in adults 
after nationwide implementation of PCV7 in the USA in 2000 and limited disease 
development caused by pneumococcal serotypes not present in the PCV7 replacing 
pneumococcal serotypes eliminated by the vaccine (replacement disease) [2-4].
Next to direct effects on invasive disease in vaccinees, expected savings from 
herd protection were also part of health economic studies in other European 
countries that introduced PCV7 into their national immunisation programmes 
[5-10]. Both the four dose (3+1) vaccine schedule and the reduced three dose 
(2+1) schedule, as implemented in Norway and the UK [11,12], are highly effective 
against invasive pneumococcal disease caused by vaccine serotypes. However, 
the net overall benefit of national immunisation programmes in many European 
countries has been reduced by increases in invasive disease caused by non–vaccine 
serotypes [12-15]. Importantly, in the first 18–30 months after the introduction 
of PCV7 in the Netherlands, France, and the UK, no overall reduction in invasive 
disease in non–vaccinees was observed [12,13,15]. 
Given that both increases in invasive disease caused by non–vaccine serotypes 
and absence of herd protection may considerably affect the cost effectiveness of 
the current Dutch vaccination programme, we set out to update cost effectiveness 
estimates for the current four dose schedule of PCV7 by using recent data on 
epidemiology and resource use. Also, we investigate the cost effectiveness of reduced 
dose schedules and vaccine price reductions combined with the implementation of 
10 valent and 13 valent pneumococcal vaccines (PCV10 and PCV13). 





We designed a decision tree analytic model structure that builds on our previously 
reported model [9,16]. Various data sources were used to populate our model; these 
included clinical trials and observational studies for effectiveness of pneumococcal 
vaccines, laboratory data for incidence and serotype distributions of pneumococcal 
disease, and registrations for resource use and costs. Figure 1 shows the disease 
model for the health effects of pneumococcal vaccination, including the possibility 
of subsequent pneumococcal disease such as non–invasive pneumonia, otitis media, 
and invasive pneumococcal disease. Assumptions regarding both costs and quality of 
life are summarised in Table 1 and are more thoroughly discussed in Appendix 1. In the 
analyses, a cohort of 180,000 newborns, representing the Dutch birth cohort, was run 
through the decision tree twice: once as a mainly vaccinated cohort (PCV7/PCV10/
PCV13); and once as an unvaccinated cohort. The analytic time frame of the study 
was five years because vaccine effectiveness could not be assumed beyond five years. 
However, long term effects of invasive pneumococcal disease were extrapolated over 
the full lifetime of the individuals in the cohort (that is, until death or 100 years).
baseline disease risks
Surveillance data on the incidence and serotype distribution of invasive 
pneumococcal disease before national implementation of PCV7 were available for 
the period 2004–2006, including data on age, primary focus of infection, resource 
use, hospital admission, and outcome [17,18]. The case–fatality rate for meningitis 
and bacteraemia without focus in children was estimated to be 9% (Table 1)[16], 
which is in line with the international literature [7,10,19]. Invasive pneumonia and 
bacteraemia with focus were assumed not to result in death in children [16]. In our 
model, severe mental and physical handicap resulting from meningitis was assumed 
to occur in 13% of cases of pneumococcal meningitis in children, of which 50% 
would require special education and 25% intensive “round the clock” institutional 
care [9]. Jansen et al. found that hearing problems occurred in 32% of cases of 
meningitis, of which 50% were serious enough to require a cochlear hearing device 
[16]. Baseline risks for non–invasive pneumonia requiring hospital admission and 
for non–invasive pneumonia and acute otitis media treated in general practitioner 
surgeries were estimated from national hospital and general practitioner records, 
respectively (see Appendix Table A).
vaccine efficacies
Vaccine efficacy against invasive pneumococcal disease was assumed at 97.4% 
after two doses for all seven serotypes of pneumococcal disease covered by PCV7 
(Table 1)[20]. This value seems to be a conservative estimate if one takes into 
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disease (all vaccine serotypes)
97.4% Lognormal (SD 0.044) 1 20
Community–acquired 
pneumonia (Hospitalized)
11.1% Lognormal (SD 0.082) 2 21
Community–acquired pneumonia 
(general practitioner)
6.0% Lognormal (SD 0.032) 3 21
Acute otitis media 7.0% Lognormal (SD 0.011) 4 22
case–fatality ratio (birth cohort)
Meningitis 9% Beta (3,32) 5 18
Pneumonia 0% N/A N/A 18
Bacteraemia with focus 0% N/A N/A 18
Bacteraemia without focus 9% Beta (2,21) 6 18
Respiratory infections 0% N/A N/A Assumed
case–fatality ratio (5 years and older)
Meningitis 9%–92% Beta (age dependent) 5 18
Pneumonia 0%–29% Beta (age dependent) 7 18
Bacteraemia with focus 0%–33% Beta (age dependent) 8 18
Bacteraemia without focus 9%–67% Beta (age dependent) 6 18
Respiratory infections 0% N/A N/A Assumed
direct costs (€)





26–2,614 Triangular (severity 
dependent)
9 16,23,24
Acute otitis media  17–381 Triangular (severity 
dependent)
4 16,23,24
Special education  
(annual costs)
9,798–16,962 Triangular (age 
dependent)
10 16
Institutional care  
(annual costs)
39,583 Triangular (29,687 
;39,583;49,478)
11 23
Cochlear implantation 56,633 Triangular (0; 0.004; 
0.01)
12 25
indirect costs in (€)
Invasive pneumnococcal 
diseaseb
0–974 Triangular (severity 
dependent)
1 18,23










115–315 Triangular (severity 
dependent)
9 16,23




Disabilityc 0.53 Beta (estimated) 11 26
bilateral hearing loss (first 
year)c 
0.45 Beta (estimated) 12 7,27
Bilateral hearing loss cochlear 
devicec
0.18 Beta (estimated) 12 7,27
All other hearing lossd 0.09 Beta (estimated) 13 26
Hospitalized bacteraemiad 0.0079 Beta (estimated) 14 7,28
Hospitalized meningitis 0.0232 Beta (estimated) 15 7,28
Hospitalized community–
acquired pneumoniae




pneumonia treated at the 
general practitionere
0.004 Triangular (0, 
0.004,0.01)
3 7




Increase in non–vaccine 
serotype invasive 
pneumococcal diseasef
100% Triangular (50%, 
100%, 150%)
N/A 12,29f
Net–indirect effect for PCV10 
and PCV13g
10% Triangular (0%, 10%, 
30%)
N/A Assumedg
Discount rate health effects 1.5% N/A N/A 30
Discount rate costs 4% N/A N/A 30
a Based on the average duration hospitalization (both IC and general hospitalisation days) and 
corresponding unit costs23. See also Appendix Table A.2 for age specific hospitalisation costs
D Indirect costs due to work loss of parents taking care of their children.
c Indirect costs due to work loss of patient unable to work due to hospitalization. 
c Per year.
d Same QALY decrement was assumed for invasive pneumonia, bacteraemia with another focus and 
bacteraemia without a focus.
e Per case.
r See also Appendix B Indirect effects in the analysed birth cohort.
g See also Appendix C. Indirect effects for those aged 5 years and older. 
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account the fact that only one vaccine failure has been reported in the Netherlands 
in the first two years after introduction of routine infant vaccination in June 2006. 
Routine vaccination for infants in a 2+1 dose schedule was introduced in Norway 
in 2006, and similarly no vaccine failures had occurred up to June 2008 [11,21]. 
Protection against invasive disease was thus estimated to last for five years in the 
base case analysis [21,31]. Furthermore, in randomised controlled settings, the 
vaccine was shown to be effective against non–invasive pneumonia and otitis media 
in children [21,22,32]. For non–invasive pneumonia, efficacy of pneumococcal 
vaccination seems to increase with diagnostic certainty [21].
In our model, we applied the efficacy estimate of 11.1% for “clinical pneumonia and 
perihilar findings” to children admitted to hospital with the diagnosis of pneumonia 
in the Netherlands [21].This definition of pneumonia seems to best fit the types of 
pneumonias treated in Dutch hospitals. An efficacy of 6.0% was assumed for patients 
who visited a general practitioner and were diagnosed with pneumonia [21]. In two 
randomised studies, PCV7 was found to prevent 6.4% to 7.0% of all cases of acute 
otitis media [21,21,33]. The interpretation of these studies for the Dutch setting is 
hampered by several factors, including the fact that the causal micro–organism is 
not recorded in cases of otitis media in the Netherlands. In our model, we used an 
overall efficacy estimate of 7.0% for otitis media on the basis of the most recent data 
from the Kaiser Permanente trial [22]. Given evidence for the duration of protection 
against non–invasive pneumonia and recent US surveillance data, we assumed that 
vaccinated children were protected against non–invasive pneumonia and otitis media 
up to their second year of life, starting after the second dose of the vaccine [18,32,34]. 
A vaccine efficacy of 97.4% against all serotypes included was assumed for PCV10 
and PCV13, similar to the assumed efficacy of PCV7. In the absence of clinical data on 
the efficacy of PCV10 and PCV13 against non–invasive pneumonia and acute otitis 
media, the efficacy of these two vaccines was assumed to increase proportionally 
with the increase in serotype coverage for invasive pneumococcal disease.
indirect effects
As well as estimations of the direct effects, we also estimated indirect effects of 
vaccination in our model. We included in our base case analysis herd protection 
against invasive pneumococcal disease for children in the birth cohort not yet fully 
protected by the vaccine and for non–vaccinated children, assuming this protection 
would be as effective as vaccination (Table 2)[12,13]. We also increased the incidence 
of invasive pneumococcal disease caused by non–vaccine serotypes to 100% for the 
analysed birth cohort (that is, we doubled the incidence of invasive pneumococcal 
disease caused by non–vaccine serotypes) on the basis of surveillance data from 
early after national introduction of PCV7 in the Netherlands and the UK [12,13]. See 
Appendix 2 for a more in depth description of the assumptions for our estimation of 
indirect effects in the birth cohort.
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No serotype information for acute otitis media and non–invasive pneumonia is 
available in the Netherlands, and serotype replacement for these diseases may be 
assumed to be already included in the vaccine efficacy estimates in the first efficacy 
studies [21,22,32]. Therefore, we did not include an additional increase of non–
vaccine serotype disease but also left out potential herd effects for otitis media and 
non–invasive pneumonia (see Appendix 2).
We assumed in our base case analysis for PCV7 that no net indirect effect 
would exist for individuals outside the modelled cohort. This assumption was made 
because no reduction in the incidence of invasive pneumococcal disease has been 
observed after the introduction of routine vaccination with PCV7 for individuals 5 
years of age or older and because the observed herd protection effect in the UK in 
the third year after introducing routine vaccination was completely countered by 
a rise in invasive pneumococcal disease caused by non–vaccine serotypes [12]. In 
this respect, net indirect effects are defined as cases of invasive disease averted by 
herd protection minus invasive cases of replacement disease. 
Net indirect effects may occur in the future, especially if serotype coverage 
is extended by a change from seven serotype vaccines to vaccines with broader 
serotype coverage [13,18]. Therefore, in the base case analysis for PCV10 and 
Table 2. Base case serotype coverage and efficacy for direct effects and assumptions on 
indirect effects for the analysed birth cohort and the remaining population (those aged 5 
years or older) for PCV–7, PCV–10, and PCV–13
pcv7 pcv10 pcv13
Serotypes covered 4,6B, 9V, 14, 18C, 19F, 23F + 1, 5, 7F + 3, 6A, 19A
Increase in invasive pneumococcal 
disease caused by non–vaccine 
serotypes in the analysed birth 
cohort (serotype replacement)
100% 100% 100%
Efficacy and level of herd protection 
against vaccine serotypes of 
invasive pneumococcal disease in 
the analysed birth cohorta
97.4% 97.4% 97.4%
Net–indirect effect in the remaining 
populationb
0% 10% 10%
a Herd protection was assumed for the entire birth cohort including those not yet (fully) protected by 
the vaccine (either too young to be vaccinated or those who received only a single dose of the vaccine) 
and non–vaccinated children (5% of a birth cohort for the Dutch situation) assuming a protection effect 
of 97,4% against vaccine serotype similar to the vaccine efficacy. 
d Net–indirect benefits are defined as the benefits due to protection against invasive pneumococcal 
disease caused by vaccine serotypes minus the increase of invasive pneumococcal disease due to 
non–vaccine serotype. The potential maximum was defined as full reduction of invasive pneumococcal 
disease cases due to vaccine serotype in the absence of any replacement. Lower percentages can 
be defined as a combination of decrease in vaccine serotype and increases in non–vaccine serotype 
invasive pneumococcal disease.
PCV7/10/13= 7/10/13–valent pneumococcal conjugated vaccine
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PCV13, a net indirect effect for invasive disease at 10% of the potential maximum 
was applied for those aged 5 years or older (see Appendix 3). In particular, the 
potential maximum was defined as prevention of all cases of invasive disease 
caused by serotypes in the vaccine and absence of any replacement disease. Net 
protective indirect benefits against otitis media and non–invasive pneumonia were 
not included in any of the analyses [34]. Given that there is much uncertainty about 
the development of indirect effects, these assumptions were varied over a wide 
range in the sensitivity analyses.
outcome measures and cost effectiveness analysis
The simulation model tracks all the specific disease cases and the deaths, costs, 
changes in QALYs and life years, and indirect effects (herd protection and serotype 
replacement). We were able to determine the net costs and net life years and 
QALYs gained by summing all the costs, life years, and QALYs and calculating the 
differences for the evaluations with and without vaccination. The incremental cost 
effectiveness ratio was calculated by dividing the net costs by either life years or 
QALYs. Health effects and cost were discounted at 1.5% and 4% for time preference, 
respectively, according to the Dutch guidelines for cost effectiveness research [30].
Incremental cost effectiveness ratios for routine vaccination were calculated 
by comparing different vaccination schedules against no vaccination. Following 
recently published evidence on the efficacy of PCV7 in reduced dose schedules 
[35,36], we investigated the effect of a three dose schedule (that is, 2+1) to test 
the effect of lower total vaccination costs (see Appendix 4). We also forecasted 
the incremental cost effectiveness of potential shifts from PCV7 to pneumococcal 
vaccines that include additional serotypes (that is, PCV10 and PCV13). 
For PCV7, the estimated current cost of €50 per dose within the Dutch national 
immunisation programme was used [9,16]. For PCV13, the officially listed price of 
€68.56 was applied, with administration costs of €5.95 being added (total cost per 
dose €74.51)[16]. For PCV10, no officially listed price is available in the Netherlands. 
Given that we know the pricing of PCV10 in other countries is pessimistic compared 
with PCV13, we assumed the total cost per dose of PCV10 at the midpoint between 
PCV7 and PCV13 (that is, €62.25)[37].
scenario and sensitivity analyses
We performed univariate, threshold, scenario, and probabilistic sensitivity analyses. 
In the univariate sensitivity analyses, all relevant parameters were varied by 25% to 
explore the impact of each parameter relative to each other. One specific threshold 
analysis was performed in which the effect of the parameter on the incremental 
cost effectiveness ratio was investigated by varying the net indirect effects on 
individuals aged 5 years or older over a range of 0% to 30%. For the probabilistic 
sensitivity analyses, parameters were generated using Monte Carlo sampling, with 
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outcome values generated by running the model 5000 times. Log normal, beta, 
and triangular distributions were used except for multinomial probabilities, where 
Dirichlet distributions were assumed (see Table 1 for specific distributions).
resulTs
cost effectiveness of pcv7
In the base case analysis, the estimated burden of pneumococcal infection for a birth 
cohort followed for five years was 170,788 cases of acute otitis media and 19,385 
cases of non–invasive pneumonia, of which 2645 cases would result in hospital 
admission (Table 3). Applying the base case assumptions, 5372 cases of acute otitis 
media and 406 cases of non–invasive pneumonia would be prevented by vaccination 
with PCV7, corresponding to gains of 27 and 2 QALYs, respectively. Additionally, 188 
cases of invasive pneumococcal disease a year were estimated in children under 5 
years of age: 65 cases of meningitis; 45 cases of invasive pneumococcal disease; 
38 cases of bacteraemia with focus; and 40 cases of bacteraemia without focus. 
In total, 71 cases of invasive disease would be prevented by vaccination with PCV7, 
corresponding to a total gain of 173 life years or 248 QALYs. In addition to the health 
gains, vaccination with PCV7 would also prevent approximately €2.2 million of direct 
costs and €0.4 million of indirect costs. Assuming a four dose schedule, the annual 
cost of vaccination is estimated at €34.2 million. Dividing the incremental costs by 
the incremental health benefits results in an incremental cost effectiveness ratio of 
€113,891 per QALY gained for PCV7. An incremental cost effectiveness ratio of less 
than €50,000 per QALY would be required for PCV7 to be regarded as potentially 
cost effective. Shifting from a 3+1 dose schedule to a 2+1 regimen could improve 
cost effectiveness of PCV7 to €82,975 per QALY (Table 4).
cost effectiveness of pcv10 and pcv13
Compared with no vaccination, vaccination with PCV10 would prevent 6124 cases 
of otitis media, 463 cases of non–invasive pneumonia, and 258 cases of invasive 
pneumococcal disease, of which 150 would be averted by net indirect effects in 
individuals aged 5 years and older. Overall these health benefits would result in a 
gain of 707 QALYs. Vaccination with PCV13 would prevent 6876 cases of otitis media, 
520 cases of non–invasive pneumonia, and 331 cases of invasive pneumococcal 
disease, resulting in a total gain of 891 QALYs. 
Dividing the incremental costs by the incremental health benefits for the 10 valent 
and 13 valent vaccines produced incremental cost effectiveness ratios of €52,947 
and €50,042 per QALY for PCV10 and PCV13, respectively. A 2+1 dose schedule 
could reduce these incremental cost effectiveness ratios to €37,891 for PCV10 and 
to €35,743 for PCV13 (Table 4). A 25% reduction in the vaccine price of PCV10 and 
PCV13 (to €50 per dose, the cost of PCV7) would reduce the cost effectiveness ratios 
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Table 3. Base–case analysis results for the analysed Dutch birth cohort. The Table shows: 
cases, direct costs and savings, life years, QALYs, direct and indirect cost savings (related 
to production losses) specified for acute otitis media, community–acquired pneumonia, and 
invasive pneumococcal disease (between brackets the additional invasive pneumococcal 
disease cases, QALYs, LY, and costs are shown related to net–indirect effects for those aged 









disease related to net 
indirect effects for 
individuals aged 5 years 
or oldera Total
cases (undiscounted)
No vaccination 170,788 19,385 188 2410 NA
PCV7 165,416 18,979 117 210 NA
PCV10 164,664 18,922 80 2260 NA
PCV13 163,912 18,865 38 2229 NA
cases averted
PCV7 5372 406 71 0 NA
PCV10 6124 463 108 150 NA
PCV13 6876 520 150 181 NA
Qalys gained
PCV7 27 2 248 0 277
PCV10 30 2 361 314 707
PCV13 34 2 470 384 891
life years gained
PCV7 0 0 173 0 173
PCV10 0 0 255 312 566
PCV13 0 0 336 381 717
direct savings (€ *1000), excluding vaccination costs
PCV7 € 126 € 375 € 1,725 € 0 € 2226
PCV10 € 144 € 427 € 2,454 € 1398 € 4422
PCV13 € 161 € 479 € 3,181 € 1696 € 5518
indirect savings (€ *1000; direct effects)
PCV7 € 320 € 74 € 46 € 0 € 440
PCV10 € 365 € 84 € 67 € 161 € 677
PCV13 € 410 € 94 € 93 € 202 € 799
a Only net indirect effects against invasive pneumococcal disease were included in the model for 
individuals aged 5 years or older. For PCV–7, no net indirect effects were included into the model for 
individuals aged5 years or older in the base case analysis.
NA= Not applicable, QALY= quality adjusted life years; PCV7/10/13= 7/10/13–valent pneumococcal 
conjugated vaccine
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Without net–positive indirect effects for those 
aged 5 years and oldera
€ 113,891b € 99,151 € 91,705 
With 10% net–positive indirect effects for those 
aged 5 years and oldera
€ 59,937 € 52,947b € 50,042b
With 20% net–positive indirect effects for those 
aged 5 years and oldera
€ 39,698 € 35,146 € 33,479
2+1–dose schedule
Without net–positive indirect effects for those 
aged 5 years and oldera
€ 82,975 € 72,083 € 66,572 
With 10% net–positive indirect effects for adults 
and elderlya
€ 43,070 € 37,891 € 35,743
With 20% net–positive indirect effects for those 
aged 5 years and oldera
€ 28,101 € 24,718 € 23,488
Reduction in the cost of the vaccine (€50 per dose) NAb € 41,106 € 31,250
Excluding herd effects in the analysed birth cohort 
for invasive invasive pneumnococcal diseasec
€ 129,069 € 57,770 € 55,055
Including herd effects in the analysed birth cohort 
for non–invasive pneumnococcal diseasec
€ 111,153 € 52,211 € 49,407
Higher utility lossesc,d € 67,581 € 40,136 € 38,664
Exclusion of productivity losses (analysis from the 
health–care perspective)c
€ 115,481 € 53,904 € 50,938
Efficacy against acute otitis media according to 
POET studyc,e
€ 78,527 € 43,048 € 41,457
a Inclusion of net–positive indirect effects (herd protection against vaccine serotype disease minus 
non–vaccine serotype pneumnococcal disease increases) see also Appendix B.
D Base–case scenario. 
c Scenarios were calculated holding all other assumptions similar to the base–case analysis (no net–
indirect benefits for PCV7 and 10% for PCV10 and PCV13). 
d Utilities reported by Prosser et al. were used for children aged up to 5 years old.[38]
e Efficacy against acute otitis media was assumed to be 33.6%, as was shown for the precursor vaccine 
of PCV–10 by Prymula et al. [39]
QALY= quality adjusted life years; PCV7/10/13= 7/10/13–valent pneumococcal conjugated vaccine; 
NA= Not applicable
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to €41,106 and €31,250, respectively. Assuming both a dose (to three doses) and a 
price reduction (to €50 per dose), the cost effectiveness ratios for PCV10 and PCV13 
would be as low as €29,013 and €21,654 per QALY, respectively.
scenario and sensitivity analyses
Figure 2 shows the parameters that produced the largest variation in the cost 
effectiveness ratio for PCV7 when varied by 25%. Apart from vaccine efficacy 
against invasive pneumococcal disease, the most important determinants of the 
cost effectiveness of PCV were the total vaccination costs, the increase in invasive 
pneumococcal disease caused by non–vaccine serotypes, and the case fatality rate for 
meningitis. In univariate sensitivity analyses for PCV10 and PCV13, generally similar 
but smaller changes in the incremental cost effectiveness ratio were observed. The 
changes were smaller because of the relative importance of indirect benefits in the 
unvaccinated population for PCV10 and PCV13. Figure 3 shows the impact of varying 
the level of net indirect effects of vaccination in individuals aged 5 years or over. At 
least 14% of the estimated net indirect effect would be needed in order to make 
PCV7 cost effective (that is, less than €50,000 per QALY). Several scenario analyses 
are displayed in Table 4, which again show the large impact of indirect effects and 
reduced dose schedules on the cost effectiveness of pneumococcal vaccination.
Finally, Figure 4 shows cost effectiveness acceptability curves for six different 
scenarios. This Figure clearly shows that administering PCV7 in a 3+1 dose 
schedule cannot be considered as cost effective compared with no vaccination. The 
incremental cost effectiveness ratios of PCV10 and PCV13 are likely to be more 
favourable than that for PCV7, yet still the total costs of vaccination should be 
reduced in order to unambiguously consider vaccination cost effective. 
discussion
Our economic analysis indicates that the current national vaccination programme 
with PCV7 in the Netherlands is not cost effective. As several papers suggest that 
lowering the number of doses from four to three will not affect the vaccine efficacy 
for the pneumococcal vaccine [11,35,36,40], we investigated the potential impact 
of such reduced–dose schedules. Although a 2+1 reduced dose schedule could 
lower the total cost of vaccination and, therefore, reduce the incremental cost 
effectiveness ratio by approximately 30%, it is unlikely that universal vaccination 
with PCV7 will become acceptable on the grounds of cost effectiveness. 
More favourable incremental cost effectiveness ratios were shown for PCV10 
and PCV13, as long as net positive indirect effects for individuals aged 5 years or 
older were included in the analyses. In particular, scenarios that used reduced total 
vaccination costs by using a 2+1 dose schedule showed that incremental cost 
effectiveness ratios would decrease down to €37,891 and €35,743 per QALY for 




figure 2. Sensitivity analysis assumptions on base case cost–effectiveness ratio (PCV7). 
Parameters were changed with 25%. Black bars show the incremental cost–effectiveness ratio 
for a 25% decrease for the parameter varied, while the grey bars show the incremental cost–
effectiveness ratio for a 25% increase the parameters (note that this was not possible for the 
vaccine efficacy). IPD= invasive pneumococcal disease; AOM = acute otitis media; PCV7= 7–valent 
pneumococcal conjugated vaccine.
figure 3. The effect on cost effectiveness ratios of varying the level of net indirect effect of 
vaccination for individuals aged 5 years or older. The horizontal dashed line shows the threshold 
at €50,000 per QALY. PCV7/10/13= 7/10/13–valent pneumococcal conjugated vaccine, QALY= 
quality adjusted life years
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PCV10 and PCV13, respectively. These ratios are likely to be considered as cost 
effective given various country specific thresholds.
strengths and weaknesses
This is the first economic evaluation of national vaccination against pneumococcal 
disease that has included serotype replacement for the analysed birth cohort 
by using post–vaccination data [12,13]. We estimated the number of cases of 
invasive pneumococcal disease averted by vaccination and the increase in invasive 
pneumococcal disease caused by non–vaccine serotypes on the basis of the most 
recent data available [18]. Given the relatively small number of cases reported 
during the surveillance period of two years, our predictions regarding the increase of 
disease caused by non–vaccine serotypes may have limited precision; however, they 
are based on the best data currently available. In particular, the estimated increase 
of 100% for invasive disease caused by serotypes not covered by PCV7 was based 
on national observational studies from the Netherlands and the UK [12,13,18]. On 
the one hand, this specific assumption may be too conservative. On the other hand, 
data from the UK show an ongoing increase in the cases of invasive pneumococcal 
disease caused by non–vaccine serotypes and no plateau has yet been reached in 
the third year after PCV7 introduction, suggesting that the eventual increase in 
disease caused by non–vaccine serotypes might even be higher [12]. There are, 
however, some important differences between the Netherlands and the UK. In 
contrast to the Netherlands, the UK uses a reduced dose schedule of PCV7 at 2, 4, 
and 13 months. Also, the introduction of PCV7 in the UK was followed by a catch–up 
 
figure 4. Cost effectiveness acceptability curves for base case vaccination schedules and for 
alternative scenarios for PCV7, PCV10, and PCV13. Black lines indicate acceptability curves for 
PCV7, grey lines for PCV10 and red lines for PCV13. PCV7/10/13= 7/10/13–valent pneumococcal 
conjugated vaccine
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programme for all children aged less than 2 years. In the Netherlands, by contrast, 
vaccination was implemented without a catch–up programme. Several alternative 
scenarios regarding serotype replacement were explored in the sensitivity analyses, 
which showed that our conclusions regarding the incremental cost effectiveness 
ratios for all three vaccines were quite robust.
In our base case analysis for PCV7, we assumed that there was no net indirect 
effect of vaccination for individuals outside the modelled birth cohort because no 
overall reduction in invasive pneumococcal disease in non–vaccinees has been 
observed in any European country, in contrast to the US [12,13,15]. The difference 
between results obtained in the US and those recorded in Europe may be partly 
explained by the 60% to 70% coverage of the seven vaccine serotypes in Europe, 
compared with the more than 80% coverage in the US [41]. This disparity leaves 
more room for replacement disease in Europe. Country specific differences in the 
circulating serotypes causing disease (inclusive of secular changes in time) could 
also contribute to the lower overall reduction of invasive pneumococcal disease in 
Europe compared with the US [42]. Furthermore, in the Netherlands, as in most 
parts of Europe, the baseline incidence rates of invasive pneumococcal disease 
in children are substantially lower than in the US and almost exclusively based on 
culture confirmed cases of children admitted to hospital [18,43]. Another potentially 
relevant difference in the introduction of PCV7 in the Netherlands compared with 
the US is the high vaccine uptake (>95%) among all newborns in the Netherlands 
for all four doses of the vaccination, which could potentially lead to more rapid 
development of replacement disease [43].
Potential net indirect effects in non–vaccinees were modelled using straightforward 
calculus. Ideally, the impact of pneumococcal vaccination should have been modelled 
using a so called dynamic transmission model, in which the transmission and carriage 
of Streptococcus pneumoniae is taken explicitly into account. However, because 
the transition dynamics of S. pneumoniae are complex and serotype dependent, and 
detailed data regarding these transmission dynamics are also quite limited, dynamically 
modelling all relevant serotypes of S. pneumoniae would be very complicated. For PCV10 
and PCV13, a net indirect effect of 10% was included in the base case analysis. This 
estimate of indirect benefit may be conservative if compared with the much higher 
net indirect protective benefits observed in the US after implementation of routine 
vaccination with similar or lower vaccine serotype coverage [2-4]. 
Furthermore, we did not include the benefits arising from the prevention of 
antibiotic resistance in our model because the impact of this inclusion is expected 
to be small given that penicillin resistance is less than 0.4% in the Netherlands [18]. 
Finally, similar to almost all previous cost effectiveness analyses for pneumococcal 
vaccination, our analytic time frame was equal to the assumed protection period, 
after which we assumed that health effects and costs would be similar in the 
vaccinated and unvaccinated group.
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comparison with other studies
The cost effectiveness of PCV7 is worse than that calculated in our previous studies 
and in other recent health economic studies [6-10,16,19,44]. This disparity is mostly 
because of the exclusion of herd protection effects and the inclusion of serotype 
replacement in our study. Other factors contributing to the worse incremental cost 
effectiveness ratio were the use of a lower death rate for invasive pneumococcal 
disease and lower indirect costs than in our previous studies [9,16].
Several recently published cost effectiveness studies included net vaccine 
benefits for unvaccinated adults and elderly people in their base case analysis 
[6,8-10,44]. These studies reported vaccination to be cost saving [6,10] or at 
least cost effective [8,9,44]. The three studies that excluded herd protection in the 
base case analysis reported relatively unfavourable cost effectiveness ratios for 
PCV7 compared with other recommended infant vaccinations [7,16,19]. When we 
excluded the increase in invasive pneumococcal disease caused by non–vaccine 
serotypes but left all other assumptions the same as in the base case analysis, 
our results were similar to those of these three studies—that is, we found an 
unfavourable cost effectiveness ratio [7,16,19].
Our cost effectiveness results show that the current vaccination schedule for 
PCV7 might be far more expensive per QALY gained compared with other routine 
infant vaccination programmes recently implemented, such as for human papilloma 
virus [45], or with other vaccines that have not yet been implemented in a national 
programme in the Netherlands, such as hepatitis B [46] and Varicella [47].
implications and future research
Administration of PCV7 at 2, 3, 4, and 11 months was introduced to the Netherlands 
as part of the national immunisation programme in 2006 partially on the basis of 
favourable cost effectiveness data. The current analysis shows unfavourable cost 
effectiveness of the PCV7 3+1 dose schedule because of increases in invasive 
disease caused by non–vaccine serotypes, which offset the herd protective benefits 
in individuals outside the analysed birth cohort. Although the cost effectiveness of 
PCV7 is unfavourable from a health economics point of view, it is favourable from a 
public health point of view—a significant decrease in cases of pneumococcal disease 
has occurred in the Netherlands over the past two years13. Switching to the 10 valent 
or 13 valent vaccine would extend the serotype coverage to a higher level than that 
currently achieved with PCV7, which might reduce the potential for disease caused by 
non–vaccine serotypes and increase the overall benefits in vaccinated children. 
Herd protective effects are more likely to occur with broad vaccine coverage, 
rendering vaccination potentially cost effective. Vaccination would be particularly 
cost effective if a more valent vaccine is used in combination with dose reductions, 
price reductions, or both. Our paper should help guide future decisions to potentially 
reduce doses of pneumococcal vaccine or to shift from PCV7 to vaccines that cover 
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additional serotypes. Further research should be directed to building a dynamic 
model to entangle and explicitly predict the indirect effects of disease replacement 
and herd protection on vaccine efficacy and thus further enhance the validity of 
cost effectiveness approaches applied to pneumococcal vaccination.
appendices
The appendices can be found at: 
http://www.bmj.com/content/suppl/2010/06/02/bmj.c2509.DC1
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We investigated the effect of the 7-valent pneumococcal conjugate vaccine (PCV7) 
programme in England on serotype-specific carriage and invasive disease to help 
understand its role in serotype replacement and predict the impact of higher 
valency vaccines. 
methods and findings
Nasopharyngeal swabs were taken from children,5 y old and family members 
(n=400) 2y after introduction of PCV7 into routine immunization programs. 
Proportions carrying Streptococcus pneumoniae and serotype distribution among 
carried isolates were compared with a similar population prior to PCV7 introduction. 
Serotype-specific case:carrier ratios (CCRs) were estimated using national data 
on invasive disease. In vaccinated children and their contacts vaccine-type (VT) 
carriage decreased, but was offset by an increase in non-VT carriage, with no 
significant overall change in carriage prevalence, odds ratio 1.06 (95% confidence 
interval 0.76–1.49). The lower CCRs of the replacing serotypes resulted in a net 
reduction in invasive disease in children. The additional serotypes covered by higher 
valency vaccines had low carriage but high disease prevalence. Serotype 11C 
emerged as predominant in carriage but caused no invasive disease whereas 8, 
12F, and 22F emerged in disease but had very low carriage prevalence. 
conclusion
Because the additional serotypes included in PCV10/13 have high CCRs but low 
carriage prevalence, vaccinating against them is likely to significantly reduce 
invasive disease with less risk of serotype replacement. However, a few serotypes 
with high CCRs could mitigate the benefits of higher valency vaccines. Assessment 
of the effect of PCV on carriage as well as invasive disease should be part of 
enhanced surveillance activities for PCVs.
inTroducTion
Streptococcus pneumoniae is a bacterium that frequently colonises the human 
nasopharynx. Apart from disease outcomes such as sinusitis, otitis media, 
and community-acquired pneumonia, which result from direct spread from 
the nasopharynx, the pneumococcus can invade the bloodstream and cause 
septicaemia, meningitis, and invasive pneumonia. Most carriage episodes, however, 
do not result in either local or systemic disease. It is believed that the propensity 
to cause invasive disease in healthy individuals—termed invasiveness—is largely 
determined by the characteristics of the pneumococcus’ polysaccharide capsule, 
although the explicit underlying mechanisms are yet to be identified [1,2]. On the 
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basis of the immune response to differences in capsular polysaccharide structure, 
more than 90 serotypes causing invasive disease have been described [3]. 
A pneumococcal conjugate vaccine (PCV7) that induces anticapsular antibodies 
against the seven serotypes, which at that time were responsible for most of the 
pneumococcal invasive disease in the United States (US), was introduced into the US 
childhood immunisation schedule in 2000 and the majority of the developed world 
subsequently. Since PCV7 is protective against invasive pneumococcal disease (IPD) 
[4] and carriage [5,6], the assumption of protection of the unvaccinated against 
vaccine type (VT) IPD through herd immunity played a major role in evaluating the 
likely impact and cost-effectiveness of vaccination [7]. Prevention of VT carriage, 
however, creates a potential ecological niche in the nasopharynx for previously less 
prevalent serotypes to emerge (replacement). 
The extent to which the benefits of herd immunity will be offset by serotype 
replacement is hard to predict [8] and may vary by country depending on local factors 
such as differences in serotype distribution before vaccination and the population 
demography. Hence, there is a need for enhanced surveillance to evaluate the effect of 
vaccination in different epidemiological settings. Most surveillance systems focus on IPD 
and have shown large reductions in the numbers of VT cases in the targeted age groups, 
irrespective of vaccine schedule [9–11]. However, differences were observed in the 
indirect effect (i.e., the degree of induced herd immunity and the level of non–vaccine-
type [NVT] replacement), the reasons for which remain unclear but may include vaccine 
coverage, time since introduction of PCV, and sensitivity of the reporting system [12]. 
Monitoring disease outcomes provides little insight into the underlying 
mechanisms that determine herd immunity and serotype replacement. For this, 
carriage data are essential. Carriage studies in children from Massachusetts 
and Norway suggest full replacement of pneumococcus in carriage after PCV7 
introduction [13,14]. The implications of changes in serotypespecific carriage 
prevalence for expression as IPD will, however, depend on the invasiveness of 
individual serotypes, which is reflected by the case:carrier ratio (CCR). Invasiveness 
has only been studied in one of these settings and was restricted to children 
[15,16]. Improving our understanding of this relationship, largely determined by the 
invasiveness potential of the replacing NVT organisms, is essential to understanding 
the effect of PCV7 in different epidemiological settings. 
In September 2006, PCV7 was introduced into the immunisation schedule in the 
United Kingdom as a 2/4/13-month routine schedule with a catch-up for children 
up to 2 y of age. Information on carriage in England prior to PCV7 introduction is 
available from a longitudinal study conducted in 2001/2002 in index children and 
their household members. We report here the results of a cross-sectional carriage 
study conducted in a demographically similar population in 2008/2009. We compare 
our post-PCV7 findings with the pre-PCV7 baseline both for carriage and IPD to help 
understand the serotype-specific effects of PCV7 on both carriage and IPD and use 
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this analysis to predict the potential impact of higher valency conjugate vaccines on 
herd immunity and replacement disease. 
meThods
study population
Children born since 4 September 2004 and thus eligible for routine or catch-up PCV 
were recruited along with family members from general practices in Hertfordshire and 
Gloucestershire. Exclusion criteria were: moderate to severe disability, cerebral palsy, 
neurological disorders affecting swallowing, ear, nose, and throat disorders affecting the 
anatomy of the ear, or immunosuppression. The NHS National Research Ethics Service 
approved the study protocol. Written informed consent was obtained from adult study 
participants and from a parent/ guardian of study children prior to enrolment. Information 
was collected on participants’ age, gender, household size, number of smokers in 
household, recent antibiotic treatment, hours in daycare and PCV7 vaccination history. 
To compare to prevaccination carriage in England, we used the results from a 
longitudinal study carried out in 2001/2002 in families attending the same general 
practices in Hertfordshire in which swabs were taken each month over a 10-mo 
period [17]. At that time, serotype 6C could not be distinguished from 6A, but in 
2009, 19 of the 122 serotype 6As from the earlier study were randomly retested, six 
of which were found to be 6C. We have assumed that this proportion (32%) holds for 
the rest of the 6A carriage isolates from the 2001/2002 study. 
specimen collection and testing
Nasopharyngeal swabs (calcium-alginate) were taken between April 2008 and 
November 2009 by trained nurses and placed directly in STGG broth. Samples 
collected at Hertfordshire were sent by same day courier to the Respiratory and 
Systemic Infection Laboratory at the Centre for Infections (RSIL). They were stored 
overnight in at 2–8uC and frozen the next morning at 280uC. Samples collected 
at Gloucestershire were stored locally at the Gloucester Vaccine Evaluation Unit at 
280uC and transferred to RSIL in batches on dry ice. On receipt the batches were 
stored at 280uC. The sample then was thawed, vortexed, and 50 ml STGG broth 
was placed onto each of Columbia blood agar plate (HPA media services) with 
optochin disc (MAST) and Streptococcus- selective Columbia blood agar plate (HPA 
media services) and streaked out. The plates were incubated overnight at 35uC 
with 5% CO2. Any colonies resembling pneumococcus were subjected to normal 
identification methods and serotyped using the standard laboratory protocol [18].
statistical analysis
Descriptive data analysis was performed in R 2.11.0 and Generalized Estimating 
Equations (GEEs) models were analysed with STATA 10.1. Exact binomial 95% 
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confidence intervals (CIs) were obtained for carriage rates in 2008/2009 by age 
group (<5, 5–20,.20 y). To account for longitudinal design in the 2001/2002 study, 
we computed these carriage rates using a GEE model with exchangeable correlation 
structure. To determine the significance of changes in carriage for individual 
serotypes between 2001/2002 and 2008/2009, a Fisher exact test was used 
because of small numbers. When comparing overall carriage as well as vaccine and 
NVT carriage between periods, this comparison took account of the longitudinal 
design of the 2001/2002 along with other covariates by using a GEE model with 
exchangeable correlation structure and factors for study period, age in years, 
gender, whether the household has a smoker, and the number of children and adults 
in the household. For comparability with previously reported changes in carriage, 
the data were stratified into two age groups (<5 and ≥5 y). 
For calculating the CCR the numbers of each serotype were extracted from the 
national surveillance database for England and Wales [19] for the epidemiological years 
2001/2002 and 2008/ 2009 and related to data from the carriage studies conducted 
in the same years (Table S1). CCRs were calculated using serotypespecific carriage 
prevalence as denominator. Ages younger than 60 y were combined in both the IPD 
and carriage datasets. 95% CIs were calculated on the basis of the 95% CIs of the 
serotypespecific carriage prevalence assuming the national incidence data on IPD to 
be complete and not based on a population sample [19]. For serotypes with estimates 
in both datasets, Spearman’s rank test was used to estimate the correlation of our 
estimates and those obtained by Sleeman and colleagues from a paediatric pre-PCV7 
carriage dataset in one region of England corrected for duration of carriage [20]. 
Simpson’s index for diversity was calculated to assess the change in diversity 
in the bacterial population following vaccination [21]. Ranked serotype distribution 
was compared to the prevaccination distribution and CIs were obtained using the 
methods described by Hanage and colleagues [22]. To ensure that only a single 
isolate per carriage episode was included we excluded consecutive swabs with the 
same serotype (this included swabs of more than one sample interval apart if the 
individual was not sampled in between) in the 2001/2002 study on the assumption 
that it was carriage persisting from the previous month.
resulTs
400 individuals were enrolled between 24 April 2008 and 9 November 2009. One 
participant withdrew before being swabbed and in 17 individuals swabbing had 
to be aborted early; these 18 participants were excluded from further analyses. 
The demographic features of the remaining 382 participants were similar to the 
participants in the 2001/2002 study, apart from the proportion of households with 
at least one smoker, which was lower in the more recent study (Table 1). Of 180 
children eligible for catch-up or infant vaccination only four were unvaccinated. 
 EFFECT OF PCV ON SEROTYPE-SPECIFIC CARRIAGE AND IPD IN ENGLAND
NINE
189
A pneumococcus was grown from 127 of the 382 (33.2%) swabs and a serotype 
determined in 123 (97%). The most prevalent serotypes were 19A (10), 23B (9), 
11C (8), 15B (8), 21 (8), and 6C (8). Compared to prevaccination levels, we found a 
significant reduction in carriage of VTs 6B, 14, 19F, 23F, and 6A. For the remaining 
PCV7 types no carriage episodes of serotypes 4 and 9V were found postvaccination, 
but prevaccination levels were too low to detect any significant change. VT 18C was 
identified in three out of 382 (0.79%) swabs in 2008/2009 and in 25 out of 3,868 
(0.64%) in the 2001/2002 study. NVTs 33F, 7F, 10A, 34, 15B, 31, 21, 3, 19A, 15C, 
and 23A significantly increased (p,0.05) in carriage with odds of 40.9, 30.8, 20.4, 
20.3, 16.5, 10.2, 8.2, 6.2, 4.5, 3.6, and 3.6, respectively. A significant increase was 
also found in serotypes 23B, 11C, 11B, 24F, and 33A, which were only detected in 
the postvaccination study. 
The proportion of swabs with VT and NVT serotypes according to age group in both 
studies is shown in Table 2. The odds ratio of VT and NVT carriage postvaccination 
compared to prevaccination using the GEE with binary outcome was estimated to be 
0.07 95% CI (0.03–0.16) and 4.40 95% CI (3.06–6.33), respectively, with, no significant 
effect on overall carriage: 1.06 95% CI (0.76–1.49) (Table 3). When applying the same 
models to individuals younger than 5 y only, we found similar patterns. In individuals aged 
5 y or older, we detected evidence for herd immunity and full serotype replacement as 
well (odds ratio [OR] 0.31 95% CI (0.04–2.49), 5.16 95% CI (1.95–13.66), respectively), 
although the reduction in VT carriage was not significant. 
Simpson’s index of diversity for the 2001/2002 samples was 0.908 95% CI (0.899–
0.917); children: 0.891 95% CI (0.878– 0.904) and adults: 0.936 95% CI (0.926–0.947). 
Table 1. Overview of numbers of participants recruited, their demographic features and 
household (HH) structures in the 2001/02 and 2008/09 carriage studies.
2001/02 2008/09
# Participants 488 382
# Swabs taken 3868 382
# Participants <5 years (%) 180 (37) 192 (50)
# Participants 5-20 years (%) 71 (15) 57 (15)
# Participants 20+ years (%) 237 (49) 133 (35)
# Proportion female 53.0% 56.4%
# HH 121 146
Median HH size (range) 4 (2-7) 4 (3-7)
Median # adults in HH (range) 2 (1-5) 2 (1-5)
Median # children in HH (range) 1 (1-3) 2 (1-4)
Proportion of smoke free HH 66.9% 81.0%
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It increased significantly in the 2008/2009 samples to: 0.961 95% CI (0.953– 0.969); 
children: 0.960 95% CI (0.949–0.971) and adults: 0.955 95% CI (0.928–0.982). 
Furthermore, the ranked frequency distribution of the serotypes, while similar in the 
prevaccination era in both children and adults in our study compared to children in 
Massachusetts, changed to become more distinct after vaccination (Figure 1). 
Prior to its introduction, PCV7 included types responsible for similar proportions 
of carriage episodes (62.2%) and disease (55.9%). In 2008/2009 the additional 
types covered by higher valency vaccines were more prevalent in IPD than carriage, 
particularly the additional three in PCV10, which comprised 32.6% of IPD but only 
4.7% of carried isolates (Table 4). 
Table 2. Number of positive VT, NVT and All (including non-typeable) carriage isolates in 2008/09. 
+The proportion for 2001/02 was calculated accounting for multiple testing of the participants.
nvT vT all
<5 years Cases 08/09 (n=192) 87 7 98
Proportion 08/09 45.3% (38.5-
52.6)
3.6% (1.0-6.2) 51.0% (43.8-58.3)
Proportion 01/02+ 15.3% (12.7-
18.3)
31.9% (28.1-36.1) 48.4% (44.1-52.7)
5-20 years Cases 08/09 (n=57) 15 0 16
Proportion 08/09 26.3% (15.8-
38.6)
0% (0-6.4) 28.1% (17.5-40.4)
Proportion 01/02+ 9.1% (6.3-12.8) 9.9% (7.3-13.3) 20.6% (16.1-26.1)
>20 years Cases 08/09 (n=133) 10 3 13
Proportion 08/09 7.5% (3-12) 2.3% (0-5.3) 9.8% (5.3-15)
Proportion 01/02+ 3.3% (2.4-4.8) 4.1% (3.0-5.5) 7.6% (6.2-9.5)
All Cases 08/09 (n=382) 112 10 127
Proportion 08/09 29.3% (24.9-34) 2.6% (1-4.5) 31.9% (27.2-36.6)
Proportion 01/02+ 8.5% (7.2-9.9) 15.2% (13.2-17.4) 24.4% (21.9-27.1)
Table 3. Odds ratios for comparing 2001/02 to 2008/09 carriage using GEE. 
<5 >5 all
VT 0.06 (0.03-0.16) abg *** 0.31 (0.04-2.49) a*** 0.07 (0.03-0.16) aeg ***, b**
NVT 4.25 (2.81-6.43) c*,g*** 5.16 (1.95-13.66) ag** 4.40 (3.06-6.33) ag***, bc*
ALL 1.03 (0.70-1.51) ab***,e* 2.46 (1.04-5.83) a***, g* 1.06 (0.76-1.49) ab***,e**
Key for significant fixed effects: a (age), b (antibiotic treatment), c(smoking), d (gender), e (adults in 
household), f (children in household), g (study period). Significance codes: 0.05 ≥ * > 0.01 ≥ ** > 0.001 ≥ ***
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figure 1. Top: Comparison in ranked-serotype distribution prior to vaccination in children in 
Massachusetts to our findings in children (left) and adults (right). For comparison with the findings with 
Hanage and colleagues, we aggregate 6A and 6C to 6A/C and 15B and 15C to 15B/C. Bottom: Changes in 
ranked serotype distribution in overall carriage in our findings from 2001/2002 to 2008/2009.
Table 4. Carriage prevalence and IPD incidence in those aged less than 60 years caused by 
serotypes included in PCV7, in PCV10 and not in PCV7, in PCV13 and not in PCV10 and the 
remaining serotypes.
2008/09 2001/02
carriage (%) % in ipd carriage (%) % in ipd
PCV7 11 (8.7) 15.2 605 (62.2) 55.9
+PCV10 6 (4.7) 32.6 2 (0.2) 10.2
+PCV13 18 (14.2) 15.8 155 (15.9) 8.9
Rest 92 (72.4) 36.4 210 (21.7) 25.0
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The ranking of carried serotypes by frequency of detection in the post-PCV7 dataset 
and their associated CCRs as estimated from our 2008/2009 carriage prevalence 
data are shown in Figure 2. CCR estimates were highly correlated (p,0.001, r = 0.72) to 
those from Sleeman and colleagues estimated from carriage incidence [20] and allow 
to distinguish the more from the less invasive serotypes. From the 15 most prevalent 
serotypes in carriage in 2008/2009 19A, 3, 7F, and 22F stand out with a generally higher 
CCR. Despite their high incidence in invasive disease serotypes 1, 8, 12F, 4, and 14 (1.14, 
0.58, 0.25, 0.22, 0.14 cases per 100,000 population, respectively, in under 60 y olds in 
2008/2009) were not detected in carriage. On the other hand, despite being found in 
2008/2009 carriage serotypes, 11C, 16A, 17A, 28F, and 33A were not found in 2008/2009 
IPD at all and only caused 0, 1, 0, 1, and 0 cases, respectively, of invasive disease out of 
over 13,000 isolates serotyped between July 2006 and June 2009. 
discussion
Our study documents the changes in carried pneumococci following the introduction 
of PCV7 in England and relates these to concomitant changes in disease in order 
to assess the invasiveness potential of the serotypes now predominating carriage. 
This knowledge is essential for understanding replacement pneumococcal disease 
and provides insight into the likely population impact of higher valency vaccines. 
As reported elsewhere [13,14], we found a major reduction in VT carriage in 
vaccinated children under 5 y, but no overall change in carriage prevalence due to 
replacement with NVTs. In contrast, there was an overall reduction in IPD in this 
age group, illustrating that the outcome of the PCV programme as expressed in 
IPD is determined by the invasiveness potential of the individual NVTs emerging 
in carriage. Overall carriage prevalence in older unvaccinated siblings and parents 
was somewhat higher post-PCV7 as found in parents of 2 y olds in a vaccine trial 
with a 2-dose or a 2+1-dose schedule in the Netherlands [23]. This finding was due 
to a large increase in NVT and a smaller nonsignificant reduction in VT carriage. 
However, IPD in these older age groups has not shown an overall increase in the UK 
[24], indicative of the lower overall invasiveness of the replacing NVTs. 
Our study shows that PCV7 provided protection against serotypes that were 
highly prevalent in both disease and carriage in the UK. The additional serotypes 
covered by PCV10 and PCV13 are now responsible for a large proportion of 
invasive disease but were found relatively rarely in carriage (Table 4). While further 
replacement in pneumococcal carriage is likely to occur after introduction of these 
higher valency vaccines, our findings suggest that since most of the potential 
replacement types identified have lower CCRs they will cause less invasive disease. 
However, serotypes like 22F and especially the ones not found in carriage but 
present in IPD (e.g., serotype 8 and 12F) could reduce the overall benefits of higher 
valency vaccines. Interestingly, the three additional serotypes covered by PCV10 
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had a very low carriage prevalence accounting for ,5% of the carried serotypes in 
2008/ 2009 but.30%of IPD cases, whereas the further three serotypes in PCV13 
are more similar to the PCV7 serotypes, being similarly prevalent in carriage and 
disease. While changing to PCV10 has therefore less potential to prevent IPD than 
PCV13, it may cause fewer perturbations in the nasopharyngeal pneumococcal 
population. Comparative carriage studies in countries using PCV10 with those using 
PCV13, or with different PCV coverage of prevalent serotypes before introduction, 
would be informative to help understand the carriage dynamics underlying serotype 
replacement. These studies would ideally be repeated cross-sectional studies to 
monitor alterations in carriage prevalence, which could be linked to changes in 
serotype-specific IPD in the same population. The latter requires the continued 
microbiological investigation of suspected cases of invasive disease, including 
those in fully vaccinated children, in order to document the serotype-specific 
changes in IPD associated with vaccine-induced changes in carriage. 
The diversity of the pneumococcal carriage population in the absence of any 
external pressure is thought to be relatively stable [22]. If this population is challenged 
by vaccination with a reduction in the dominance of a few highly prevalent types, the 
diversity increases and the population takes time to return to the previous level of 
diversity. Hanage and colleagues suggested methods of assessing these changes: 
Simpson’s index of diversity and the concept of a typical distribution for the ranked 
frequency of the serotypes [22]. Applying these to our prevaccination carriage data, 
we see similar diversity in children and slightly higher diversity in adults, although the 
significance of this difference was not consistent between both methods. However, 
we found an increase in overall diversity in 2008/2009 as well as in children and in 
adults (although not significant in adults), consistent with the PCV7-induced changes 
in the bacterial population still evolving at that time. Evidence for this can also be 
found in the ongoing changes in non-PCV7 IPD in 2009/2010, prior to introduction 
of PCV13. These show a continuing increase in the six additional serotypes covered 
by PCV13 but a decrease in non-PCV13 serotypes in children under 2 y compared 
with 2008/ 209 [25]. With the introduction of PCV13 in the UK in March 2010 [26], 
it will not be possible to evaluate further the longer term impact of PCV7 on carriage 
and IPD, but it is important to note that PCV7 may continue to have an effect and 
therefore not all future changes will necessarily be attributable to PCV13. 
Recently developed molecular serotyping methods found up to nine times higher 
proportions of multiple carriage than detectable with standard WHO culturing 
methods [27]. Using the WHO method we identified one (0.26%) multiple carriage 
episode in 2008/2009 and four (0.10%) in 2001/2002. Undetected episodes of 
multiple carriage would result in over estimation of CCRs. However, direct comparison 
of molecular and conventional serotyping methods have so far only been performed 
on specimens from developing countries where carriage prevalence is very high 
[28,29]. In such settings, molecular methods might reveal more multiple carriage 
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episodes than in countries such as England where carriage prevalence is lower. 
Furthermore, there is some evidence that detecting multiple serotype carriage is 
likely to primarily uncover carriage episodes of serotypes previously found to be less 
prevalent [30]. Therefore we believe that the potential bias introduced by the WHO 
standard culturing methods would have little impact on our inferences from the 
CCR, because we focus on the serotypes more common in carriage. 
Our study has some limitations. First, the earlier study had a longitudinal design 
while the recent study was cross-sectional. However, we accounted for multiple 
testing of individuals in the earlier study as well as differences in age distribution 
within the age groups, gender, exposure to smoke, and household size by using a GEE, 
which is designed to fit the parameters of a generalised linear model in the presence 
of unknown correlation. Second, owing to the lack of power of serotype-specific 
carriage data in adults, we pooled data of children and adults to derive the CCR, despite 
different age distributions in the samples for IPD and carriage. Previously reported CCR 
estimates for children and adults in England and Wales [19] using the carriage data 
from the earlier study are highly correlated (Figure S1), supporting our use of pooled 
carriage data from children and adults in the later study. Third, secular changes in 
serotype distribution in IPD can occur in the absence of vaccination [31], which may 
be due to alterations in carriage prevalence. With the cross-sectional design of the 
2008/ 2009 study, we were not able to account for these. However, in England the only 
major secular change in the serotypes causing IPD observed over the last decade has 
been in serotype 1, which was not detected in either our pre- or post-PCV7 carriage 
studies. Fourth, invasion is thought to follow shortly after acquisition of carriage rather 
than being a constant risk throughout the duration of carriage [32]. Thus, a further 
potential limitation of our study is that we estimate CCRs using carriage prevalence 
rather than the incidence of new carriage episodes, the latter being derived using 
prevalence and carriage duration. Few data on serotype-specific duration of carriage 
are published, and for the serotypes newly emerging after introduction of PCV7, no 
information is available. Therefore, we used carriage prevalence to get an estimate 
of the CCRs. Where information on CCRs estimated using carriage incidence was 
available [20], we found a high correlation with our estimates. Furthermore, our 
estimates for the CCRs were consistent with those derived from 2001/2002 carriage 
and IPD (unpublished data), showing that this measure is stable over time. Hence 
we are confident that our estimates of the CCR can distinguish serotypes with lower 
invasiveness from those with higher invasiveness. 
In conclusion, our study illustrates the value of generating carriage data 
in parallel with IPD surveillance data to help understand the serotype-specific 
changes in IPD observed in different epidemiological settings and predict the effect 
of higher valency vaccines. We provide evidence that the incremental benefit on IPD 
of the recent switch from PCV7 to PCV13 in the UK, while likely to be substantial, 
may be somewhat offset by increases in serotypes 8, 12F, and 22F. Such emerging 
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serotypes with high CCRs are potential candidates for inclusion in future conjugate 
vaccines. More research to elucidate the serotypespecific capsular properties 
[2,33] or other factors associated with carriage and invasiveness is needed in order 
to understand better the likely impact of future conjugate vaccines. 
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To inform national policy making on the use of the 13-valent pneumococcal vaccine 
among risk groups we estimated the increased risk of invasive pneumococcal 
disease (IPD) outcomes among clinical risk groups. Three years of post 7 valent 
pneumococcal conjugate vaccine (PCV7) data was included to investigate the herd 
protection effects. 
methods
Over 22,000 IPD patients in England (March 2002-March 2009 - aged 2 and over) 
were linked to their hospitalisation records. The prevalence of risk factors in these 
patients was compared to the prevalence of risk factors in the general population. 
results
There was an increased odds of hospitalisation (Odds ratio (OR) 11.7 2-15 years; 
7.6 16-64; 2.7 65+) and death (OR 2.4 2-15 years, 3.9 16-64, 1.2 65+) from IPD 
among risk group. The most important risk factors that predict IPD are chronic liver 
disease, immunosuppression, and chronic respiratory diseases. Herd protection 
effects due to introduction of the 7-valent vaccine were identical in both patient 
groups as shown by the similar decline in the proportion of IPD caused by PCV7 
serotypes in risk and non risk groups.
conclusions
There is a marked increased risk of IPD among those with certain clinical conditions, 
suggesting potential benefit from a targeted vaccination approach. However, 
the indirect protection from conjugate vaccination of children suggests PCV 
vaccination of high risk groups may not provide substantial additional benefit once 
herd immunity takes effect.
inTroducTion
Development of evidence-based guidelines for the prevention of infectious disease 
by vaccination requires an understanding of the population groups most likely to 
become infected or to have severe disease or worse outcomes. Identification of 
high-risk groups allows a selective vaccination programme to be employed, as 
exemplified by the targeting of vaccination in the recent H1N1 (2009) pandemic 
to the most vulnerable [1,2]. The 23 valent pneumococcal polysaccharide (PPV23) 
vaccine has been recommended in the UK since 1992 [3] for prevention of invasive 
pneumococcal disease (IPD) in those with various clinical conditions considered 
to be at increased risk of IPD [4] though uptake has been low [3]. There is 
however limited evidence on the magnitude of the increased risk for these various 
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clinical groups by age compared with the general population. Moreover, there is 
little information on the degree and duration of protection from PPV23 in these 
targeted high-risk groups [5,6]. Pneumococcal conjugate vaccines (PCVs) that 
are more immunogenic than PPV23 may provide a better alternative for protection 
of high-risk patients [7-9]. However, they are more costly [10] and cover a lower 
proportion of the serotypes causing IPD than PPV23. 
To help evaluate the potential utility of offering the 10-valent (PCV10) or 
13-valent (PCV13) conjugate vaccine to individuals in high-risk groups, we identified 
patients with IPD admitted to hospital in England and compared the prevalence of 
risk factors in this group with that in the general population. Among the hospitalised 
patients with IPD we compare the case-fatality ratio and the serotype distribution 
before and after the introduction of PCV-7 in September 2006 and the coverage 
that would be achieved with higher valency vaccines for patients with high risk 
conditions compared to those without.
meThods
ascertainment of risk factors in the general population
Information on the prevalence of clinical risk factors in the general population was 
estimated from a Department of Health (DH) survey of the uptake of PPV23 using 
data extracted from 55.6% of the general practices in England, together covering 
60% of the population [11-13]. Risk groups recommended for PPV23 vaccination in 
the Green Book (Immunisation Against Infectious Disease) [4] were identified from 
the diagnostic codes [14] used to record clinical conditions and medication in the 
electronic patient records of GP Practices. The clinical groups as extracted from the 
GP records are listed in table 1. Patients with any of the clinical conditions comprise 
the “One or more risk factors” group in Table 2. The total number of patients registered 
in the participating practices and the number of patients with one of the risk group 
diagnostic codes by individual risk and age group were extracted (age groups 2-15, 
16-64 and 65 years and over). The total estimated number of people in England by 
risk- and age group was extrapolated based on total population estimates [15].
There are three groups that are in the Green Book risk group definitions but, due 
to the way the data are recorded at the GP are not included in the group with one 
or more risk factors. These are asthma patients on continuous or repeated steroids 
who have no other chronic respiratory disease code; other patients on steroids 
who have no other immunosuppression code; and patients with recently diagnosed 
malignancies (who are assumed to be receiving chemotherapy) who have no other 
risk factors. Those three risk groups are not included in this analysis. The number 
of individuals with no underlying risk factors was derived from the difference in 
number between the total population in the PPV23 uptake data extract and those 
flagged as having one or more risks. 
THE EFFECT OF UNDERLYING CLINICAL CONDITIONS ON THE RISK OF DEVELOPING IPD
TEN
203
ascertainment of risk factors for hospitalised ipd cases 
Risk factor information for hospitalised patients with IPD was obtained by linking 
the national dataset of laboratory confirmed IPD cases in England and Wales held 
by the Health Protection Agency (HPA) [16,17] with an extract from the Hospital 
Episode Statistics (HES) database. A laboratory confirmed case of IPD is defined 
as identification by culture of S.pneumoniae or (more rarely) antigen detection or 
polymerase chain reaction (PCR), in a normally sterile site. Identification of the 
same invasive serotype in the same individual within 30 days was regarded as the 
same episode. The national IPD data set covers all patients with IPD diagnosed by 
a laboratory in England and Wales. The HES data set contains clinical information 
on all patients in National Health Service (NHS) hospitals in England [18], this 
includes fifteen diagnostic fields in which the primary diagnosis and other clinical 
conditions of the patient are specified using the tenth revision of the International 
Classification of Disease coding system (ICD-10). As the HES data set is too large 
to use in the linkage all hospital admissions with an ICD-10 code indicating possible 
acute pneumococcal disease (listed in online appendix table 1) in any diagnostic 
field were extracted from HES between April 2002–March 2009. Linkage was based 
on NHS number or postcode, date of birth and sex. Underlying clinical conditions 
were identified using an ICD-10 code list mapped to the READ codes used in the 
PPV23 uptake survey (see online appendix table 2) to make sure we compared like 
with like. Because of the lack of medication codes in HES and the inability to identify 
patients with a recently diagnosed malignancy it was not possible to identify 
patients on steroids or chemotherapy. Patients with IPD in these groups and with 
no other risk group code are therefore included in the “no risk” group in line with 
the way patients are grouped in the PPV23 uptake survey. When multiple episodes 
in the HES database could be linked to a case in the national IPD dataset (based 
on an admission date between one week before to one month after the specimen 
date), diagnostic codes for all linked episodes were used. Deaths recorded in the 
HES dataset were considered to be related to the IPD episode if occurring within 
30 days after the specimen date and were used to derive case fatality rates (CFRs) 
by risk group. Disease possibly related to alcoholism was assigned using ICD-10 
codes from Harboe et al [19]. Linkage of the IPD and HES datasets and subsequent 
analysis was done in R version 2.12.0.
statistical analysis
The risk of being hospitalised with IPD if in a risk group compared with the risk of 
being hospitalised if not in any risk group was estimated by comparing the odds 
of being in a risk group in hospitalised IPD cases with the odds of being in a risk 
group in the general population (PPV23 uptake survey data). The odds ratios will 
approximate relative risks because IPD is a rare event. Odds ratios are calculated 
with 95% confidence intervals (Wald method). Although presented results are based 
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on the whole study period (2002-2009), outcomes were checked for significant 
changes before and after PCV-7 vaccination which started in September 2006. 
To be able to compare the IPD in each risk group over the different age groups 
we estimated the incidence of IPD in the HES year April 2008 to March 2009. 
Incidence in specific risk groups was derived from the annual incidence for those 
without risk factors (estimated based on the total laboratory confirmed cases in 
England multiplied by the percentage of patients without risk factors divided by the 
mid-2008 population in England) multiplied by the odds ratio for each risk group as 
measured over the whole study period (2002-2009).
Comparison of mortality between those with and without underlying conditions 
was based on comparing the odds of death among hospitalised cases in the risk-
group to the odds of death among hospitalised cases in the non-risk group. 
sensitivity analysis
To test the robustness of the results we performed a sensitivity analysis with 
pneumococcal labelled disease (ICD10 codes A403, B953, G001, J13 and M001) in 
the unmatched HES dataset. The results of the sensitivity analysis are presented in 
the online appendix, table 3. This sensitivity analysis showed that the odds ratios 
for various risk groups in the unmatched HES cases with pneumococcal code was 
similar to that in the HES cases that could be linked to an IPD record.
Table 1. Description of the risk groups
Asplenia/splenic dysfunction Includes conditions such as homozygous sickle cell disease 
and coeliac syndrome that may lead to splenic dysfunction
Chronic Respiratory Disease Includes chronic obstructive pulmonary disease (COPD) and 
chronic bronchitis, emphysema1 
Chronic Heart Disease Includes ischaemic heart disease requiring treatment, 
congenital heart disease, hypertension with cardiac 
complications, and chronic heart failure
Chronic Kidney Disease Includes nephrotic syndrome, chronic kidney failure and 
kidney transplantation
Chronic Liver Disease Includes cirrhosis, biliary atresia and chronic hepatitis
Diabetes Includes diabetes mellitus requiring insulin or oral 
hypoglycaemic drugs but excludes diabetes that is diet 
controlled
Immunosuppression Includes those who are immunocompromised by disease, 
such as HIV or leukaemia, asplenia or splenic disfunction
Cochlear Implants Includes individuals with cochlear implants
Cerebrospinal Fluid Leaks Includes individuals with cerebrospinal fluid leaks, following 
trauma or brain surgery
1 For our analysis patients with Asthma were excluded as explained in the text.




prevalence of risk factors in the general population
The largest risk group in England are those with chronic heart disease, with just 
over 3 million patients (table 2); patients with cochlear implants was the smallest 
with around 3,500 patients. Overall, 13% of the general population had one or more 
risk factors, and 45% in those aged 65 years and over. Of the total patients in a risk 
group, 59% were aged 65 years and over. 
Table 2. Absolute estimated number of people in risk groups as defined in the 2009 PPV23 
uptake survey of registered GP patients in England, extrapolated to the population of 
England in 2009 
age group 2-15 years 16-64 years 65+ years Total (2+)
Total cohort 8,373,700 33,671,300 8,434,300 50,479,300
































































































1 Does not include those with asthma on steroids, other steroid users, and those with recently 
diagnosed malignancy.
2 This includes Patients with HIV Infection, Asplenia, or dysfunction of the spleen, malignancies 
affecting the immune system and Bone Marrow Transplants.
3 Bone marrow transplantation on or after 1/4/2003.




Of the 38,055 patients aged over 2 years in the national IPD data set in the study 
period, 22,298 (59%) could be linked to a HES admission in the same time period. 
The numbers of linked cases by age group were 1,507 aged 2-15, 9,577 aged 16-64 
and 11,214 aged 65 years and over. The proportion linking increased over time, from 
48% in April 2002 to March 2003 to 65% in 2008/09, which is attributed to better 
data completion in the fields used for linkage in the IPD dataset. No linked IPD/HES 
records were found for patients with cochlear implants, bone marrow transplants or 
cerebrospinal fluid leaks, precluding further analysis in these groups.
risk of ipd by clinical condition and age group
Of the 22,298 patients with a linked record, 11,541 (52%) had ICD diagnostic codes 
indicating a risk group. The effect of having an underlying clinical condition on the 
risk of hospital admission for IPD was most marked in children aged 2 to 15 years, 
with nearly a 12 fold increase (11,7; 95% CI 10.2-13.3) in IPD in those with any of 
the specified conditions compared to those without (Table 3). For adults aged 16-64 
years there was a 7.6 (7.3%-7.9%) fold increase and for 65+ year olds a 2.7 (2.6-2.8) 
fold increase. The overall IPD incidence per 100,000 in the HES year April 2008 to 
March 2009 was 4.8 in 2-15 yrs olds, 8.3 in 16-64 year olds and 56.7 in 65+ yrs olds. 
The annual incidence was substantially higher for those in a risk group; incidence in 
the immuncompromised and chronic liver disease groups were particularly high at 
around 100 per 100,000 for all age groups. 
Among children aged 2-15 years, immunosuppression resulted in the highest 
risk with an odds ratio of 41 (35-48), increasing to 100.8 (44.7-227.2) in those with 
HIV. The second most important risk group in children is liver disease with an odds 
ratio of around 30 (15.3-57.2). Diabetes and heart disease are the least strongly 
related to IPD among children with an odds ratio of 3.8 (2-7.3) and 4.1 (3.1-5.5%) 
respectively albeit still elevated above no risk children. 
In the age group 16 to 64 years, liver disease had the highest risk, with an odds 
ratio of 33.3 (30.7-36.1); of the 652 patients identified with chronic liver disease 
477 (73%) were linked to alcoholism. The second most important risk group is 
immunosuppression (odds ratio 17.1 (16.0-18.3), and 61.2 (51.3-72.9) for those 
with HIV) and respiratory disease (16.8; 15.7-18). The risk group with the lowest 
odds ratio among this age group is asplenia and/or dysfunction of the spleen. 
Among those aged 65 years and over the highest risk was among those with 
immunosuppression with an odds ratio of 11.7 (11-12.4). Among the elderly the 
risk group asplenics and kidney disease had odds ratios below one. 
risk of a fatal outcome by clinical condition and age group
The CFRs for those with and without underlying clinical risk conditions, and the odds 
of dying if in a risk group are shown in Table 4. The overall CFR increased markedly 
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with age from 2.2% (1.6%-3.1%) in children to 31.5% (30.9%-32.6%) in those aged 
65+ years. Within each age group, CFRs were higher for those with than those without 
underlying clinical conditions, with odds ratio 2.5 (1.2-5.1) in children, 3.9 (3.4-4.4) 
in 16 to 64 year olds and 1.2 (1.1-1.3) in the 65+ age group. The highest CFR (53.3%) 
was among patients with liver disease aged 65 years and over, and the lowest (1.8%; 
1.2%-2.7%) among non-risk group children (apart from the diabetes and HIV groups 
in which no deaths were observed due to low numbers). The greatest risk of death was 
in asplenic patients compared to non- risk group children (odds ratio of 20.9; 5.2-84).
effect of pcv7 on serotype distribution 
Table 5 shows the proportion of IPD by year caused by the serotypes covered by PCV7 in 
patients over 16 years of age with and without risk factors. Consistent with the indirect 
(herd protection) effect of the PCV7 vaccination programme on older age groups 16, 
there was a progressive reduction in PCV7 serotypes which was similar in those with and 
without risk factors. In 2008/9, PCV10 would cover 36% (34%-38%) and PCV13 61% 
(58%-63%) of the remaining IPD in those in a risk group and the extra 10 serotypes in 
PPV23 but not in PCV13, would cover an additional 22%. The comparable proportions for 
those not in a risk group were 47% (44%-50%), 64% (62%-67%) and 27% respectively. 
Table 5. The overall percentage of patients in a risk group by HES year (April to March) in 
patients aged 16 years and above, and the percentage coverage for different valency 
vaccines for those with and without risk factors. 
2005-2006 2006-2007 2007-2008 2008-2009
Overall percentage  
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Since the overall proportions of IPD cases in a risk group was similar before and after 
the introduction of PCV7, the overall reduction in IPD incidence post-PCV7 as estimated 
by Miller et al 17 is likely to be similar in risk and non risk groups.
discussion
Our study confirms the elevated risk of IPD in those with underlying clinical 
conditions for whom PPV23 vaccination is currently recommended. Both the 
incidence of infection and the case fatality rate are increased, especially among 
the immunocompromised, and those with chronic respiratory conditions or liver 
disease. A high proportion of the liver disease in adults (73%) was alcohol related, 
suggesting that life style rather than hepatic problems per se may have been 
implicated in the increased risk of IPD. However, risk in children with liver disease 
were similarly elevated. The relative low odds ratios in those with asplenia/splenic 
dysfunction may reflect the current policy of actively advocating immunisation and 
antimicrobial prophylaxis in this particular high-risk group. The effect of being in a 
risk group was less marked in those aged 65 years and over in whom the incidence 
of IPD rises sharply even in those without any predisposing conditions. 
While there are a number of studies that have described the prevalence of clinical 
risk factors in patients with IPD, there is a paucity of data that allows quantification of 
the risk in terms of absolute incidence or incidence relative to that in healthy individuals. 
Klemets et al linked 4,365 patients with IPD in Finland with other health registries to 
estimate the incidence of IPD in patients aged 18+ years with various clinical conditions 
[20]. Among immunocompromised patients, IPD incidence varied from 33.4 to 547.2 per 
100,000, broadly similar to the range we found; rates were lower in immunocompetent 
patients with diabetes mellitus, chronic pulmonary disease and cardiac failure, ranging 
from 12.0–47.1 per 100,000). However, there were no comparisons with those without 
such risk factors, no age stratification and no information on infecting serotype. In a 
case control study among children (< 18 years) in Denmark those with haematological 
malignancy and chronic renal disease were at particularly increased risk of IPD (52.1 
and 14.4 higher respectively) broadly similar to elevated risk we found [21]. In the 
United States, a case control study in children aged under 5 years with IPD confirmed 
the greatly elevated risk for those with immunosuppression and showed that PCV7 
vaccination was effective in reducing the excess risk [22]. 
A selective PPV23 vaccination programme targeted at those in high-risk groups 
was in place during our study period and by 2009 had achieved an uptake of around 
12% among 2-15 year olds, 34% among 16-64 year olds and 68% among those aged 
65 years and over (personal communication F. Begum, DH/HPA). The lower odds ratios 
for risk group patients aged 65+ years compared with younger age groups is unlikely 
to reflect their higher coverage with PPV23 than in other age groups, as the coverage 
in 65+ year olds without risk factors was similar following the extension of the PPV23 
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programme to all those aged 65+ years between 2003 and 2005. The proportion 
of disease caused by the serotypes included in PPV23 is slightly lower for the risk 
group patients, which might suggest a small vaccine effect. However, this difference 
is mainly caused by the greater contribution of serotype 1 to IPD in the non-risk 
group. Serotype 1 is highly invasive with a propensity to cause disease in otherwise 
healthy individuals, whereas serotypes with a low invasiveness potential ie prevalent 
in carriage but rare in disease [23], act more like opportunistic pathogens for those 
with underlying risk factors [24]. Those less invasive, opportunistic serotypes are less 
likely to be indentified for inclusion in higher valency vaccines, which is consistent 
with somewhat lower coverage observed among the high risk groups.
Even if the PPV23 programme targeted at high-risk individuals has reduced their 
risk of IPD, the incidence of disease in these groups is still greatly elevated with a 
disproportionately high case fatality rate, especially among children and younger 
adults. Immunocompromised patients, especially those that are infected with HIV, 
are at particularly high-risk of IPD and it is in these groups that conjugate vaccines 
may offer an immunological advantage [7]. However, there was a reduction in IPD 
caused by the serotypes covered by PCV7, indicating a herd protection effect, which 
was similar in those with and without risk factors. Any direct benefit of vaccinating 
high-risk adults with PCV10 or PCV13 which covered 36% and 61% respectively of 
the serotypes causing IPD in high-risk adults in 2008/9, will therefore diminish over 
time as these additional serotypes become eliminated from the population. PPV23 
offered additional serotype coverage of 22% in 2008/9 for those in high-risk groups. 
The incidence of IPD caused by the 10 serotypes only in PPV23 may increase in the 
future depending on the extent of serotype replacement associated with PCV10 or 
13 and whether the replacing serotypes are covered by PPV23. 
Our study has a number of limitations. Firstly, we relied on different data sets to 
identify the proportion of IPD cases and the general population with risk factors. For 
the IPD cases we relied on relevant clinical conditions being recorded in one of the 
discharge diagnosis fields which may be more incomplete than in the GP records 
which were used for the denominator population. Failure to identify IPD cases in 
high-risk patients with their consequent inclusion in the “no risk” group would result 
in underestimation of the odds ratio. Similarly, inclusion of patients on steroids or with 
recent malignancies in the “no risk” denominator for the general population will tend 
to reduce odds ratios. Our estimates are therefore likely to be conservative. Secondly, 
non-matching HES admissions with specific pneumococcal codes were not included 
in the main analysis. Sensitivity analysis using only pneumococcal ICD codes revealed 
similar odds ratios (online appendix table 3) suggesting no major bias as a result of 
the incomplete matching of IPD cases with HES admissions. Thirdly, there were no 
HES codes that allowed the identification of asthmatic or other patients on steroids or 
those a recently diagnosed malignancy who are likely to be immunosuppressed from 
chemotherapy, precluding any estimates of the risk of IPD in these specific patient 
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groups. For those on chemotherapy, it seems reasonable to assume that their risk is 
similar to that of other immunosuppressed patients – an assumption that is supported, 
at least in children, by the Danish and US case control studies [21, 22]. Other studies 
have reported a doubling of the risk of IPD in asthma patients, with the highest rates in 
those with more severe disease requiring medication or frequent hospital admission 
[25, 26]. A fourth limitation of our study is that the prevalence of risk factors in the 
general population was based on data obtained in 2009 whereas the risk factor data 
for IPD cases was an average over the period 2002 to 2009. A few groups showed 
a minimum two fold change in odds ratios over time, for example, HIV patients who 
showed a change in odds ratio from 176.9 (72.7-430.4) between 2002-2005 to 32.02 
(4.5-228.0) between 2006-2009. This may be associated with the increasing use of 
highly active anti-retroviral therapy, which reduces the risk of IPD, though it remains 
around 10 fold higher in treated HIV patients than in the general population as shown 
in a recent HPA study [27]. In that study, which linked IPD cases with the national 
HIV database, the risk of IPD in HIV positive adults aged 15-44 years was found to be 
around 50 times higher than in the general population. These elevated risks are close 
to the 61.2 odds ratio found in our study by an independent method. Finally we did not 
investigate the risk associated with having more than one co-morbidity, which is the 
situation for some patients. The odds ratios shown for individual risk conditions may 
therefore be elevated by the existence of associated co-morbidities.
It has been suggested that part of the increased risk of IPD in patients with 
underlying disease may be the result of a lower threshold for hospital admission of 
such patients rather than just a greater incidence or severity of disease [28]. This 
is supported by the Danish study that showed that patients with chronic conditions 
that required frequent hospital visits were also at increased risk of admission for an 
episode of IPD [21]. Even if part of the elevated risk is due to a greater propensity to 
investigate and admit patients with underlying conditions, the resultant health care 
costs associated with the admission are nevertheless the same, irrespective of the 
reason for admission. Moreover, the outcome of infection, as measured by the case 
fatality rate, was higher in patients with underlying conditions. 
In conclusion, our study has shown a marked increased risk of IPD and of a fatal 
outcome in patients with various clinical conditions. It provides an evidence base 
for the targeted vaccination approach with PPV23 adopted by many countries, or if 
an age based vaccination approach is adopted, that evaluating the coverage among 
risk groups is key. Quantification of the increased risk allows an assessment of the 
cost effectiveness of offering the potentially more effective conjugate vaccines to 
these high-risk individuals. However, any such assessment needs to take account 
of likely future changes resulting from the introduction of PCV10 or 13 vaccination 
programmes for children on the pneumococcal serotypes causing IPD in the general 
population and in high-risk groups, as our study shows that the herd protection 
benefits from PCV occur similarly in high risk and healthy individuals. 
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To estimate the cost effectiveness of vaccinating people with high risk conditions 
against invasive pneumococcal disease using the 13 valent pneumococcal conjugate 





People aged 2 years and older at increased risk of invasive pneumococcal disease 
due to chronic kidney disease; splenic dysfunction; HIV infection; a compromised 
immune system; chronic heart, liver, or respiratory disease; or diabetes. Main 
outcome measures Costs, gains in life years and quality adjusted life years (QALYs), 
and incremental cost effectiveness ratios. 
results
Increasing indirect protection resulting from the vaccination programme of infants 
using the 13 valent pneumococcal conjugate vaccine means that the burden of 
disease preventable by targeting high risk groups will diminish in time. Under base 
case assumptions—that is, no overall impact on non bacteraemic pneumonia in 
high risk groups and assuming the high risk vaccination programme would be 
launched two to three years after the infant programme—the incremental cost 
effectiveness ratio was estimated to be more than £30,000 (€37,216; $48,210) 
per QALY gained for most risk groups. If, however, the vaccine does offer protection 
against non-bacteraemic pneumococcal pneumonia or the vaccine was introduced 
concomitantly with the infant 13 valent pneumococcal conjugate vaccination 
programme then vaccinating high risk people would (more) likely be cost effective. 
Sensitivity analyses showed that the cost effectiveness was particularly sensitive to 
assumed herd benefits and vaccine efficacy estimates.
conclusion
Under base case assumptions it is unlikely that a pneumococcal vaccination 
programme aimed at risk groups could be considered cost effective. Uncertainty 
could be substantially reduced by establishing the effectiveness of the 13 valent 
pneumococcal conjugate vaccine against non-bacteraemic pneumococcal 
pneumonia, particularly in at risk groups. 




People with certain clinical conditions such as immunocompromised patients and 
those with chronic heart or lung disease are at increased risk of invasive pneumococcal 
disease and related mortality [1]. To prevent disease among these high risk groups 
many countries recommend vaccination with the 23 valent polysaccharide vaccine, 
which has been available since the 1980s. Nevertheless, the efficacy and duration 
of protection of this vaccine is limited, and the antibody response to revaccination 
is reduced [2,3]. The use of conjugated pneumococcal vaccines could potentially 
overcome the limitations of the 23 valent polysaccharide vaccine. In children the 
seven valent pneumococcal conjugate vaccine has been shown to be highly effective 
in preventing invasive pneumococcal disease caused by vaccine related serotypes 
[4]. Data on the efficacy in adults, elderly people, and high risk groups are, however, 
scarce, with most studies focusing on immunogenicity rather than on efficacy 
[3]. The limited data on efficacy that are available suggest that pneumococcal 
conjugate vaccines are effective in preventing invasive pneumococcal disease (and 
possibly pneumonia) in adults and children infected with HIV, a group in whom 
the 23 valent polysaccharide vaccine is ineffective [5,6]. As the pneumococcal 
conjugate vaccines are more expensive, there is a need to assess whether the use 
of these vaccines is justified. Such an assessment is complicated by the interaction 
(at a population level) between a targeted risk based programme and vaccination of 
children. The introduction of seven valent pneumococcal conjugate vaccine in the 
infant immunisation programme led to a dramatic decline in incidence of invasive 
pneumococcal disease due to vaccine serotypes in all age groups (including those 
in risk groups)[7]. However, these decreases were partly offset by a simultaneous 
increase in disease caused by non-vaccine serotypes, reducing the impact on overall 
invasive pneumococcal disease [8].
In the infant programme in the United Kingdom, as elsewhere, the seven valent 
pneumococcal conjugate vaccine has recently been replaced by the 13 valent 
pneumococcal conjugate vaccine. This higher valency vaccine covers six additional 
serotypes, including the key replacement serotypes 19A and 7F. Similar herd effects 
for the additional serotypes, as observed for the seven serotypes included in the 
seven valent pneumococcal conjugate vaccine after its implementation, can be 
expected in time. However, high risk groups could potentially still benefit from the 
faster and greater effects of direct vaccination with the 13 valent pneumococcal 
conjugate vaccine compared with waiting for the indirect benefit from the herd 
immunity against the vaccine serotypes generated by the infant programme. 
We estimated the effectiveness, costs, and cost effectiveness of vaccinating 
high risk groups in England using the 13 valent pneumococcal conjugate vaccine, 
taking into account that herd benefits of the current infant 13 valent pneumococcal 
conjugate vaccine programme will diminish the potential impact of a specific 
programme for high risk groups over time.




We estimated the costs, health benefits, and cost effectiveness of vaccination 
of high risk groups with the 13 valent pneumococcal conjugate vaccine on top of 
the current risk based vaccination programme with the 23 valent polysaccharide 
vaccine. This was done because the existing programme with the 23 valent 
polysaccharide vaccine is likely be continued despite the potential introduction of 
a risk based programme using the 13 valent pneumococcal conjugate vaccine. In 
addition our risk estimates for pneumococcal disease were estimated in the current 
situation in which a risk based programme using the 23 valent polysaccharide 
vaccine is already in place (albeit with a low uptake of vaccination).
As infants are already vaccinated with the 13 valent pneumococcal conjugate 
vaccine, we restricted our analysis to high risk patients aged 2 years and older. The 
perspective was from that of the National Health Service, as recommended in the 
United Kingdom [9]. 
model and population
We developed a cohort model to determine the cost effectiveness of vaccinating 
specific high risk groups with the 13 valent pneumococcal conjugate vaccine. Groups 
included in this analysis were based on a recent study among patients admitted to 
hospital in England with culture confirmed invasive pneumococcal disease, which 
compared the prevalence of clinical risk factors in the general population with that 
in patients admitted to hospital with invasive pneumococcal disease [7]. The study 
sample comprised 22,298 patients admitted to hospital between April 2002 and 
March 2009 with an admission record in the hospital episode statistics database for 
England that could be linked with the dataset of the national invasive pneumococcal 
disease laboratory held at the Health Protection Agency [7]. 
In the current analysis we differentiate between people who are immunocompromised, 
such as those with HIV, asplenia, or splenic dysfunction or who respond poorly to the 
vaccine, such as people with chronic kidney disease; and those in immunocompetent 
risk groups such as patients with chronic heart, liver, or respiratory disease and people 
with diabetes [7].
The analytical time frame of the study was until 2021 (we assume that after 
this time the additional benefits of vaccination would be negligible). However, we 
extrapolated the long term effects of invasive pneumococcal disease over the full 
lifetime of the participants in each cohort—that is, until death or 100 years. 
incidence of invasive pneumococcal disease and mortality risks
Using the most recent data available we estimated age group and risk group specific 
incidences. Firstly, we calculated age specific incidences of invasive pneumococcal 
disease for the general population, including cases confirmed by polymerase chain 
reaction and culture from the epidemiological year 2009-10 (in this paper we refer 
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to epidemiological years, which run from July to June, unless stated otherwise) [8]. 
These incidences were subsequently used to estimate the incidence of invasive 
pneumococcal disease in high risk people using the prevalence of clinical risk 
factors among the general population and the prevalence among the linked patients 
admitted to hospital with invasive pneumococcal disease [7]. From the same 
databases we estimated the age specific share of meningitis and empyema to the 
total invasive pneumococcal disease burden to allow the inclusion of specific costs 
related to these outcomes. We also obtained age group and risk group specific case 
fatality ratios for invasive pneumococcal disease from this same study [7]. 
invasive pneumococcal disease sequelae
Invasive pneumococcal disease may lead to long term sequelae, especially in the 
case of meningitis. We obtained the risk of different types of sequelae from a recent 
meta-analysis [9]. As patients can have multiple sequelae, we assigned all possible 
combinations on the basis of the prevalence of the individual conditions and reweighted 
them such that the overall risk to develop any sequela was equal to the pooled prevalence 
of 31.7% as estimated by the meta-analysis. We obtained the losses in overall quality 
adjusted life years (QALYs) using the most severe QALY weight in the combination.
non-bacteraemic pneumococcal pneumonia
To assess whether to include an effect of the 13 valent pneumococcal conjugate 
vaccine on non-bacteraemic pneumococcal pneumonia in the base case we looked 
at the impact of the seven valent pneumococcal conjugate vaccine on the overall 
incidence of non-bacteraemic pneumonia in high risk children. For this we obtained 
the number of episodes of non-specified pneumonia (ICD J18.X, mentioned in any 
diagnostic code) and the number of deaths for the same cases (within 30 days of 
admission) for the years 1997-98 up to 2009-10 (data from 2002-03 to 2009-10 
were used for deaths) from the hospital episode statistics database in children 
aged less than 5 years. Next, we divided individual cases into risk or non-risk groups 
based on the same ICD codes (see appendix 9 in supplementary file) as used for 
invasive pneumococcal disease, and we calculated incidences. An interrupted time 
series analysis showed that the incidence of pneumonia requiring admission to 
hospital in non-high risk children aged less than 5 years (that is, those eligible for 
vaccination) was significantly reduced after the introduction of the seven valent 
pneumococcal conjugate vaccine, whereas the incidence in high risk children of 
the same age was not significantly reduced (see appendix 1 in supplementary 
file). Based on the striking difference between risk and non-risk groups, and the 
additional uncertainty about the contribution of Streptococcus pneumoniae to 
non-bacteraemic pneumonia, particularly in high risk children, we decided not 
to include an overall impact on non-bacteraemic pneumonia in the base case 
analysis for the high risk groups. We did, however, explore the potential impact of 
ECONOMIC ANALYSIS OF VACCINATING RISK GROUPS WITH PCV-13
ELEVEN
223
including an effect against non-bacteraemic pneumonia in specific analyses. For 
this we used the data on age specific incidence for all cause pneumonia for the 
year 2010 from hospital episode statistics and projected these forward assuming 
the same incidence as in 2010. Next we assumed that S pneumoniae would be the 
causal agent in 42% of the patients in high risk groups admitted to hospital with 
non-bacteraemic pneumonia on the basis of the results of the two most recent UK 
studies available [10,11]. We then assumed that the contribution of the vaccine 
serotypes to pneumococcal pneumonia would decline in line with the herd effect of 
the infant vaccination programme on invasive pneumococcal disease.
indirect effects
In virtually all countries the introduction of the seven valent pneumococcal conjugate 
vaccine was followed by a large reduction in invasive pneumococcal disease owing 
to vaccine serotypes in vaccinated and unvaccinated age groups, with the indirect 
benefits in some age groups partially offset by a concomitant increase in invasive 
pneumococcal disease due to non-vaccine serotypes [4]. This was also the case in 
the United Kingdom in which the seven valent pneumococcal conjugate vaccine was 
introduced in September 2006 with a vaccination schedule of 2, 4, and 13 months, 
and catch-up vaccination for children aged up to 2 years [8]. In April 2010, the 13 
valent pneumococcal conjugate vaccine replaced the seven valent vaccine in the 
infant vaccination programme. 
To predict the future decrease in invasive pneumococcal disease due to vaccine 
serotypes in unvaccinated age groups, we divided the serotypes into those covered 
by the seven valent vaccine and those included in the 13 valent vaccine but not in 
the seven valent pneumococcal conjugate vaccine. In both cases we used age group 
specific (2-4, 5-14, 15-44, 45-64, and >64 years) UK data on incidence of vaccination 
before and after the introduction of the seven valent vaccine. The prevaccination 
period included the incidence data for the years 2000-06, whereas the post-
vaccination period included data up to four years after the introduction of the vaccine 
(2006-10). Using the age group specific annual incidence (adjusted for underlying 
trends in case ascertainment) we fitted a Poisson regression model adjusting for the 
population size to predict the future reduction in cases of invasive pneumococcal 
disease due to the vaccine serotypes (see appendix 2 in supplementary file).
We consequently used the predicted annual decrease in vaccine serotypes to predict 
the incidence of the additional serotypes (except for serotype 3, see below) in the 13 
valent vaccine—that is, we assumed that the herd effects for the additional serotypes 
in this vaccine would be similar to those observed for the serotypes in the seven valent 
vaccine after the introduction of the routine infant vaccination programme using the 
seven valent pneumococcal conjugate vaccine in 2006 [7]. The only difference was that 
we delayed the herd effects for the six additional serotypes in the 13 valent vaccine 
by one year as the introduction of the vaccination programme using the 13 valent 
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pneumococcal conjugate vaccine was not combined with a catch-up programme. This 
assumption is supported by the most recent data from the Health Protection Agency, 
which show no indication of any herd effect yet in people aged 5 years and older, 15 
months after implementation of the routine infant vaccination programme using the 
13 valent pneumococcal conjugate vaccine [12]. Furthermore, in the Netherlands, 
where the vaccination programme using the seven valent pneumococcal conjugate 
vaccine was launched without a catch-up, herd effects were not observed in the first 
year after implementation in contrast with the United Kingdom [13].
We did not include serotype replacement effect in the model as we assumed 
that it would not affect the incremental cost effectiveness ratio because changes 
in invasive pneumococcal disease due to non-vaccine serotypes are expected to be 
the same irrespective of the implementation of the risk group programme. 
vaccine efficacy, number of vaccine doses, duration of protection
Although the efficacy of the seven valent vaccine in healthy infants is well established, 
the available data for risk groups and adults is scarce, with most studies reporting 
data on immunogenicity rather than efficacy [3]. Data on the efficacy of the 13 
valent pneumococcal conjugate vaccine is limited [12]; the current licence for the 
use in infants and children from 6 weeks to 5 years of age and adults aged 50 years 
and over was based on immunogenicity rather than efficacy data [14] (see appendix 
3 in supplementary file for an overview of available data).
Considering the limited data available, we carried out a formal elicitation of 
expert opinion on vaccine related variables to construct a probability distribution 
that represents the experts’ knowledge and uncertainty [15]. The objectives 
of the elicitation were to estimate the efficacy of the 13 valent pneumococcal 
conjugate vaccine (against invasive pneumococcal disease and non-bacteraemic 
pneumococcal pneumonia) and the duration of protection after one dose of the 
vaccine (as in the base case analysis) or two doses of the vaccine. Importantly, 
recent data from our group show that the serotype 3 component of the 13 
valent pneumococcal conjugate vaccine seems to be ineffective against invasive 
pneumococcal disease caused by this serotype [16]. Therefore, in the model we 
also assumed no protection against disease or carriage for serotype 3. 
Specific details on the method of elicitation can be found in appendix 4 in 
the supplementary file. Briefly, we asked five members of the Pneumococcal 
Subcommittee of the Joint Committee on Vaccination and Immunisation to give 
an estimate for the efficacy of the 13 valent pneumococcal conjugate vaccine in 
risk groups based on the available efficacy data for the seven valent pneumococcal 
conjugate vaccine and immunogenicity data for both the seven valent and the 
13 valent pneumococcal conjugate vaccines. We used the estimates to create 
distributions for vaccine effectiveness using the Sheffield elicitation framework 
[15]. Final distributions can be found in table 1.
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life years and Qaly estimates
As the life expectancy between the general population and high risk groups differs 
[17,18], we calculated specific background mortality for people at high risk (and 
for the general population for validating purposes). Data were gathered from the 
Royal College of General Practitioners database (including 0.8 million patients; 
more than 1% of the UK population) over a period of six years (2005 to 2010). We 
grouped the patients by risk factor (based on Read codes mapped to ICD-9 codes) 
and calculated the number of person years and deaths in the high risk group. Using 
these data we calculated background mortality (see appendix 5 in supplementary 
file). We also calculated the mortality for non-risk groups and validated these 
against life tables from the Office for National Statistics [19]. In addition to life 
years gained we also calculated QALYs gained by vaccination. For patients admitted 
to hospital for invasive pneumococcal disease, we used losses in QALYs of 0.0079 
per case for bacteraemia and 0.0232 per case for meningitis [20]. We assumed 
that non-bacteraemic pneumococcal pneumonia resulted in a QALY loss of 0.006 
per case [21]. In addition to acute losses in QALYs, we also linked specific losses in 
QALYs to the sequelae due to meningitis based on a Dutch study [22] (see table 1 
for specific losses in QALYs). 
costs
All costs are reported in pounds sterling at 2009-10 prices. Where necessary we 
inflated these using the hospital and community health services pay and price index 
[23]. As the perspective was from that of the healthcare provider, we included only 
direct costs. We used recommended procedures to estimate the costs for patients 
admitted to hospital with invasive pneumococcal disease. The NHS healthcare 
resource group software was used, which combines procedure codes and ICD-10 
diagnostic codes to output the most relevant healthcare resource group code. 
We subsequently assigned these codes a cost from the National Schedule of 
Reference Costs for NHS trusts. As the patients included in our analysis are all high 
risk, we included only those for which it was likely that the invasive pneumococcal 
disease episode was the main cause for admission to hospital—defined as those 
patients who had a primary diagnostic code related to an invasive pneumococcal 
disease code (see appendix 6 in supplementary file). Table 1 displays the costs 
and probabilities related to invasive pneumococcal disease. The costs of hospital 
admission for non-bacteraemic pneumococcal pneumonia were based on reference 
costs for pneumonia. We used the weighted average costs based on the number 
of non-elective admissions for pneumonia without complications (NHS reference 
costs code WADZ11C). Patients who had meningitis without sequelae were assumed 
to have a single outpatient appointment after discharge; we obtained the cost of 
treatment and care for patients with sequelae after meningitis from a previous cost 
effectiveness analysis [24].
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The total cost per dose of 13 valent pneumococcal conjugate vaccine was 
estimated at £56.61, consisting of the price of the vaccine (£49.10) and 
administration costs (£7.51).
scenario and sensitivity analysis
We carried out univariate, threshold, scenario, and probabilistic sensitivity analyses. 
In the univariate sensitivity analyses, relevant variables were based on the 5% 
and 95% quantiles to explore the impact of uncertainty around each variable. A 
threshold analysis was done in which we varied the vaccine price to investigate the 
effect on the incremental cost effectiveness ratio.
In specific scenario analyses we explored the impact of changes in vaccine 
efficacy, vaccine waning, delaying the herd effect of the infant vaccination 
programme using the 13 valent pneumococcal conjugate vaccine, assuming life 
expectancy of the general population (rather than using the life expectancy of 
people in high risk groups), and the effect of discounting. 
For the probabilistic sensitivity analyses, we generated variables using Monte 
Carlo sampling with outcome values generated by running the model 5000 times 
using Latin hypercube sampling. When quantitative data about uncertainty around 
variables were available we used log normal and β distributions (see table 1 for 
specific distributions). When only a single point estimate was available, we assumed 
a normal distribution with a coefficient of variation of 0.25. For all the sensitivity 
analyses it was assumed that the vaccination programme would be launched in 
2012-13 (two to three years after the infant programme). 
outcome measures and cost effectiveness analysis
The simulation model tracks the incidence of invasive pneumococcal disease and 
non-bacteraemic pneumococcal pneumonia, the number of deaths, costs, QALYs, and 
life years. We calculated the net costs, life years gained, and QALYs by summing all the 
costs, life years, and QALYs and calculating the differences for the evaluations with 
and without vaccination. The incremental cost effectiveness ratio was calculated by 
dividing the net costs by either the life years gained or QALYs gained. Health effects and 
cost were both discounted at 3.5% according to the UK guidelines [25]. In the analyses 
we compared the possible impact of vaccination using the 13 valent pneumococcal 
conjugate vaccine with that of the current situation. Currently, adults aged more than 
65 years and people in at risk groups aged 2 years or more are recommended to 
be vaccinated with the 23 valent polysaccharide vaccine[26]; however, uptake of the 
vaccine is relatively low, especially in those aged less than 65 years (see appendix 7 
in supplementary file) [7]. We assumed that the 13 valent pneumococcal conjugate 
vaccine, would be used in addition to the 23 valent polysaccharide vaccine. 
Finally, we assumed that the uptake of the 13 valent pneumococcal conjugate 
vaccine would be similar to the annual influenza programme in the United Kingdom, 
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at 34.5% in the age group 2-16, 53.6% in the age group 16-65, and 72.4% in the 
age group 65 and older [27] and that vaccination with the 13 valent pneumococcal 
conjugate vaccine would be offered irrespective of previous vaccination with the 23 
valent polysaccharide vaccine.
resulTs
incidence of invasive pneumococcal disease, vaccine efficacy, 
indirect effects, and life expectancy
Among high risk groups the highest incidence of invasive pneumococcal disease 
was in young people infected with HIV and the lowest in those with chronic heart 
disease, diabetes, or splenic dysfunction (see appendix 8 in supplementary file for 
estimated incidence of invasive pneumococcal disease among high risk groups). 
Table 1 shows the estimates for vaccine efficacy based on the elicitation of 
expert opinion and the estimated costs associated with different types of invasive 
pneumococcal disease. Appendix 2 in the supplementary file presents the Poisson 
regression for invasive pneumococcal disease due to vaccine serotypes after the 
introduction of the seven valent pneumococcal conjugate vaccine. Finally, appendix 
5 in the supplementary file shows the life expectancy for people in high risk groups. 
Total burden in high risk groups
Without a vaccination programme based on risk groups, but taking into account 
the likely herd effects of the infant vaccination programme using the 13 valent 
pneumococcal conjugate vaccine, the model predicts that from 2012-13 to 2020-21 
about 1333 cases of invasive pneumococcal disease due to vaccine serotypes would 
occur in people at high risk (table 2). This corresponds to a total loss of about 5900 
life years or 6200 QALYs (undiscounted). The herd impact of the infant vaccination 
programme using the 13 valent pneumococcal conjugate vaccine is large; preventing 
an additional 6200 invasive pneumococcal disease cases due to vaccine serotypes 
corresponding to an additional 30 400 QALYs lost compared with a continuing infant 
vaccination programme using the seven valent pneumococcal conjugate vaccine.
impact on budgets
A risk based vaccination programme would require 4.1 million vaccine doses 
(assuming the same vaccine uptake as the annual influenza vaccination 
programme), resulting in a total cost of around £233m (of which £202m is 
attributed to the vaccine and the remainder to administration costs). Focusing on 
specific high risk groups, in whom vaccination would be most cost effective, could 
reduce the costs substantially. For example, vaccinating people with chronic liver 
disease would result in a total net cost of £4.6m. Furthermore, table 3 also shows 
the impact on budgets of assuming a higher coverage among all risk groups (80% 
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Table 1. Variables used in economic model
variables expected value distribution reference
age specific incidence See Appendix 8 NA See methods
Odds of IPD* Age and risk group 
dependent*
Log normal [7], see 
methods
Case fatality ratio† Age and risk group 
dependent†
β [7], see 
methods





Share of empyema in total 




vaccine efficacy against invasive pneumococcal disease‡
High risk immunocompetent:
 Aged <65 years 0.71 β (α 2.1, β 0.863) See methods
 Aged ≥65 years 0.63 β (α 2.01, β 1.19) See methods
High risk immunocompromised:
 Aged <65 years 0.53 β (α 1.59, β 1.41) See methods
 Aged ≥65 years 0.43 β (α 1.21, β 1.62) See methods
vaccine efficacy against non–bacteraemic pneumococcal pneumonia‡
High risk immunocompetent:
 Aged <65 years 0.46 β (α 1.88, β 2.19) See methods
 Aged ≥65 years 0.40 β (α 1.47, β 2.2) See methods
High risk immunocompromised:
 Aged <65 years 0.33 β (α 1.24, β 2.55) See methods
 Aged ≥65 years 0.27 β (α 1.27, β 3.47) See methods
Waning immunity (per year)§
High risk immunocompetent:
 Aged <65 years 0.11 See methods See methods
 Aged ≥65 years 0.25 See methods See methods
High risk immunocompromised:
 Aged <65 years 0.24 See methods See methods
 Aged ≥65 years 0.26 See methods See methods
prevalence of sequelae after meningitis
Deafness 0.08 β (mean 0.08 SE 0.03) [9]
Mild hearing loss 0.21 β (mean 0.21 SE 0.02) [9]
Seizures and hydrocephalus 0.07 β (mean 0.07 SE 0.02) [9]
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Spasticity or paresis 0.09 β (mean 0.09 SE 0.01) [9]
Cranial nerve palsy 0.12 β (mean 0.12 SE 0.04) [9]
Quality adjusted life year losses
Hospital admission  
for meningitis
0.023 β (mean 0.023 SE 0.031) [21], [20]
Hospital admission  
for bacteraemia¶
0.0079 β (mean 0.079 SE 0.083) [21]
Hospital admission for non–
bacteraemic pneumonia
0.006 Normal  
(mean 0.006 SD 0.0015)
[21],[20] 
Quality of life weights
Deafness 0.81 β (mean 0.81 SE 0. 028) [22]
Mild hearing loss 0.91 β (mean 0.91 SE 0.015) [22]
Seizures 0.83 β (mean 0.83 SE 0.015) [22]
Hydrocephalus 0.62 β (mean 0.62 SE 0.021) [22] 
Spasticity or paresis 0.67 β (mean 0.67 SE 0.023) [22]
Cranial nerve palsy 0.67 β (mean 0.67 SE 0.023) [22] 
costs (£)
Case of meningitis** 6509 Normal (mean 6509 SD 405) See methods
Case of empyema** 7538 Normal (mean 7665 SD 444) See methods
Short hospital stay  
for other IPD**
825 Normal (mean 839 SD 3.93) See methods
Case with long stay for other IPD:
  With excess days  
in hospital**
8977 Normal (mean 9129 SD 142) See methods
  Without excess days  
in hospital**
3022 Normal (mean 3073 SD 19) See methods
Admitted to hospital for 
pneumonia
661 Normal (mean 672 SD 168) See methods
Chance of long hospital  
stay for IPD
0.61 β (α 5075 β 8257) See methods
Chance of excess days  
during long stay for IPD
0.46 β (α 2328 β 5075) See methods
Lifetime costs after meningitis:
 In first year 6591 Log normal (mean 8.7 SD 0.4) [24]
 In subsequent years 203 Log normal (mean 8.7 SD 0.4) [24]
Outpatient follow–up  
for meningitis
382 Log normal (mean 5.2 SD 0.4) [24]
Table 1. continued
variables expected value distribution reference
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Cost of PCV13 49.10 Fixed [42]
Administration costs 7.51 Fixed [42]
other variables
Herd effect due to infant 
vaccination
See Appendix2 Normal See Appendix 2
Life expectancy among  
high risk groups
See Appendix 2 NA See Methods
Discount rate for costs  
and health effects
3.5% NA 25
*Odds ratio of IPD comparing risk groups to non–risk groups. Specific odds ratios can be found in Van 
Hoek et al.[7] 
†Age specific case fatality ratios can be found in Van Hoek et al.[7]
‡After single dose during first year of vaccination. Efficacy estimates do not apply for serotype 3 (see 
method section) [16]. Estimates of vaccine efficacy after two doses are listen in Appendix 4.
§Annual waning factor was calculated by using the experts estimation of vaccine efficacy during first 
and third year after vaccination using annual exponential decay of immunity.
¶Same quality of life year decrement was assumed for invasive pneumonia, bacteraemia with focus, 
and bacteraemia without focus.
**Mean costs were sampled from a normal distribution with a mean equal to the log normal mean and 
standard deviation equal to the standard error of the log normal mean.
Table 1. continued
variables expected value distribution reference
Table 2. Total burden of IPD due to vaccine serotype (undiscounted) over nine year period 
(2012–13 to 2020–21) in people at high risk.
variables




Without high risk vaccination and without 
herd protection benefits of PCV13*
7522 1895 34,251 36,579
Cases prevented by the herd effects of the 
infant PCV13 programme†
6189 1538 28,397 30,382
Without high risk vaccination and with herd 
effects of additional six serotypes in PCV13
1333 357 5854 6197
With high risk group vaccination (including 
herd effects of infant programme)‡
927 247 4033 4274
Averted burden by high risk vaccination 
(incremental effects)§
406 110 1821 1923
*Only including herd effect due to serotypes included in PCV7 (excluding herd effect due to the six 
additional serotypes included in PCV13.)
†Herd effects due to the additional six serotypes in PCV13 based on incidence after vaccination with 
PCV7 (see methods and Appendix 2).
‡Vaccination uptake to be assumed similar to that of annual influenza uptake (see methods).
§Numbers may not add up owing to rounding.
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uptake) and the impact assuming the same annual coverage as for the 23 valent 
polysaccharide vaccine (see appendix 7 in supplementary file). If coverage is no 
higher than that achieved by the 23 valent vaccine, then the impact on budgets 
would be much reduced, as this programme only achieves poor levels of uptake.
cost effectiveness
The base case analysis (excluding a possible impact against non-bacteraemic 
pneumococcal pneumonia) assumed it would be possible to start vaccinating at 
risk groups in the epidemiological year 2012-13. Using a threshold of £30,000 for 
a willingness to pay for a QALY gained,25 only vaccination of patients with chronic 
liver disease (table 4) would be deemed cost effective. People infected with HIV was 
the second most favourable at risk group, with an incremental cost effectiveness 
ratio of £61,200 per QALY gained. Vaccinating all other at risk groups would not be 
considered cost effective, with an incremental cost effectiveness ratio of more than 
£80,000 per QALY gained. 
impact of time on cost effectiveness 
The expected indirect benefits as a result of the infant vaccination programme limit 
the direct effect of targeting high risk groups. As a result the cost effectiveness 
of vaccinating at risk groups decreases over time as indirect benefits accrue. If 
a programme targeted at high risk groups had been initiated in 2009-10, then 
Table 3. Budget impact (total costs) of vaccinating different risk groups (£m) with PCV13 
according to assumed uptakes.
risk group
assumed uptake*
similar to influenza 
programme (base case)* 80%
similar to annual 
ppv23 programme†
Any risk group 233 290 17.8
Splenic dysfunction 6.3 8.9 0.35
Chronic respiratory disease 34.1 41.5 2.80
Chronic heart disease 116 1411 9.60
Chronic kidney disease 71.5 83.4 6.40
Chronic liver disease 4.64 6.4 0.24
Diabetes 59.2 75.2 4.15
Immunocompromised 17.9 24.0 1.12
Infected with HIV 0.37 0.54 0.01
*Annual influenza coverage 34.5% in 2–15 year olds, 53.6% in 16–65 year olds, and 72.4% in those 
aged ≥65 years [27]. Sum of costs of separate risk groups are higher than total costs of any risk group 
as people may have more than one underlying condition.
†Annual uptake 4.1% in 2–15 year olds, 1.5% in 16–65 year olds, and 7.2% in those aged ≥65 years). 
See Appendix 7.
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vaccinating immune compromised people and people with chronic respiratory 
disease and HIV infection could also be deemed cost effective (incremental cost 
effectiveness ratio of ≤£30,000 per QALY). Figure 1 shows the impact of time on the 
incremental cost effectiveness ratio for the years 2009-10 up to 2015-16. 
sensitivity analyses 
Table 4 shows the impact on the incremental cost effectiveness ratio of assuming 
an overall impact on non-bacteraemic pneumonia. If included, even vaccinating 
the whole group at increased risk of invasive pneumococcal disease might be 
considered cost effective, with an incremental cost effectiveness ratio of £17,500 
per QALY. Figure 2 shows the maximum costs of vaccination for it to be considered 
cost effective. These costs will decrease with a decreasing net effect of the vaccine 
in time. In the base case (no overall impact on non-bacteraemic pneumonia) the 
vaccine costs have to be reduced for all risk groups, except for patients with chronic 
liver disease, to consider a risk group programme to be cost effective. 
The results of the scenario analyses (table 5) and the univariate sensitivity 
analysis (fig 3) show that the predicted herd effects of the infant programme 
and vaccine efficacy have a large impact on the incremental cost effectiveness 
ratios. For instance, if there are no herd effects resulting from the additional types 
now included in the infant vaccination programme then the cost effectiveness of 
targeting all high risk groups would be reduced from over £180,000 to around 
£47,000 per QALY gained. Other important factors were the price of the vaccine, the 
risk and age group specific incidence, and the case fatality ratio. Also, the scenario 
figure 1. Impact of time on incremental cost effectiveness ratio. QALY=quality adjusted life year
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Table 4. Incremental cost effectiveness ratios (ICERs) in £/QALY per risk group assuming 






Any risk group 183,680 17,503
Splenic dysfunction 1,204,091 37,686
Chronic respiratory disease 90,243 14,832
Chronic heart disease 161,063 16,043
Chronic kidney disease 493,682 22,641
Chronic liver disease 20,324 10,825
Diabetes 269,750 18,459
Immunocompromised 90,720 24,296
Infected with HIV† 61,239 28,144
* Assuming no overall impact on non bacteraemic pneumonia in high risk group.
†When the assumption was made that life expectancy of people infected with HIV would be similar to high 
risk immonocompetent people [43,44], ICERs were estimated at £54,409/QALY in base case analysis 
and at £25,717/QALY when an effect against non–bacteraemic pneumococcal pneumonia was included.
figure 2. Maximum costs per vaccinee (including costs of vaccine and administration) to consider 
risk group vaccination cost effective (incremental cost effectiveness ratio of ≤£30 000 per quality 
adjusted life year)
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figure 3. Univariate sensitivity analysis for any at risk group. Variables were changed over their 
5% and 95% quantiles, with exception of share of meningitis and empyema, which were varied 
by 50%. Incidence was altered by varying odds of invasive pneumococcal disease in those with 
risk factors compared with those without. Bar for lower vaccine efficacy are cut-off for all at risk 
groups except immunocompromised patients. Please note that the scales of the figures vary. 
QALY=quality adjusted life year
analysis showed that the additional benefits of a second dose were outweighed by 
the doubling of the costs. 
probabilistic sensitivity analysis
Figure 4 shows the cost effectiveness acceptability curves for the risk groups in 
whom the incremental cost effectiveness ratio was less than £100,000 per QALY. 
It is clear that if the vaccine does not offer protection against non-bacteraemic 
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pneumococcal pneumonia then only vaccinating patients with chronic liver disease 
is likely to be considered cost effective, but by assuming an overall impact against 
non-bacteraemic pneumococcal pneumonia, vaccinating any of the at risk groups 
would probably be cost effective. 
discussion
Although the herd effects of the infant vaccination programme using the 13 valent 
pneumococcal conjugate vaccine will in time indirectly protect people at high risk, the 
burden of preventable pneumococcal disease will remain high during the first years 
after the introduction of the vaccination programme. Vaccinating all groups at high 
risk of invasive pneumococcal disease with the 13 valent pneumococcal conjugate 
figure 4. Results of probabilistic sensitivity analysis.
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vaccine would have a large impact on budgets, therefore targeting specific high risk 
groups may be more attractive although this would require general practitioners to 
identify subgroups among those at increased risk. Our analysis shows that unless 
the 13 valent pneumococcal conjugate vaccine also offers protection against non-
bacteraemic pneumococcal pneumonia, vaccination is unlikely to be considered 
cost effective for most at risk groups. 
The assumptions about vaccine efficacy and effectiveness, and in particular 
that against non-bacteraemic pneumococcal pneumonia, had a large impact on 
our results, and a great deal of uncertainty surrounds these estimates. Although 
evidence from randomised controlled trials would be preferable to expert opinion, 
by the time results are available [28] the potential benefits of vaccinating high risk 
groups are already largely limited by the expected herd effects. 
strength and weaknesses of the study
This is the first economic evaluation of vaccination against pneumococcal disease in 
specific high risk groups using the 13 valent pneumococcal conjugate vaccine. The 
two most influential variables on the outcome were the assumed herd protection 
benefits from the infant pneumococcal vaccination programme and the vaccine 
effectiveness against non-bacteraemic pneumococcal pneumonia.
Dynamic models have been used to predict the herd effects of the infant vaccination 
programme but their reliability critically depends on the structure and underlying 
assumptions, such as vaccination coverage, difference in case-carrier ratios between 
serotypes, and the level of competition between vaccine serotypes and non-vaccine 
serotypes in carriage [18,29]. Hence any such model predictions are subject to 
considerable uncertainty. Therefore we decided to predict the future herd effects 
by using Poisson regression models, assuming that the decrease in the additional 
serotypes (with the exception of serotype 3) would be similar to those observed after 
the introduction of the seven valent pneumococcal conjugate vaccine. Nevertheless, 
the herd effect for the six additional serotypes in the 13 valent pneumococcal 
conjugate vaccine might be different from those in the seven valent vaccine owing to 
differences in carriage, transmissibility, and the potential to cause disease [30,31]. 
We also assumed that the herd effects would be similar among high risk and non-high 
risk groups, as this was previously also observed for invasive pneumococcal disease 
due to serotypes in the seven valent pneumococcal conjugate vaccine.7 However, 
as the less invasive serotypes primarily affect people at high risk and the additional 
serotypes included in the 13 valent pneumococcal conjugate vaccine are the more 
invasive, people at high risk might benefit less from herd effects compared with healthy 
people [32]. This may also explain the failure to find a reduction in non-bacteraemic 
pneumonia in children at high risk compared with healthy children. 
Another key assumption was the vaccine efficacy against invasive pneumococcal 
disease and non-bacteraemic pneumococcal pneumonia. The main reason for not 
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including an effect against non-bacteraemic pneumococcal pneumonia in the base 
case analysis was that the time series analysis did not show any measurable effect 
on admissions due to pneumonia in high risk children eligible for vaccination with 
the seven valent pneumococcal conjugate vaccine, whereas a significant reduction 
was observed in non-high risk children of the same age. This might be explained by 
different pathogens (viral or bacterial) causing pneumonia in high risk populations and 
for those with pneumococcal pneumonia, a different serotype distribution in high risk 
compared with low risk people. As we had the ability to analyse our surveillance data 
by whether patients had comorbidities, which would seem essential for deciding on a 
risk based vaccination programme, our assumption of the effectiveness against non-
bacteraemic pneumonia differs from two previous analyses [33,34]. We do, however, 
also note that the effect of being in an at risk group on increasing the risk of invasive 
pneumococcal disease is more noticeable in children than in adults [7], which might 
mean that our assumption of lack of a direct effect of the 13 valent pneumococcal 
conjugate vaccine on non-bacteraemic pneumonia in adults may be conservative [5], 
yet consistent with the BMJ guidelines for economic evaluations [7,35]
Finally, we note that the impact of non-bacteraemic pneumococcal pneumonia 
was high in our analysis despite a relatively low vaccine efficacy being used in 
combination with a relatively high waning rate (table 1).
The cost effectiveness of vaccination depends heavily on the probability of 
developing disease. In our analysis this was based on the observed odds of invasive 
pneumococcal disease in risk groups compared with those not in risk groups and 
the absolute incidence of non-risk group related disease. One of the caveats of 
the risk factor study was that patients were attributed to risk groups on the basis 
of the presence of specific discharge codes. Some of the risk groups might not 
have been consistently recorded. The odds for people with asplenia were low in 
the study, with no obvious increased probability of developing disease, resulting 
in unfavourable incremental cost effectiveness ratios. Although this might be 
explained by successful prophylaxis by antibiotics or polysaccharide vaccine, it is 
possible that people with asplenia were poorly recorded. 
Therefore the cost effectiveness of some of the described risk groups might 
have been underestimated, although sensitivity analyses showed that our 
conclusions remained valid when we increased the incidence. Also, the future 
incidence of pneumococcal disease due to vaccine serotypes may be affected by 
changes in the epidemiology of viral respiratory tract infections, such as happened 
with pandemic A/H1N1 2009 influenza [36]. This caused a noticeable increase in 
invasive pneumococcal disease in the age groups with the highest incidence of 
H1N1 infection [36], and, given the overlap between the risk groups for influenza 
and invasive pneumococcal disease, selective vaccination of high risk groups with 
the 13 valent pneumococcal conjugate vaccine might help mitigate the effects of 
future increases in such viral infections. 
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comparison with other studies
This is the first cost effectiveness analysis of the 13 valent pneumococcal conjugate 
vaccine focusing specifically on people at increased risk for invasive pneumococcal 
disease. As far as we know, two other studies have focused on the cost effectiveness 
of vaccinating non-infant populations [33,34]. A main difference is that these studies 
focused on older adults (>50 years [34] and 65 [33] years), whereas our study specifically 
focused on risk groups of people aged 2 years and older. Both these studies showed 
that for these specific age groups a vaccination programme could be considered cost 
effective, whereas we in the base-case analysis conclude that a vaccination programme 
in unlikely to be considered cost effective. The main driver for this difference is that in 
the base case analysis we assumed that the 13 valent pneumococcal conjugate vaccine 
would not have an overall impact on non-bacteraemic pneumonia. This difference was 
further driven by the assumption that vaccine would not be effective against serotype 
3, as early data from England and Wales suggests that this component of the 13 valent 
vaccine does not seem to provide direct protection to vaccinated people [16]. However, 
this assumption was based on a few cases of invasive disease due to this serotype in 
children in England and Wales and future data are necessary to answer the outstanding 
question on the efficacy of this serotype. 
Other differences between our study and these two age based studies are 
that we had detailed data on the risk of disease, the life expectancy of high risk 
populations, and specific costs per invasive pneumococcal disease episode 
available, all based on primary data as opposed to estimates from the literature or 
databases. Furthermore, compared with the Dutch study we were able to explicitly 
take herd effects into account for the unvaccinated population as recent data has 
become available that could be used for the prediction of these effects [8].
We showed in the current study that these herd effects have a major impact 
on cost effectiveness. It is desirable that specific cost effectiveness studies from 
a European perspective become available to guide decision making in European 
countries rather than using cost effectiveness estimates from the United States. 
Previous decisions to introduce the infant pneumococcal vaccination programmes 
in European countries largely relied on herd immunity estimates from the United 
States that were subsequently shown not to be applicable elsewhere [3]. 
implications and future research
We found that the cost effectiveness of the 13 valent pneumococcal conjugate 
vaccine programme based on risk group will mainly depend on the time of using the 
vaccine and its effectiveness, in particular against non-bacteraemic pneumococcal 
pneumonia. Since most countries have replaced the seven valent pneumococcal 
conjugate vaccine with the 13 valent vaccine, herd effects are likely to decrease the 
burden of preventable pneumococcal disease over time rendering any additional 
preventive efforts less cost effective. If the 13 valent vaccine does protect against 
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non-bacteraemic pneumococcal pneumonia in high risk groups the programme may 
be cost effective if introduced early enough before the full effect of herd immunity 
is manifested, or if the expected herd immunity effect is less than expected. Policy 
makers may prefer to delay any decision about the use of the 13 valent vaccine in 
high risk groups until the results of the trial currently being done in the Netherlands 
to assess its efficacy against non-bacteraemic pneumonia in elderly people are 
available [28]. However, such a wait and see policy would possibly reduce the need 
for the additional vaccination effort. Another option for governments to consider 
would be sharing the risk with the manufacturer; on the basis of the uncertainty 
around the cost effectiveness a price reduction could be negotiated that remains 
valid until the data on efficacy become available. The implementation of a risk based 
vaccination programme using the 13 valent pneumococcal conjugate vaccine in the 
United Kingdom has been considered by the UK Joint Committee on Vaccination 
and Immunisation, with the final decision being not to introduce such a programme 
largely dependent on the outcome of our study [37]. As many other European 
countries lack the various high quality epidemiological data sources available in 
the United Kingdom or lack the statistical power owing to their population size 
to conduct their own analyses this study will also provide them with important 
evidence. Specific cost effectiveness ratios cannot directly be extrapolated from 
England to other countries but we believe that the general conclusion is informative 
for those countries that introduced the 13 valent pneumococcal conjugate vaccine 
around the same time and have a similar uptake of vaccination. Some European 
countries are, however, already recommending the 13 valent pneumococcal 
conjugate vaccine for at risk groups or adults. For example, in Austria and Greece 
the 13 valent pneumococcal conjugate vaccine is recommended for those aged 50 
and older [38,39], whereas in France, parts of Germany, and Italy the vaccine is 
being recommended for (specific) risk groups [40,41].
Finally, we note that in addition to considerations about cost effectiveness, 
decision makers need to estimate carefully the possible uptake of vaccination, 
considering the potentially large impact on budgets of a risk based vaccination 
programme using the 13 valent pneumococcal conjugate vaccine. 
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Differences in pathogenicity between pneumococcal serotypes are important when 
assessing the potential benefit of different valency vaccines. We investigated the 
effect of serotype on clinical presentation, outcome and quality of life lost from 
invasive pneumococcal disease (IPD) in the context of the 7, 10 and 13 valent 
pneumococcal conjugate vaccines (PCV7, PCV10, PCV13). 
method
Serotyped IPD cases in England were linked to the national dataset of hospital 
admissions for April 2002 to March 2011. Based on patients’ diagnostic codes 
and vital status at the end of the admission, disease focus (meningitis, empyema, 
sepsis or respiratory disease) and case fatality rates by serotype and age group (5, 
5-64 and 65 years and over) were obtained. Using these data the quality adjusted 
life years (QALY) lost from the IPD remaining when use of PCV7 stopped in 2010 was 
estimated for the serotypes covered by higher valency vaccines. 
results
The linked dataset contained 23,688 cases with information on diagnosis, mortality 
and serotype. There were significant differences between serotypes in the propensity 
to cause meningitis, death and QALY loss in each of the investigated age groups. As 
a result, vaccines’ coverage of disease burden differed by endpoint. For example, 
in children under 5 years in 2009/10, PCV10 covered 39% of meningitis, 19% of 
deaths and 28% of the QALY loss of attributable to IPD, whereas the respective 
percentages for PCV13 were 65%, 67% and 66%. The highest QALY loss per serotype 
in this age group was for 6A. Non-PCV serotypes causing the highest QALY loss were 
22F and 33F in < 5 year olds and 31 in older individuals. 
conclusion
Marked differences exist between serotypes in clinical presentation and outcome 
which should be considered when evaluating the potential impact of higher valency 
vaccines on overall disease burden and associated QALY loss.
inTroducTion
Streptococcus pneumoniae is a commonly carried bacterium that causes both 
invasive and non-invasive disease. There are 90+ known serotypes of S. pneumoniae, 
each characterised by the molecular structure of its polysaccharide capsule [1]. 
Since capsular differences between serotypes have been linked to such properties 
as carriage prevalence [2,3], propensity to cause invasive disease [4,5,2], and 
case fatality [6–8], each serotype could theoretically be regarded as a separate 
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pathogen [4]. Differences in the pathogenicity and thus clinical impact of different 
serotypes are important from a public health perspective because available vaccines 
are serotype-specific, and only target a small subset of the known serotypes. 
Introduction of the first pneumococcal conjugate vaccine that protected against 
seven of the most common serotypes in developed countries (PCV7) had a profound 
effect on serotype-specific carriage prevalence and caused replacement of vaccine 
types by serotypes not included in the vaccine [9,3,10,11]. The overall impact of 
this change in carriage prevalence on pneumococcal-attributable morbidity and 
mortality is dependent on the inherent pathogenicity of the replacing serotypes 
compared with the previously predominant vaccine types. 
To evaluate the potential benefit of introducing higher valency conjugate 
vaccines, as well as assessing the potential impact of previously uncommon 
and less studied emerging serotypes, it is important to have information on the 
invasiveness potential and clinical impact of different serotypes. The latter would 
ideally include disease focus (eg meningitis, empyema or sepsis), risk of long term 
sequelae and life years lost as a result of the infection. Expression of the serotype-
specific clinical impact in terms of quality of life endpoints would incorporate these 
multiple facets of disease burden and provide a measure to use in cost-utility 
evaluations of different intervention strategies, for example, replacing of PCV7 by 
newer 10 valent (PCV10), 13 valent (PCV13) or higher valency conjugate vaccines.
The aim of this study was to investigate serotype-specific differences in clinical 
presentation of IPD and impact on quality of life in the context of the newly available 
PCV vaccines and the existing 23 valent polysaccharide vaccine (PPV23) which, 
although covering a higher number of serotypes, is poorly immunogenic in children 
and largely used in risk groups and the elderly. The Health Protection Agency holds 
one of the largest datasets of invasive pneumococcal disease (IPD) in the world [12] 
with an annual total of nearly 5000 cases in England and Wales serotyped in recent 
years. This national dataset has been used to monitor vaccine effects such as herd 
immunity and serotype replacement after the introduction of PCV7 in 2006 as a 2+1 
infant programme [11] and has provided an early indication of the direct effect of 
PCV13 introduced in April 2010 [13]. Its availability provides a unique opportunity 
to document the effect on clinical presentation and quality of life of the different 
serotypes causing IPD over a nine year period spanning the introduction of PPV23 for 
all 65+ year olds, and the universal infant PCV7 and PCV13 vaccination programmes. 
meThods
construction of the dataset 
Microbiology laboratories in England and Wales voluntarily report electronically all 
clinically significant pneumococcal isolates (obtained by culturing or DNA based 
methods) to the Health Protection Agency (HPA) [11] and are actively requested to 
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refer these isolates to the Respiratory and Systemic Infection Laboratory (RSIL) for 
serotyping. Isolates referred to RSIL are confirmed as pneumococci and serotyped 
with antisera (Statens Serum Institut, Copenhagen) using standard methods. IPD 
reports with the same serotype within 30 days in the same individual are regarded 
as the same episode. As the clinical detail routinely available for IPD cases in the 
national dataset is limited, more comprehensive information on disease focus and 
outcome by serotype was obtained by linking the laboratory confirmed IPD cases 
in England (excluding IPD cases from Wales) with the dataset of hospital episode 
statistics (HES; Copyright © 2012, Re-used with the permission of The Health and 
Social Care Information Centre. All rights reserved) which is only available for England 
(10), using National Health Service (NHS) number or a full match on date of birth, 
sex and postcode. In HES, information on the duration, diagnoses (coded according 
to the International Classification of Disease series 10, ICD10), operative procedures 
and deaths during admission are recorded. All admissions with a code specific for 
IPD, or disease presentations which are likely to be related to acute pneumococcal 
disease were extracted from the HES database for the administrative years April 2002 
to March 2011. The list of ICD10 codes used in the extraction can be found in the 
Supplementary Material S1. Hospital admissions which were on-going the week before 
and up to a month after the date of the positive culture were included in the analysis. 
Linkage and subsequent analysis was performed in R 2.12.0 (www.R-project.org).
classification of disease focus and impact on quality of life
Disease focus was established using the clinical classifications published by the 
Healthcare Cost and Utilization Project [14] with some minor adjustments; convulsions 
(ICD-10 “R56”) were included in the meningitis classification, empyema was included 
as a separate condition based on ICD-10 code “J86” and the different respiratory 
classifications (pneumonia, lower and upper respiratory tract infections) were grouped 
into one broad respiratory disease category (excluding empyema). Categorisation was 
based on all ICD-10 diagnosis codes for an admission rather than just the primary 
diagnosis, thus highlighting the most important focus of the pneumococcal-related 
infection. Where patients had multiple pneumococcal related diagnoses the most 
severe was chosen in the order; meningitis, empyema, sepsis, respiratory disease 
and other. For the serotype-specific analyses only serotypes isolated from at least 
50 episodes of IPD were included. Cases for which only the serogroup was known, and 
cases serotyped as 6A but not tested for 6C were excluded from the analysis. 
Mortality was based on the discharge information within HES. Only deaths 
within 30 days of the culture date were regarded as pneumococcal-attributable. 
As serotype distribution, disease presentation, and mortality varies between age-
groups, data are presented for the age groups 0-4 years, 5-64 and 65+ years. 
To compare the loss in quality adjusted life years (QALYs) by serotype an average 
QALY loss per case of 0.0079 was assumed for hospitalisation with a non-meningitis 
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focus [15], 0.023 QALY loss for hospitalisation due to meningitis [15] with a further 
0.255 QALY loss for each remaining life year applied to the 31.7% of meningitis 
cases expected to have long term sequelae [16]. Empyema is severe in the acute 
phase [17], and in absence of a published QALY loss estimates for empyema, the 
QALY loss for meningitis was applied. No QALY loss from sequelae of empyema was 
included as the long term outcome is good [17]. For fatal cases, we used one QALY 
for each lost life year as expected by the gender specific life expectancy which is 
based on the 2010 mortality rates for England [18]. When conducting economic 
analyses future disease burden is normally discounted to reflect a time preference, 
therefore we added a discount rate of 3.5% per annum, as recommended by the 
National Institute for Health and Clinical Excellence (NICE) [19].
statistical analysis
To assess differences between serotypes we calculated the odds ratio of developing 
meningitis and death for a given serotype compared to serotype 14. This is because 
serotype 14 had the greatest number of samples, and has previously been used as 
a reference for intra-serotype comparisons [7]. To correct for potential confounding 
due to age (years), gender, socio-economic factors, co-morbidities, study year and 
alcoholism we used a binomial logistic regression for meningitis and mortality. Due to 
the bimodal distribution of the QALY loss we show a p-value based on the difference 
of 1000 bootstrap samples for the mean of the given serotype and serotype 14 (this 
approach precluded correction based on potential confounders). For all tests the 
(adjusted) p-values are presented in the paper and the obtained odds are included 
in the Supplementary Material S1. Socio-economic deprivation was based on the 
rank in the deprivation index, as published by the Department for Communities and 
Local Government in the UK [20]. This index is assigned to a small geographical area 
(lower super output area) and related to the postcode of the patient at the time of 
admission as recorded in HES. The deprivation index is not updated every year so 
to reduce the effect of changes of deprivation over time we divided the rank into 
quartiles, as it is less likely that a neighbourhood will change so extensively that it 
moves over quartiles. Co-morbidities were scored based on the Charlson index, where 
the included conditions were crossed mapped with ICD-10 codes [21]. In the analysis 
the Charlson index was sub-grouped into “no-comorbidities”, “Charlson score 1-2” 
and “3 and above”. As alcoholism is not a part of the Charlson index patients were 
identified for alcohol related problems based on the codes used by Harboe et al [6]. 
To assess the precision of the estimates, binomial confidence intervals are 
presented for mortality and the 2.5% and 97.5% percentiles of 1000 bootstrap 
samples for the mean QALY loss.
To investigate the proportion of IPD (and its various disease outcomes) that was 
possibly preventable by the different pneumococcal vaccines (PCV7, PCV10, PCV13 
and PPV23) at the time PCV13 was introduced in April 2010, the number of cases by 
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age group and clinical endpoint was estimated for each serotype. This was achieved 
by multiplying the serotype specific percentage with meningitis, the case fatality 
rate (CFR) or QALY loss as measured over the full period with the absolute serotype 
distribution in the period April 2009 to March 2010. In this calculation the serotypes 
with less than 50 cases were included.
resulTs
linkage success 
The linkage was increasingly successful over the years, with 50% of IPD cases linked 
to a HES admission in 2002/2003 rising to 76% in 2010/2011, resulting in a total of 
33,196 linked cases over the nine year period from England. Of these, 23,688 (71%) 
had information on ICD-10 diagnoses, mortality and infecting serotype (2,605, 
10,389 and 10,694 for the age groups <5,5-65 and 65 and over). The matched cases 
had a similar serotype and age distribution to the unmatched cases, suggesting 
that there were no major biases with respect to these variables as a result of the 
incomplete linkage (see figure S-1 and S-2 in the Supplementary Material S1).
For the under 5 year olds there was a total of 51 different serotypes in the 
matched dataset; however many did not achieve the pre-specified minimum of 
50 cases leaving only 14 serotypes (comprising 86% of the cases) for analysis. 
Among 5-64 year old patients, 67 different serotypes were identified, with only 26 
(comprising 96% of the cases) having enough cases for individual analysis. Among 
the 65 years and over, 62 different serotypes were recorded, with 29 (comprising 
97% of the cases) having enough for individual analysis. 
serotype- specific disease focus 
Within each age group, the clinical presentation differed significantly between 
serotypes, even after correcting for co-morbidities and socio-economic factors, see 
Figure 1 and the Supplementary Material S1. Among children under 5 years, serotype 
18C was the most likely to cause meningitis, with 52% of the patients presenting 
with this outcome, followed by 19F (46%) and 6B (45%). All three serotypes were 
significantly more likely to cause meningitis compared to serotype 14 (31%). The 
non-PCV serotypes, 22F and 33F, had a percentage with meningitis of 37% and 
40% respectively. The lowest proportion of meningitis cases was among serotypes 
1 (10%), 3 (14%) and 19A (24%), although only serotype 1 and 3 were significantly 
different from serotype 14. The serotypes causing a low burden of meningitis had a 
relatively high percentage of children presenting with empyema; serotype 3 (45%), 
1 (37%) and 19A (17%) showed the highest proportions with empyema whereas 
only 0-3% of the serotypes associated with meningitis (6A, 19F, 18C 22F and 33F) 
caused empyema. The percentage of IPD resulting in meningitis was lower in the 
age group 5-64 years than in the under 5 year olds (10% vs 33%). Compared to 
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figure 1. The distribution of disease focus (meningitis, Empyema, respiratory diseases, sepsis 
and other) per serotype grouped by vaccine type and age group. The line shows the absolute 
percentage of patients with meningitis for serotype 14, which was used as reference in the logistic 
regression. The p-values of this regression are shown above each bar. When there are no serotypes 
with ≥50 cases an empty plot is shown. a)Under 5 years, b) 5-64 years, c) 65 years and over
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serotype 14 (7% with meningitis in this age group), serotypes 6A (34%), 10A (32%), 
and 23A (28%) were significantly more likely to cause meningitis, as were 6B, 19F, 
18C, 35F and 15B. Serotype 1 rarely caused meningitis (1%), followed by 31 (4%) 
and 7F (6%). Again serotype 1 was linked to empyema, with 16% of cases having 
this presentation, followed by 7F (6%). Serotypes more likely to cause meningitis 
rarely caused empyema - 6A (1%), 10A (1%) and 23A (0%).
For the age group 65 years and over few cases presented with meningitis or 
empyema. The serotypes most likely to cause meningitis were 35F (13%), 6C (10%) 
and 18C (10%). For empyema, serotype 1 showed the strongest association (6%) 
followed by 7F and 12F (both 3%).
In the regression analysis, having no co-morbidity was significantly associated 
with a higher probability of developing meningitis in the patients above 5 years of 
age (odds 1.88 and 2.51 respectively). The other confounders were not significantly 
associated with meningitis and/or no trends by year or socio-economic factors 
were identified. Disease focus over time (results not shown) was stable. 
serotype-specific mortality
The case fatality among under 5 year olds was low (overall 3%). The serotype with 
the highest case fatality rate was 6A with 7%, followed by 19F with 5%, and 9V and 
serotype 3 (5%) (see Figure 2 and the Supplementary Material S1). Serotype 4 (0%) 
had the lowest case fatality rate followed by serotypes 1, 7F and 6B each with 1%. 
However, none of these case fatality rates differed significantly from serotype 14 
(3%). Non PCV types 22F (3%) and 33F (3%) had an average mortality. 
Among the age group 5-64, (overall CFR 10%) serotypes 31 (33%), 11A (30%) 
and 19F (21%) had the highest case fatality rates; serotypes 1 (3%), 7F (4%) and 
8 (6%) had the lowest rates. Serotype 3, 19F, 19A, 6A, 9N, 11A and 31 (the last 3 
serotypes are not included in any current conjugated vaccine), were all significant 
higher compared to serotype 14 (8%), only serotype 1 was significantly lower.
Patients aged 65 years and over had the highest case fatality rate (overall 30%). 
Serotypes most likely to be associated with a fatal outcome were 19F (41%), 31 
(40%), and 3 (39%), all significantly different from serotype 14 (29%). The lowest 
case fatality rates were for serotypes 1 (17%), 7F (20%) and 12F (21%), all three 
significantly lower than serotype 14.
Confounders associated with mortality in all age groups were meningitis (p 
value: <0.01; <0.01; 0.03 for the age groups <5, 5-64 and 65+ years respectively), 
and co-morbidities (p values: 0.06; <0.01, <0.01 respectively). Among the age group 
5-64 years there was a decline in mortality over time (reducing the odds to 0.6 in 
2010-2011 compared to 2002-2003) and a declining risk of mortality by declining 
social-economic deprivation (an odds of 0.7 in the least deprived status compared 
to the most deprived). These trends were not observed for the other age groups.
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figure 2. Serotype-specific differences in mortality between serotypes. The line shows the 
absolute case fatality rate for serotype 14, which was used as reference in the logistic regression. 
The p-values of this regression are shown above each bar. The whiskers show the 95% confidence 
intervals based on a binomial distribution. When there are no serotypes with ≥50 cases an empty 
plot is shown. a) Under 5 years, b) 5-64 years, c) 65+ years
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Qaly loss by serotype
The lowest overall QALY loss per serotype among children under 5 years was 
serotype 1 (0.43 per case) followed by 4 (0.71) and 7F (1.15). The highest QALY loss 
was among serotypes 6A (2.86). 19F (2.53) and 9V (2.05). Serotype 22F scored 
1.62 and 33F 1.83 (see Figure 3 and the Supplementary Material S1for more detail). 
Within the age group 5-64 years the difference between the low and high burden of 
disease serotypes was more marked. The serotypes causing the highest QALY loss 
were 31 (6.34), 11A (5.82) and 19F (4.34). Serotype 1, 7F and 8 had the lowest QALY 
loss 0.57, 0.95 and 1.17 respectively. 
Among the 65 years and over the differences between serotypes in QALY loss per 
case declined again, with serotypes 1 (1.38), 38 (1.42), and 7F (1.52) at the low end 
of the spectrum and 19F (3.09), 31 (2.95) and 3 (2.93) on the high end.
We performed a sensitivity analysis (results not shown) because a significant 
decrease of mortality was observed for 5-64 years over the period. We adjusted the 
QALY loss for each death before July 2006 by replacing it by p*(QALY loss for death) 
+ (1-p)*(multiplication with the odds for mortality in the second half of the period 
(July 2006 onwards) and adding the QALY loss for meningitis) where p was the adjusted 
odds ratio of mortality after July 2006 compared to before July 2006 by age. Doing so 
resulted in slightly lower QALY losses, and only minor changes in the ranking of serotypes.
burden of ipd potentially preventable by different valency vaccines 
in england before pcv13 introduction
The contribution of the vaccine-specific serotypes to the overall burden of IPD 
in England changed over the study period, largely due to the impact of PCV7 on 
serotype distribution. For 2009/2010, the last administrative year before PCV13 
introduction, the contribution of the different vaccine-specific serotype groupings 
to the overall burden of IPD and its associated QALY loss are shown in Table 1 by age 
group. For children under 5 years, the cumulative coverage for PCV10 was 41% for 
all IPD, 39% for meningitis and 19% for mortality, and 28% for the total QALYs lost. 
For PCV13 the coverages were 75%, 65%, 67% and 66% respectively for the same 
outcomes. PCV13 therefore covered 1.8 times more IPD cases compared to PCV10, 
1.6 times more meningitis, 3.5 times more mortality, and 2.4 times the total QALYs 
lost. For patients 5-64 years, PCV13 covered 1.4 times more cases of IPD, 2 times 
more cases of meningitis, 2.2 times more cases of mortality and 2.1 times as much 
QALY loss as PCV10. Among the 65 years and over, PCV13 covered 2.2 times more 
IPD cases compared to PCV 10, 2.0 times more meningitis cases, 2.6 times more 
fatal cases and 2.5 times the number of QALYs lost.
deaths and life years lost due to ipd, england 2009/2010
In 2009/2010 there were 5,719 cases of IPD confirmed by culture or polymerase chain 
reaction in the England IPD dataset. Based on the age-specific serotype distribution 
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figure 3. Serotype specific differences in QALY loss (discounted – see text) between serotypes and 
age groups. The line shows the absolute QALY loss for serotype 14, which was used as reference. 
The p-values of the bootstrap comparison are shown above each bar. The whiskers show the 95% 
CI based on 1000 bootstrap samples of the mean. When there are no serotypes with >50 cases an 
empty plot is shown. a) Under 5 years, b) 5-64, c) 65 and over
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in that year and the disease focus and outcome for each serotype averaged over 
the nine year study period, there was an estimated total of 591 meningitis cases 
and 1,010 deaths in 2009/2010 year attributable to IPD, with an associated QALY 
loss of 18,454 (11,638 discounted) in England. The contribution of different age 
groups to these cumulative totals varied considerably (Table 2). The main burden 
of meningitis was among the young and the middle age group, but the majority of 
deaths were among the ≥ 65year olds (71%). For QALY loss (undiscounted), most of 
the burden was in the age group 5-64, though after discounting their QALY loss was 
similar to that in the ≥ 65 year age group. 
discussion
Our study documents the clinical presentation, mortality and impact on the quality 
of life of the prevalent pneumococcal serotypes causing IPD in England in recent 
Table 1. Cumulative proportion of meningitis, mortality and QALY loss (discounted) in 
2009/2010 in England attributable to invasive pneumococcal disease covered by different 
valency vaccines. 
cumulative contribution pcv7* pcv10** pcv13*** ppv23
remaining  
% non-vaccine types
<5 year olds IPD 5% 41% 75% 90% 10%
Meningitis 8% 39% 65% 88% 12%
Mortality 6% 19% 67% 85% 15%
QALY 7% 28% 66% 86% 14%
QALY (disc) 7% 28% 66% 86% 14%
5-64 year olds
IPD 10% 43% 61% 90% 10%
Meningitis 14% 24% 49% 78% 22%
Mortality 12% 23% 52% 86% 14%
QALY 12% 25% 52% 86% 14%
QALY (disc) 12% 24% 52% 86% 14%
≥ 65 year olds
IPD 12% 23% 51% 81% 19%
Meningitis 11% 19% 38% 65% 35%
Mortality 13% 21% 53% 81% 19%
QALY 13% 21% 53% 81% 19%
QALY (disc) 13% 21% 53% 81% 19%
* Contains serotypes 4,6B,9V,14,18C,19F,23F. ** Contains additional serotypes 1,5,7F.
*** Contains additional serotypes 3, 6A,19A,
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years. The serotype-specific clinical presentations were broadly stable over time, 
consistent with reflecting an inherent property of each serotype. To our knowledge, 
this is the first attempt to compare disease outcome between serotypes based on 
QALY loss and incorporating acute disease burden, long term sequelae, mortality and 
life years lost. Our results add to the understanding of the role of the capsular type 
of S. pneumoniae in determining pathogenicity and can guide decision making on 
the potential health gain of introducing vaccines with improved serotype coverage
Assigning QALY weights to different disease states is a well-established 
approach for comparing the potential health gain of different therapeutic or 
prophylactic interventions as it combines both duration and quality of life in a single 
measure. While for non-fatal diseases QALY estimation can be problematic because 
of reliance on subjective measures, for IPD the QALY differences between serotypes 
are mainly driven by the life years lost – a more objective measure. We believe QALY 
loss estimates provide a better platform to distinguish between serotypes causing 
a low and high disease burden than simply reporting mortality or meningitis rates. 
Expressed in QALYs the main IPD burden was found amongst 5-64 year olds, where 
the higher number of life years lost outweighed the higher case fatality rate among 
the ≥ 65 year olds with their lower life expectancy.
Serotypes with a high and low case fatality rate in our study were the same 
serotypes found to be linked to a high and low case fatality rate in a study in Denmark 
[6] and in a review on mortality by capsular type that included data from 9 different 
studies from the United States, Europe, Africa and the Middle East spanning the 
period 1952 to 2010 [22]. This supports the view that high or low mortality is a 
stable feature for those serotypes, though there was less consistency between the 
studies for the serotypes which were not on the extremes. Our results show that the 
differences between serotypes are most marked in the age group 5-64 years. This 
may reflect the greater vulnerability of the very young and elderly populations to IPD 
which may in part mask the inherent differences between serotypes. 














Total % total % total % total % Total %
0-4 572 10% 161 27% 17 2% 2414 13% 831 7%
5-64 2735 48% 310 53% 277 27% 9646 52% 5589 48%
65+ 2413 42% 119 20% 716 71% 6394 35% 5218 45%
Total 5719 100% 591 100% 1010 100% 18454 100% 11638 100%
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It is not clear how the capsular differences between serotypes affect clinical 
presentation and outcome (22). Differences in capsular size or molecular structure 
could possibly lead to a different interaction of the bacteria with its environment 
(including other bacteria in the nasopharynx) and/or immune system in the 
blood, brain or other tissues. Although the capsule is the major virulence factor 
[23], there are other factors such as surface proteins and enzymes, and the major 
toxin pneumolysin, which determine virulence. If these non-capsular virulence 
factors are also associated specifically with certain serotypes then some of the 
characteristics attributed to differences in serotype per se may be spurious. Whole 
genome sequencing has also identified a number of highly variable pathogenicity 
islands within the pneumococcal genome, with considerable variation between 
strains. Some serotypes are highly clonal while others exhibit considerable genetic 
diversity [24]. The extent to which genetically diverse strains within the same 
serotype exhibit different behaviour in terms of clinical presentation and outcome 
cannot be assessed by our study and would require parallel genetic information. 
Another caveat in attributing the observed characteristics to specific serotypes is 
that differentiation into serotypes within a serogroup is still evolving as shown for 
6A for which the original serotyping methods failed to distinguish to 6A from 6C 
[25], each with a different clinical outcome.
Host factors can also affect clinical presentation, as shown by the lower propensity 
to develop meningitis in individuals aged over 5 years with co-morbidities. In 
addition, factors such as ethnicity, socio-economic or other environmental factors 
could influence disease focus as suggested by the strong association between 
serotype 1 and meningitis in west-Africa. In our study, as in a hospital-based study 
in Spain [26], serotype 1 was predominantly associated with empyema. Therefore 
caution should be exercised in translating our results to all epidemiological settings. 
Our study has the potential limitation that we were not able to link all cases in 
the national IPD dataset with a HES admission. Failure to match could be due to 
an incomplete initial extract from the HES database omitting relevant diagnoses 
that could denote IPD, or be due to non-hospitalised invasive disease or incomplete 
information in the fields used in matching. Thus there is the possibility of a selection 
bias, excluding certain clinical presentations or more mild disease. However the 
similarity between the linked and the unlinked dataset in age and serotype distribution 
suggests that the linked subset is representative of the complete dataset. 
From our analysis PCV13 is predicted to protect against a substantially greater 
burden of invasive disease than PCV10, especially mortality, based on its additional 
coverage of serotypes 3, 6A and 19A, and the serotype distribution in 2009 in 
England. However when deciding between the two vaccines, additional factors 
need to be taken into account. These include the serotype distribution and burden 
of non-invasive disease, the potential to prevent disease due to non-typeable 
Haemophilus influenza with PCV10 (which is conjugated to Haemophilus influenzae 
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protein-D [27]) and indirect effects due to differences in carriage prevalence of the 
serotypes covered by each vaccine; for example the extra three serotypes in PCV10 
compared with PCV7 (1, 5 and 7F) have a very low carriage prevalence, due to this low 
carriage there is potential less space for replacement disease by non-vaccine types 
compared to the extra serotypes in PCV13, which are more prevalent in carriage [3]. 
The overall impact on the burden of IPD of each vaccine may therefore be affected by 
the potential for serotype replacement and the invasiveness of the replacing strains 
[3]. For the emerging non PCV serotypes 11A, 31, 10A and 9N could be prioritised for 
inclusion in future conjugated vaccines, as they have a relatively high QALY loss.
In conclusion, from our large linked dataset with information on serotype 
and clinical outcome, we were able to confirm marked and stable differences in 
morbidity and mortality between pneumococcal serotypes, provide estimates for 
the proportion of cases by age group and serotype with meningitis, empyema and 
mortality, and derive the estimated annual QALY loss from IPD four years after the 
introduction of PCV7 in England. While many of the clinical outcomes seem to be 
robustly linked to the capsular type, extrapolation of our findings to populations 
with vastly different epidemiological and socio-economic backgrounds should be 
done carefully. Our findings have relevance for future work on capsular differences 
and interaction with the host immune system, and can inform decision modelling of 
the relative merits of vaccines with different serotype-composition. 
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In the immunisation schedule in England and Wales, the 7-valent pneumococcal 
conjugate vaccine (PCV-7) was replaced by the 13-valent vaccine (PCV-13) in April 
2010 after having been used since September 2006. The introduction of PCV-7 was 
informed by a cost effectiveness analysis using an infectious disease model which 
projected herd immunity and serotype replacement effects based on the post-
vaccine experience in the United States at that time. 
aim
To investigate the cost effectiveness of the introduction of PCV-13.
method
Invasive disease incidence following vaccination was projected from a dynamic 
infectious disease model, and combined with serotype specific disease outcomes 
obtained from a large hospital dataset linked to laboratory confirmation of invasive 
pneumococcal disease. The economic impact of replacing PCV-7 with PCV-13 was 
compared to stopping the use of pneumococcal conjugate vaccination altogether.
results
Discontinuing PCV-7 would lead to a projected increase in invasive pneumococcal 
disease, costs and loss of quality of life compared to the introduction of PCV-13. 
However under base case assumptions (assuming no impact on non-invasive 
disease, maximal competition between vaccine and non-vaccine types, time 
horizon of 30 years, vaccine price of £49.60 a dose + £7.50 administration costs 
and discounting of costs and benefits at 3.5%) the introduction of PCV-13 is only 
borderline cost effective compared to a scenario of discontinuing of PCV-7. The 
intervention becomes more cost-effective when projected impact of non-invasive 
disease is included or the discount factor for benefits is reduced to 1.5%.
conclusion
To our knowledge this is the first evaluation of a transition from PCV-7 to PCV-13 
based on a dynamic model. The cost-effectiveness of such a policy change depends 
on a number of crucial assumptions for which evidence is limited, particularly the 
impact of PCV-13 on non-invasive disease.
inTroducTion
Streptococcus pneumoniae is responsible for significant morbidity and mortality 
in England and Wales, particularly in young children, the elderly and the 
immunocompromised [1]. It can infect mucosal tissue in the respiratory tract to 
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cause conditions such as upper respiratory tract infections, conjunctivitis and acute 
otitis media. Invasive disease occurs when it spreads to normally sterile sites such 
as the bloodstream and meninges, causing more severe symptoms such as pleural 
empyema, septicaemia and meningitis [2]. Pneumonia due to S. pneumoniae is also 
commonly (though not exclusively) invasive.
Two types of pneumococcal vaccines are used in the United Kingdom. The 
23-valent pneumococcal polysaccharide vaccine (PPV-23; Merck & Co) has been 
available since the 1980s, but displays low efficacy, has a short duration of protection 
and is poorly immunogenic in children under two years old [3]. It is currently used 
routinely in clinical risk groups and adults aged 65 years and over [4]. Pneumococcal 
conjugate vaccines elicit longer lasting immune memory, are immunogenic in 
infants, and have the additional benefit of preventing nasopharyngeal carriage, thus 
reducing the likelihood that vaccinated individuals will transmit infection to other 
individuals. This can generate indirect (herd) protection, and so has the potential 
for population-level benefits beyond the groups targeted by vaccination [5]. 
The 7-valent pneumococcal conjugate vaccine (PCV-7; Wyeth, now Pfizer) was 
introduced into the UK infant immunisation schedule in 2006 with a 2+1 schedule 
[6] following favourable cost-effectiveness analyses. This was based on projecting 
indirect protection in non-vaccinated groups and serotype replacement from the 
post-vaccination experience in the United States [7]. Vaccine introduction was 
followed by a sharp reduction in invasive pneumococcal disease caused by vaccine 
serotypes in immunised children but also in adults who were mostly unvaccinated. 
However, this was largely offset by a larger than expected increase in disease caused 
by non-vaccine pneumococcal serotypes [8;9].
In April 2010 Pfizer discontinued marketing PCV-7 in the UK and replaced it 
with a 13-valent pneumococcal conjugate vaccine (PCV-13). In this paper we focus 
on the cost-effectiveness of introducing PCV-13 compared to discontinuing PCV 
vaccination altogether. 
meThods
invasive pneumococcal disease following pneumococcal vaccination
A dynamic transmission model, described in detail by Choi et al. [10] was used to 
estimate the annual number of invasive pneumococcal disease (IPD) cases that are 
likely to occur following the introduction of PCV-13 in April 2010. The model was fitted 
to the total annual number of IPD cases confirmed by culture for PCV-7 types, the 
five new serotypes included in PCV-13 (excluding serotype 1, see below), and all non-
vaccine serotypes (NVT), between epidemiological years 2005/06 and 2008/09. The 
model assumed an initial vaccine efficacy of 52% against carriage of vaccine serotypes 
(26% for partially vaccinated infants) and 100% efficacy against IPD; however vaccine 
protection is assumed to wane with an average duration of 5 years. Herd immunity was 
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estimated using a dynamic transmission model; serotype replacement was estimated 
using a competition parameter of 0, which means that an individual carrying a vaccine 
serotype (VT) is fully protected against acquisition of S. pneumoniae due to NVT so 
that there is complete replacement in carriage of VTs with NVTs.
The dynamic model did not explore the impact of vaccination on serotype 1 
because its pre-vaccination epidemiology shows a cyclical pattern (as in other 
countries [11]). Therefore we inflated the number of IPD cases by the average 
annual incidence of IPD cases caused by serotype 1 between 2000 – 2006 [12]. 
Also, as the transmission model was only fitted to data on culture-confirmed IPD 
(i.e. excluding PCR confirmed cases), we increased the number of IPD cases based 
on the observed percentage of the overall cases which were confirmed using PCR 
in the national surveillance system (5.4% for the under 1s, 14.4% for 1 to 14 and 
0.66% for the those aged 15 and over). 
invasive disease outcomes
Samples from patients with bacterial infections are often sent to the Health Protection 
Agency (HPA) for microbiological testing. If S. pneumoniae is discovered during 
this testing, they are usually serotyped. Cases with serotype information recorded 
between April 2002 and March 2011 were matched to the Hospital Episode Statistics 
database, which contains all admissions to National Health Service hospitals in 
England. This created a dataset of ~25,000 IPD cases with known serotype, diagnostic 
codes, duration of admission and mortality. Disease outcomes in the dataset were 
classified into meningitis, empyema, sepsis, pneumonia and other. The vaccine-
specific (PCV7 serotypes, six additional PCV13 serotypes and non-vaccine serotypes) 
risk of developing each of these foci of disease, as well as the subsequent probability 
of death and the duration of hospitalisation resulting from the disease episode were 
estimated from the dataset. The methodology of matching and serotype-specific 
disease outcomes as observed in this dataset has been previously published [13]. 
To represent the uncertainty in outcomes of IPD estimated from this dataset, we 
took 10,000 bootstrap samples (with replacement) from the original database and 
obtained for each sample the probability of developing disease with one of the five 
disease foci, the subsequent probability of death and the duration of hospitalisation 
for the six age categories (under 2 years, 2-14 years, 15-64 years, 64-74 years 
and 75+ years) and three serotype categories. The frequency distributions of the 
observed probabilities and hospitalisation days are shown in the online-material. 
From these 10,000 samples, we subsequently selected 1,000 by Latin hypercube 
sampling for probabilistic sensitivity analyses.
 non-invasive disease outcomes
The effect of pneumococcal vaccination on primary care consultations and 
hospitalisations for non-invasive disease was estimated by fitting a linear model of 
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the change in these outcomes over the period 2005/6 to 2008/9 to changes in invasive 
pneumococcal disease due to PCV-7 and non-PCV-7 serotypes. Separate models 
were fitted for otitis media consultations, pneumonia consultations and pneumonia 
hospitalisations, and stratified by the age groups <1 year, 1 year, 2-4 years, 5-9 
years and 10-14 years. A description of the model fitting is included in appendix I. 
The incidence of consultations for otitis media and community-acquired pneumonia 
(regardless of aetiology) was estimated using data from The Health Improvement 
Network (THIN), a database of three million active patients representative of the 
UK population [14]. For pneumonia hospitalisations, cases in the Hospital Episode 
Statistics database with a diagnostic code for unspecified pneumonia (ICD-10 code 
J18) were used. Both these data sets show a slight decline in the number of cases 
between 2005/6 to 2007/8 in 0-15 year olds, followed by a possible increase in 
2008/9. The assumptions on pneumococcal attributable disease are influential on the 
outcome of the model fit. Therefore two scenarios were included: a base case scenario 
where a fixed number of pneumonia cases every year was considered to be caused by 
non-pneumococcal pathogens, and an alternative scenario where a fixed proportion 
of annual cases of pneumonia was assumed to be non-pneumococcal attributable. 
costs
Costs for hospitalised cases of bacteraemia, meningitis and pneumonia were 
obtained from standard NHS reference costs (codes WA03Y, AA22Z and DZ11A 
respectively) [15]. The cost per bed day for each of these presentations was 
multiplied by the number of bed days obtained from the analysis of the hospital data. 
For non-invasive pneumonia reference costs for pneumonia without complications 
(DZ11C) were used. No information was available on the duration of stay for the 
recorded hospitalisations; therefore the reference costs for an admission were 
used, which are based on an average duration of ~ 4 days [15].
The cost of a primary care consultation was obtained from standard sources, 
based on a surgery consultation inclusive of direct care staff and qualification costs 
[16]. Prescription costs for pneumonia were estimated based on a 6-capsule pack 
of azithromycin [17]. For bacteraemia and meningitis, prescription costs were 
based on a single dose of cefotaxime before transfer to hospital [17]. Antibiotics 
are not generally recommended for treatment of otitis media [18].
Hospital outpatient visits for meningitis and otitis media respectively were costed 
using NHS reference costs for miscellaneous disorders of the nervous system (code 
AA25Z) and minor ear procedures in children without complications (code CZ08T) 
[15]. A previous study estimated that only about 1% of otitis media consultations 
required an outpatient follow-up visit [7]. Meningitis patients without sequelae 
were assumed to have a single outpatient appointment following discharge. The 
cost of treatment and care for meningitis survivors with sequelae was obtained 
from case notes described in a previous cost-effectiveness analysis [7].
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The cost of a single dose of PCV-13 was assumed to be £49.60, the prices at which 
the vaccines are available on the National Health Service [17]. Since a competitive 
tender is likely to result in lower prices, the threshold price for cost-effectiveness 
was also explored. Vaccine administration costs of £7.51 were assumed based on 
the item of service payment to general practitioners for vaccination. 
utilities
The QALY loss for acute meningitis was based on estimates by the parents of children 
hospitalised for meningitis (with full recovery) [19]. QALY loss for other invasive outcomes 
requiring hospitalisation was based on the estimated utility loss for hospitalisation 
due to occult bacteraemia presented in the same study. The survey results were not 
adjusted for the duration of hospitalisation since no duration information was included 
in the outcome descriptions presented to parents. The QALY loss for an episode of 
pneumonia not requiring hospitalisation were based on a United States-based cost-
effectiveness evaluation [20]. Since only a point estimate was reported, the value was 
assumed to range between no utility loss and the loss associated with an inpatient 
hospitalisation for pneumonia. The QALY loss for an episode of otitis media was based 
on the EQ-5D utilities elicited from parents of children with otitis media in the placebo 
arm of a trial of topical steroids [21]. QALYs lost were estimated by subtracting the 
area under the utility curve, linearly interpolating between utility scores at baseline and 
3 months, and assuming that children were back to normal health at 9 months.
Quality of life weights for sequelae of bacterial meningitis were obtained from 
a Dutch survey among paediatricians using the EQ-5D instrument [22]. The risk of 
different types of sequelae was obtained from a recent meta-analysis [23]. To match 
sequelae categories in the meta-analysis with those in the Dutch study, hearing loss 
was matched to the quality of life for “mild hearing loss” unless it exceeded 70 dB in both 
ears, in which case it was matched to “deafness”, seizures were matched to “epilepsy”, 
spasticity, paresis and palsy were matched to “leg paresis” while hydrocephalus was 
matched to “mild mental retardation”. We assumed that patients could develop any 
combination of the individual sequela proportional to the individual risk of each of 
them. We rescaled the risk of these combinations such that the risk of at least one 
kind of sequela per patient did not exceed 31.7%, as reported in the meta-analysis 
[23]. Patients with more than one type of sequela were assumed to have the QALY loss 
associated with the most severe type. Using this method, the overall average QALY loss 
of a patient developing sequelae was estimated to be 0.255 a year.
cost-effectiveness analysis
The cost-effectiveness analysis was performed from a health care payer’s 
perspective. In the base case, a discount rate of 3.5% per annum was used for costs 
and benefits, in conjunction with a 30 year time horizon. The analysis was performed 
in R 2.15.0 (www.r-project.org)




When both the sample mean and its standard error were available, beta distributions 
were used to represent probabilities and utilities, and lognormal distributions to 
represent costs. When only the sample mean was available, a triangular distribution 
was used, with minimum and maximum based on the plausible minimum and 
maximum values the parameter could take. For costs obtained from NHS reference 
costs [15] lognormal distributions were fitted to the reported means, upper and 
lower quartiles. The parameters used and their distributions are shown in Table 1.
scenarios
The effect of pneumococcal vaccination on non-invasive disease outcomes such as 
non-invasive pneumonia and otitis media is unclear, and is likely to be influenced 
by replacement by both non-vaccine pneumococcal serotypes and other organisms 
[24;25]. Consequently, we also considered a scenario where no change in non-
invasive disease outcomes was assumed.
Model results using a discount rate of 3.5% for costs and 1.5% for QALYs are also 
presented, as well as a scenario using an infinite time horizon.
resulTs
changes to the burden of disease
Figure 1 shows the estimated health care costs and QALYs that may be saved by 
the introduction of PCV-13 vaccination in 2010. Most costs are saved by preventing 
non-invasive disease, while for QALYs saved, the majority of the contribution comes 
from invasive disease. Table 2 compares the annual number of cases, health care 
costs and QALYs lost due to pneumococcal disease during the final year of PCV-7 
vaccination, and after at least 30 years of either discontinuing pneumococcal 
vaccination or changing to PCV-13.
 cost-effectiveness
The cost effectiveness of introducing PCV-13 instead of discontinuing pneumococcal 
conjugate vaccination is shown in Figure 2. Using a threshold of £30,000 per QALY 
gained, introducing PCV-13 is cost-effective in 100% of parameter combinations 
sampled if non-invasive disease outcomes are included, but only 53% if they are 
not. The total costs of the vaccination program, accumulated and discounted over 
30 years will exceed the billion pounds (£1,004,639,395).
Threshold vaccine cost
The threshold price per dose of PCV-13 vaccine for vaccination to be cost-effective 
under thresholds of £20,000 and £30,000 per QALY gained in the base case scenario 
is £50.54 and £71.85 respectively (Figure 3). When non-invasive endpoints are 
excluded, this drops to £32.76 and £49.71.
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figure 1. Incremental health care cost saved (above) and QALYs (below) saved by PCV-13 vaccination 
(start in 2010) compared to stopping infant pneumococcal vaccination. Boxes show the median and 
interquartile range of 1,000 samples, while whiskers show the full range excluding outliers.
figure 2. Cost-effectiveness acceptability curves showing the probability that PCV-13 vaccination 
beginning in 2010 will be cost-effective (compared to stopping infant pneumococcal vaccination). 
(cost per dose: £49.60 + £7.51 administration costs, discounting: 3.5%)




Using an infinite time horizon, discounting of benefits at 1.5% per annum instead 
of 3.5% makes PCV-13 more cost-effective; under this scenario PCV-13 is cost-
effective even without considering non-invasive endpoints. However, excluding 
serotype 1 from the analysis makes PCV-13 unlikely to be cost-effective without 
non-invasive endpoints, and only marginally so with non-invasive endpoints. 
Assuming a different scenario in the estimation of non-IPD disease (see above and 
appendix) only has a mild effect on the cost effectiveness (see Figure 4). 
discussion
Our economic evaluation of PCV-13 vaccination is based on a transmission dynamic 
model which estimates direct and indirect effects of vaccination targeting serotypes 
included in PCV-7, in PCV-13 but not PCV-7, and not in PCV-13. The evaluation shows 
that PCV-13 is borderline cost-effective (with 53% of the simulations below the £30,000 
threshold) at current UK over-the-counter prices compared to stopping pneumococcal 
conjugate vaccination altogether, unless benefits due to prevention of non-invasive 
disease are taken into account or future benefits are discounted at a lower rate.
figure 3. Threshold price per dose of PCV-13 for vaccination to be cost-effective (compared to 
stopping infant pneumococcal vaccination) using a threshold of either £20,000 or £30,000 per 
QALY gained. Boxes show the median and interquartile range of 1,000 samples, while whiskers 
show the full range excluding outliers. Base case assumptions are used, i.e. 3.5% discount rate for 
costs and benefits, 30 years time horizon, point estimate for the case ascertainment adjustment 
and full protection against non-PCV-13 serotypes.
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Table 1. Summary of parameters used in the economic evaluation.
parameter mean distribution reference
Hospital bed day
… for bacteraemia £308 Lognormal (mean 5.73 sd 0.40) [15]
… for meningitis £261 Lognormal (mean 5.56 sd 0.29) [15]
… for pneumonia £299 Lognormal (mean 5.70 sd 0.31) [15]
Lifetime costs following meningitis
… in the first year £6080 Lognormal (mean 8.71, sd 0.36) [7]
… in subsequent years £185 Lognormal (mean 5.22, sd 0.40) [7]
GP consultation £35 Fixed [16]
GP prescriptions
… for otitis media or pneumonia £10.74 Fixed [17]
… for bacteraemia or meningitis £2.14 Fixed [17]
Outpatient follow-up
… for meningitis £346 Lognormal (mean 5.85, sd 0.44) [15]
… for otitis media £116 Lognormal (mean 4.75, sd 0.37) [15]
Vaccination costs
… for PCV-13 (dose) £49.60 Fixed [17]
… for administration (dose) £7.51 Fixed Department 
of Health
QALY loss
… for a hospitalisation for pneumococcal 
bacteraemia or pneumonia
0.079 Beta (mean 0.0079 se 0.031) [19]
… for meningitis 0.023 Beta (mean 0.023 se 0.083) [19]
… for a pneumonia outpatient visit 0.0037 Triangular (min 0, max 0.0074, 
mode 0.0038)
[20]
… for otitis media 0.0035 Beta (mean 0.0035 se 0.56) [21]
Quality of life weights
… for deafness 0.81 Beta (mean 0.81, se 0.028) [22]
… for mild hearing loss 0.91 Beta (mean 0.91, se 0.015) [22]
… for epilepsy 0.83 Beta (mean 0.83, se 0.015) [22]
… for mild mental retardation 0.62 Beta (mean 0.62, se 0.023) [22]
… for paresis 0.67 Beta (mean 0.67, se 0.047) [22]
Sequalae prevalence
… for deafness 0.08 Beta (mean 0.08, se 0.03) [23]
… for mild hearing loss 0.21 Beta (mean 0.21, se 0.02) [23]
… for seizures 0.07 Beta (mean 0.07, se 0.02) [23]
… for hydrocephalus 0.07 Beta (mean 0.07, se 0.02) [23]
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The impact of vaccination on non-invasive disease endpoints was not evaluated 
in the transmission model. It is difficult to infer directly, because pneumococcal 
serotypes causing invasive and non-invasive disease differ, and hence may be affected 
differently by vaccine protection, herd immunity and replacement by other serotypes 
or organisms. We estimated the potential vaccine impact on non-invasive endpoints 
by attributing the change in invasive pneumococcal disease since the introduction 
of PCV-7 to changes in health care attendances for otitis media and pneumonia. 
This method, while necessary due to data limitations (i.e. the lack of microbiological 
confirmation and serotyping for non-invasive disease), raises a number of issues. 
Firstly, although there was a reduction in GP consultations for otitis media in the 
THIN database following PCV-7 introduction, no such decline is observable in data 
from the Royal College of General Practitioners sentinel surveillance of general 
practitioners in England and Wales [26]. Indeed, a Finnish PCV-7 trial found that 
a decrease in pneumococcal-related otitis media in the vaccinated cohort due to 
vaccine serotypes was almost completely compensated for by an increase in otitis 
media due to non-vaccine serotypes [27]. Secondly, models were only fitted to GP 
and hospital visits and therefore did not include mortality. Although the mortality 
due to non-invasive disease is very low among those ages under 15, inclusion of 
this outcome might have made the non-invasive disease scenario even more cost-
effective. Therefore scenarios that include the impact of non-invasive disease are 
subject to greater uncertainty than scenarios without. When the effect of vaccination 
on non-invasive disease is removed, PCV-13 vaccination remains cost-effective, 
albeit very marginally. The uncertainty around vaccine impact on non-invasive 
endpoints is difficult to reduce due to lack of data on non-invasive endpoints. This 
highlights the necessity of sentinel microbiological surveillance for non-invasive 
bacterial respiratory disease, as is already taking place for viral organisms [24].
A key debate surrounding pneumococcal conjugate vaccination that is highly 
influential in determining its cost-effectiveness is the degree of serotype replacement 
… for spasticity or paresis 0.09 Beta (mean 0.09, se 0.01) [23]
… for cranial nerve palsy 0.12 Beta (mean 0.12, se 0.04) [23]
… for visual impairment 0.02 Beta (mean 0.02, se 0.02) [23]
Proportion non-IPD caused by S. pneumoniae
Otitis media 0.285 Beta(mean 0.285, se 0.085) see 
appendix
Pneumonia 0.245 Beta(mean 0.245, se 0.085) see 
appendix
Table 1. continued.
parameter mean distribution reference
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to be expected after vaccine introduction. The base case scenario we used assumes 
that there is complete replacement in carriage with non-vaccine serotypes once 
carriage of serotypes in PCV-13 starts to decrease. This is based on the observation 
that there was almost complete replacement in carriage of the seven PCV-7 serotypes 
by non-PCV-7 serotypes following the introduction of PCV-7 vaccination in the United 
Kingdom. Hence the degree to which PCV-13 vaccination will be beneficial depends 
on the propensity of the vaccine serotypes to cause invasive disease when carried, 
figure 4. Threshold price per dose of PCV-13 for vaccination to be cost-effective (compared to 
stopping infant pneumococcal vaccination) using a threshold of either £20,000 or £30,000 per 
QALY gained. Boxes show the median and interquartile range of 1,000 samples, while whiskers 
show the full range excluding outliers. Scenarios shown are: (a) no inclusion of serotype 1 (upper 
left), (b) infinitive time horizon (upper right) (c) discount rate of 1.5% for benefits (lower left) (d) 
changing the assumption in the disease burden of non-invasive disease that is pneumococcal-
related from a constant number to a percentage of all non-invasive disease (lower right).
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Table 2. Annual number of cases, health care costs and QALYs lost due to pneumococcal 
disease during the final year of PCV-7 vaccination, and after at least 30 years of either 
discontinuing pneumococcal vaccination or of changing to PCV-13. 
final year of 
pcv-7






Meningits 662 886 678
Bacteremia 1,039 1,154 907
Pneumonia 3,345 3,609 2,575
Other focus 172 210 196
Overall 5,528 6,130 4,451
Non-invasive disease
Otitis Media 176,376 285,729 89,190
Pneumonia (GP+Hospital) 4,746 10,657 2,363
deaths:
Meningits 90 101 96
Bacteremia 224 248 195
Pneumonia 423 462 349
Other focus 16 17 21
Overall 760 835 666
costs:
Invasive disease
Hospital £22,729,874 £25,141,469 £19,193,916
GP £393,811 £470,968 £348,690
Sequelea £2,071,974 £2,850,566 £2,107,250
Non-invasive disease
Hospital £3,580,642 £4,727,592 £1,801,225
GP £6,466,996 £10,639,157 £3,269,921
Total costs £31,662,654 £43,829,752 £26,721,002
Qalys lost:
Invasive disease
Meningits 1,228 1,466 1,297
Bacteremia 2,059 2,266 1,805
Pneumonia 3,325 3,535 2,686
THE COST-EFFECTIVENESS OF PCV-13
THIRTEEN
279
Other focus 202 219 269
Sequelae 915 1,324 919
Non-invasive disease
Otitis Media 413 697 207
Pneumonia 6 25 3
Total QALYs lost 8,148 9,532 7,186
Table 2. continued
final year of 
pcv-7




compared to non-PCV-13 serotypes. If the replacing (non-vaccine) serotypes are 
less invasive or virulent, then vaccination is likely to be beneficial despite not altering 
the overall prevalence of pneumococcal carriage. Post-PCV7 experience gives hope 
for replacement with less invasive serotypes [28], but this cannot be guaranteed. 
Hence an essential feature of our analysis is the use of a unique dataset linking 
pneumococcal serotypes detected in invasive cases with their clinical presentations.
Another point of discussion is the application of the same vaccine efficacy (80% 
over the first year) against all serotypes. Recent findings suggest that the vaccine 
efficacy against serotype 3 might be lower compared to the other vaccine types [29]. 
If this is true, then PCV-13 introduction will be less cost-effective than estimated.
Beside PCV-13, a 10-valent conjugate vaccine is also available (PCV-10 or 
Synflorix(R)). This vaccine was not considered for introduction in England and Wales 
[30] and was therefore omitted from this study. Given that the serotype formulation 
and impact on invasive and non-invasive disease of PCV-10 differs from PCV-13, a 
scenario with introduction of PCV-10 instead of a discontinuation of PCV-7 could be 
investigated in a situation where introduction of this vaccine is considered. 
Several recent studies have been published of the cost-effectiveness of 
introducing PCV-13 in Europe [31-35], North America [36], Latin America [37], Asia 
[38;39] and Australia [40]. The studies only presented outcomes which included non-
invasive disease, making a comparison to our main results difficult. However, all but 
two of these studies [34;38] found PCV-13 introduction to be clearly cost-effective. 
There are a number of differences between studies and ours in terms of setting, 
population, incidence of pneumococcal disease and health care costs that contribute 
to the difference in conclusions. There are also two important methodological 
differences. Firstly, all but one of the published studies used a static model, which 
makes realistic representation of herd immunity and serotype replacement following 
PCV-13 vaccination problematic, particularly since no country in the world has had 
sufficient post-PCV13 experience yet. Only one analysis used a dynamic model [39]; 
however, this model did not include competition between vaccine and non-vaccine 
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serotypes and hence could not explore the effect of serotype replacement. Secondly, 
although several studies compared PCV-7 and PCV-13 vaccination programmes 
[34-36;38;40] none compared introducing PCV-13 to discontinuing PCV-7. Replacing 
PCV-7 with PCV-13 is less cost-effective than introducing PCV-13 in a situation 
with no pneumococcal vaccination, since the effect on existing vaccinees is likely 
to persist for a number of years. To our knowledge this is the first economic study 
based on a dynamical model to examine a change of vaccine from PCV-7 to PCV-13, 
which is a highly relevant question to the many countries already using PCV-7 prior 
to its replacement on the market by its manufacturers. 
APPENDICES AND ONLINE MATERIAL
The appendices and online material can be found at: http://www.sciencedirect.
com/science/article/pii/S0264410X12014636
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The aim of the research was to support sound vaccine-related decision making. 
The decisions which were supported were the introduction of Herpes Zoster vaccine 
in England and Wales (chapter 2), withholding childhood Varicella vaccination 
(chapter 4 & 5), recommendation of pandemic influenza vaccination of risk-
groups (chapter 6 & 7), the introduction of a successor of PCV-7 in the Netherland 
(chapter 8), and the decision whether or not to vaccinate risk-groups with PCV-13 
(the official decision was still pending on the day of writing the conclusion; 
chapter 9, 10 & 11). The cost-effectiveness model of PCV-13 (chapter 13) was 
originally performed to be used in a procurement process, however due to a lack of 
contenders in the procurement it was never used in practice. 
Given that most of the presented research was actually used to underpin decision 
making it can be suggested that the main aim was accomplished. However the main 
aim was to support sound decision making, thus the presented work should have 
improved the final decision. A claim which cannot be made from the fact that the 
work was used. Therefore in the conclusion of this thesis the short comings of the 
presented work will be explored. 
To highlight the various short comings and blind spots of the presented research it will 
help to disentangle the way information is used in a decision which is based on a cost-
effectiveness analysis. To do so we can structure the information and analysis used into 
several hierarchical layers, see figure 1. The basis of the pyramid is the raw data; this 
includes the number of cases (surveillance data), the number of cases in the vaccine 
arm compared to the placebo arm (clinical trial data), the number of people in the 
vaccinated cohort (population data), the people who receive a vaccine (coverage data), 
the cost of a treatment or vaccine (cost data), the impact of disease on the different 
dimensions of health-related quality of life (EQ-5D data), the number of people who 
were infected (seroprevalence data), the carriage of the pathogens (prevalence data), 
the social structure and contacts of the population (contact data), etcetera. Analysis 
of the raw data can extract information and extend our knowledge. This data analysis 
can be seen as the second tier in the pyramid. Data analysis included in this layer are for 
example the estimation of vaccine efficacy parameters, the calculation of a QALY loss, 
the estimation of the percentage of susceptibles (by age) by the use of infectious disease 
models (combining incidence data, contact data, seroprevelance data and population 
data). The estimation of absolute incidence among risk groups etcetera. The outcomes 
and conclusions from the separate analysis from the second tier are brought together to 
estimate an overall reduction in the costs and burden of disease and are placed in relation 
to the overall programme costs, therefore the third tier in the hierarchical pyramid is the 
cost-effectiveness framework. The outcome of this third tier is presented graphically in a 
cost-effectiveness plain, and numerically in the cost-effectiveness ratio. Within decision 
making there is one more tier, the top of the pyramid, this is the decision rule, the rule 




In England the decision rule for public health interventions is based on the 
decision rule defined by the National Institute of Clinical Excellence (NICE). This 
decision rule is not strictly formulated, as in that an intervention should be 
introduced when the cost per QALY is below a certain threshold. However, when the 
cost per QALY is below £20.000 the recommendation can be based on the cost-
effective outcome alone. When the cost per QAY is between £20,000 an £30,000 
there is need for more caution towards introduction, and subsequent arguments 
has to be made; for example the innovative nature of the intervention. When the 
cost per QALY is above £30,000 a very strong case has to be made to prove that the 
intervention is an effective use of tax payers’ money [1].
In the Netherlands the decision rule is much less clear compared to England. In the 
Netherlands the consideration of an intervention being value for money depends on the 
severity of the disease and the innovative nature of the intervention. When the disease is 
not severe the threshold is low, the lowest being €10,000 per QALY, when the disease is 
severe and the patients would die immediately or will suffer a very low quality of life when 
the intervention is withhold, the cost/QALY threshold can be up to €80.000 per QALY [2]. 
For vaccinations, where a plethora of disease severities are prevented the threshold is 
therefore unclear, thresholds of €20,000 [3] ; €40,000 [2] and €50,000 [4] are quoted 
to be adequate, leaving a lot of space for individual interpretation.
Although the two decision rules are by definition not using an explicit threshold 
per QALY, this can be the case in practice. In England vaccines are introduced on 
recommendation of the Joint Committee of Vaccination and Immunsation (JCVI); 






this recommendation should include an assessment which demonstrate cost-
effectiveness [5]. In practice the JCVI recommends the introduction of a vaccine 
before the price is known, as the procurement follows the positive recommendation. 
Therefore the JCVI state that the vaccine should be introduced when a price can be 
negotiated under which the programme is cost-effective [6]. Within the procurement 
process a benchmark price is defined, this benchmark price reflects the maximum 
price per dose to remain cost effective. When the price per dose in the procurement 
(corrected for certain award criteria) is above this benchmark price the offer will be 
rejected [7]. This suggests that there is an explicit threshold, however since these 
vaccine prices are kept in confidence the exact threshold is unknown. 
In this decision pyramid there are lots of uncertainties and unknowns. From bottom 
to top: Data can be missing, or data collection can be biased, therefore starting the 
analysis with a flawed base. Analysis can be performed poorly, with inappropriate 
comparisons, or there can be uncertainties generated by model choice or approach, 
resulting in a distorted cost-effectiveness model. The cost-effectiveness model can 
be too simplistic, for example leaving out essential parts or investigates unrealistic 
scenarios or is heavily reliant on assumptions for which there is not much evidence. 
All those shortcomings accumulate in the robustness of the final decision. 
However there are several reasons why the decision rule itself might be 
wrong (besides the uncertainties within the data-decision pyramid), so that a 
suboptimal decision is made even given a perfect cost-effectiveness analysis. The 
shortcomings of the decision rules will sound theoretical, but there are practical 
shortcomings which should be borne in mind when drawing conclusion from the 
analyses presented in this thesis. 
First of all the following short comings are the most applicable for England, as in 
England public health decisions use the NICE guidance which has a more explicit 
threshold to define cost-effectiveness (£20.000-£30.000/QALY). NICE has the 
decision rule in place to optimize the budget allocation [8] of the National Health 
Serivce (NHS). In theory all possible health care interventions should be lined-up 
and money should be invested in the interventions with the lowest cost per QALY, 
until the complete budget is spent. In doing so the last intervention you are still 
able to fund will mark a cost per QALY. In practice it is impossible to line-up all 
possible health care interventions, therefore the decision rule is in place, where you 
can assess for each individual intervention if it is worth the money. This makes each 
analysis a piecemeal analysis [9]. Where not all options of spending the budget are 
compared together in one go, but where options are analysed on an individual basis 
and where decisions are made using the cost per QALY threshold. All CEAs in this 
thesis are piecemeal analyses. The decision rule should select the most effective 




The second problem is that NICE is optimizing the allocation of the NHS budget 
and vaccines are not funded out of this budget, but funded separately. Therefore 
it can be questionable whether the same cost per QALY should be applied. Thirdly, 
the NICE guidance mentions that in cases of a large budget impact (almost always 
the case for vaccines) the threshold is advised to be lower (due to the high budget 
impact you will compete with interventions who have a lower cost/QALY compared 
to the threshold, therefore in theory your new intervention should be more efficient 
as the intervention you will push out). It is therefore possible that the threshold 
does not reflect the available budget. 
Fourthly, a cost-effectiveness analysis is a partial analysis, it focuses only on the 
disease burden and costs related to the particular disease intervention and exclude 
wider implications. Although there is a slight difference between countries; in the 
UK CEA includes only direct benefits, compared to the Netherlands where CEA does 
include indirect costs as work loss. Nevertheless for both countries the analysis 
remains partial as it is still focusses only on costs and burdens directly linked to only 
one particular disease, and does not include the wider implications. For example 
pandemic influenza [10]; when a pandemic hits health care workers may become 
ill, leading to constrains in the availability of health care workers affecting patients 
who are in the hospital for other reasons. Vaccination against pandemic influenza 
will reduce the disease burden among health care workers and therefore have a 
wider impact on the treatment of other patients, benefits which are not included in 
our analysis in chapter 7. This partiality is an important shortcoming. Although the 
impact of partiality can be reduced by incorporating more effects into the analysis, 
it is impossible to include all effects, or to foresee all implications, therefore any 
analysis will always be partial, focussed on only a part of the possible outcomes. 
Fifthly, the time preferences are uncertain. The time preference in cost-
effectiveness analysis are reflected in the time-horizon and the discounting. This 
time preference can become very important in the case of vaccination, where 
health benefits can happen far into the future, see for example chapter 5 with the 
cost-effectiveness of childhood vaccination against Varicella zoster. Unfortunately 
the time preferences within the population are very hard to estimate, and might 
be partially irrational or poorly consider the impact on future generations [11]. 
Therefore the actual used time horizon and discount rate is perhaps more based 
on assumption than on a population preference or on a strong rational. These 
preferences are very important in the interpretation of any outcome of the cost 
effectiveness models and can therefore result in suboptimal decisions. 
Given the shortcomings listed above various improvements can be suggested for 
the work presented in this thesis. The suggestion can be divided into improvements 




The improvements within the pyramid will affect the multiple tiers, from the collection 
of raw data, the analysis to the decision. For the research on varicella there are several 
improvements for the CEA models, firstly more data should be collected on the long term 
QALY loss by age for HZ as our approach was based on the experience of pain which 
assumed a constant relation between pain and QALY loss over the years after onset. 
In the infectious disease model the HZ disease incidence by age was only explained by 
the waning of immunity and boosting by varicella. However the incidence of zoster by 
age can be due to various other factors which were not included in the model, possibly 
over estimating the relation between the two diseases, and hence over estimating the 
impact of the childhood vaccine on the HZ burden. Closely monitoring HZ disease in 
countries where the vaccine has been introduced is therefore important. As childhood 
vaccination was not considered cost-effective other applications of the vaccine should 
be investigated, such as the vaccination of susceptible adolescents. The difficulty of an 
adolescent programme is however the identification of those who are still susceptible. 
Possible future research could therefore include the elucidation of the sensitivity and 
specificity of asking the adolescent/parent about their chickenpox history. 
In the research on the cost-effectiveness of pandemic influenza A/H1N1 2009 the 
estimation of hospitalisation rates was weak, as it was based on the observations in the 
containment phase, when there was an active surveillance possibly leading to a higher 
likelihood to be hospitalised. A disease with very similar symptoms compared to other 
diseases, has to be monitored over several layers of care (antiviral consumption, GP 
visits, hospitalisations and morality) which is complicated to do. Systems to estimate 
the hospitalisation or death rate in a statistical sound way can be set-up and developed 
and tested each year on seasonal influenza. One of the parameters particularly difficult 
to monitor was the prevalence of symptoms in the population over the course of a 
pandemic. To improve the monitoring of symptoms online surveillance systems were 
set up, in the Netherlands (www.degrotegriepmeting.nl) before and in England (www.
flusurvey.org) during the 2009 pandemic. Such online systems rely on a great number 
of registered volunteers who notify their flu-like symptoms on a weekly basis. Maybe 
these online system cover the need for future outbreaks, however the preparation can 
be improved by experimenting with weekly telephone surveys, selecting a perhaps more 
representative sample from the general population. Another system which can be set-up 
is the measurement of background immunity. In the 2009 pandemic this measurement 
was performed by testing residual laboratory samples. This system can be improved 
in two ways, firstly there can be an improved blood sample database reflecting the 
general population and secondly more knowledge can be gathered about the relation 
of antibodies and immunity, in particular against influenza strains previously circulated 
in the population. The existence of background immunity is important to access the 
possible problems by age group. Also protocols can be written and an infrastructure can 




In the analysis on the cost-effectiveness of PCV-13 it is assumed that the 
invasiveness of serotypes will remain constant, leading to a sustained reduction of 
disease if less-invasive serotypes increase in carriage. However given the genetic 
plasticity of the pneumococcus this does not have to be the case. Monitoring this 
invasiveness in parallel with carriage, will be important to understand and predict the 
post-vaccine disease burden. Given the benefits of a linked dataset of the confirmed 
cases containing serotype information with the medical records and the possibility 
to automate data analysis, linkage should be done on a routine basis, and outcomes 
should be routinely published, as this will improve the understanding of the disease. 
The relation of the role of co-infections in the disease burden caused by pneumococcus 
should be studied in more depth, as prevention of other diseases might reduce the 
burden of pneumococcal disease or vice versa. One of the main remaining challenges 
is the evaluation of the overall effect of PCV-vaccines on the burden of non-invasive 
disease, such as pneumonia. This group includes a much larger number of cases 
compared to invasive disease, leading to significant costs and QALY losses. The 
observed post-vaccination all cause pneumonia disease trends are hard to interpret, 
especially if they are split by risk and non-risk group patients (chapter 11).
The threshold cost per QALY is also an implicit award, because when you prevent 
the loss of one QALY this has a maximum value of £20-30,000 pounds in England 
and minimal €10,000 euro in the Netherlands. On the long term industry will 
therefore maximize their profit and set their price accordingly. As with any reward 
system it will therefore be important to update and maintain the methodology of 
the measurement of the quality of life, to guarantee a sound working system. In this 
the use of generic instruments to measure the quality of life are practical but may 
not be complete. For example the EQ-5D (used in chapter 6) constrains the quality 
of life to 5 dimensions, with each a score of only 3 levels. Therefore aspects which 
affect the quality of life beyond the 5 dimensions or in between the 3 levels is missed 
and are therefore not valuated in the decision making. In response to the latter 
shortcoming recently EuroQol presented a version with 5 levels for each dimension 
[12]. Another issue in context of the EQ-5D which merits constant update, or at 
least every 5 or 10 years, is the validation of the tarrif by use of time trade-off or 
standard gamble methods, because the perception of disease severity do change 
over time. Policy makers should be fully aware of these shortcomings, and policy 
should be in place to constantly improve and maintain the QALY measurement. 
The weight the cost-effectiveness verdict receives in the final decision deserves 
constant evaluation. As mentioned above, in England the cost-effectiveness model 
forms the basis for the procurement process to comply with the recommendation 
from the JCVI. This direct application of the cost-effectiveness model outcome might 
be too explicit given the uncertainties within the analysis and the imperfections 




prepared by a small number of analysts who are not on the committee. Given the 
numerous decisions, assumptions and uncertainties within the CEA model the 
influence of these analysts can actually be large on the final introduction. Although 
these analysts are (perhaps) excellent they are not on the committee. Therefore 
the decision JCVI should make is whether or not the vaccine should be introduced 
given a certain (true) vaccine price. However this decision process will require a full 
understanding of the assumptions within the model by all participants. To obtain 
this involvement there should be more interaction between the analysts and the 
decision maker in the process of the analysis, as well as a strict confidentially 
agreement as knowledge of the vaccine price is commercially sensitive.
These short comings do not mean that the cost-effectiveness analysis is not valuable. 
It is a useful tool to understand the issues of a vaccination programme in detail. It forces 
consideration of the disease burden and/or costs. It is a structured approach, strongly 
propagating rational decision making, of which the outcome can be communicated to 
the public. All these aspects are useful additions to the decision making process.
A common theme in this thesis is the application of vaccines to control transmission 
or to prevent disease. For each of the three vaccines discussed there are issues 
with universal vaccination. Regarding varicella zoster there is a potential indirect 
effect on the burden of HZ, in case of the pandemic A/H1N1 2009 influenza vaccine 
universal childhood vaccination was not recommended due to the relative late 
arrival of the vaccine in respect to the peak and the concentration of severe disease 
among risk groups. For pneumococcal vaccination the verdict was the opposite of 
the influenza vaccination, introduction of vaccination among the risk groups was 
not thought to be cost-effective due to the indirect effects of the childhood vaccine, 
making vaccination with PCV of other groups in the population less valuable. 
Among all three diseases the reason why certain vaccination programmes were less 
optimal were due to different reasons. This makes it hard to draw generic conclusions for 
this thesis, apart from that it is very important to consider disease specific characteristics 
in measuring and predicting the direct and indirect impact of the vaccination programme.
Let me finish this thesis with a quote from the Groningen (the Netherlands) born 
mathematician Daniel Bernoulli, who perhaps can be seen as the founding father 
of the field of vaccine decision making due to his work on smallpox inoculation. 
Although stated in 1760 (published in 1766) it is still timely [13]. 
“I simply wish that, in a matter which so closely concerns the well-being of mankind, 
no decision shall be made without all the knowledge which a little analysis and 
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To build up immunity by means of a vaccine is a very successful strategy to prevent 
infectious diseases. When vaccines are applied on a population level they are also a 
good way to prevent or control the spread of infectious disease.
In the application of vaccines there are many choices to be made: for example 
the number of doses, the concentration, the timing of these doses (by age), which 
risk groups should be vaccinated, and which price is value for money. To determine 
what a good decision is with respect to these choices, we look at the possible 
consequences of these decisions and express these consequences in costs and 
benefits. The costs are those of the vaccination program, and the benefits are the 
prevented costs of disease (drugs, doctor visits, hospital visits and lost work time) 
and the gained health (quality of life).
The discipline of health economics is focused on the measurement of these 
costs and benefits in health. Within health economics various methods are 
developed; for example measuring the quality of life, discounting of future costs 
and benefits and decision-making guidelines to distinguish between good and poor 
interventions in respect to benefits and costs. However in the application of these 
techniques a detailed knowledge is essential about the effect of the vaccine, and 
the transmission of infectious diseases within the population. These latter factors 
are studied within the fields of vaccinology and epidemiology. In epidemiology 
we use computer models to simulate the spread of am infectious disease and 
predict the effects of vaccination. In this thesis health economics, vaccinology and 
epidemiology come together in analyses to underpin decision making regarding 
the vaccination programme against three different pathogens: Varicella zoster, 
Influenza and Steprococcus pneumoniae.
varicella zoster
The first part of this thesis deals with the use of a vaccine to reduce disease burden 
caused by Varicella zoster. Varicella zoster is a virus that causes chickenpox and 
shingles, so there is one virus and two diseases. If a person gets infected for the first 
time it will get chickenpox, but once he/she is well again the virus remains in his/her 
body and it can reactivate later in life as shingles. There is a vaccine developed against 
this virus which is available in two different concentrations: a low concentration 
to vaccinate children and a high concentration to immunize elderly. Therefore you 
can ask if one or both of these vaccines should be introduced. In chapter 2 & 3 we 
investigate whether vaccinating the elderly (60 +) in England (Chapter 2) or the 
Netherlands (Chapter 3) is a good idea, and in chapter 4 and 5 we investigate whether 
vaccinating children (in addition to the elderly) is worth the costs (in England).
For shingles it is that the older you are the more likely it is you will get the disease, 
but also the more likely that the disease will be severe. Unfortunately, it is also less 
likely that the vaccine is effective at an older age. Through these three effects it is 
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best to vaccinate late, around 70 years of age, otherwise there is not enough disease 
to prevent, but also not too late, because at an older age the vaccine does not work 
sufficiently any more. Whether the vaccine is considered value for money differs 
between England and the Netherlands. In England, using the English incidence and 
the rules for conducting cost-effectiveness studies, set by the National Institute 
for Health and Clinical Excellence (NICE), the vaccine can be considered cost-
effective, as the costs are less than 30,000 pounds per Qality Adjusted Life Year (a 
unit for quality of life). In Netherlands, using Dutch incidence and Dutch guidelines 
and assuming the price paid by the Centre for Disease Control (CDC) in the United 
States the vaccine is just a little too expensive given the predicted benefits.
The question of whether to vaccinate children is more difficult. This because there 
are (strong) reasons to believe that there is a relationship between chickenpox and 
shingles: the body develops a specific immune response each time it encounters 
the virus (signs of illness need not be exhibited). Without contact with the virus 
this specific immunity will disappear and increase the risk of reactivation of the 
dormant virus as shingles. This effect is important because it means that as the 
probability of encountering the virus declines, such as case when transmission is 
reduced by a childhood vaccination program, reactivation of the virus as shingles 
becomes more likely. Since almost everyone has had chickenpox as a child, almost 
everyone has an increased risk of shingles in case of such childhood program.
The impact of this effect on a population level is examined in Chapters 4 and 5. In 
these chapters we use mathematical models to study the transmission of chickenpox 
and its relationship with shingles. Our research shows that if you look over the 50 
years after the introduction of a childhood chickenpox vaccine there is an increase 
of shingles, even if you vaccinate all older vaccinates against shingles. However when 
you look at the long term, that is more than 80 years into the future, then you reduce 
the total disease burden among children and elderly because vaccinated children 
are less likely to develop shingles. The question whether a childhood vaccination 
program is cost effective depends therefore on how policy makers validate future 
costs and benefits. If you aim for the long term benefits, and you are convinced that 
these long terms benefits can be achieved, the introduction of the vaccine can be 
cost-effective. However, on the shorter term (for example 30 years) an introduction 
is not cost-effective due to the expected increased incidence of shingles.
influenza
The second pathogen discussed in this thesis is influenza, the virus that causes flu. 
Flu is a disease which affect many people each year, and takes many lives. However, 
despite the fact that many people get ill the severity of the disease is poorly described 
in the context of quality of life. Measuring the quality of life is part of health economics 
and the unit of measurement is called QALY (Quality Adjusted Life Year), where a value 
of 1 QALY is equivalent to one year enjoyed in perfect health. There are several methods 
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to measure the quality of life. One of these methods is called the EQ-5D, which stands 
for the 5-dimensional scale developed by EuroQol. The scale divides the quality of life 
in 5 dimensions: mobility, self-care, activities, pain and anxiety/depression. For each 
scale, there are three possibilities: not affected, slightly affected, severely affected. 
This generates a total of 125 combinations. The total QALY loss can be calculated 
based on scores given by healthy people to health states corresponding to the 5 
dimensions and the time the patient suffers from the disease.
In the first few weeks after the pandemic H1N1v flu emerged in England in 2009 
all new cases were recorded and monitored. This made it possible to send an EQ-5D 
questionnaire to patients and compare those who tested positive for influenza and 
those who tested negative. In total 655 questionnaires were sent and resulted in a 
total of 269 responders who met the inclusion criteria: fever plus another symptom 
of flu (186 H1N1v & 83 controls). Between the pandemic flu patients and controls 
there was not much difference in disease severity and the implications for quality 
of life: with a score of 2.74 QALD (Quality Adjusted Life Day) for H1N1v patients and 
2.92 QALD for controls. However, the pandemic flu patients stayed longer at home, 
most likely due to specific advice from their GP. 
An important part of the contingency plan for a pandemic flu is the decision whether 
or not to produce and purchase a pandemic vaccine. Early in the pandemic of 2009 
the British government decided to purchase a vaccine against the pandemic H1N1v 
virus. However it takes time to develop and produce a vaccine, so much time that 
the first doses of the vaccine were not available until mid-October 2009. The arrival 
of the vaccine raised the question: to whom should they be given? And are the 
costs related to the distribution of the vaccine worth it? To answer these questions 
it was necessary to estimate how many people can still become ill after October 
2009. As the population during a pandemic is almost constant and assuming that 
when people have had the flu they cannot get it again it is possible to estimate 
how many people are still eligible to get the disease. At least, when it is known how 
many people have had it and how many people cannot get it. People who cannot 
get it are people who were already immune before the pandemic flu arrived, for 
example because they were previously exposed to a H1N1 flu virus. In England 
there were two epidemic waves, one before the school summer holidays and one 
after. As the vaccine became available in October, it was possible to use the data 
from before and after the holiday to inform the mathematical model. This model 
combines the knowledge of immunity against H1N1 (which indicated that many 
elderly people were protected against infection), the estimated number of cases 
until that day and the growth rate of the epidemic curve after the summer break. 
It was possible to estimate the total number of people who were already infected 
and hence how many people were still eligible for infection and subsequent what 
the impact could be form a vaccine. Various different vaccination strategies were 
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simulated: vaccinating only children, vaccinating risk groups, vaccinating elderly 
and vaccinating everyone. Since children play a dominant role in the transmission 
of flu, vaccination of children has the biggest effect on the number of flu cases, 
much more compared to vaccinating the elderly. When children do not get flu, a 
lot of older people won’t get flu either. However, vaccination against pandemic 
influenza is a race against the clock; every day you vaccinate later you reduce the 
chance that you have a significant impact on the overall outbreak size. On the day 
that the vaccine was available, 21 October 2009, it was clear that the clinical effects 
of H1N1 were very mild, with low mortality and low hospitalization, and people who 
went to the hospital were mainly patients in a risk group. The mild symptoms in 
combination with the fact that by the end of October many children already had 
encountered the virus the outcome of our analysis is that there should be a focus 
on risk groups in the distribution of the vaccine.
streptococcus pneumoniae
The third part of the thesis deals with the transmission and disease caused by 
Streptococcus pneumoniae, a bacterium which inhabits the nasopharynx. To 
understand this section it is important to know that there are different types of 
this bacterium, called serotypes. There are over 90 different serotypes known. For 
reasons that are not entirely clear there is a difference in the transmission and 
disease severity between serotypes. There is also serotype-specific immunity. 
Pneumococci cause ear infections, pneumonia and meningitis. The highest disease 
incidence is among children and elderly. It is also important to know that there 
are different vaccines available, there is a polysaccharide vaccine against 23 
serotypes and there are conjugate vaccines against 7, 10 and 13 serotypes. The 
7 valent vaccine was available first and the 10 valent and 13-valent arrived later 
(PCV7 and PCV13 are from the same manufacturer). Since April and September 
2006, the 7-valent pneumococcal vaccine (PCV-7) was introduced respectively 
in the Netherlands and England, and was replaced by PCV-10 in April 2011 in the 
Netherlands and by PCV-13 in England on April 2010. Although the vaccine is 
expensive it was still considered cost-effective because the vaccine protects not 
only against disease but also against transmission. As with influenza, children play a 
driving role in the transmission, when the children are vaccinated the transmission 
declines and the elderly are indirectly protected. However, there was a possibility 
that other serotypes would increase in transmission when the transmission of 
vaccine serotypes stopped due to the vaccine. The vaccine serotypes are therefore 
being replaced by non-vaccine serotypes. The experience in America, where the 
vaccine was introduced in 1999, was used as an indicator for introduction in the 
Netherlands and England. In America hardly any replacement was observed and 
therefore the vaccine was introduced. However soon after introduction in England 
and the Netherlands there were indications that the replacement might be higher. 
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In chapter 8 and 9, we examine what the implications are of this higher replacement 
on the cost effectiveness of PCV-7 and whether it actually did occur. We do the latter 
by looking for the presence of Strep. pneumoniae in the nasopharynx of children 
and their parents. The conclusion of these two chapters was that when there is 
a high degree of replacement the cost-effectiveness worsens and that there is 
indeed a great degree of replacement, so much that there is no decline in the total 
percentage of people who carry pneumococcus. 
Because the PCV-13 conjugated vaccine seems to protect more effectively 
against the 13 serotypes compared to the 23-valent polysaccharide vaccine we can 
ask whether risk-groups should be vaccinated with 13-valent vaccine instead of the 
polysaccharide vaccine. In chapter 10 and 11, we examine this question. First by 
determining the additional risk of invasive disease in various risks groups (Chapter 
10) and subsequently we investigated whether vaccination is cost-effective. However 
when the children are vaccinated others are indirectly protected, including patients 
in risk-groups, therefore the added benefit of vaccinating risk-groups with the 
13-valent vaccine is marginal, and if there is a benefit this is only for a short duration 
after introduction of PCV-13 as herd immunity takes effect in the period after.
Due to the high degree of replacement the difference between serotypes 
become more important. When serotypes cause less severe disease there may be 
a decline in the expected overall disease-burden after introduction of the vaccine. 
To investigate this, we linked hospital data to serotype information, by doing so it 
was possible to investigate whether there is a difference in the degree of meningitis 
and mortality between the different serotypes. Subsequently we expressed this 
difference in the overall loss in quality of life for the different serotypes. This 
knowledge of the differences between serotypes was summarized by vaccine-types 
and used in an evaluation of the cost effectiveness of a switch of PCV-7 to PCV-13 
in England and Wales (chapter 13). Showing that introduction of PCV-13 was more 




Het opbouwen van immuniteit door middel van een vaccin is een erg succesvolle 
strategie om ziektelast veroorzaakt bij infectie ziekten te voorkomen. Wanneer 
een vaccin op populatie niveau wordt gebruikt is het ook een goede manier om de 
verspreiding van de infectieziekte in de populatie te controleren of te elimineren.
In de toepassing van vaccins zijn er vele keuzes die gemaakt moeten worden: het 
aantal doses, de concentratie van die doses, het moment van die doses (leeftijd), 
welke risicogroepen moeten worden gevaccineerd, en de prijs die men bereid is te 
betalen. Voor elk van deze keuzes, zijn er goede, minder goede en slechte keuzes. 
Om te bepalen wat een goede en een minder goede keuze is kijkt men naar de 
mogelijke gevolgen van die keuzes en drukt deze gevolgen uit in kosten en baten. 
De kosten zijn de kosten voor het vaccinatie programma, en de kwantitatieve baten 
zijn het voorkomen van ziekte gevallen met de daarbij behorende kosten, zoals 
medicijnen, arts bezoek, ziekenhuis bezoek, verloren werktijd en de kwalitatieve 
baten in gezondheid gemeten in de kwaliteit van leven. 
De gezondheids-economie houdt zich bezig met het meten van kosten en baten 
van gezondheid. Binnen de tak van de gezondheids-economie zijn er verschillende 
methoden ontwikkeld om dit te doen. Dit zijn bijvoorbeeld methoden voor het meten 
van de kwaliteit van leven, verdiscontering van toekomstige kosten en baten en een 
besluitvormingsregel om onderscheid te maken tussen interventies waarvoor de 
kosten opwegen tegen de opbrengst. In de toepassing van deze technieken is echter 
ook gedetaileerde kennis nodig over de werking van een vaccin en de transmissie van 
de infectieziekten waartegen het vaccine werkt. Deze factoren worden bestudeerd 
binnen de vakgebieden van vaccinologie en epidemiologie. Binnen de epidemiologie 
wordt er gebruik gemaakt van computermodellen om de verspreiding van ziekten 
te simuleren en om de gevolgen van een vaccin te voorspellen. In dit proefschrift 
komen de gezondheids economie, vaccinologie en epidemiologie samen en worden 
toegepast in vaccinatie beslissingen voor drie verschillende ziekteverwekkers: 
Varicella zoster, Influenza en Steprococcus pneumoniae. 
varicella zoster
Het eerste gedeelte van dit proefschrift gaat over het gebruik van een vaccin om 
de ziektelast door Varicella zoster te verminderen. Varicella zoster is een virus dat 
waterpokken en gordelroos veroorzaakt, er is dus één virus en twee ziekten. Als je voor 
de eerste keer in aanraking komt met het virus krijg je waterpokken, echter nadat je 
weer beter bent blijft het virus in je lichaam waardoor het virus later weer actief kan 
worden als gordelroos. Tegen het Varicella zoster virus is er een vaccin en dit vaccin is 
in twee verschillende concentraties beschikbaar: een lage concentratie om kinderen 
te vaccineren en een hoge concentratie voor ouderen. Hierdoor rijst de vraag of we 
één of beide vaccins moeten gebruiken. In hoofdstuk 2 & 3 onderzoeken we de vraag 
of we de ouderen (60+) in England (hoofdstuk 2) of Nederland (hoofdstuk 3) moeten 
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vaccineren tegen gordelroos, en in hoofdstuk 4 & 5 onderzoeken we of het vaccineren 
van kinderen (naast de ouderen) de moeite waard is (in Engeland). 
Voor gordelroos geldt dat hoe ouder je bent hoe meer kans je hebt om de ziekte te 
krijgen, maar ook hoe erger de ziekte is wanneer je het krijgt en, helaas, hoe minder 
de kans dat het vaccin goed werkt. Door deze drie zaken kun je het beste vrij laat 
vaccineren (rond 70 jaar), omdat anders er niet voldoende ziekte wordt bestreden, 
maar ook weer niet te laat, want dan werkt het vaccin niet voldoende. Of de prijs van 
het vaccin het waard is verschilt tussen Engeland en Nederland. In Engeland, gebruik 
makend van de Englse incidentie en regels voor het uitvoeren van kosten effectiviteits 
studies is het vaccin het waard, dat wil zeggen dat het minder kost dan 30.000 Britse 
pond per Qality Adjusted Life Year (een eenheid voor kwaliteit van leven). In Nederland, 
gebruik makend van Nederlandse incidentie en Nederlandse regels, en uigaande van 
de prijs die het ‘Centre for Disease Control’ (CDC) in de Verenigde Staten betaalt is 
het vaccin net iets te duur in verhouding tot de opbrensten. 
De vraag of we de kinderen moeten vaccineren is moeilijker te beantwoorden. 
Er zijn namelijk (sterke) redenen om aan te nemen dat er een relatie is tussen 
waterpokken en gordelroos. De relatie is dat het lichaam een speciefieke 
immuunresponse aanmaakt elke keer wanneer het in aanraking komt met het virus 
(je hoeft niet perse ziek te worden). Wanneer je niet in aanraking komt met het virus 
verdwijnt de specificiteit van de immuunrespons wat de kans op een reactivatie van 
het virus verhoogt. Dit effect is belangrijk, want dit betekent dat wanneer je niet meer 
met het virus in aanraking komt, zoals het geval is wanneer de transmissie van het 
virus veel minder wordt door het vaccineren van alle kinderen, je meer kans hebt op 
een reactivatie van het virus als gordelroos. Aangezien bijna iedereen waterpokken 
heeft gehad als een kind geldt dit voor een groot gedeelte van de populatie. 
Hoe erg dit is hebben we onderzocht in hoofdstuk 4 en 5. In deze hoofdstukken 
maken we gebruik van wiskundige modellen om de verspreiding van waterpokken 
te bestuderen en de relatie met gordelroos. Uit ons onderzoek blijkt dat wanneer 
je de kinderen vaccineert en je kijkt over de komende 50 jaar er een toename is 
van gordelroos, zelfs als je alle ouderen vaccineert tegen gordelroos. Echter kijk 
je op de lange termijn, meer dan 80 jaar in de toekomst, dan is vaccinatie tegen 
waterpokken positiever, want dan verminder je de ziekte omdat gevaccineeerd 
kinderen minder kans hebben op gordelroos. De vraag of het waard is, want het kost 
veel geld, hangt of hoe je de opbrengsten in de toekomst waardeert. Als je de lange 
termijn voordelen erg belangrijk vindt en je bent ervan overuigd dat de lange termijn 
voordelen behaald kunnen worden dan is de introductie van het vaccin het waard. 
Echter als het vaccin zich moet terug betalen op de kortere termijn (bijvoorbeeld 30 




De tweede ziekteverwekker besproken in dit proefschrift is Influenza, het virus dat griep 
verooorzaakt. Griep is een ziekte die elk jaar vele mensen treft en vele levens eist. Echter, 
ondanks dat er veel mensen ziek worden is de ernst van de ziekte slecht beschreven 
in de context van kwaliteit van leven. Het meten van de kwaliteit van leven is een tak 
van de gezondheidseconomie. Deze tak probeert een numerieke waarde te geven aan 
de staat van het leven. Het hanteert een eenheid met de naam QALY wat staat voor 
Quality Adjusted Life Year, waar een waarde van 1 QALY gelijk staat aan 1 jaar genoten 
in perfecte gezondheid. Er zijn verschillende methoden om deze waarde te meten. 
Een van de ontwikkelde methoden heet de EQ-5D, wat staat voor de 5 dimensionale 
schaal ontwikkeld door EuroQol. De schaal deelt de kwaliteit van leven in 5 dimensies: 
mobiliteit, zelfredzaamheid, normale activiteiten, pijn en depressie. Voor elke schaal 
zijn er drie mogelijkheden; niet, een beetje, erg. Dus in totaal zijn er 125 verschilende 
mogelijkheden om de schaal in te vullen. De score wordt vertaald naar QALYs door 
middel van een vergelijking met scores die gezonde mensen hebben gegeven aan een 
gezondheidsstatus die overeenkomt met de aangegeven score op de 5 dimensies. 
Toen de pandemische griep H1N1v in 2009 opkwam werden in England gedurende 
de eerste paar weken alle nieuwe gevallen geregistreerd en gevolgd. Dit maakte het 
mogelijk om patiënten die positief waren getest voor influenza een EQ-5D vragenlijst 
voor te leggen, net als mensen die negatief waren getest. De laatst genoemde groep 
kon figureren als controle groep. In totaal verstuurden we 655 questionnaires naar 
patiënten waarvan er in totaal 269 reageerden die voldeden aan de inclusie criteria: 
koorts plus een ander symptoom van griep (186 H1N1v & 83 controles). Tussen de 
pandemische grieppatiënten en de controles zat niet veel verschil qua ernst van de 
ziekte en de implicaties voor de kwaliteit van leven, 2.74 QALD voor H1N1v patienten 
en 2.92 QALD voor controles. Echter de pandemische grieppatiënten bleven langer 
weg van hun werk, meest waarschijnlijk door specifiek doktersadvies. 
Een belangrijk onderdeel van het opgestelde rampenplan voor een pandemische griep 
is de productie en aanschaf van een pandemisch vaccin. Al vroeg in de pandemie van 
2009 was besloten door de Engelse overheid om een vaccin tegen het pandemische 
H1N1v virus aan te schaffen. Echter, het kost tijd om een vaccin te produceren, zoveel 
tijd dat de eerste doses van het vaccin niet beschikbaar waren voor half oktober 2009. 
Het arriveren van nieuwe doses brengt de vraag: aan wie moet het gegeven worden? 
En zijn de gemaakte kosten voor het verspreiden van het vaccin het waard? Om deze 
vraag te beantwoorden moet je een schatting maken van hoeveel mensen nog ziek 
kunnen worden na oktober 2009. Aangezien de bevolking tijdens een pandemie in een 
land nagenoeg constant is en onder de aanname dat wanneer je de griep hebt gehad 
je het niet weer krijgt kun je een schatting maken van hoeveel mensen de ziekte nog 
kunnen krijgen. Tenminste, als je weet hoeveel mensen de ziekte hebben gehad en 
hoeveel mensen de ziekte soieso niet konden krijgen omdat ze al immuun waren 
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voordat de pandemische griep arriveerde, bijvoorbeeld doordat ze al eens eerder een 
H1N1 griep hadden gehad. Voor Engeland waren er twee epidemische golven, één 
voor de zomervakantie en eentje erna. Aangezien het vaccin in oktober beschikbaar 
kwam was het mogelijk om de data van voor en na de vakantie te gebruiken voor 
het bijstellen van het computersimulatiemodel. Dit model combineert de kennis van 
immuniteit tegen H1N1v, dat aangaf dat veel ouderen beschermd waren tegen een 
infectie en de geschatte gevallen van de griep. Op basis van de groeisnelheid van de 
epidemische curve na de vakantie was het mogelijk om een schatting te maken van 
het aantal mensen (incl. kinderen) dat het virus al had gehad, en dus hoeveel het nog 
konden krijgen en vervolgens wat de mogelijke impact zou zijn van vaccinatie. We 
testten verschillende vaccinatie strategieën, zoals enkel het vaccineren van kinderen, 
het vaccineren van risicogroepen, het vaccineren van ouderen en het vaccineren van 
iedereen. Omdat kinderen een erg dominatne rol spelen in de transmissie van griep 
heeft het vaccineren van kinderen het grootste effect op het aantal griep gevallen, veel 
groter dan het effect van het vaccineren van ouderen, dit omdat wanneer kinderen het 
niet krijgen veel ouderen het ook niet krijgen. Echter, vaccinatie tegen pandemische 
griep is een race tegen de klok, elke dag dat je later vaccineert verklein je de kansen 
dat je een significante impact hebt op de totale grootte van de uitbraak. Op de dag 
dat het vaccin beschikbaar was, 21 oktober 2009, was het duidelijk dat de klinische 
gevolgen van H1N1v erg mild waren: een lage mortaliteit, een lage hospitalisatie 
en de mensen die naar het ziekenhuis gingen waren voor het grootste gedeelte in 
risicogroepen. De milde symptomen in combinatie met het feit dat tegen het eind 
van oktober erg veel kinderen het virus al hadden gehad maakte dat de uitkomst van 
onze analyse was dat een grote campagne tegen pandemische griep niet de moeite 
waard bleek. De eerste doses zouden beschikbaar moeten zijn voor risicogroepen. 
Dit is onder de aaname dat je de kosten voor het vaccin al hebt afgeschreven en dat 
alleen de toedieningskosten van het vaccin er toe doen. 
streptococcus pneumoniae
Het laatste gedeelte van het proefschrift gaat over de transmissie en ziekte veroorzaakt 
door Streptococcus pneumoniae, een bacterie die groeit in de neusholte. Voor het 
begrijpen van het onderzoek is het erg belangrijk om te weten dat er verschillende typen 
zijn van deze bacterie, zogenoemde serotypen. Er zijn wel 90 verschillende serotypen 
bekend. Om redenen die niet geheel duidelijk zijn is er een verschil in transmissie 
en ernst van de ziekte tussen de verschillende serotypen, ook is de immuniteit 
serotype-specifiek. Pneumokokken veroorzaken onder andere oorontsteking, long 
ontsteking en meningitis, waarbij de hoogste incidentie van ziekte voorkomt bij 
kinderen en bij ouderen. Het is belangrijk om te weten dat er verschillende vaccins 
zijn; een polysacharide vaccin tegen 23 serotypen en geconjugeerde vaccins tegen 
7, 10 en 13 serotypen, waarbij het 7-valent vaccin het eerst beschikbaar was en het 
10-valent en 13-valent pas later op de markt kwamen (PCV7 en PCV13 is van dezelfde 
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fabrikant). Sinds april en september 2006 is het 7-valent pneumokokkenvaccin 
(PCV-7) ingevoerd in respectievelijk Nederland en England. Echter, PCV-7 werd 
vervangen door PCV-10 in april 2011 in Nederland en in april 2010 vervingen de 
Engelsen PCV-7 voor PCV-13. Het vaccin is erg kostbaar, maar was het toch waard 
om in te voeren omdat het vaccin, naast de ziekte ook de transmissie voorkomt. Net 
als bij influenza spelen de kinderen de belangrijkste rol in transmissie. Wanneer er 
door vaccinatie geen transmissie meer is tussen kinderen worden de ouderen indirect 
beschermd. Je vaccineert alleen kinderen maar je voorkomt ziekte bij kinderen én 
ouderen. Echter, er was een mogelijkheid dat andere serotypen op zouden komen 
wanneer de transmissie van serotypen waar tegen is gevaccineerd wordt gestopt. De 
vaccin-serotypen worden vervangen door niet-vaccin-serotypen (replacement). De 
ervaringen in Amerika, waar het vaccin PCV-7 al in 1999 was geïntroduceerd, werden 
gebruikt als een leidraad voor introductie in Nederland en Engeland. In Amerika was 
nauwelijks iets van een vervanging waargenomen. Al snel na introductie waren er 
indicaties dat deze vervanging groter zou kunnen zijn in Nederland en Engeland. In 
hoofdstuk 8 en 9 onderzoeken we wat de gevolgen kunnen zijn van deze vervanging 
op de kosteneffectiviteit van PCV-7 en of deze vervanging daadwerkelijk heef plaats 
gevonden. Dit laatse doen we aan de hand van de aanwezigheid van Streptococcus 
in de neusholte van kinderen en hun ouders. De conlcusie van de twee hoofstukken 
is: wanneer er een grote mate van vervanging is verslechterd de kosteneffectiviteit. 
Tevens blijkt dat er inderdaad een grote mate van vervanging is, zoveel dat er geen 
enkele daling is in het totale percentage mensen dat streptokokken bij zich draagt. 
Omdat het PCV-13 vaccin beter lijkt te werken tegen de 13 serotypen dan het 
23-valent vaccin, kunnen we de vraag stellen of we risicogroepen moeten vaccineren 
met het 13-valent vaccin. In hoofstuk 10 en 11 onderzoeken we deze vraag, eerst 
door de extra kans op ziekte vast te stellen voor de verschillende risicogroepen 
(hoofdstuk 10) en vervolgens door te onderzoeken of vaccinatie kosten effectief is. 
De uitkomst is dat wanneer de kinderen worden gevaccineerd en dus andere mensen 
indirect worden beschermd, de extra voordeel van het vaccineren van risicogroepen 
met het 13-valent vaccin maar van korte duur is. 
Door de hoge mate van vervanging wordt het belangrijk wat de eigenschappen 
zijn van de serotypen die de plaats overnemen. Wanneer deze serotypen minder erge 
ziekte veroorzaken kan er een verschuiving zijn in de verwachte ziektelast door de 
introductie van het vaccin. Om dit te onderzoeken hebben we ziekenhuisgegevens 
gekoppeld aan serotype informatie. Hierdoor was het mogelijk om te onderzoeken 
of er een verschil is in de mate van meningitis en sterfte tussen de verschillende 
serotypen. We gaven het verschil aan in het verlies van QALYs. Deze kennis tussen 
het verschil tussen serotypen hebben we opgesomd in vaccin-typen en gebruikt 
in een evaluatie van de kosteneffectiviteit van de switch van PCV-7 naar PCV-13 
in England. De conclusie van deze analyse is dat het introduceren van PCV-13 een 
betere keuze is dan het stoppen met pneumokokken vaccinatie.
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